 
North Carolina Genomic Evaluation by Next -generation Exome 
Sequencing, 2 (NCGENES 2)  
 
 
 
NCT number  [STUDY_ID_REMOVED]  
Document Date  03/12/2020  
 
 
  
 
 
 
 
 
North Carolina Genomic Evaluation by Next -generation Exome Sequencing, 2  
(NCGENES 2)  
  
March 12 , 2020  
  
 
 CONTENTS  
ABOUT THE PROTOCOL ________________________________ ________________________________ ___________________  7 
PROTOCOL FORMATTING  ________________________________ ________________________________ ____________________  7 
Headings  ________________________________ ________________________________ ______________________________  7 
Font  ________________________________ ________________________________ ________________________________ __ 7 
ABBREVIATIONS  ________________________________ ________________________________ ___________________________  8 
NCGENES 2 OVERVIEW  ________________________________ ________________________________ ___________________  9 
STUDY FLOW - ENROLLMENT , CONSENT , VISIT 1, RETURN OF RESULTS AND FOLLOW -UP ________________________________ _ 10 
OVERVIEW OF NCGENES  2 CLINICAL PROTOCOL INTERVENTIONS  ________________________________ __________________  13 
NCGENES  2 CLINICAL STUDY ROLES  ________________________________ ________________________________ _________  14 
ENROLLMENT OVERVIEW  ________________________________ ________________________________ _______________  15 
PARTICIPANT REFERRAL  ________________________________ ________________________________ ____________________  15 
PARTICIPANT ELIGIBILITY  ________________________________ ________________________________ __________________  15 
Mark Participant as Ineligible Manually  ________________________________ ________________________________ ____  16 
PARTICIPANT SELECTION  ________________________________ ________________________________ ___________________  16 
For Participant’s with a status of ‘Not Selected’ or ‘Participant Ineligible’  ________________________________ _________  16 
For Participant’s with a status of ‘Selected’  ________________________________ ________________________________ __ 17 
For Participant’s with missing selection criteria that must be obtained on the enrollment call  __________________________  17 
ENROLLMENT CALL ________________________________ ________________________________ _______________________  17 
Enrollment Call Strategy  ________________________________ ________________________________ _________________  17 
Parent Eligibility  ________________________________ ________________________________ _______________________  18 
Parent Consent  ________________________________ ________________________________ ________________________  19 
Randomization 1  ________________________________ ________________________________ _______________________  19 
Protocol if unable to complete enrollment call  ________________________________ ________________________________  19 
PROVIDER NOTIFICATION OF NCGENES  2 PARTICIPANT  ________________________________ __________________________  19 
UNC Genetics and Metabolism Clinic  ________________________________ ________________________________ ______  20 
UNC Pediatric Neurology Clinic ________________________________ ________________________________ ___________  20 
Mission Health Fullerton Genetics Clinic  ________________________________ ________________________________ ____  20 
REMINDER CALL – 1 WEEK PRIOR TO VISIT  ________________________________ ________________________________ ______  21 
Call Strategy  ________________________________ ________________________________ __________________________  21 
VISIT 1  ________________________________ ________________________________ ________________________________ __ 22 
OVERVIEW  ________________________________ ________________________________ ______________________________  22 
PREPARATION FOR VISIT 1 ________________________________ ________________________________ __________________  22 
Compiling the Participant Folder  ________________________________ ________________________________ __________  22 
What to Bring to Clinic  ________________________________ ________________________________ __________________  23 
VISIT 1 PROCEDURES  ________________________________ ________________________________ ______________________  24 
Arrival to Visit 1  ________________________________ ________________________________ _______________________  24 
Collecting the Intake Survey  ________________________________ ________________________________ ______________  25 
Pre-visit Survey  ________________________________ ________________________________ ________________________  26 
Audio Recording and the Clinic Visit  ________________________________ ________________________________ _______  26 
Post-visit survey  ________________________________ ________________________________ ________________________  27 
Determining Developmental Age  ________________________________ ________________________________ ___________  28 
Study Intervention 2  ________________________________ ________________________________ _____________________  29 
Distribution of Parent and Child Compensation  ________________________________ _______________________________  32 
Biospecimen collection  ________________________________ ________________________________ __________________  32 
STUDY WITHDRAWAL & NO SHOW PROTOCOL  ________________________________ ________________________________ __ 32 
Withdrawal  ________________________________ ________________________________ ___________________________  32 
Investigator Withdrawal  ________________________________ ________________________________ _________________  33 
No Shows  ________________________________ ________________________________ _____________________________  33 
ALERT PROTOCOL FOR NCGENES  2 DISTRESSED ADULT PARTICIPANTS  ________________________________ ______________  33 
The clinical project director will:  ________________________________ ________________________________ __________  34 
The study coordinator will:  ________________________________ ________________________________ _______________  34 
The study psychologist will: ________________________________ ________________________________ _______________  34 
 
 VISIT 1 POST-VISIT PHYSICIAN SURVEY AND PHENO TIPS________________________________ ___________________________  35 
NCGENES 2 Patient Tracking Instructions for Physicians/Providers  ________________________________ ______________  35 
PHONE CONSENT TO INTERVENTION 2 ________________________________ ________________________________ _________  36 
Scheduling Call  ________________________________ ________________________________ ________________________  36 
Call for Consent(s) to Intervention 2  ________________________________ ________________________________ ________  36 
RETURN OF RESULTS  ________________________________ ________________________________ ____________________  38 
OVERVIEW  ________________________________ ________________________________ ______________________________  38 
AFTER VISIT 1: ALL PARTICIPANT GROUPS  ________________________________ ________________________________ _____  39 
ROR FOR NO GS PARTICIPANTS  ________________________________ ________________________________ ______________  40 
Defining Results for No GS  ________________________________ ________________________________ _______________  40 
Timing of RoR Tasks for No GS  ________________________________ ________________________________ ____________  40 
ROR FOR GS PARTICIPANTS  ________________________________ ________________________________ _________________  42 
Results for GS  ________________________________ ________________________________ _________________________  42 
Timing of RoR Tasks for GS  ________________________________ ________________________________ ______________  42 
TRACKING PARTICIPANT COMPENSATION  ________________________________ _______________________________  44 
REQUESTING CASH AND GIFT CARDS AT UNC  ________________________________ ________________________________ ___ 44 
PURCHASING GIFT CARDS FOR MISSION PARTICIPANTS  ________________________________ ____________________________  44 
REQUESTING CHILD NONMONETARY GIFTS AT UNC  ________________________________ ______________________________  44 
REQUESTING CHILD NONMONETARY GIFTS AT MISSION  ________________________________ ___________________________  45 
TRACKING OF PARENT AND CHILD COMPENSATION  ________________________________ _______________________________  45 
COMPENSATION FOR FOLLOW -UP TASKS  ________________________________ ________________________________ _______  45 
INTERNAL REPORTING/TRACKING  ________________________________ ________________________________ _______  46 
ENROLLMENT REPORT  ________________________________ ________________________________ _____________________  46 
PROVIDER REPORT  ________________________________ ________________________________ ________________________  46 
PARTICIPANT ELIGIBILITY TRACKING ________________________________ ________________________________ __________  46 
PARTICIPANT MAILINGS  ________________________________ ________________________________ _________________  47 
GENERAL MAILING PROCEDURES  ________________________________ ________________________________ _____________  47 
Tracking System Mailings Page  ________________________________ ________________________________ ___________  47 
Completing the Mail Merge  ________________________________ ________________________________ _______________  47 
Mailing -Pre-postage protocol  ________________________________ ________________________________ _____________  48 
MAILING 1 – INTRO LETTER AND BROCHURE  ________________________________ ________________________________ ____  51 
To complete this mailing:  ________________________________ ________________________________ ________________  51 
Relevant Documents  ________________________________ ________________________________ ____________________  51 
MAILING 2 – PRE-VISIT PACKET  ________________________________ ________________________________ ______________  51 
To Complete this Mailing:  ________________________________ ________________________________ ________________  52 
Relevant Documents  ________________________________ ________________________________ ____________________  53 
MAILING 3 – PRE-ROR PACKET  ________________________________ ________________________________ ______________  53 
To Complete this Mailing:  ________________________________ ________________________________ ________________  53 
Relevant Documents:  ________________________________ ________________________________ ____________________  53 
MAILING 4 – 2 WEEK POST-ROR PARENT SURVEY  ________________________________ _______________________________  53 
To Complete this Mailing:  ________________________________ ________________________________ ________________  54 
Relevant Documents:  ________________________________ ________________________________ ____________________  54 
MAILING 5 – GIFT CARD AND THANK YOU FOR 2 WEEK SURVEY  ________________________________ ____________________  54 
To Complete this Mailing:  ________________________________ ________________________________ ________________  54 
Relevant Documents:  ________________________________ ________________________________ ____________________  54 
MAILING 6 – 6 MONTH POST-ROR PARENT SURVEY  ________________________________ ______________________________  54 
To Complete this Mailing:  ________________________________ ________________________________ ________________  55 
Relevant Documents:  ________________________________ ________________________________ ____________________  55 
MAILING 7 – FINAL GIFT CARD AND THANK YOU FOR 6 MONTH SURVEY ________________________________ ______________  56 
To Complete this Mailing:  ________________________________ ________________________________ ________________  56 
Relevant Documents:  ________________________________ ________________________________ ____________________  56 
USING THE TRACKING SYSTEM  ________________________________ ________________________________ __________  57 
LOGGING IN ________________________________ ________________________________ _____________________________  58 
 
 KEY TERMINOLOGY : TASK V . STATUS  ________________________________ ________________________________ _________  60 
Tasks  ________________________________ ________________________________ ________________________________  60 
Statuses  ________________________________ ________________________________ ______________________________  60 
MAIN TRACKING SYSTEM PAGES  ________________________________ ________________________________ _____________  61 
Homepage  ________________________________ ________________________________ ____________________________  61 
Participants List ________________________________ ________________________________ ________________________  62 
Mailings Page  ________________________________ ________________________________ _________________________  65 
General Documents Page (Not Participant Specific)  ________________________________ ___________________________  66 
Individual Participant Page  ________________________________ ________________________________ ______________  67 
TRACKING SYSTEM ROLES  ________________________________ ________________________________ __________________  79 
TRACKING SYSTEM TASKS: STEP -BY-STEP GUIDES  ________________________________ _______________________  80 
PATIENT ELIGIBILITY AND SELECTION  ________________________________ ________________________________ _________  80 
INTRO LETTER AND BROCHURE  ________________________________ ________________________________ ______________  82 
ENROLLMENT CALL (WITH SELECTION ) ________________________________ ________________________________ ________  82 
Introduction  ________________________________ ________________________________ ___________________________  82 
Selection  ________________________________ ________________________________ ______________________________  85 
Parent Eligibility  ________________________________ ________________________________ _______________________  88 
Consent  ________________________________ ________________________________ ______________________________  90 
Randomization  ________________________________ ________________________________ _________________________  91 
VISIT 1 APPOINTMENT PACKET – WITH (OUT) PRE-VISIT PREP ________________________________ _______________________  93 
REMINDER CALL FOR VISIT 1 ________________________________ ________________________________ ________________  94 
CONFIRM VISIT 1 APPOINTMENT DATE AND PROVIDER  ________________________________ ____________________________  95 
PRE-VISIT 1 PARENT QUESTIONNAIRE  ________________________________ ________________________________ _________  96 
Completion in the Tracking System  ________________________________ ________________________________ _________  96 
Entry of Paper Form in the Tracking System  ________________________________ ________________________________ _ 97 
VISIT 1 – COLLECT INFO ABOUT INTAKE COMPLETION  ________________________________ ___________________________  104 
BASELINE INTAKE  ________________________________ ________________________________ ________________________  106 
Completion in the Tracking System  ________________________________ ________________________________ ________  106 
Entry of Paper Form in the Tracking System  ________________________________ ________________________________  107 
PARENT PERMISSION TO AUDIO TAPE CLINIC VISIT ________________________________ ______________________________  122 
POST-VISIT 1 PARENT QUESTIONNAIRE  ________________________________ ________________________________ _______  123 
Completion in the Tracking System  ________________________________ ________________________________ ________  123 
Entry of Paper Form in the Tracking System  ________________________________ ________________________________  124 
POST-VISIT 1 CLINICIAN QUESTIONNAIRE  ________________________________ ________________________________ _____  134 
QUESTIONNAIRES – COLLECTION METHOD  ________________________________ ________________________________ ____  145 
COLLECT DEVELOPMENTAL AGE ________________________________ ________________________________ ____________  146 
RANDOMIZATION TO GENOME SEQUENCING  ________________________________ ________________________________ ___ 147 
VISIT 1 PARENT HIPAA  ________________________________ ________________________________ ___________________  148 
GENOME SEQUENCING CONSENT  ________________________________ ________________________________ ____________  149 
RANDOMIZATION 2 ASSENT  ________________________________ ________________________________ ________________  150 
GENOME SEQUENCING ASSENT  ________________________________ ________________________________ _____________  151 
VISIT 1 – PARENT REIMBURSEMENT  ________________________________ ________________________________ __________  152 
PARENTAL DISTRESS FOLLOWUP  ________________________________ ________________________________ ____________  153 
VISIT 1 BIOSPECIMAN COLLECTION  ________________________________ ________________________________ __________  154 
SALIVA KIT TASKS  ________________________________ ________________________________ _______________________  155 
Visit 1 CLIA Saliva Kit Due to No Blood Drawn - Mailing  ________________________________ _____________________  155 
Visit 1 BSP Saliva Kit Due to No Blood Drawn - Mailing  ________________________________ ______________________  156 
Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Mailing  ________________________________ ____________________  157 
Visit 1 BSP Saliva Kit Due to Insufficient Sample - Mailing  ________________________________ _____________________  158 
Visit 1 CLIA Saliva Kit Due to Failed Results - Mailing  ________________________________ ________________________  159 
Visit 1 BSP Saliva Kit Due to Failed Results - Mailing  ________________________________ ________________________  160 
Visit 1 CLIA Saliva Kit Due to No Blood Drawn - Received ________________________________ _____________________  161 
Visit 1 BSP Saliva Kit Due to No Blood Drawn - Received  ________________________________ _____________________  162 
Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Received  ________________________________ ___________________  163 
Visit 1 BSP Saliva Kit Due to Insufficient Sample - Received  ________________________________ ____________________  164 
Visit 1 CLIA Saliva Kit Due to Failed Results - Received  ________________________________ _______________________  165 
Visit 1 BSP Saliva Kit Due to Failed Results – Received  ________________________________ _______________________  166 
 
 PRE-ROR PACKET – NO GS WITHOUT PRE-VISIT PREP ________________________________ ___________________________  167 
PRE-ROR PACKET – GS WITH PRE-VISIT PREP ________________________________ ________________________________ __ 167 
PRE-ROR PACKET – GS WITHOUT PRE-VISIT PREP ________________________________ ______________________________  167 
CALENDARING  ________________________________ ________________________________ _________________________  168 
NCGENES 2 BIOSPECIMEN PROTOCOL  ________________________________ ________________________________ __ 169 
OVERVIEW  ________________________________ ________________________________ _____________________________  169 
COLLECTING BLOOD SAMPLES AT VISIT 1 ________________________________ ________________________________ _____  171 
Pre-Visit 1: Preparation of the Blood Collection Kit  ________________________________ __________________________  171 
After the Visit: Collection and Distribution ________________________________ ________________________________ __ 171 
SALIVA COLLECTION FOR CHILD PARTICIPANTS  ________________________________ ________________________________  177 
Overview  ________________________________ ________________________________ ____________________________  177 
Saliva Kit Mailing Preparation  ________________________________ ________________________________ ___________  178 
SALIVA COLLECTION FOR PARENTS /RELATIVES  ________________________________ ________________________________  181 
Overview – Parent/Relative  ________________________________ ________________________________ ______________  181 
Saliva Kit Mailing Preparation  ________________________________ ________________________________ ___________  181 
Mailed Saliva Kit Tracking – for samples processed and logged into the BSP LIMs  ________________________________ __ 182 
ECU – Saliva Sample Request/Need  ________________________________ ________________________________ _______  182 
Mission Health – Saliva Sample Request/Need  ________________________________ _______________________________  183 
BIOSPECIMEN PROCESSING , DISTRIBUTION AND REPORTING  ________________________________ _______________________  183 
Samples processed and distributed by the UNC Biospecimen Processing Facility (BSP)  ______________________________  183 
Samples processed and POSITIVE OR UNCERTAIN RESULTS reported by the UNC Molecular Genetics CLIA Lab (UNC 
MGL)  ________________________________ ________________________________ _______________________________  183 
Samples processed and POSITIVE OR UNCERTAIN RESULTS reported by the Fullerton Genetics (CLIA) Laboratory at 
Mission Health  ________________________________ ________________________________ ________________________  186 
Sample reporting of NEGATIVE RESULTS by UNC NON -CLIA RENCI System - All Sites  ____________________________  184 
APPENDICES ________________________________ ________________________________ ____________________________  185 
APPENDIX I. ETIOLOGY CRITERIA  ________________________________ ________________________________ ____________  185 
APPENDIX II. STUDY STATUSES  ________________________________ ________________________________ _____________  188 
APPENDIX III. RANDOMIZED RECRUITMENT  ________________________________ ________________________________ ____  189 
APPENDIX IV. PRE-CLINIC AND IN-CLINIC ACTIVITIES LIST FOR RESEARCH ASSISTANT AND STUDY COORDINATOR ____________  191 
APPENDIX V. ADDRESS , BARCODE , AND SHIPPING LABEL INFORMATION AND INSTRUCTIONS  _____________________________  197 
Required label printers and labels  ________________________________ ________________________________ ________  197 
DYMO LabelWriter Setup Instructions  ________________________________ ________________________________ _____  197 
Printing Barcode Labels  ________________________________ ________________________________ ________________  198 
Printing Address Labels  ________________________________ ________________________________ ________________  199 
APPENDIX VI. SHOPPING LIST FOR ECU  AND MISSION  ________________________________ ___________________________  200 
APPENDIX VII.  PARTICIPANT DISTRESS CALL FORM ________________________________ _____________________________  202 
APPENDIX VIII.  NCGENES  2 PARTICIPANT SALIVA LETTER  ________________________________ ______________________  203 
APPENDIX IX. NCGENES  2 SALIVA KIT MAILING INSTRUCTIONS (PARTICIPANT ) ________________________________ ______  204 
APPENDIX X. ENLARGED ORAGENE OG 575  SALIVA KIT INSTRUCTIONS  ________________________________ _____________  205 
APPENDIX XI. NCGENES  2 PARENT SALIVA LETTER  ________________________________ ____________________________  206 
APPENDIX XII.  NCGENES  2 SALIVA KIT MAILING INSTRUCTIONS (PARENT ) ________________________________ _________  207 
APPENDIX XII.  PARENT CONSENT TO DNA  COLLECTION  ________________________________ _________________________  208 
APPENDIX XIII.  BIOSPECIMEN PROCESSING FACILITY (BSP)  – NCGENES  2 OVERVIEW  ________________________________ _ 209 
APPENDIX XIV.  BSP  BLOOD PROCESSING FOR NCGENES  2 – INCLUDES DNA  EXTRACTION  _____________________________  210 
APPENDIX XV.  BSP  SALIVA PROCESSING – DNA  EXTRACTION ________________________________ _____________________  213 
APPENDIX XVI.  CLIA  CLINICAL LAB – PROCESSING , STORAGE , GENETIC ANALYSIS AND REPORTING  ______________________  218 
APPENDIX XVII.  UNC  MGL  – BLOOD DNA  EXTRACTION FOR NCGENES  2 ________________________________ __________  220 
APPENDIX XVIII.  UNC  MGL  – SALIVA DNA  EXTRACTION FOR NCGENES  2 ________________________________ _________  223 
APPENDIX XIX.  UNC  MGL  - IDENTITY TESTING PROTOCOL FOR NCGENES  2 ________________________________ ________  225 
APPENDIX XX.  UNC  MGL  - CLIA  CONFIRMATION OF GENETIC VARIANT FOR NCGENES  2 _____________________________  228 
APPENDIX XXI.  MISSION HEALTH MGL  – BLOOD DNA  EXTRACTION FOR NCGENES  2________________________________ _ 232 
APPENDIX XXII.  MISSION HEALTH MGL  – SALIVA DNA  EXTRACTION FOR NCGENES  2 _______________________________  238 
APPENDIX XXIII.  MISSION HEALTH MGL  - IDENTITY TESTING PROTOCOL FOR NCGENES  2 _____________________________  240 
APPENDIX XXIV.  MISSION HEALTH MGL  - CLIA  CONFIRMATION OF GENETIC VARIANT FOR NCGENES  2 _________________  245 
 
 APPENDIX XXV.  CLIA  LAB TRACKING IN NCGENES  2 GENOMIC MOLECULAR WORKBENCH (GMW)  _____________________  258 
APPENDIX XXVI.  REGISTERING FOR UNC  LMS  AND UNC  EPIC  TRAINING  ________________________________ ___________  262 
APPENDIX XXVII.  CREATING A UNC  EPIC  ORDER  ________________________________ ______________________________  263 
APPENDIX XXVIII.  CREATING A MISSION HEALTH CERNER ORDER  ________________________________ _________________  272 
APPENDIX XIX.  MISSION HEALTH CERNER EHR  TRAINING  REQUIREMENTS  ________________________________ ______  273 
APPENDIX XXX.  LABORATORY DIRECTORY  ________________________________ ________________________________ ___ 274 
APPENDIX XXXI.  STUDY COORDINATOR CONTACT INFORMATION  ________________________________ __________________  275 
APPENDIX XXXII.  SUPPLIES AND ORDERING INFORMATION  ________________________________ _______________________  276 
APPENDIX XXXIII.  NCGENES  2 BSP  LAB REQUISITION FORM ________________________________ ____________________  279 
APPENDIX XXXIV.  NCGENES  2 UNC  MGL  PATIENT BLOOD CLIA  LAB FORM  ________________________________ _______  280 
APPENDIX XXXV.  EXAMPLE OF COMPLETED UNC  MGL  PATIENT BLOOD CLIA  LAB FORM _____________________________  281 
APPENDIX XXXVI.  EXAMPLE OF COMPLETED UNC  MGL  PATIENT SALIVA CLIA  LAB FORM ____________________________  282 
APPENDIX XXXVII.  EXAMPLE OF COMPLETED UNC  MGL  PARENT /RELATIVE SALIVA CLIA  LAB FORM____________________  283 
APPENDIX XXXVIII.  NCGENES  2 PARENT /RELATIVE SALIVA UNC  MGL  ADDITIONAL FORM ___________________________  284 
APPENDIX XXXIX.  MISSION FGC  LABORATORY REQUISITION FORM (3 PAGES ) ________________________________ _______  285 
APPENDIX XL.  USING THE LIMS  SYSTEM AT THE BSP ________________________________ ___________________________  288 
APPENDIX XLI.  TIPS FOR INTERVIEWING  ________________________________ ________________________________ ______  291 
APPENDIX XLII.  SC AND RA CHECKLISTS  ________________________________ ________________________________ _____  305 
APPENDIX XLIII.  CLIA  TEMPLATE FOR REPORTING POSITIVE RESULTS  ________________________________ ______________  307 
 
 
 ABOUT  THE PROTOCOL  
Protocol Formatting  
Headings  
Main:  CENTERED, BOLD, & UPPERCASE (SIZE 14 FT.)  
Sub-heading I: Flushed left, bold , blue  (Size 1 4 ft) 
Sub-heading II: Flushed left, bold (Size 1 3 ft) 
Sub-heading II I: Indented left, bold-italics, blue  (Size 12 ft)  
Sub-heading IV: Indented left, bold-italics  (Size 12 ft)  
Sub-heading V: Indented left , underlined  (Size 12 ft)  
 
Note:  Boxed (Size 11 ft)  
 
Emphatic Note:  Boxed, blue -background (Size 11 ft)  
 
Font  
Type: Avenir Next Cyr  (Body)  
Size: 11 ft  
Body:  Flushed Left  
 
Statuses should be referenced in upper case  
References to pages in tracking should be italicized.  
 
Study documents, especially mail merged documents, should be downloaded directly from IRBIS  folder to ensure that the 
most recent edited and authorized document versions are being used. Other documents can be downloaded from IRBIS 
and copied on appropriately colored paper (see below), HOWEVER careful attention should be paid to use the current 
version of the document. IF ANY change to a copied form is made and subsequently approved by IRB, all old copies of 
the form must be discarded,  and a new original obtained. Careful attention should be paid that current versions of all 
documents are being used.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS . 
 
 Abbreviations  
BSP Bio-Specimen Processing Facility  
CDW  Carolina Data Warehouse for Health (sometimes referenced as CDWH)  
CLIA  Clinical Laboratory Improvement Amendments Laboratory  
DOB  Date of Birth  
EMR  Electronic medical record  
GC Genetic Counselor  
MRN  Medical Record Number  
NC TraCS  North Carolina Translational & Clinical Sciences Institute  
NCGENES 
2 North Carolina Genomic Evaluation by Next -gen Exome Sequencing, phase 2  
PI Principle Investigator  
QPL  Question prompt list  
RA Research Assistant  
SC Study Coordinator  
 
 
 
 NCGENES 2  OVERVIEW  
 
NCGENES 2 stands for the North Carolina Genomic Evaluation by Next -gen Exome Sequencing , phase  2. The research 
study investigates  ways parents  understand what to expect at their child’s doctor visit and resourc es that might allow 
parents  to speak more easily with their child’s doctor. Parents who decide to take part in this research will be paid up to 
$170 for their tim e and their child may be offered a special test called exome sequencing , free of charge. This special test 
may help clinicians  identify  a reason for their child’s condition. Understanding a child’s condition may , in turn,  help 
providers and parents /legal guardian s plan for the child’s care. Importantly, this study also attempts to understand 
differences between people who have an easy time getting health care and people who do not.  The diagrams on the next 
few pages illustrate the over all flow of the NCGENES 2 study, from pa rticipant referral to follow -up surveys. New users  
should study  these pages in detail to understand the structure of the study . 
 
  
 
 Study Flow - Enrollment,  Consent,  Visit 1, Return of Results and Follow -Up 
 

 
 Overview of NCGENES 2 Clinical Protocol Interventions  
*NOTE: Planned enrollment is 850, for ease of distribution across groups 800 was used here.  
**NOTE: Clinic Visit 2 (V2) is now called Return of Results (RoR) because the vast majority of participants  do not return 
to clinic for a second visit, instead results are provided by phone.   

 
 NCGENES 2 Clinical Study Roles  
Study task in NCGENES are distributed between team members with distinct roles. These roles are based in part on the 
various  blinding statuses necessary to perform each task.  Different roles also have access to different data within the study 
tracking system . The pri ncipal distinction in role s exist s between the Study Coordinator (SC) and Research Assistant 
(RA). The table below list s all the clinical roles , their level of blinding, and the tasks the y perform.  
 
 
Role1 Blinding Status  Tasks  (Not exhaustive , may vary by site ) 
Study Coordinator  Unblinded  to participant 
randomizations as the occur  Eligibility and Selection, Enrollment, 
Mailing 2  & 3, Consents/Assents , 
Biospecimen Collection  
PI/Clinical Project 
Director  Unblinded throughout  Oversee study design, resolve 
implementation issues  
Research Assistant  Blinded to Intervention 1 
randomization through clinic visit  
Unblinded to intervention 2  Mailing 1, Pre - and Post -Visit Surveys, 
Audio Recordings, RoR Parent  Mailings , 
Biospe cimen  Collection  
Data Analyst/Programmer  Unblinded throughout  Generates enrollment reports, ensures clean 
data 
Lab Staff  Blinded to identify ing 
information on participants  Analyze s biospecim ens and record s results  
Genetic Counselor  Blinded to Intervention 1 
randomization  through clinic visit  
Unblinded to intervention 2  Post-RoR Provider surveys, 
Consents/Assents (if necessary)  
Clinicians  Blinded to Intervention 1 
randomization through clinic visit  
Unblinded to intervention 2  Post-Visit and Post -RoR Provider Surveys, 
PhenoTips, Return results  
 
 
  
 
1 The same person can hold multiple different roles across sites and therefore have different blinding statuses at each.  
 
 ENROLLMENT OVERVIEW  
 
This section  of the  protocol describes the participant enrollment process for NCGENES 2  up to the 1st clinic visit.  
 
Participan t Referral  
The set of all potential participants in the NCGENES 2 study is comprised of children  (less than 16  years of age ) referred 
for a disorder with unknown but suspected genetic etiology, who are scheduled in  the Pediatric Neurology or Pediatric 
Genetics and Metabolism  clinics at the University of North Carolina at Chapel Hill , the Pediatric Genetics clinic at East 
Carolina University in Greenville, NC, or the Pediatric Genetics  and Metabo lism clinic at  Mission Health in Asheville, 
NC. Each participant will have an initial  status of “ Referred ” in the NCGENES 2 Tracking System . Referred participant s’ 
scheduling and demographic information will either be populated nightly from the UNC Carolina Data  Warehouse for 
Health (CDW )1 or will be entered manually into the stud y’s tracking s ystem  following review of schedulin g information 
in the Electronic Medical Record (EMR) . Study staff will use this tracking system throughout the  enrollment and data 
collection process, starting with manual  entry  or auto -population of patient scheduling data and  the identification of 
eligible pa rticipant s.2 
 
Participant Eligibility  
Eligible participants  must : 
• Be less than 1 6 years of age  at the time  eligibility is determin ed 
• Be referred to a participating clinic  with an appointment at least 3 weeks away with one of the study physicians  
• Have an unknown  but likely genetic etiology for their disorder  (See Appendix  I on page 185 ) 
 
If the study coordinator cannot determine the eligibility  of a child due to inconclusive data on the ir condition, they should 
consult directly with the primary study physician at th eir respective site . If eligibility is still in question, staff should 
contact Dr. Jonathan Berg  (jonathan_berg@med.unc.edu ) for a final determination of eligibility.  Once a determination 
 
1 If the participant data is uploaded to the tracking system automatically from the EMR, the primary guardian is set as the pri mary 
guarantor (i.e. the insurance policy holder). For this study, the primary guardian must be the consenting parent/caregiver. I f the 
consenting parent is not the primary guarantor, this information should be corrected by study staff during the introduction to the 
Enrollment Call  (see page 67) task by entering the correct parent’s name in the field following “May I Speak with.”  
2 The process for entering participants manually into the tracking system is explained in detail in the “ Using the Tracking System ” 
section of the protocol on page 54 . 

 
 is made, p articipant eligibility information should be entered in the tracking system by completing the “Patient Eligibility 
and Selection” task for that participant. Detailed instructions on completing this ask can be found in the “ Tracking 
System Tasks ” section on page 80 . 
 
Status Update: Participants who meet the eligibility criteria will be given the status of “ Participant eligible .” Participants 
who do not meet the criteria will be given the status of “ Participant ineligible .” Appendix II  on page 188  provides a 
flowchart of study statuses.  
 
Mark  Participant as Ineligible  Manually1 
In some cases, a  participant  status may need to be changed to “Ineligible ” manually.  Detailed instructions for changing a 
participant’s status manually can be found in the “ Using the Tracking System ” section of the protocol on page 70 .  
 
The following situations require a participant be marked ineligible manually : 
1. If prior to completion of the “Patient eligibility and selection ” task , 2 EMR review  reveals the patient/family  
a. permanently canceled their visit to UNC  
b. has been s een previously at a ny genetic  clinic  (regardless of how long ago that appointment occurred)  
2. If after completion of the “Patient eligibility and selection”  task, but prior to e nrollment,3 it is discovered the 
patient/family  
a. permanently canceled their visit to UNC  
b. needs an interpreter  
c. other  
i. has been seen at any genetic  clinic  
ii. has received a diagnosis  
 
If the participant is marked “ineligible – permanently cancelled visit 1” due to impacts of the COVID -19 pandemic and 
suspension of research, the corresponding note should begin with the following:  “During the time period of Covid -19 the 
participant’s clinic appointment was cancelled. Per EMR review it was determined the participant is no longer coming to 
the study clinic.”  Additional explanations of the specific situation should also be noted (e.g. parent/guardian declined 
rescheduling participant’s {INSERT DATE} clinic appointment)  
 
Participant  Selection  
Eligible pa rticipa nts are ‘selected’  in or out of the study using a method called randomized recruitment  (See A ppendix III 
on page 189 ). Selection into the study will be based on  an algorithm designed to create a cohort with 60% from under -
served or under -represented populations and 40%  from  served  populations  at enrollment.  In NCGENES 2, under -served 
and under -represented populations are defined by race, ethnicity and insurance status.  Specifically , under -served and 
under -represented are defined as either Non-White  OR Hispanic OR having Medicaid, charity care, or no insurance . 
Participants with one or more of the defining characteristics  will automatically be ‘selected’ to the study . Randomized 
recruitment is used to designate all other eligible p articipants as “SELECTED” or “NOT SELECTED” and is done in the 
background of the tracking system.  This process is prompted by completion of  the “Patient eligibility and selection” task. 
Detailed instructions for completing this task can be  found in the “ Tracking System Tasks ” section of this protocol on 
page 80 .  
 
For Participant ’s with a status of ‘ Not Selected ’ or ‘Participant Ineligible’  
This is a final study status for this participant  and n o further action is required.  
 
 
1 All statuses entered manually are final statuses . Only tracking system administrators can change these statuses once they are set.  
2 This set of circumstances applies only at sites where patients are automatically referred into the tracking system. At sites where 
patient data is entered into the tracking system manually, such situations should not arise, as these cases will not be ente red into 
tracking in the first place. See Eligibility Criteria  for more detail.  
3 Such situations usually occur during the enr  
 
 For Participant ’s with a status of ‘Selected ’ 
Mail the Introductory Letter ( See Mailing 1  in the participant mailings section  on page 51 ). Participants that have been 
selected into the study will have a status of “ pending ” in the tracking system  for their enrollment call (or for their 
enrollment call with selection) until they are approached for enrollment into the study . Enrollment call s with and without 
selection should then be placed about 7 days  after Mailing 1 to obtain initial consent to randomization 1. In some cases,  
enrollment  calls may be placed closer to Mailing 1 (i.e. less than 7 days after) in order to allow sufficient time to for 
recruitment . 
 
For Participant ’s with missing selection criteria that must be obtained on the enrollment call  
When participant study selection criteria are completely unknown  or the known informatio n is insufficient to determine 
whether the participant  is under -served /under -represented , participant s will still have the status of “ Participant Eligible ”. 
In this case, the Introductory Letter and Study  Brochure  should be mailed (See Mailing 1  in the participant mailings 
section on page 51 ). An “ Enrollment  Call with selection ” should then be placed 7 days  after Mailing 1  has been sent . 
During this call , the pa rents of these participant s will be asked  to provide  the missing selection criteria and selection will 
be completed during  the call. The participant ’s status will change when selection is completed . If the participant  is 
selected , the tracking system will prompt the staff member to proceed with enrollment.  If the participant  is not selected , 
the tracking system  will prompt  the staff member  to conclude the call . 
 
Enrollment Call  
The Study  Coordinator will use the parent’s contact information from the tracking system to  facilitate the enrollment call 
to determine parent eligibility and invite the parent and child into the study. In NCGENES 2 , both the parent and child are 
participants.  
 
The primary components of the enrollment call are  to: 
 
1. Determine the parent’s eligibility for the study  
2. Verbally c onsent the parent into the study  – focus ed on intervention 1  
3. Randomize the parent to intervention 1 ( pre-visit education or no pre -visit education ) 
4. Confirm the parent ’s mailing address  
5. Inform  the parent of parking/travel assistance to the study -related clinic visit , and of compensation for 
completion of study surveys .  
 
This section details practical instructions for completing the enrollment call. The enrollment call should be completed in 
concert with the “Enrollment call (with sele ction )” task in the tracking system . A step -by-step guide to completing that 
task can be found in the “ Tracking System Tasks ” section of this protocol on page 82 . 
 
(See IRBIS  for the Enrollment Call Script s) 
 
Enrollment Call Strategy  
Attempts to reach the parent or legal guardian should be spread throughout the day with calls during the morning ( 9 AM 
to Noon, afternoon (No on to 5PM), and evening ( 7 to 8 PM) – in some cases weekend calls may be needed and should 
focus on Saturdays , 9 AM to 4 PM . Over a  period  of approximately 5 - 14 day s, 1-5 attempts should be made to reach the 
parent on file . Once an enrollment call is made, the participant ’s status becomes “APPROACHED”. This status will serve 
as the overall denominator for much of the reporting.   
 
If the study staff member does not feel comfortable contacting a person because of personal conflict, it is their 
responsibility to find another study staff member who is willing to approach the participant and follow the enrollment 
protocol.  
 
Early Phase Enrollment  
 
 During roll -out at each site, enrollment may need to be restricted based on the capacity of the clinic to handle multiple 
participants in a short time period. In these cases, all eligible participants should be screened as such. From the list of 
eligible participants, the study coordinator should begin contacting parents gradually. If the study coordinator reaches 
their enrollment capacity, they should immediately stop contacting eligible participants. If a previously approached parent 
calls the study coordinator back expressing interest after this point, the  study coordinator should say the following:  
 
“Thank you very much for returning our call.  Unfortunately,  at this time, we are only able enroll one patient each day 
in this research study and someone else has been scheduled to participate on the same day as your appointment.  
Again,  we really appreciate your call back.  Please remember that your child is still scheduled to see Dr. {NAME} on 
{VISIT DATE/TIME} in the Genetics Clinic.  Dr. {NAME} and the clinic staff are looking forward to seeing you and 
your child on that date.  
 
Goodbye.”  
 
Mark Participant as Failed Approach  Manually1 
Participant s will have a status of “FAILED APPROACH” i f the participant ’s parents  are: 
• not able to be reached (e.g. bad contact information)  
• not reached within the number of a ttempts per protocol (max=5 calls)  
• not reached by phone 3 or more weeks prior to the participant ’s outpatient clinic visit . 
 
Mark Participant as No Approach Manually  
Participants will have a status of “ NO APPROACH” if study staff does not attempt to enroll an eligible  participant. This 
can happen if  
• insufficient staffing  prevents  enrollment from being  conducted 3 or more weeks before the visit  
• the patient completes their visit before being enrolled due to  
o the visit being rescheduled unbeknownst to staff  
o the visit being scheduled as telemedicine or while staff cannot perform in -clinic research activities , e.g.  
during the COVID -19 pandemic suspension of research activities.  
If a participant is marked “No Approach,” a note should be created in the tracking system explaining the reason for this 
status change.  
If the participant is marked “No Approac h” due to impacts of the COVID -19 pandemic and suspension of research, the 
corresponding note should begin with the following: “No Approach due to COVID -19: Patient completed visit during 
suspension of in -person clinic research activities.” Additional explanations of the specific situation (e.g. telemedicine 
visit) should  also be noted.  IF PARENT WAS APPROACHED, BUT ENROLLMENT WAS INTERRUPTED:  the 
note should begin with the following: “ Interrupted enrollment due to Covid -19. See communication log/notes section in 
tracking for details.”  
 
The “FAILED APPROACH” status should be manually applied in the tracking system by the study coordinator. Detailed 
instructions for changing a participant’s status manually can be found in the “ Using the Tracking System ” section of the 
protocol on page 70 . 
  
 
Parent Eligibility  
The study coordinator will use the participant  tracking system and enrollment script to determine eligible parents and 
enroll parents into the study. Parents/legal guardians eligible for invitation to the NCGENES 2 study will be:  
 
1. 18 years of age or more  
2. able to sign legal documents for your child (excludes foster parents)  
3. willing and able to attend the study -related clinic visit  
 
1 All statuses entered manually are final statuses . Only tracking system administrators can change these statuses once they are set.  
 
 4. able to complete surveys in English (NOTE: Spanish enrollment is planned for the future)  
 
If the study coordinator reaches  the parent and perform s the parent eligibility screening, the enrollment status will 
automatically update to ‘PARENT ELIGIBLE’ or ‘PARENT INELIGIBLE’. ‘PARENT INELIGIBLE’ is a final study 
status and no further action is required. Those parents determined to be eligible  will continue to the next step : parent 
consent to intervention/randomization 1.1 
 
Mark Participant as Refused Manually2 
A participant ’s status should be manually marked refused when a participant refuses to complete a study activity. This is 
initiated by the participant and occurs during a data collection activity (e.g., enrollment call, pre -visit survey, post -visit 
survey).  Detailed instructions for changing a participant’s status manually can be found in the “ Using the Tracking 
System ” section of the protocol on page 70 .  
 
Parent Consent  
Eligible parents will be invited to participate in the study and consented. If the study coordinator consent s the parent, the 
enrollment status will be updated to ‘PARENT CONSENTED’. Parents who refuse or decline to consent will have an 
updated status of ‘REFUSED -AT ENROLLMENT (INTERVENTION I)’. The status change is triggered when a parent 
answers “no” to the que stion: Do you want to join the first part of the NCGENES research study? All parents who 
decline/refuse participation will be asked if they would l ike to indicate a reason for their decision.  If a reason is provided, 
it should be recorded in the tracking system when the participant ’s status is changed.  
 
Randomization 1  
Parents who consent to be in the first part of the study will be randomized into either the pre -visit education or no pre -visit 
education groups (i.e. intervention 1). The group assignment will be based on a block randomization scheme. A 
participant is ran domized into a group when the study coordinator clicks “Yes” and “Next” in the consent part of the 
enrollment call that is captured in the tracking system  (See on page 90 ). The status determination will automatically 
appears on the next screen in the tracking system.3 Based on this status  (and after conclusion of the call), the study 
coordinator or another unblinded study staff person should mail a Pre -Visit Packet to the participant with or without Prep 
materials (See Mailing 2  in the participant mailings section on page 51 ). 
 
Protocol if unable to complete enrollment call  
For any attempts to contact the parent for the enrollment call, the following statuses should be recorded in the 
communication log4 as appropriate, along with any additional relevant information : 
• Parent not available  
• No one answers the telephone  
• Call disconnected  
• Wrong phone number  
• Phone disconnected  
 
Provider  Notification of  NCGENES 2 Participant  
 
1If the parent is determined to be eligible but the enrollment call is not completed, the participant’s status will be “PARENT 
ELIGIBLE” until the call is completed. This situation can occur, when the parent does not have time to complete the enrollmen t call, 
so the call is scheduled for a future date/time.  
2 All statuses entered manually are final statuses . Only tracking system administrators can change these statuses once they are set  
3If the tracking system fails at this point in the call, the study coordinator should complete the call and inform the parent they will 
learn their group assignment when they receive the study materials. Then the coordinator should inform the Sheps team of the tracking 
system failure and ask that they provide the intervention 1 assignment. Once this information is obtained study Mailing 2 sho uld occur 
and the tracking system updated once the failure has been resolved.  
4For detailed instructions on using the communication log, see the “ Using the Tracking System ” section of this protocol on page 60 . 
 
 After a participant has been enrolled, study staff must notify the clinician of their patient ’s status as an NCGENES 2 
participant. The protocol for this notification varies by clinic.  
 
UNC Genetics and Metabolism Clinic  
For patients seen in the UNC Genetics and Metabolism Clinic, the Study Coordinator will place the phrase “NCGENES 
Participant” in the clinic calendar in MEDGIS (the Genetics and Metabolism EMR system).  
 
UNC Pediatric Neurology Clinic  
For patients seen in the UNC Pediatric Neurology clinic, the study coordinator emails the neurology nurse at least two 
times a month, informing them of the patients whose parents have agreed to participate in NCGENES 2. These actions 
allow clinicians and c linical teams to know that the patient -parent pair are NCGENES 2 participants.  
 
Mission Health  Fullerton Genetics Clinic  
For patients seen in the Mission Health Fullerton Genetics Clinic, the Study Coordinator will enter the phrase 
“NCGENES2 Participant” in the clinic calendar in Cerner (the Mission EMR system).   
 
 Reminder Call – 1 week prior to visit  
Study staff should call to remind a participant about their study research visit approximately 1 week prior to the visit. A 
version of this script can be found in IRBIS . This event will be captured i n the participant’s Communication Log  (See 
page 68).1 
 
The purpose of this call is to:  
1. Remind the parent about their research visit  
2. Remind the parent to complete the documents mailed to them and bring them to the clinic  
3. Discuss travel to the clinic  
4. Answer any questions the parent may have about their pending study visit  
 
Call Strategy  
Calls to  the parent should be spread through the day with calls during the morning (9 AM to Noon), afternoon (Noon to 
5PM), and evening (7 PM to 8 PM) – in some cases weekend calls may be needed and should focus on Saturdays, 9 AM 
to 4 PM. Staff should  make 1 -2 calls in a 5 day period  with the latest one happening 1 or 2 business days before the visit.  
 
1 In the tracking system, the reminder call task is displayed as “Completed” if the study staff member reached the parent or left a 
message for the parent. The reminder call can also have the statuses of “Canceled” or “Not Done”. The “Not Done” status could  result 
if a reminder call is not completed at all.  
 
 VISIT  1 
Overview  
This section of the protocol outlines the procedures that should be followed before, during a nd after the clinic visit. The 
Visit 1 protocol includes information for preparing for a clinical visit, confirming participant clinic date, documentation 
collection, conducting pre -visit surveys, facilitating audio recording of clinic visit, conducting post -visit survey s, 
invitation to and consenting for intervention/ randomization #2 (genomic sequencing) , and distribution of incentives . This 
section also covers special topics for clinic visit  1 which include participant distress and no -show  protocols  and 
information for physician surveys and entry of PhenoTips  information . 
 
 
Most of the tasks in visit 1 are conducted by the study RA and Study Coordinator. The RA greets the families and handles 
all tasks up to the post -visit survey after which the RA transitions the participants to the SC.  
 
Preparation for Visit 1  
Detailed task lists for the study coordinator and research assistant can be found in Appendix IV (see page 191.  To 
prepare for a clinic visit, both the Study C oordinator and  RA should ensure that all electronic devices needed for clinic are 
fully charged, including audio recorder s, tablet s and iPad s.  
 
Additionally, study staff should download movies/cartoon content on the iPad/tablet for child participants weekly. Prior to 
the clinic visit, the Study Coordinator compiles a hard copy folder for each participant and, if necessary, books a 
consultation roo m in the clinic where randomization, payment, child gift/snack distribution and genomic sequencing -
related consenting will take place.  
 
 
Compiling the Participant Folder  

 
 The Participant Folder principally contains  a complete set of Visit 1 documents (used if electronic system fails).  No 
indication of study randomization status should be included in or on the participant’s folder. This folder is then given 
to the RA so that it can be brought to the clinic for use.  The participant folder should be compiled as follows:  
 
1. Label a Manila Folder with the participant’s NCG ID.  
2. With the folder open  flat and label positioned in the top right corner, place a sticky note on the left side of the 
folder  with the parent and child ’s name, child ’s age, and provider’s name.  
3. On the right side of the folder, clip the following items:  
a. Envelope with parent participant cash compensation ($70)  
b. Blood draw bag with the following items:  
i. Study ID Labels  (5) 
ii. 2 Lab requisition form (BSP should be printed on Blue Paper and CLIA will be printed on white 
paper)  
iii. Blood draw tubes  (2) 
iv. Additional blood draw bag (1)  
4. Gather the following study documents and place them in the order indicated:  
a. Intake Questionnaire1 with stamped return envelope and ID label  
b. Parent Pre -visit survey  
c. Permission to Audio Tape form  
d. Parent Post -visit survey  
e. Clinician Post -Visit Survey  
f. Blank Blue Sheet to Separate RA and SC forms  
g. Consent to Randomization 2 form (3) 
h. If necessary, Assent to Randomization 2 (3)  
i. HIPAA Authorization (3)  
j. Yellow Paper with reminder to get signature for compensation2 
k. Consent to Genomic Sequencing ( 3) 
l. If necessary, Assent to Genome Sequencing (3)  
m. Post-genomic sequencing consent brochure  
n. Blank CLIA Order Form  
5. Once compiled, th ese documents should be placed inside the Manila folder, and the folder should be closed and 
secured with a binder clip.  
 
What to Bring to Clinic  
In addition to the participant folder , there are  several  items that the RA and the Study Coordinator should bring with them 
to the clinic. These items are placed in rolling bags for secure transport to clinic.  
 
RA Clinic Bag Contents  
• iPad tablet  for child participants  with updated videos/cartoons  
• Study Tablet , Power cord  and Mouse  (ensure stylus is in tablet – bring an extra stylus)   
• Copy of  Intake Survey  and a postage paid envelop e with address for mail return , if necessary  
• Charged , numbered  audio recording device  & charger  
• Participant research folder  secured with binder clips  (See above ) 
• Laminated card of instructions for Clinician  survey and PhenoTips  
• Laminated sheet with MDs and genetic counselor names  (Optional)  
• Hard copy RA checklists  (Optional)  
• Post-it notes  
 
1 Note:  Intake form must be for the age that the child was at the time of eligibility.  Children 24 months old should get the toddler  2-3 
year old survey and NOT the 12 -24 months form  
2 The envelope with parent compensation and assent should be pulled out immediately after flipping the yellow sheet over. These  
documents should be put out in the open where they can be seen and not missed when the visit ends.  
 
 • Pens  
 
Study Coordinator Clinic Bag C ontents  
• Study tablet with stylus (more than one if needed ) 
• iPad with updated videos/cartoons (more than one if needed ) 
• numbered audio recorder with case (more than one if needed ) 
• Chargers for all 3 electronic devices listed above  
• Extra stylus  
• Snacks  
• Hard copy receipt book for parent compensation in the event electronic tablet version fails  
• Pens (for completion of forms if tracking fails)  
• Post-it notes  
• Children’s gifts – age appropriate  
 
To make sure the audio recorder is charged:  
1. Turn on the recorder by sliding the POWER/HOLD switch toward “POWER.”  
2. Check that the battery has three bars.  
3. If the battery doesn’t have three bars, charge the battery.  
 
To charge the battery:  
1. Connect the USB cable to the USB port of a computer.  
2. While the recorder is turned off, connect the USB cable to the bottom of the recorder.  
3. Press the PLAY/OK button to start charging, which takes about three hours.  
4. Charging Is complete when the battery says “F”.  
 
Visit 1 Procedures  
Arrival to Visit 1  
The RA, blinded to the participant’s randomization statuses (pre -visit preparation and genomic sequencing), will 
coordinate with anyone who will be assisting with the clinic/research visit (e.g., study coordinator, student volunteer, 
and/or other research and clinical staff). Prior to leaving for the research appointment, if the RA does not see the SC in the 
NCGENES office, they should inform the SC by text or phone that they are on their way to clinic or have arrived at clinic. 
The RA should arrive at the clinic at least 15 - 20 minutes prior to the research visit. Upon clinic arrival, the RA should 
begin looking for the patient and their parent. About 20 - 30 minutes before the research appointment, the SC will check 
EPIC  or Cerner  to learn if the patient has arrived and will continue to monitor EPIC /Cerner until the patient arrives. By 
text, the SC will inform the RA of the patient’s status per EPIC at the time of the initial EPIC review and periodically 
until the patient’s arrival.  
 
The first portion of the research visit is typically conducted in the waiting room. Upon participant  arrival  and after the 
parent checks the child in at the clinic reception desk , the RA should greet the participants (child and parent) in the clinic  
waiting room . The RA  should introduce  them selves and confirm the parent’s and child ’s names . When the RA is with the 
family in the waiting area  or has esco rted the family to a consultation room (depending on clinic) , they should ask the 
parent if they may offer pre -recorded videos to the child – prior to the child seeing the iPad. The RA may have a student 
volunteer who accompanies them to the clinic to entertain the child and any sibling (s) with the video/waiting room toys.  
 
Wrong parent? If the parent who brings the child to the clinical encounter is NOT the parent who consented by phone, 
the parent who is with the child MUST be consented to the study to complete the pre - and post -visit surveys. A note must 
be placed in the tracking system on participant’s individual page to indicate that this has happened (See “ Notes ” section 
on page 72 ), and an email sent to the Study Biostatistician (Laura Farnan at UNC: laura_farnan@med.unc.edu ) to 
explain this.  
 
 
 Participant  Late?  If a participant  shows up 20 minutes late for a clinic appointment, the clinic check -in staff must obtain 
provider approval for the participant  to have the clinic appointment. Therefore, if a participant is 15 -20 minutes late for 
their clinic appointment, the RA should ask the provider/genetic counselor if the participant will be seen upon arrival. If 
the answer is “Yes”, the RA should ask if the y can also complete the study pre -visit survey. If the answer is “Yes”, the 
RA should continue to wait for the participant. And upon arrival, complete their usual study actions as quickly as possible. 
The RA should inform the SC of the provider/genetic cou nselor’s response to these questions, either by text or in -person. 
If neither of these options are possible the RA should send the SC an email.  
If the provider/genetic counselor informs the RA that a participant will not be seen or that the study pre -visit survey 
cannot be completed, the RA should obtain the reason for this event and inform the SC by either text or in -person of this 
event and the related reason. If neither of these options are possible the RA should send the SC an email .1 
 
Participant  Missed Clinical Appointment?  See No Show Protocol . 
 
Confirm Visit 1 appointment date and provider  
When parent has checked into the clinic  and the child has been offered the iPad (if parents allow) , the RA should confirm 
the Visit 1 details. The purpose of this task is to confirm the participant’s appointment date and provider. This is 
particularly important if a participant  ends up being seen by a different physician in a particular clinic. Confirmation of 
this sets the NCGENES visit 1 date for the study.  Detailed instructions on completing this task can be found in the 
“Tracking System Tasks ” section on page 95 . Following the appointment date and provider confirmation , the RA should 
turn their attention to the parent and remind the parent about what will happen during the visit and should ask the parent if  
they have brought their completed intake survey . 
 
Collect ing the  Intake Survey  
Participants should have completed the Intake Survey  prior to their research visit and should have brought the completed 
document with them to the clinic. If the participant has their completed form, collect it at the beginning of the research 
appointment. When you collect the document briefly check for its  completion (especially for the child’s partial social 
security number )-this step can also be done while the parent is completing the pre -visit survey.  Record the collection of 
the completed Intake Survey in the participant  tracking system by completing th e “Visit 1 -Collect Info about Intake 
Completion ” task . 
 
Parent forgot their completed intake survey?  If the participant completed the survey at home but failed to bring it with 
them to the study visit, provide the parent with a labeled envelope with prepaid postage  and a blank copy of the intake 
form (in case the parent cannot locate the completed form) . Inform the parent that they should use the provided envelope 
to return the survey by mail . 
 
Parent didn’t complete  intake  survey? If the participant did not complete the Intake Survey , two things can be don e: 
1. If the participants arrive with substantial time before their doctor visit , parent can complete intake form in the clinic 
after completing the pre -visit survey .  
2. If the participant cannot complete the survey in clinic , parent should  be provided with another Intake Survey  with a 
labeled envelope with prepaid postage . Inform the parent that they should use the provided envelope to return the Intake  
Survey  by mail . 
 
The collection status of the intake survey should be recorded in the tracking system. This is done by completing the “Visit 
1-Collect Info about Intake Completion” task in the tracking system. Detailed information on completing this task can be 
found in the “ Tracking System Tasks “ section on page 104 . Additionally, i f the intake survey is not collected during the 
clinic visit, a note should be made  (using the Notes tab in the pa rticipant ’s tracking system page  (see page 72) that 
includes information about whether the intake survey was completed or not prior to the visit.  
 
 
1 When possible the SC will contact the RA via text or phone, to remind them to check with the provider/genetic counselor to le arn if 
the participant will be seen and if so, can the pre -visit survey occur.  
 
 Additional Notes on Document Collection  
The task “Questionnaires -Collection Method” allows for tracking the type of questionnaire collection for the 
Baseline/Intake, Pre -visit Parent, Post -visit Parent, and Post -Visit Clinician surveys. This task should be completed by the 
RA but may be completed by other study staff members. The RA or staff member will note if the questionnaire was 
completed by phone, on the tablet, or by paper.  For details on completing this task, see the “ Tracking System Tasks ” 
section on page 145 . 
 
Parent attempts to give RA QPL?  The parent has been provided with instructions to give their question prompt list 
(QPL) (“Visiting a pediatric specialist: It’s OK to ask questions.”) to their child’s physician . If the parent tries to hand the 
QPL  to the RA , the RA should inform them to give the QPL to their child’s physician . If this happens , the RA may say the 
following:  “You may ask anyone on your child’s medical team these questions, but please make sure to give this list to the 
doctor .” 
 
Pre-visit Survey  
After  addressing the Intake Survey, the RA will administer the  Pre-Visit Questionnaire using the tablet. Instructions on 
accessing the Pre -Visit survey  can be found in the “ Tracking System Tasks ” section on page 96 . Before handing the 
tablet to the parent, read the instructions on the initial page of the survey and let them know they can consult you if they 
have any questions. The pre -visit survey s hould take  most participants  about 15-20 minutes. When the parent has finished  
the survey, the system should automatically log off the user so that the parent cannot get to other software to on the tablet . 
The RA should  ensure that the parent has clicked on finish and finalize and close the survey window.  The RA should then 
access the tracking system and go to the participant’s individual page to en sure that the Pre-visit survey status is 
completed (if you fail to close the initial par ticipant task list menu you will need to refresh the screen to see the completed 
status for that task ).  
 
If tracking system is not available, the parent should complete a paper copy of the survey  that has a participant study ID 
label placed in the upper right -hand corner . Read the instructions on the initial page of the survey and let them know they 
can consult you if they have any questions.  Hard copies  of completed surveys should be manually entered within 24 
hours of completion. However, if a hardcopy is received on a Friday, it must be manually entered by 5:00  pm the 
following Monday. When the parent has finished the survey the RA should  check to see that the survey has been finished 
and the tablet is back on the appropriate home screen . For instructions on uploading documents to the tracking system, see 
the “ Using the Tracking System ” section on page 74 . 
 
Audio Recording  and the Clinic Visit  
Prior to the visit, the  RA should ensure the  audio recorder is properly charged and in the clinic bag (See page 22). 
 
Consenting the Parent to Audio Recording  
The RA should consent the parent to audio recording by completing  the “Parent Permission to Audio Tape Clinic Visit” 
task. This consenting should occur in  the clinic waiting room or after you enter the clinic room with the participants for 
the appointment . For detailed information on completing this task , see the “ Tracking System Tasks ” section 121. 
 
Tracking system down?  If the tracking system is down, consent the parent to audio recording using the paper version of 
the consent in the participant’s folder. After the  visit, when the tracking system is working again , upload this paper 
version to the participant documents tab  (see page 74). Then , complete the “Parent Permission to Audio Tape Clinic 
Visit”  task and, if the parent consented,  write “Completed Document on Paper”  in the signature fiel d. 
 
Once the consent process is complete, the RA should remind the parent of what to expect after their clinic visit before 
setting up the audio recording. To do so, the RA should tell the parent the following:  
“When you are done, I’ll bring you to meet with Tracey (or whoever is helping that day), the study 
coordinator/genetic counselor, where you will receive your reimbursement, some snacks and a gift for [child ’s name ]. 
This is also where you will get a chance to hear more about the special research test that your child may have a 
chance to get. You might remember that we mentioned this test to you when we spoke to you by phone a few weeks 
ago.” 
 
  
Setting-up in the Clinic Room to Collect Audio 
If the parent consents to audio recording, the RA will be responsible for initiating audio recording in  the clinic room  
ideally immediately before the genetic counselor OR the physician if no counsel or will be seeing the patient. If, however, 
this is not possible , audio recording can be initiated after the patient has  been placed in a clinic room.   
 
To begin recording with an Olympus DS -2500 recorder:  
1. Turn on the recorder by sliding the POWER/HOLD switch toward “POWER.”  
2. Press the NEW button on the side of the recorder to create a new file.  
3. Press the REC button to start recording.  
4. The indicator light will glow orange and the record symbol  will appear on the display.  
5. Place the recorder near the sound source . 
 
The RA should state  the audio recorder number immediately after beginning recording. The RA should exit the room once 
the audio recording has been set up and should wait outside the room until the end of the visit.  
 
During th e visit, regardless of whether the parent has consent to audio recording, the RA should text or call  the Study 
Coordinator  to let them know the  parent has completed the pre -visit activities.  
 
At the Conclusion of the Clinic Visit  
Once the visit is over and all medical staff has left the room,  the recorder should be turned off and stored in the RA rolling 
bag. At the earliest, t his can occur after the physician leaves the room but before they return with the hard copy version of 
the patient’s clinic summary.  
 
To stop recording with an Olympus DS -2500 recorder:  
1. Press the STOP button to stop recording.  
2. If you want to append additional recordings to the same file, press the REC button again.  
3. Turn off the recorder  by sliding the POWER/HOLD switch toward “POWER” and hold ing it for 0.5 seconds or longer.  
 
If you have any additional questions, please consult the instruction manual for the recorder:  
http://www.olympusamerica.com/cpg_section/cpg_support_product.asp?id=1620  
 
After returning to  the office , the audio recording content should be uploaded to the secure folder accessible via the 
participant  tracking system . Detailed instructions on uploading these files can be found in the “ Using the Tracking 
System ” section on page 66 . If the battery power is low (<2 bars), upload file after recording device has been charged.  
 
Post-visit survey  
Once the audio recording has been completed, the RA will administer the post -visit survey. Based upon available space, 
the post -visit survey will be completed in the exam room, clinic waiting room or the assi gned NCGENES consultation 
room.  By working with the clinic nurse/genetic counselor/observing overall clinic flow,  the RA will establish the location 
for the post -visit survey.  The RA  will escort the family to th is location and then provide a tablet with pre -recorded videos 
to the child. Next, the RA wil l log in to tablet and provide the survey to the parent. Instructions on accessing the Pre -Visit 
survey can be found in the “ Tracking System Tasks ” section  on page 123 . Before handing the tablet to the parent, read 
the instructions on the initial page of the survey and let them know they can consult you if they have any questions.  
 
Before the RA leaves the parent to complete their survey, they should remind them of the study visit that will follow its 
completion by saying the following:  
“When you are done, I’ll bring you to meet with Tracey (or whoever is helping that day), the study 
coordinator/genetic counselor, where you will receive your reimbursement, some snacks and a gift for patient’s 
name. This is also where you will get a chance  to hear more about the special research test that your child may 
have a chance to get. You might remember that we mentioned this test to you when we spoke to you by phone a 
few weeks ago.”  
 
   
The RA should stay nearby as the parent completes the survey should they  have questions or difficulties. While the parent 
is completing the survey, the RA should notify the study coordinator that the participants will soon be ready (10 – 20 
mins) to complete the second part of the research visit (i.e. meet with the SC) . When the parent has finished the survey, 
the system should automatically log off the user so that the parent cannot get to other software to on the tablet. The RA 
should ensure that the pare nt has clicked on finish and finalize and close the survey window. The RA should then access 
the tracking system and go to the participant’s individual page to ensure that the Post-visit survey status is completed (if 
you fail to close the initial participant task list menu you will need to refresh the screen to see the completed status for that 
task).  
 
When the post -visit survey is completed, t he RA will escort the family to the  assigned NCGENES  consultation room  if 
necessary . While walking to this room, the RA can orient the family to the next steps of the research visit (e.g., introduce 
opportunity to be in the second part of the study , compensation, etc. ).  
 
Once the SC, RA, and family are all in  the consultation room , the RA will introduce the study coordinator (or unblinded 
study staff member)  and give them the participant ’s research folder . If necessary (and there are no scheduling conflicts) 
the student volunteer or RA will stay to help entertain the child/sibling while the SC talks with the family and/or help 
escort the family to phlebotomy.  
 
RA Notifications  
Before  the SC begins their portion of the research visit, the RA must notify the SC either via text or in -person of the 
following:  
1) If the physician has or dered bloodwork for the patient  
2) Of any non -standard clinic operations, such as time sensitive blood work or another clinic appointment that is 
scheduled for the same day as the research visit  
3) The physician’s determination of the participant ’s developmental age  (for participant s 7 years of age or older)  
4) Feedback provided by any of the providers regarding the project  
 
Determining Developmental Age  
Since p articipants who are development ally age 7 years or older1 are asked by the SC to provide assent to participate in 
intervention 2 of the NCGENES study , the RA and SC must collect the developmental age of any child participant 
chronologically age 7 or older at the time of their first visit. Developmental age must be collected  before the family is 
consented to study intervention 2 (i.e. genomic sequencing).   
 
It is up to the RA to collect the developmental age of relevant participants. When the RA confirms the Visit 1 
Appointment and Provider in the tracking system, a “ Collect Developmental Age ” task will appear for any participant 7 
years or older chronologically. This indicates that a developmental age should be collected for this participant.  The RA 
will need to consult with the provider after the visit to collect the developmental age of the child from them. The RA 
should record this developmental age by completing the “ Collect Developmental Age ” task in the tracking system (see 
page 146) and by making a note of the participant’s developmental age in the participant’s folder.  If the participant is over 
7 developmentally, the tracking system will automatically generate the required assent forms for the SC/GC to review 
with the participant.  The SC/GC should also verbally co nfirm  the developmental age  with the RA.  
  
 
1 Pediatric participants in NCGENES 2 must be <16 years at eligibility determination. The age -specific study documents sent to parent 
participants are based on the age determined at eligibility. Pediatric participants may age -up while actively in the study,  but age is 
treated as static in the study. Assent is based on the child’s developmental  age at Visit 1.  
 
 Developmental age not available?  If the provider does not inform the RA of a child's developmental age, the RA should 
ask the counselor (for genetics patents) or Betty (for neurology patients) if the provider has given them this information. I f 
not, the RA should ask the counselor/Betty if the doctor can be reached so that the developmental age can be obtained. 
The RA should inform the person obtaining consent for study intervention 2 of the above ASAP.  
 
The person obtaining consent for study intervention 2 will inform the parent of the following:  
 • a developmental age from the provider is required for continued participation  
 • unfortunately, this information is currently unavailable, so the study team is working to contact the provider  
 • once this information is obtained, they (i.e. the person who is obtaining consent) will contact the parent  
After informing the parent of the situation, provide the family with snacks as appropriate and walk them to the 
phlebotomy area or exit as necessary.  
 
If the developmental age is determined after the parent and child have concluded their visit and left the clinic,  next 
steps will depend on the developmental age of the child. If the provider says the participant is developmentally age 7 or 
older, the SC should inform the family  by phone  that they are unable to participate in the second part of the study as both 
parental consent and their child assent are required for participation and the time period for obtaining this permission has 
passed. If the provider says the child is developmenta lly less than age 7, the SC will inform the family they will able to 
participate in the second part of the study, and that the necessary forms for this participation will be sent to them. Then 
follow the protocol for Phone Consent to Intervention 2  on page 36 . 
 
Study Intervention 2  
When th e parent and child arrive in the consultation room, t he study coordinator will thank the parent for participating in 
the study  and remind them that they have spoken previously on the phone during the enrollment call (or state that they are 
the person mentioned during this call that would speak with them about the second part of the NCGENES study) . Then 
the SC will  ask that the family make themselves comfortable in the room and  inform the parent of the next steps (i.e. 
discuss the second part of the s tudy, escort them to check -out/phlebotomy ). The SC will ask the parent for permission to 
offer the child  an iPad with pre -recorded videos and a snack. The SC should  inform the parent of the types of snacks (in 
order to avoid providing something that the child is allergic to or the parent would not like for them to have). This will be  
done before the child sees the iPad and snacks.  If the parent gives permission for the iPad/snacks , the SC should provide 
the child with these items . The coordinator will then begin review ing consent form 1 with the paren t (i.e. Consent to 
Randomization).  
 
Parent cannot extend visit to provide consent?  In some cases, a parent and child may not have the time and/or ability to 
extend their visit and complete the consenting process in person. While it is strongly preferred for consents to occur in 
person, such cases may necessitate a phone consent to intervention 2 . If the parent cannot consent in  person immediately 
following their clinic visit , but would still like to remain in the study, the SC/GC can offer them the option of a phone 
consent. The SC/GC should still attempt to complete as much of the study visit as possible, namely distribution of 
reimbursement.1 If the option of a phone consent is requested by a parent, the SC/GC should note this in the tracking 
system and follow the Phone Consent to Intervention  2 protocol on page 36  to complete the consent.2 
 
The SC will discuss consent form 1  (i.e. Consent to Randomization to Genome Sequencing)  with the parent by reviewing 
this form  screen -by-screen on the SC ’s laptop and in general conversation.  For detailed instructions on this task in the 
tracking system, see the “ Tracking System Tasks ” section on page 146 . The parent should be offered several 
opportunities to ask any questions and receive an answer from the SC . The SC should remind the parent of their ability to 
ask questions  periodically during their discussion of the consent.  The SC also informs the parent that (1) they will receive 
 
1 Reimbursement may also be completed by mail if absolutely necessary and should not, in any circumstances, be withheld should a 
parent decline the offer of consent. Reimbursement is for study activities already completed (i.e. surveys, Visit 1) and is n ot contingent 
upon a parent hearing an explanation of consent.  
2 Only child participant’s with a developmental age less than 7 are eligible for phone consent. Any participant requiring assen t cannot 
give that assent by phone and must do so in person to continue in the study.  
 
 a paper copy of any consent form discussed with them (and their child ) and (2) they may contact the SC via the study 
number and email address that is on these forms if the y have  any questions following the study visit.  
 
Both parents present?  If both parents are present, the SC will inform the parents that for consistency the parent who 
provided consent via telephone must also sign the consent forms for the second part of the study  should  the family decides 
to continue with study participation. The non -consenting parent will be informed they can also ask any questions they 
have during this time and can look at the laptop or follow along via a paper version of the consent.   
 
If the  Parent Consents  
If consent form 1 is signed , the SC will review the HIPAA  consent following the same procedure as consent form 1  (see 
above) . For detailed instructions on this task, see the “ Tracking System Tasks ” section on page 148 .  
 
All participants who consent to the genomic sequencing randomization MUST also have a signed HIPAA document to 
continue participation in the study. If a participant refused to sign the HIPAA document, they must be manually given the 
final status of REFUSED  and a note detailing the reason for this change should be added to the participant’s log.  
 
After the HIPAA consent is signed, the parent/family will be informed of the intervention 2 assignment (i.e. genomic 
sequencing or non -genomic sequencing). This status will appear on the participant’s individual page  (see page 67). 
 
If the participant  is assigned to non -genomic sequencing , the parent/family will be informed that have not been 
assigned to be offered genomic sequencing. The SC  should  inform the parent/family  that their remaining study 
participation will consist of completing  follow -up surveys  and having their child’s information obtained until they are 18 
years of age as discussed  during the consent process . The SC should then thank the family for their time, provide parent 
and child  compensation as described below , and escort  them  to either phlebotomy ( for provider bloodwork ), check -out, or 
towards the  appropriate hospital exit.  
 
If the participant  is assigned to genomic sequencing,  the SC will inform the parent/family that they have been assigned 
to be offered genomic sequencing. Then the SC or Genetic Counselor  will review consent form 2 (i.e. Consent to 
Genomic Sequencing) following the same procedure as consent form 1 (see above) . For detailed instructions on this task 
in the tracking system, see the “ Tracking System Tasks ” section on page 149 . If the parent signs consent form 2 , The 
SC/GC will proceed with biospecimen collection and parent compensation.   See b elow section s entitled “ Biospecimen 
Collection ” on page 32  and “Distribution of Parent and Child  Compensation ” on page 32  for further detail . 
If the Parent Declines  
If the parent declines to sign either consent form 1 or the HIPAA  consent,  the parent/family will be informed their 
study participation ends at the conclusion of th e study visit. In the tracking system, the SC should exit whichever consent 
form they are viewing with the parent and mark the participant “Refused” manually with the reason  “Declined at Visit 1 – 
Intervention 2” and a short explanation .1 The SC  should  thank the family for their time, provide parent and child  
compensation as described below , and escort them to either phlebotomy ( for provider bloodwork ), check -out, or towards 
the appropriate hospital exit.   
 
If the parent declines to sign  consent form 2,  the parent/family will be informed  that their remaining study participation 
will consist of completing follow -up surveys and having their child’s information obtained until they are 18 years of age 
as discussed during the consent process. The SC should then thank the family for their time,  provide parent and child 
compensation as described below , and escort them to either phlebotomy (for provider bloodwork), check -out, or towards 
the appropriate hospital exit. These participants will have a status of “Declined Consent/Assent to GS .” 
 
 
1  See page 18 for more information on marking participants refused.  
 
 Tracking system down?  If the tracking system is down, all consents/assents should be administered using the paper 
version s in the participant’s folder. After the visit, when the tracking system is working again, upload th ese paper version s 
to the participant documents tab  (see page 74). Then, complete the corresponding tracking system  tasks and, if the 
parent consented, write “Completed Document on Paper”  in the signature field s. 
 
Obtaining assent  
If the child’s developmental age is 7 or greater ( see above ), the SC/GC must collect assent from that child for the parent 
and child to continue in the study.  Assent for randomization (i.e. Assent form 1) and assent for genomic sequencing (i.e. 
Assent form 2) are obtained by the SC /GC in the same manner as outlined above for obtaining parental consent for 
intervention 2. Further details on  these tasks can be found in the “ Tracking System Tasks ” section on page 150 . Assent 
forms are  typically discussed once the parent consent process is complet e. In rare occasion s, assent form 1 is discussed 
after the parent signs  the HIPAA  consent  form , and then assent form 2 is discussed after the parent signs the parent 
consent form 2.   
 
These  alternative time periods for obtaining assent are necessary  because parents  may be more  interested in hearing about 
the second part of the study , while  participant s are tired and/or need time to become engaged in the process or are focused 
on the iPad/snacks. The SC should use their judgement as to when to begin the assent process. The SC should inform  the 
parent of the timing of the assent process and check their agreement . If they agree , the SC can proceed  with th at timing . If 
there is disagreement , the SC should defer to the parents preferences .  
 
Regardless of the timing of the assent process, the SC starts the process by re -introducing themselves to the participant . 
Then, the SC  asks the  participant  if they have any questions about why they are seeing the SC or what they heard the SC 
discuss with the ir parent (s). After questions are answered, the SC tells the participant  what will happen next (i.e. they will 
talk about the study by looking at the laptop and talking) and that they can ask the SC questions, their parent(s) questions 
about their talk with the SC or ask their parent(s) to call the SC if they have questions later. Then , the SC begins the assent 
process.  
 
Note: The assent process should involve more discussion than  a screen by screen review on the SC’s laptop, 
especially with younger participant s. 
 
If the participant  signs assent form 1 , they are told if they are in the group of kids that are asked to give a little bit of 
their blood (about 1 -2 teaspoons) or if they are in the group of kids that do not have to do anything extra then what the 
doctor has already talked to their parent(s) a bout during their doctor’s visit. The participant  is asked if they have any 
questions, and if so, the questions are answered. Then depending upon the intervention 2 assignment the SC proceeds with 
assent 2 or with prov iding child  and parent compensation as described below .   
 
Note:  parent(s) are given a copy of the assent forms that are discussed with their child.  
 
If the participant  declines  signing assent form 1 , the SC informs the parent(s) and participant  that study participation 
for intervention 2 cannot proceed. In the tracking system, the SC should exit (without saving) the current task  and mark 
the participant “Refused” manually with the reason “Declined at Visit 1 – Intervention 2” and a short explanation.1 Then 
the SC thanks the family for their time, provides parent and child  compensation as described below, and escorts them to 
either phlebotomy (for provider bloodwork) , check -out, or towards the appropriate hospital exit.  
 
If the participant  declines assent form 2,  the SC informs the participant  that no genetic sequencing will be done but the 
participant would continue to be in the NCGENES 2 study and the parent would be provided with follow -up surveys.  
Then the SC thanks the family for their time, provides parent and child  compensation as described below, and escorts 
them to either phlebotomy (for provider bloodwork) or check -out, or towards the appropriate hospital exit.  These 
participants will have a status of “Declined Consent/Assent to GS ” 
 
 
1  See page 18 for more information on marking participants refused.  
 
 Cases of discordant consent/assent. If a child can assent to participate in Intervention 2, both the parent and child must 
agree to continue participation. Further, both parent and child must have concordant consent/assent for the check boxes 
related to the study’s continued access to the ch ild’s medical records and for the disclosure of medically actionable 
secondary findings.  If the child is 7 years or older chronologically and developmentally, the parent must consent AND 
the Child must assent for the participants (parent -child pair) to remain in NCGENES.  
 
If the consent and assent are discordant, a participant should be manually given the final status of REFUSED and a note 
detailing the reason for this change should be added to the participant’s log in the study’s tracking system.  
 
Distribution of Parent and Child  Compensation  
At the completion of the consent/assent process parents will sign for compensation through the “Visit 1 -Parent 
Reimbursement” task. For detailed instructions on this task see the “Tracking System Tasks ” section on page 152 . If the 
tracking system does not work, the SC will use a receipt book to complete this task. The study coordinator fills in the 
amount provided to the parent according to what was completed before and during visit 1. Child participants  in the study 
will be offered a nonmonetary gift at the end of visit 1.  For more information on participant compensation, see the 
“Tracking Participant Compensation ” section on page 35 . 
 
Biospecimen collection  
After the  appropriate forms are signed (i.e.  parental consent form 2 and if necessary , assent form 2)  and the parent and 
child  compensation have been distributed, the SC escorts the family to the phlebotomy area appropriate to that clinic. At 
UNC, the SC will direct the participant s to UNC’s Women ’s Hospita l for phlebotomy check -in. If the patient is having 
provider bloodwork, the SC escorts the parent to the individual check -in area. If the patient is no t having provider 
bloodwork, the SC escorts the family to the area where they can pull a number  for general check -in. At Mission, the SC 
will direct the family to the phlebotomy area of the Mission Children’s Hospital.  
 
When the participant  is called for blood draw, the SC should escort the family to the blood draw area and inform the 
phlebotomist of the need to use the research blood tubes  immediately after the provider’s blood order is filled .  The SC 
will pass the phlebotomist the labeled research blood tube either right before they are to be filled or places them next to 
the tubes for the provider’s  bloodwork, depending upon the level of SC assistance needed.  
 
SC assistance  
When necessary, the SC assists the phlebotomist/parent in holding the child  for blood draw, as well as trying to keep them 
calm for this procedure. Assistance is typically needed , however the SC should take care not to obstruct the phlebot omist . 
 
See biospecimen protocol  regarding sample labeling, collection , lab distribution , processing, and reporting.  
 
Study Withdrawal & No Show Protocol  
The protocols in this section involve changing a participant’s status using the  “Change Status” button on the individual 
participant’s page in the tracking system. Further instructions on this process, can be found in the “ Using the Tracking 
System ” section on page 70 . 
 
Withdrawal  
A participant could be considered withdrawn under two circumstances : 
1. When a participant asks to be withdrawn from the study. When this request occurs, a withdrawal form is 
completed by the study coordinator or RA. This request is initiated by the participant and occurs  at any  time. 
2. Or, during study contact for non -data collection activities, such as making the reminder call. This action is 
initiated by a member of the study team.  
 
In either case, the participant should be marked “Withdrawn ." 
 
 
 Investigator Withdrawal  
Participants are subject to investigator withdrawal when:  
1. A pediatric patient is found to have a confirmed genetic related diagnosis  during Visit 1 . This would be 
considered “Investigator Withdrawal -At Clinic Visit 1 (Intervention 1)”. These participants will/can complete the 
Intake Survey, Pre - and Post -Visit Surveys but are not considered for Genetic Sequencing part of the study  (i.e. 
intervention 2) . Parents can receive up to $70 in compensation, and the child  will receive a nonmonetary gift . 
2. NCGENES study staff unable to attend the research/clinic appointment (e.g. due to illness or othe r conflict). 
Participants that attend their clinical appointments, can receive up to $40 ($10 for parking and $30 if they 
submit a completed Intake Survey).  
3. A participant (child or adult) was ineligible at the time of enrollment BUT this was only discovered after 
participant  was already enrolled  (e.g at Visit 1) . For example, a participant  has a confirmed genetic diagnosis 
prior to the enrollment (i.e. this diagnosis does not occur  at Visit 1), but this diagnosis was not disclosed during 
the enrollment call and was not found in the patient’s medical record. In these cases, all the data associated 
with this participant will be removed for the analytic database.  
o If the pa rticipant  is found to be ineligible for reasons which preceded their enrollment , the following 
phrase should be copied into the reason text box  when changing the participant’s  status : “Participa nt 
was ineligible at the time of enrollment BUT this was only discovered after participant  was already 
enrolled, thus participant  coded as ‘Investigator Withdrawal ’ and data removed from analytic database.”  
 
No Shows  
Participants are considered a No Show  if the study staff are unable to complete the research visit with a consented 
participant.  
 
No Show – Research Visit ONLY  
A participant should be considered a  “No Show – Research Visit ONLY ” if there is not enough time for the study staff to 
complete the research visit tasks (e.g. pre - and post - survey  or consenting process ) at the time of the clinic visit  AND the 
participant must be assented and is thus ineligible for phone consent.  This can happen if a participant arrives to the clinic 
at or after their scheduled clinic appointment time  or if the participant has multiple clinical visits that conflict with the 
research visit protocol.  In this case, participants are censored from the study.  
 
No Show – Research and Clinic Visit  
A participant should be considered a “No Show – Research and Clinic Visit ” if they miss their clinical appointment 
completely. In this case, the participant is given 30 days to  reschedule their appointment .1 If they do reschedule their 
appointment in 30 days to some date in the future,  they can still participa te in the study.  Participants may be rescheduled 
up to 3 times.  
 
If the participant is not rescheduled for an appointment within 30 days  after their original appointment date, the participant 
is coded with a final status of “No Show ”. The SC will periodically monitor EPIC to determine if the participant  has been 
rescheduled and work with the tracking system team and other study  team members to complete necessary steps based 
upon the participant’ s reschedule status.  The study  biostatistician  will generate regular reports  to indicate participants 
whose statuses should be changed to a “No Show. ” 
 
Alert Protocol for NCGENES 2 Distressed Adult Participants  
Parent/Caregiver participant distress is evaluated through the parent’s or caregiver’s completion of study surveys. When 
responses are entered into the tracking system, the system will score the GAD7 (anxiety measure) and the PHQ8 
(depression measure). The  measures appear on the questionnaires listed below:  
• Pre-clinic visit 1 parent  survey:   
 
1 The appointment does not need to occur within 30 days; it must be rescheduled within 30 days.  
 
 o Question 6, A -G (GAD7, anxiety, 7 items)  
o Question 6, H -O (PHQ8, depression , 8 items)  
• Post-Return of results  (2 weeks after RoR) parent survey:   
o Question 21 *, A-G (GAD7, anxiety, 7 items)  
o Question 21 *, H-O (PHQ8, depression, 8 items)  
• Final Follow up (6 months after RoR) parent survey:   
o Question 14 *, A-G (GAD7, anxiety, 7 items)  
o Question 14 *, H-O (PHQ8, depression, 8 items)  
*Question numbers subject to change  
 
Both the GAD7 and the PHQ8 should be scored (separately) as follows:  
• Not at all=0, Several days=1, More than half the days=2, Nearly every day=3  
• Sum the items to create measure score  
• If a participant scores 15 to 21 on the GAD7 (indicating severe symptoms) AND/OR scores 20 to 24 on the PHQ8 
(indicating severe symptoms), the system will create an alert.  
 
IMPORTANT NOTE:  For any surveys administered by paper or over the phone , the data should  be entered directly into 
the electronic data collection system within 24 hours of collection or first thing Monday morning if the data is collected 
late on Friday afternoon. Expedient data entry will allow for rapid distress score calculation, alert repor ting, and 
appropriate follow -up action according to the protocol described above.  
 
Immediately upon data entry, the tracking system will score each measure . If scores meet the thresholds specified above,  
the system will automatically s end an email alert to the study coordinator and study clinical project director, notifying 
them of the participant’s alert status and distress score(s). The system will also generate the “Parental Distress Follow -up” 
task to appear in the participant ’s individual page in the tracking system.  
 
The clinical project director will:  
1. Share this information with the study coordinator within 24 hours of email receipt.  
 
The study coordinator will:  
1. Complete the “Parental Distress Follow -up” task by selecting the “Get Started” button .  
2. Complete the first section of the Distress Call Form  (See Appendix VII ) and email it to the study clinical 
psychologist within 24 hours of receiving the alert notification by the Director and via the tracking system. The 
email should be sent with delivered and read request. If the read request is not returned within 24 hours,  the study 
coordinator will also call the study psychologist to confirm that they have received the emailed form. If the alert is 
received on a Friday afternoon, the study coordinator will contact the study psychologist by end of day on the 
following Monda y.  
3. Provide resources to distressed participant via email or regular US mail, using the appropriate distress documents 
(see IRBIS ) as requested by the study psychologist.  
4. Email the study PIs to inform them that the psychologist has been notified about a severely distressed participant.  
5. Be responsible for recording all alert protocol actions taken in the tracking system  under the participant’s alert 
task. 
6. Report on the status of action taken for severely distressed NCGENES 2 caregivers/adult participants at Steering 
Committee meetings (when relevant).  
 
The study psychologist will:  
1. Follow up with the participant (e.g., by phone, or in -person) within two weeks, making a minimum of three call 
attempts, to assess the report of distress and determine if any relevant support/resources need to be provided. If 
these resources are needed, th e study psychologist will inform the study coordinator.   
2. The study psychologist will follow the Distress Screening Script (see IRBIS ) developed for this study to evaluate 
the participant.  
 
 NOTE:  The NCGENES 2 study does not include items about suicidality, and thus individuals flagged for high distress 
may or may not be experiencing suicidal ideation. One goal of screening high distress individuals is to determine if people 
are experiencing suici dal ideation or other symptoms that may require referral to specific resources for suicide prevention 
or therapy. A suicide screening script is provided for use in cases that a participant signals possible suicidal ideation 
during study interactions or in this screening call.  
Complete the bottom section of the Distress Call Form (regardless of whether they were able to reach the 
participants of not) and return it via email to the study clinical Project Director (Jeannette Bensen, 
jeannette_bensen@med.unc.edu ) and the Study Coordinator (Tracey Grant, traceyg@unc.edu ). 
 
Visit 1 Post -visit Physician Survey and PhenoTips  
The physician will complete the MD survey on their own using their login in for the tracking system. They will receive an 
email notification the patient’s physician survey is ready for completion with an email reminder every 24 hours after the 
clinic visit  (due date).  
 
NCGENES 2 Patient Tracking Instructions for Physicians/Providers  
1. Login to https://ncgenes2.sirs.unc.edu  
by entering your email and password  
2. You will land on a page automatically that is the MD Survey tab  
a. Click on the ‘GO TO SURVEY’ for the relevant patient  
b. Complete the Survey  
i. Click Save – this will return you to the MD Survey  
landing page.  You will note that the patient whose  
survey you completed no longer appears on this screen  
3. Click on the PhenoTips tab  
a. Click on the PhenoTips button for the relevant patient  
b. PhenoTips will open in a new window  
c. Login with your PhenoTips username and password  
i. NOTE: this is not necessarily the same as your login  
for the Patient Tracking System  
d. Complete PhenoTips entry of patients – save and logout  
e. You must also logout of the patient tracking system which  
is still open in another window  
4. If you cannot access PhenoTips from the tab in the patient tracking system,  
try copying and pasting this link into a web browser:  
   https://phenotips.med.unc.edu/  
  
 
 Phone Consent to Intervention  2 
In some cases, a parent and child pair may not have the time and/or ability to extend their visit and complete the 
consenting process in person. While it is strongly preferred for consents to occur in person, such cases may necessitate a 
phone consent to intervention 2. If the parent cannot con sent in person immediately following their clinic visit, but would 
still like to remain in the study, the SC/GC can offer them the option of a phone consent. The SC/GC should still attempt 
to complete as much of the s tudy visit as possible, namely distribution of reimbursement.1 If the option of a phone consent 
is requested by a parent, the SC/GC should do as follows .2 
 
Scheduling Call  
Within a week from the completion of Visit 1, the SC will call the parent participant to explain the process of phone 
consent. The SC will explain that certain forms will need to be reviewed, signed by the parent, and returned before the 
child and parent c an continue with the study, and that reviewing these forms will require an additional phone call. The SC 
will ask whether that call can be scheduled and, if the participant agrees, attempt to schedule a follow -up call 1 to 2 weeks 
from the current date. Th is call should be recorded in the Communication Log  and the follow -up call entered into the 
NCGENES Outlook Calendar . The SC should also complete Mailing 4  at the conclusion of the call and record this in the 
communication log.  
 
Call for Consent(s) to Intervention 2  
In many ways, the flow of the phone consent process mimics that of the in -person consent. When the SC reaches the 
parent participant, they will first confirm that they have received hard copies of the consent and HIPAA forms.  
 
Mailing not received? Phone consent may not proceed without the parent possessing physical copies of the 
consent/HIPAA forms. If they have yet to receive the mailing, schedule a future call with the parent.  
 
The SC will ask them to collect their forms so that they can review them and answer any questions they might have. The 
SC will discuss consent form 1 with the parent by reviewing the f orm and by general conversation. The parent will be 
offered several opportunities to ask and have answered any questions and during the discussion by the SC. The SC also 
informs the parent that 1) they should keep one copy of the consent form and 2) they can contact the SC via the study 
number and email address that is on thes e forms if there are any questions following the study visit. For detailed 
instructions on completing this task in the tracking system, see the “ Tracking System Tasks ” section on page 146 .3 
 
Both parents present?  If both parents are present, the SC will inform the parents that for consistency the parent who 
provided consent via telephone must also sign the consent forms for the second part of the study should the family decides 
to continue with study participation . The non -consenting parent will be informed they can also ask any questions they 
have during this time and can look at the laptop or follow along via a paper version of the consent.   
 
If the Parent Consents  
 
1 Reimbursement may also be completed by mail if absolutely necessary and should not, in any circumstances, be withheld should a 
parent decline the offer of consent. Reimbursement is for study activities already completed (i.e. surveys, Visit 1) and is n ot contingent 
upon a parent hearing an explanation of consent.  
2 Only child participant’s with a developmental age less than 7 are eligible for phone consent. Any participant requiring assen t cannot 
give that assent by phone and must do so in person to continue in the study.  
3 The tracking system should be used to record the parents stated decision. If the parent consents, the SC should record “Conse nt by 
Phone” in the parent’s signature box and place their own signature in the box for witness. When the hard copy of the consent  is 
received from the parent by mail, it should be scanned and uploaded to the participant’s document page. If there are any disc repancies 
between the hard copy consent and the tracking system, the hard copy takes precedence. Should significant differences  exist, the SC 
should consult the study director, Jeannette Bensen.  
 
 If consent form 1 is signed , the SC will review the HIPAA consent by following the same procedure outlined above. For 
detailed instructions on this task in the tracking system, see the “ Tracking System Tasks ” section on page 148 .1 After the 
HIPAA consent is signed, the parent/family will be informed of the intervention 2 assignment (i.e. genomic sequencing or 
non-genomic sequencing). This status will appear on the participant’s individual page  (see page 67). 
 
All participants who consent to the genomic sequencing randomization MUST also have a signed HIPAA document to 
continue participation in the study. If a participant refused to sign the HIPAA document, they must be manually given the 
final status of REFUSED  and a note detailing the reason for this change should be added to the participant’s log.  
 
If the participant is assigned to non -genomic sequencing , the parent/family are informed that have not been assigned to 
be offered genomic sequencing. Then, the SC informs the parent/family, their remaining study participation will consist of 
completing follow -up phone interviews and having their child’s information obtained until they are 18 years of age as 
discussed during the consent process. Next, the SC should t hank the family for their time and ask that they place any 
signed forms in the prepaid envelope they received and mail them as soon as possible.  
 
If the participant is assigned to genomic sequencing,  the SC will inform the parent/family that they have been assigned 
to be offered genomic sequencing. Then the SC or Genetic Counselor, depending on clinic, will review consent form 2 
(i.e. Consent to Genomic Sequencing) by following the same procedure outl ined for consent form 1. For detailed 
instructions on completing this task in the tracking system, see the “ Tracking System Tasks ” section on page 149 .2 If the 
parent signs consent form 2, the SC/GC will explain that the next step involves collecting a sample of the child’s saliva 
for analysis. In order to do this, the SC will be mailing a saliva kit to the parent as soon as they (the SC) receive the sig ned 
consent forms from the parent. The SC should ask the parent to place all signed forms in the prepaid envelope they 
received and mail them as soon as possible. When the forms are received,   
If the Parent Declines  
If the parent declines signing either consent form 1 or the HIPAA consent,  the parent/family should be informed that 
they will no longer be participating in the study.  In the tracking system, the SC should exit (without saving) the current 
task and mark the participant  “Refused” manually with the reason “Declined at Visit 1 – Intervention 2” and a short 
explanation.3  The SC should then thank the family for their time and ensure they have received proper reimbursement for 
their visit, either in person or by mail.  
 
If the parent declines signing consent form 2,  the parent/family should be informed that their remaining study 
participation will consist of completing follow -up phone interviews and having their child’s information obtained until 
they are 18 years of age as discussed during the consent process. The S C should then thank the family for their time and 
ensure they have received proper reimbursement for their visit, either in person or by mail. These participants will have a 
status of “Declined Consent/Assent t o GS.”  
 
 
1 The tracking system should be used to record the parents stated decision. If the parent consents, the SC should record “Conse nt by 
Phone” in the parent’s signature box and place their own signature in the box for witness. When the hard copy of the consent  is 
received from the parent by mail, it should be scanned and uploaded to the participant’s document page. If there are any disc repancies 
between the hard copy consent and the tracking system, the hard copy takes precedence. Should significant differences  exist, the SC 
should consult the study director, Jeannette Bensen.  
2 See above note.  
3  See page 18 for more information on marking participants refused.  
 
 RETURN OF RESULTS  
 
Overview  
Currently in NCGENES 2, the term “Return of Results” (RoR) is used in two senses: (1) to refer to the general time 
period following Visit 1/Biospecimen Collection and (2) to refer to the process/task of returning results to participants 
who were randomized  and consented to the genomic sequencing group. The RoR process flow can be seen in the diagram  
below.  This diagram is broken apart and explored in detail in the sections that follow.  
 

 
 After Visit 1: All Participant Groups  
At Visit 1, NCGENES participants are randomized into two groups, Genome 
Sequencing (GS) and No Genome Sequencing1 (No GS). Much to the RoR 
process differs depending on the randomization arm of the participant. 
However, a few things can be generally stated about the process:  
 
1. Post-Visit Provider Activities  – Providers will be asked to 
completed a Post -Visit 1 Clinician Questionnaire and enter patient 
clinical data in the NCGENES2 PhenoTips  Web Software regardless 
of the participant’s randomization.  
 
2. Usual care – Providers should  not adjust their plan of care for a 
participant based on their participation in NCGENES 2 or their 
randomization. Providers should complete and return the results of 
any non -NCGENES 2 diagnostic tests  according to their usual 
practices and timelines.  
 
3. Pre-RoR Mailing  – All participants will receive a “Pre -RoR” 
mailing of some type. The contents and timing of that mailing 
depend and the participant’s randomization. See below for more 
detail.  
 
4. Post-RoR Provider Survey(s) – Providers will be asked to 
complete a 2 -part post -RoR questionnaire for each NCGENES 2 
participant.  The content and timing of these questionnaires depends 
upon the randomization  and documented treatment  of the 
participant . 
a. Part 1  addresses the utility of diagnostic tests (including 
genome  sequencing, if applicable) and plan for continued care of the patient.  The participant’s primary 
genetic /neurology  provider, usually a physician, will always complete  this part of the survey.  
b. Part 2  addresses the actual process of returning results, i.e. the interaction with the pa rticipant’s 
caregiver(s). Whoever completes part 1 of the survey for a participant  will indicate all parties that took 
part in returning results, e.g. genetic counselors or nurses.  Each  of those  participating provider s will 
complete a copy of part 2 of the survey for that participant.  
 
5. Post-RoR Parent/Caregiver Survey (s) – Parent participants will be asked to complete a post -RoR questionnaire  
2 weeks and 6 months after results have been returned . The content and exact timing of these questionnaires 
depends upon the randomizatio n, documented treatment , and age  of the participant.  Questionnaires will be mailed 
to participants, but may also be  completed by phone on request.   
 
1 This group also includes participants who are randomized to genome sequencing, but decline to receive it.  

 
 RoR for No GS Participants  
The Return of Results process for No GS participants is 
generally simpler than that for GS pa rticipants. That being 
said, certain linitation of this clincial trial do create quriks 
that may be confusing to staff, providers, and participants.  
  
Defining Results  for No GS  
Unlike their GS counterparts, GS participants have no 
standardized  diagnostic test ( i.e. exome sequencing 
perform ed by NCGENES 2) that might reliably produce 
results returned to the patient ’s caregivers. Instead, “results” 
for No GS participants should be understood as  the results  
of all diagnostic tests ordered  (if any1) by the participant ’s 
provider during their first visit .  
 
Timing of RoR Tasks for No GS  
Because the actual timelines for return of results for No GS 
participants will vary widely, the timelines surrounding 
RoR research tasks for these participants have been set 
chronologically to mimic, as best as possible, the timelines 
expected for participants in the other arm of the study. This 
means that the timing will rarely correspond to usual 
clinical practice  in terms of returning results of diagnostic 
tests ordered at Visit 1. This is a necessary limitation of the 
study  that should be understood by study staff should other 
stakehol ders express confusion at the process.  
 
Pre-RoR Mailings  – No GS  
Pre-RoR Mailings for No GS participants will always be 
sent exactly 5 months  after the participant’s Visit 1. For 
more information on completing this mailing, see Mailing 3  
in the Mailings section on page 53 . Staff should complete 
the “Pre-RoR Packet - No GS without Pre -Visit Prep” task  
in the tracking system upon completion of this mailing.  
 
RoR Date  – No GS  
Functionally, the RoR Date for No GS participants is 
always set at 6 months after Visit 1. This date determines 
the windows in which post-RoR Parent Surveys are sent and received . Providers may also indicate in their Post -RoR 
surveys a date when results from all diagnostic tests ordered at Visit 1 where returned to the participants  (i.e. the date the 
final result from these tests was returned) . While this information is important to the study, it does not determine timelines 
for No GS participants.  
  
 
1 In some cases, the provider may not have ordered any diagnostic tests during the first visit. Even in these situations, the p articipant 
(and their provider) will receive post -RoR questionnaires tailored to that specific case.  

 
 Provider Post-RoR Surveys – No GS  
Providers of No GS participants will receive an 
email notification  (Fig. 1)  exactly 5.5 months 
after visit one that  informs them a Post -RoR 
survey is due.  Providers can access this survey 
using the link in the email or from the MD 
surveys tab in their tracking system account.  
Once Part 1 of the provider survey is complete, 
Part 2 will be triggered automatically. If the 
initial provider  is completing Part 2 of the survey, 
they will be automatically directed to it upon 
completion of Part 1. Any other provider 
desig nated to complete Part 2 will receive an 
emai l notification . Surveys should be completed as 
quickly as possible to minimize recall bias.  
 
Parent Post -RoR Surveys – No GS  
Each parent will be sent two surveys after the RoR Date.  These surveys will be mailed to the parent s, filled out, and 
returned. Parent’s also have the option of completing surveys by phone.  
Post-RoR 2 Week Parent Survey  
The first parent survey should be completed roughly two weeks  after the RoR date.  The window for completing the Post -
RoR 2 week Parent survey is 0 -6 weeks after return of results. For No GS participants, this means the 2 week survey 
should be completed between 6 -7.5 months after Visit 1. Exactly six months after Visit 1 , study staff will mail a survey to 
parents of participants not randomized to GS. For more details on this mailing, see Mailing 4  in the mailings section.  Staff 
should complete the “ Post-RoR - Parent 2 Week Questionnaire Mailing ” task in the tracking system upon completion of 
this mailing.  When the parent returns a completed Post -RoR 2 week survey by mail, staff should complete the “Post -RoR 
- Parent 2 Week Questionnaire Mailing - Received” task in the tracking system, the paper copy of the survey should be 
scanned and uploaded in the partic ipants documents, and the data in the survey should be entered in the “Post -RoR – 
Parent 2 Week Questionnaire” task in the tracking system. This da ta entry should be done regardless of whether the 
survey was completed within the given window. Finally , staff should send a thank you note with gift card to the parent 
(See Mailing 5 ). 
Post-RoR 6 Month Parent Survey  
The first parent survey should be completed roughly six months after the RoR date. The window for completing the Post -
RoR 6 month Parent survey is 5 -7 months after return of results. For No GS participants, this means the 6 month survey 
should be completed  between 11 -13 months after Visit 1. Exactly eleven months after Visit 1, study staff will mail a 
survey to parents of participants not randomized to GS. For more details on this mailing, see Mailing 6  in the mailings 
section. Staff should complete the “Post -RoR - Parent 6 month Questionnaire Mailing” task in the tracking system upon 
completion of this mailing. When the parent returns a completed Post -RoR 6 month survey by mail, staff should complete 
the “Post -RoR - Parent 6 month Questionnaire Mailing - Received” task in the tracking system, the paper copy of the 
survey should be scanned and uploaded in the part icipants documents, and the data in the survey should be entered in the 
“Post -RoR – Parent 6 month Questionnaire” task in the tracking system. This data entry shoul d be done regardless of 
whether the survey was completed within the given window. Finally, staff should send a thank you note with gift card to 
the parent (See Mailing 7 ). 
 
  FIGURE 1 

 
 RoR for GS Participants  
The Return of Results process for GS 
participants  is complex and depends upon 
multiple teams contributing to perform tests, 
return results, and document the process . 
  
Results for GS  
“Results” for GS participants refers =to the 
results of NCGENES 2 exome sequencing. 
NCGENES 2 staff will collect two 
biospecimen s from e ach participant 
randomized to GS. One specimen will be sent 
to a CLIA lab to process and hold for potential 
confirmation. The other sample will be sent to 
UNC’s Biospecimen Processing Facility. From 
there, DNA will be extracted and sent for 
sequencing. When data from sequencing 
returns, a n analyst will be assigned to review 
any reported variants and perform a 
preliminary assessment of clinical 
significance. This report will be presented at 
regular Molecular Sign -Out committee  
meetings. If no variants are deemed clinically 
significant (i.e. results are negative), the re sults 
will be reported directly to the child’s 
provider. If results are positive or uncertain, 
variants will be sent to the CLIA lab for 
confirmation. Confirmed positive/uncertain 
results will be posted in the patient’s EMR.  
 
Timing of RoR Tasks for GS  
Unlike no GS participants, the timelines for RoR tasks for GS participants are variable and depend on upon the 
completion of tasks by a variety of NCGENES 2 teams.  Because of this, timely completion of tasks  is critical, particularly 
to ensure Post -RoR parent surveys can be collected within an acceptable timeframe.  
 
Pre-RoR Mailings – GS 
Pre-RoR Mailings for GS participants will always be sent as soon as an analyst is assigned to interpret th at participant’s 
sequencing data . For more information on completing this mailing, see Mailing 3  in the Mailings section on page 53 . Staff 
should complete the “Pre -RoR Packet - GS without Pre -Visit Prep”  or “Pre -RoR Packet - GS with Pre -Visit Prep”  task in 
the tracking system upon completion of this mailing.  
 
RoR Date – GS 
The RoR Date for GS participants is set in one of two ways.  
 
Prior to August  2020 , the RoR Date was only set by the provider(s) during Part 2 of the Post -RoR Clin ician 
Questionnaire. In that portion of the survey, the provider(s) will be asked to indicate when all planned communications 
associated with returning the exome sequencing results for the participant were complete. This date determines the 
windows in which post -RoR Parent Surveys are sent and received. However, because there may be a delay between the 
provider completing their survey(s) and the actual RoR date, NCGENES also uses the date of completion of Part 1 of the 
Post-RoR survey as a temporary RoR date until Part 2 of the survey  is complete. Since Part 1 of the survey can only be 

 
 completed after results are returned, this allows study staff to quickly move forward on administering parent surveys 
without interfering with standard clinical practice.  
 
As of August 2020, NCGENES staff will perform weekly checks of the EMR for any participant for whom results have 
been posted to t he tracking system. I f these checks reveal that NCGENES 2 results have been returned, the staff member 
will enter that RoR Date  into the “Edit Info” page on the participant’s page in tracking. This will trigger the post-RoR 
Parent survey tasks.  
 
The Post -RoR Provider Part 1 trigger will remain in place. However, if any Parent RoR tasks trigger on that basis, UNC 
staff will immediately review the patient’s EMR , determine the RoR Date, and enter it into tracking to trigger the 
remaining Post -RoR parent tasks.   
 
Provider Post -RoR Surveys – GS 
Providers of No GS participants will receive an email 
notification (Fig. 2) as soon as the molecular analysis for that 
participant is complete  that informs  them they have results and 
that a Post -RoR survey is due. Providers can access this survey 
using the link in the email or from the MD surveys tab in their 
tracking system account. Once Part 1 of the provider survey is 
complete, Part 2 will be triggered automatically. If the initial 
provider is completing Part 2 of the survey, they will be 
automatically d irected to it upon completion of Part 1. Any other 
provider designated to complete Part 2 will receive an email 
notification. Surveys should be completed as quickly as possible 
to minimize recall bias.   
 
Parent Post -RoR Surveys – GS 
Each parent will be sent two surveys after the RoR Date. These surveys will be mailed to the parents, filled out, and 
returned. Parent’s also have the option of completing surveys by phone.  
Post-RoR 2 Week Parent Survey  
The first parent survey should be completed roughly two weeks after the RoR date. The window for completing the Post -
RoR 2 week Parent survey is 0 -6 weeks after return of results. As soon as an RoR Date is confirmed , study staff will mail 
a survey to participants randomized to  the GS Group . For more details on this mailing, see Mailing 4  in the mailings 
section. Staff should complete the “Post -RoR - Parent 2 Week Questionnaire Mailing” task in the tracking system upon 
completion of this mailing. When the parent returns a completed Post -RoR 2 week survey by mail, staff should complete 
the “Post -RoR - Parent 2 Week Questionnaire Mailing - Received” task in the tracking system , the paper copy of the 
survey should be scanned and uploaded in the participants documents, and the data in the survey should be entered in the 
“Post -RoR – Parent 2 Week Questionnaire” task in the tracking system. This data entry should be done regardless of 
whether the survey was completed within the given window. Finally , staff should send a thank you note with gift card to 
the parent (See Mailing 5 ). 
Post-RoR 6 Month Parent Survey  
The first parent survey should be completed roughly six months after the RoR date. The window for completing the Post -
RoR 6 month Parent survey is 5 -7 months after return of results. Exactly 5 months after the RoR Date , study staff will 
mail a survey to parents of participants not randomized to GS. For more details on this mailing, see Mailing 6  in the 
mailings section. Staff should complete the “Post -RoR - Parent 6 month Questionnaire Mailing” task in the tracking 
system upon completion of this mailing. When the parent returns a completed Post -RoR 6 month survey by mail, staff 
should complete the “Post -RoR - Parent 6 month Questionnaire Mailing - Received” task in the tracking system, the paper 
copy of the survey should be scanned and uploaded in the part icipants documents, and the data in the survey should be 
entered in the “Post -RoR – Parent 6 month Questionnaire” task in the tracking system. This data entry should be done 
regardless of whether the survey was completed within the given window. Finally , staff should send a thank you note with 
gift card to the parent (See Mailing 7 ). 
 FIGURE 2 

 
 TRACKING P ARTICIPANT  COMPENSATION  
 
The study coordinator will distribute compensation at the appropriate study time points. The breakdown for cash  
compensation  to the parent can be seen below.  
 
This section explains how compensation is acquired and tracked by NCGENES study staff.  
 
Requesting Cash and Gift Cards at UNC  
1. Staff s hould request 2 weeks before a need cash advance . 
2. Once a cash advance is deposited to the clinical director’s  personal checking account (auto -deposit) , another cash 
advance  should be immediately initiat ed. U p to 2 cash advances may be outstanding when submitting new cash 
advance requests . 
3. To complete  a cash advance request, ask for the cash advance request form from Minh Quach, tell him the amount 
need ed, receive via email, print , sign and return the originally signed doc to Minh (no scanned docs) . Minh  will 
get Jonathan  Berg’s co-signature.  
4. Receipt the distribution of money by ID#, date, amount with participants’ signature. This is done in the tracking 
system (receipt book used if tracking system does not work). The tracking system will create a printable 
spreadsheet of current charges (date to date) that I can be signed and given to Minh to justify each cash advance.  
5. Study cash must be spent within 60 days, otherwise staff will need to provide justification of unspent money  (e.g., 
participant  no shows etc.)  
Gift cards will be purchased with cash requested following the protocol above.   
 
Purchasing Gift Cards for Mission Participants  
Gift cards will be purchased by a Mission study team member and maintained in a locked box until needed.  
 
Requesting Child  Nonmonetary Gifts at UNC  
The study coordinator will:  
1. Request the P -Card from Laura Milko, NCGENES 2 Project Manager to make gift purchases  
2. Purchase gifts and make two copies of the receipt  
3. Submit the original receipt to Minh  
4. Keep an Excel spreadsheet that tracks the distribution of each purchased item  

 
 5. Submit the tracking spreadsheet to Minh Quach along with one copy of the corresponding receipt, when all of the 
items on a receipt have been distributed  
6. Keep one copy of the receipt for the NCGENES team records  
 
Requesting Child  Nonmonetary Gifts at Mission  
The study coordinator will be responsible for purchasing gifts, storing in secure location, and having appropriate gift 
available for each participant (by gender and age).  Purchase/reimbursement processes have been determined and agreed 
upon with the Principal Investigator and the Mission Research Institute.  
 
Tracking of Parent and Child  Compensation  
Following the completion of visit 1, the SC will complete the Excel tracking spreadsheets to indicate distribution of parent 
compensation and child  gift selection (i.e. child  compensation), and periodically update the clinical project director on the 
status of compensation distribution . The Excel document tracks the Participant ID#, date of compensation distribution, 
amount distributed, and whether the parent's signature was obtained (Y/N). After all the funds from each cash/gift card 
request have been dist ributed (typically to the amount of $700 or compensation for 10 participants), the SC will inform 
the clinical project director  of completion of fund distribution. Additionally, the SC will inform the clinical project 
director when a purchase is needed for nonmonetary gifts and when related submissions to Minh Quach occur.  
 
Compensation for Follow -up tasks  
After completion of the Return of Results and Final Follow -up surveys, the parents will be mailed gift cards. The gift 
cards will be tracked by recording the card amount, type and number of the gift card.  
 
 
 INTERNAL REPORTING /TRACKING  
 
To assist with providing study updates to senior study staff/study sponsor, the below spreadsheets/reports are completed.  
 
Enrollment Report  
The NCGENES Steering Committee meets twice a month to discuss overall study activities. Prior to each meeting, the 
biostatistician, Laura Farnan, creates a pre -visit 1 enrollment, visit 1 participation, and participation report. Each of these 
reports are stratified by served and underserved. The biostatistician works with the clinical project director and the study 
coordinator to identify and resolve any concerns regarding these reports. Then the clinical project director presents these 
reports during the S teering Committee meeting. If the director is unable to attend the meeting, the reports are presented by 
the study coordinator.  
 
Provider Report  
Beginning in February 2019, the biostatistician creates a report demonstrating the completion rate of provider surveys and 
PhenoTip data entry. Data in this report is displayed per provider in each UNC clinic. The SC works with the 
biostatistician to resol ve any questions regarding this report. Then the SC submits this report on a weekly basis to the 
project PI and clinical project director.  
 
Participant Eligibility  Tracking  
During the participant  eligibility screening process, if the SC is unable to determine eligibility, they discuss the situation 
with the clinical project director/project PI.  Based upon these discussions, eligibility is determined, and the decision is 
reflected in the tracking system/eligibility report.  
 
Participant s that are discussed with the PI, the biostatistician includes in the eligibility report. For this report the SC 
provides the biostatistician the following information to be included in the report:  the participant ’s name, medical record 
number, a summary of the situation, and the eligibility decision. For eligible participant s, the SC also provides the 
biostatistici an the NCGENES study ID number.  
 
This report is used by the SC and clinical project director as a resource when discussing future participant s with unclear 
eligibility and to review the completeness o f the study inclusion criteria.  
 
 PARTICIPANT MAILINGS  
 
This section contains step-by-step guides for completing all study mailings. First, this section address es general mailing 
procedures (e.g. mail -merge , postage) . Then, it details the steps for each specific mailing, starting with normal study 
mailings and moving to biospecimen collection mailings  
 
Study documents, especially mail merged documents, should be downloaded directly from IRBIS  to ensure that the most 
recent edited and authorized document versions are being used. Other documents can be downloaded from IRBIS and 
copied on appropriately colored paper (see below), HOWEVER careful attention should be paid to use the current version 
of the document. IF ANY change to a copied form is made and subsequently approved by IRB, all old copies of the form 
must be discarded and a new original obtained. Careful attention should be paid that current versions of all documents are 
being used.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS . 
 
General Mailing Procedures  
Tracking System Mailings Page  
All study mailings begin from the Mailing s Page in the tracking system. This page generates mail merge lists (excel files) 
with participant contact information and trac ks when mailings get sent. A detaile d description of the Mailings Page can be 
found in the “ Using the Tracking System ” section on page 65 . 
 
Completing the Mail Merge  
Once a mail merge excel document was been generated by the tracking system and download ed to a user’s computer, staff 
must use the mail merge function in Microsoft Word to print the letter(s) specific to each mailing. The process to 
complete these mail merges is largely the same  for each mailing  
 
1. Download the appropriate  letter from IRBIS  and open it in Word.1  
2. In Word, select the “Mailings” tab from the ribbon.2 
3. Select “Start Mail Merge” and then “Letters.”  
4. Click “Select Recipients,” “Select an existing list,” and then find and select the appropriate  excel sheet 
downloaded from the tracking system . 
 
1 The letters necessary for each mailing are listed in that mailing’s section below. You may also consult the “IRBIS – Cheat Sheet” for 
clarification on the appropriate file to download. This is a separate file; contact Peter Newman -Matthews if you do not h ave a copy.  
2 Screenshots from Microsoft Office display Windows version of these programs. Other versions may appear differently.  

 
  
(Optional: Some letters differ depending on clinic. For these letters, only relevant participants should be included 
in the merge. Steps 5 -6 demonstrate the process of filtering by clinic)  
 
5.  Click “Edit Recipient List”  
6. Sort by the field RVISITclinic and select only the appropriate clinic for the specific letter.  
7. Select “Preview Results.”  
8. Click “Finish & Merge” and then “Print documents.”  
In most cases, a mailing will contain at least one mail merge document. If a staff member encounters any issues with the 
mail merge function o r cannot locate the required documents, please contact Peter Newman -Matthews 
(peter@med.unc.edu ) for assistance.  
 
Mailing -Pre-postage protocol  
Each study site follows a different process in terms of ordering/printing postage. This section outlines these processes.  
 
UNC  

 
 1. Go to site:  https://portal.facilities.unc.edu/masterpg/slipMain.aspx  
 
2. If you are visiting this site for the first time, you will need to associate the project account with your onyen. 
If you have already done this, skip to step 3 : 
a. Click the green “+” sign to add the NCGENES 2 account to your onyen  
b. Click “Create New Favorite”  
c. Enter content listed below in the appropriate boxes  
Favorite Name:  NCGENES 2  
Business Unit:  UNCCH  
Fund:  25210  
Department:  423501 (updated 3/31/15)  
Source:  49000  
PC B us Unit:  CHOSR  
Project:  5113853 (updated 6/12/2019)   
Activity:  1 
d. Slick the “Save New Favorite” button.  
e. Close the window.  
 
3. Type your onyen and click “lookup” and the account information  will automatically populate.  
4. For the chartfield string click the drop down arrow and select the account.  

 
 5. For the campus box, you will initially need to manually enter: “7240” then going forward this number will be 
available via the dropdown arrow.  
6. Click “get standard slips”  
7. On the next page, enter today’s date and click 1st Class full Charge and then enter the # of items you are mailing.  
8. Use snipping tool to get “snip” of postage authorization slip. Save it and email it to Minh Quach at the end of each 
the month  (mquach@email.unc.edu ) 
9. Print the postage slip and cut along the dotted lines Paper clip it to the top of the mail and take it to the 
Bioinformatics Building mailroom on the Basement floor. The mailroom closes at 4:00pm; therefore, ideally all 
mail should be taken to the mailroom by 3:30pm to increase the likelihood of same day processing.  
 
Note:  
University Mailing Service Contact  
Nicole Ferrell  
Quality Assurance Specialist  
Located in the Bioinformatics Building  
Email: colee84@email.unc.edu   
Office #: 919.962.5075  
 
ECU (TBD)  
 
Mission  
Once the Mailing 2 packet is assembled and placed in the envelope, stamps (purchased and held by the Study 
Coordinator) are placed on the envelope according to weight; calculator can be accessed on USPS site if needed.  For 
example:  
• A Pre -Visit Prep envelope weighing 3.8 oz would require $1.45 in postage.  
• An envelope without the Pre -Visit Prep weighing 2.8 oz would require $1.30 in postage.  
 
Study mailings are then placed with other outgoing mail in the Laboratory reception area.  
 
 
  
 
 Mailing 1  – Intro Letter and Brochure  
All participant s who are selected or pending selection into the study will have a clinic -specific introductory letter and 
study brochure mailed to the parent’s address recorded in the tracking system. This mailing should be processed daily.  
 
To complete this mailing : 
 
1. Download the clinic -specific Intro letter from IRBIS , complete the mail merge , and print.  
2. Print 1 Intro ductory  Brochure  for each mailing.  
3. Affix postage  and address labels . 
4. Deliver to appropriate mailing deposit /box.  
 
Once the letters are printed, the y should be placed in standard envelopes with appropriate labels.  There are  more steps 
here.  
 
Relevant Documents  
 
Document  File Name ( Names in italics vary by site/clinic )  
Introductory Brochure  NCGENES_2_Study_Brochure_Recruitment_[DATE]  
Intro Letter  NCG2_Intro_Letter_UNC_Genet_initial_contact_Merge_[DATE]  
Mail merge excel sheet  NCGENES2_Intro_Letter_and_Brochure_[DATESTAMP].xlsx  
 
 
Mailing 2  – Pre-Visit Packet  
All parents who consent to participate in the study will be sent a study mailing that includes:  
 
• Reminder letter for research and doctor appointment with a map of the UNC Health Care Main Medical Campus  
• Instruction sheet for that describes the order in which forms in the study mailing packet should be completed  
• Information sheet (essentially a summary of the phone consent)  
• Intake Survey (Versions of survey vary by age1) 
• Pre-Visit Materials ( Dependent on randomization 1 assignment - These additional documents are for parents 
randomized to receive pre -visit educational materials.)  
o Pre-Visit Guide  
o Question Prompt List  
 
This mailing should be packaged after completing an enrollment call and sent the day it is put together.  
 
Note:  Except for the reminder letter, all of the other previously listed items should be pre -printed in bulk on the 
appropriately colored paper.  
 
  
 
1 Pediatric participants in NCGENES 2 must be <16 years at eligibility determination. The age -specific study documents sent to parent 
participants are based on the age determined at eligibility. Pediatric participants may age -up while actively understudy, b ut age is 
treated as static in the study. However, for assent, age must be based on the child’s age while at visit 1.  
 
 To Complete this Mailing:  
1. Download the Visit 1 Appointment Reminder  letter from IRBIS , complete the mail merge , and print.  
2. Print/collect and package the following attachments : 
a. For participants randomized into the pre -visit prep arm  
• Instruction Sheet A   (on white paper)  
• Information Sheet A    (on blue paper)  
• Age-appropriate  Intake Survey  (on yellow paper)  
• Pre-Visit Prep Envelope with  
o Pre-visit Guide  
o Question Prompt List  
b. For participants randomized out of  the pre -visit prep arm  
• Instruction Sheet B   (on white paper)  
• Information Sheet B   (on blue paper)  
• Age-appropriate  Intake Survey  (on yellow paper)  
3. Affix postage  and address labels . 
4. Deliver to appropriate mailing deposit/box.  
 
To simplify Mailing 2, study coordinators are encourage d to create separate files /sectionals for the two versions of the 
Visit 1 appointment packets (i.e. pre -visit prep and no pre -visit prep). The Pre -Visit Guide and Question Prompt List can 
be pre -printed together and enclosed in an individual envelope with a pre-visit envelope label. Those envelopes can be 
stored alongside  the Instruction sheet A  and Information sheet A. A separate file/sectional can house  the contents of the 
Version B packet for the packets without Pre -Visit Preparation : Instruction Sheet -B and Information Sheet -B.  
 
The Intake Survey is child -age specific  and does not differ across pre -visit prep assignments. Be sure to include the 
correct version of the survey for the participant . Include the survey version for the age of the participant  at the time th at 
their eligibility was determined . 
 
Important notes about age in NCGENES 2:   Pediatric participants in NCGENES 2 must be <16 years at eligibility 
determination. Intake surveys  sent to parent participants are based on the child’s age at their determin ation  of eligibility. 
The following table clarifies the age ranges found on intake surveys : 
 
 Survey Age Bracket  Clarified Age Range  
 1-12 mos  From birth until 1 day prior to 1st birthday (includes infants <1 month old)  
 13-24 mos  From 1st birthday until 1 day prior to 2nd birthday  
 2-4 yrs  From 2nd birthday until 1 day prior to 5th birthday  
 5-7 yrs  From 5th birthday until 1 day prior to 8th birthday  
 8-12 yrs  From 8th birthday until 1 day prior to 13th birthday  
 13-18 yrs  From 13th birthday until 1 day prior to 16th birthday (excludes patients >16 years old)  
 
  
 
 Relevant Documents  
Document  File Name ( Names in italics vary by site/clinic )  
Visit 1 Appointment 
Reminder Letter  NCGENES_2_V1_Appt_Reminder_Letter_Mail_Merge_[DATE]  
Intake Survey  Intake Survey [DATE] for [Age Range] clean  
Information Sheet  NCGENES_2_Information_sheet_Version_A_clean_[DATE]  
NCGENES_2_Information_sheet_Version_B_clean_[DATE ] 
Instructions Sheet  NCGENES 2 Instructions Sheet with Previsit_[DATE]  
NCGENES 2 Instructions Sheet without Previsit_[DATE]  
Pre-Visit Booklet  Pre-Visit Booklet_post CCT input -- FINAL [DATE]  
Question Prompt List  NCGENES QPL_1 page flyer [DATE] -jsb cr.pptx  
Mail Merge Excel Document  NCGENES2_Visit_1_Appointment_Packet_ -
_without_Pre_Visit_Prep_[DATESTAMP].xlsx  
NCGENES2_Visit_1_Appointment_Packet_ -
_with_Pre_Visit_Prep_[DA TESTAMP ].xlsx  
 
Mailing 3 – Pre-RoR Packet  
Adult  participants who consent ( with assent as necessary ) to the Randomization to Genome Sequencing will receive some 
version of a Pre -Return of Re sults Packet  regardless of their randomization to intervention 1 or 2. This mailing contains a 
letter reminding parents that they  will receive a survey after they’ve received results . Participants randomized to exome 
sequencing and pre-visit prep will also receive some pre -return of results education al materials.  
 
To Complete this Mailing:  
1. For participants randomized to receive Exome Sequencing and Pre-Visit Prep:  
a. Download the “pre-ROR Packet Letter – GS and Prep ” letter from IRBIS , complete the mail merge , and 
print.  
b. Print  and attach  the Pre RoR prep  brochure with Question Prompt List  
2. For all other participants,  download the “pre-ROR Packet Letter – NO RoR ” letter from IRBIS , complete the 
mail merge , and print.  
3. Affix postage  and address labels . 
4. Deliver to appropriate mailing deposit/box.  
 
Relevant Documents : 
Document  File Name ( Names in italics vary by site/clinic )  
Pre-RoR Packet Letter  NCGENES_2_pre -RoR_PACKET Letter_GS_and_Prep_Arm [DATE]  
NCGENES_2_pre -RoR PACKET_Letter_NO_RoR_Prep [DATE]  
Pre RoR Prep brochure  NCGENES 2 pre ROR prep_FINAL  
Mail Merge Excel Document  NCGENES2_Pre -RoR_Packet_ -_No_GS_without_Pre -Visit_Prep_[DATESTAMP].xlsx  
NCGENES2_Pre -RoR_Packet_ -_ GS_without_Pre -Visit_Prep_[DATESTAMP].xlsx  
NCGENES2_Pre -RoR_Packet_ -_ GS_with_Pre -Visit_Prep_[DATESTAMP].xlsx  
 
Mailing 4 – 2 Week Post -RoR Parent Survey  
Adult participants who consent their children (with assent as necessary) to the Randomization to Genome Sequencing will 
receive some version of a Post-RoR 2 week survey  regardless of their randomization to intervention 1 or 2. This mailing 
contains a cover letter and one of four surveys depending upon the participant . 
 
  
 
 To Complete this Mailing:  
1. Download the RoR 2 Week Survey  Letter from IRBIS , complete the mail merge , and print.  
a. For participants consented to genome sequencing : 
i. If the participant was randomized to Pre -Visit Prep , attach the “RoR 2 Week Parent Survey [DATE] 
Paper ES and Previsit Prep” Survey  
ii. If the participant was randomized out of  Pre-Visit Prep , attach the “RoR 2 Week Parent Survey [DATE] 
Paper ES and  NO Previsit Prep” Survey  
b. For participants who did not receive genome sequencing:  
i. If the participant received some diagnostic testing , attach the “RoR 2 Week Parent Survey [DATE] 
Paper No ES and Diagnostic Testing ” Survey  
ii. If the participant did not  receive any diagnostic testing , attach the “RoR 2 Week Parent Survey [DATE] 
Paper No ES and No Diagnostic Testing ” Survey  
2. Create a return envelope and include in the mailing  
3. Affix postage  and address labels . 
4. Deliver to appropriate mailing deposit/box.  
 
Relevant Documents : 
Document  File Name ( Names in italics vary by site/clinic )  
RoR 2 Week Survey  Letter  RoR 2 week survey cover letter_[DATE]  
RoR 2 Week Survey s RoR 2 Week Parent Survey [DATE] Paper ES and Previsit Prep  
RoR 2 Week Parent Survey [DATE] Paper ES and NO Previsit Prep  
RoR 2 Week Parent Survey [DATE] Paper No ES and Diagnostic Testing  
RoR 2 Week Parent Survey [DATE] Paper No ES and No Diagnostic Testing  
Mail Merge Excel Document  NCGENES2_P ost-RoR_ -
_Parent_2_Week_Questionnaire _Mailing _[DATESTAMP].xlsx  
 
Mailing 5 – Gift Card and Thank You for 2 Week Survey  
Whenever a completed 2 week Post -RoR Parent Questionnaire  is returned by the parent, a thank you card should be sent 
to the parent along with a gift card for $30 (See Tracking Participant Compensation ). This mailing should be sent even 
if the survey was completed outside the technical window for completion.  
 
To Complete this Mailing:  
1. In a thank you card, write the following  message:  
 “Thank you for completing and returning your survey! It will be a few months  before the next 
 study step which is a survey.  Please let us know if you have any questions or changes to your 
 contact information. Thank you for your continued participation in NCGENES!  
 [include a name and best contact method #]”  
2. Place a gift card in the thank you card and place both in an envelope.  
3. Affix postage  and address labels  (using mail merge  from tracking system) . 
4. Deliver to appropriate mailing deposit/box.  
 
Relevant Documents:  
Document  File Name ( Names in italics vary by site/clinic )  
Mail Merge Excel Document  NCGENES2_Post -RoR_ -
_Parent_2_Week_Questionnaire_ Gift_Card_ Mailing_[DATESTAMP].xlsx  
Thank You Text  Text_inside_Thank_You_Notes_NCGENES_[DATE]  
 
Mailing 6 – 6 Month Post -RoR Parent Survey  
 
 Adult participants who consent their children (with assent as necessary) to the Randomization to Genome Sequencing will 
receive some version of a Post -RoR 6 month survey regardless of their randomization to intervention 1 or 2. This mailing 
contains a cove r letter and one of several surveys depending upon the participant ’s age and clinical history . 
 
To Complete this Mailing:  
1. Download the RoR 6 month  Survey Letter from IRBIS , complete the mail merge , and print.  
a. For participants consented to genome sequencing , attach the “ RoR 6 Month Parent Survey [DATE] [AGE 
RANGE] Paper Diagnostic Testing” Survey  for the age of the participant.  
b. For participants who did not receive genome sequencing:  
i. If the participant received some diagnostic testing , attach the “RoR 6 Month Parent Survey [DATE] 
[AGE RANGE] Paper Diagnostic Testing” Survey for the age of the participant.  
ii. If the participant did not  receive any diagnostic testing , the “RoR 6 Month Parent Survey [DATE] [AGE 
RANGE] Paper NO Diagnostic Testing” Survey for the age of the participant.  
2. Create a return envelope and include in the mailing  
3. Affix postage  and address labels . 
4. Deliver to appropriate mailing deposit/box.  
 
The 6 month Post -RoR Survey is child -age specific . Be sure to include the correct version of the survey for the 
participant. Include the survey version for the age of the participant at the time of the survey’s mailing . 
 
Important notes about age in NCGENES 2:   Pediatric participants in NCGENES 2 must be <16 years at eligibility 
determination. Intake surveys sent to parent participants are based on the child’s age at their determination of eligibility.  
The following table clarifies the age ranges found on intak e surveys:  
 
 Survey Age Bracket  Clarified Age Range  
 1-12 mos  From birth until 1 day prior to 1st birthday (includes infants <1 month old)  
 13-24 mos  From 1st birthday until 1 day prior to 2nd birthday  
 2-4 yrs  From 2nd birthday until 1 day prior to 5th birthday  
 5-7 yrs  From 5th birthday until 1 day prior to 8th birthday  
 8-12 yrs  From 8th birthday until 1 day prior to 13th birthday  
 13-18 yrs  From 13th birthday until 1 day prior to 16th birthday (excludes patients >16 years old)  
 
 
Relevant Documents:  
Document  File Name ( Names in italics vary by site/clinic )  
RoR 6 Month Survey Letter  RoR 6 month survey cover letter_[DATE]  
RoR 6 Month Survey s RoR 6 Month Parent Survey [DATE] [AGE RANGE] Paper NO Diagnostic Testing  
RoR 6 Month Parent Survey [DATE] [AGE RANGE] Paper Diagnostic Testing  
Mail Merge Excel Document  NCGENES2_Post -RoR_ -
_Parent_ 6_Month _Questionnaire_Mailing_[DATESTAMP].xlsx  
 
  
 
 Mailing 7 – Final Gift Card and Thank You for 6 Month Survey  
Whenever a completed 6 month Post -RoR Parent Questionnaire is returned by the parent, a thank you card should be sent 
to the parent along with a gift card for $60 (See Tracking Participant Compensation ). This mailing should be sent even 
if the survey was completed outside the technical window for completion.  
 
To Complete this Mailing:  
 
1. In a thank you card, write the following message:  
 “Thank you for completing your final survey with NCGENES 2!  
 [include a name and best contact method #]”  
2. Place a gift card in the thank you card and place both in an envelope.  
3. Affix postage  and address labels  (using mail merge  from tracking system).  
4. Deliver to appropriate mailing deposit/box.  
 
Relevant Documents:  
 
Document  File Name ( Names in italics vary by site/clinic )  
Mail Merge Excel Document  NCGENES2_Post -RoR_ -
_Parent_ 6_Month _Questionnaire_Gift_Card_Mailing_[DATESTAMP].xlsx  
Thank You Text  Text_inside_Thank_You_Notes_NCGENES_[DATE]  
 
 
 
 
 USING THE TRACKING SYSTEM  
 
A web -based tracking system has been developed for the management of the NCGENES 2 project. The tracking system 
originates, facilitates  and/or records every study activity . In other words, it is the central tool of study staff . The tracking 
system can be accessed in several different ways.  Users should be cautious of which site they are using, as any data 
entered on the live site will be part of the study record.   
 
Each study location  (UNC, Mission, ECU) has a  corresponding tracking site independent  from the others. While the 
URLs for each are identical, a user ’s log -in information will dictate which tracking site they view . The study location  of a 
tracking site will be indicated in its header  (See Homepage  on page 61 ). If a study staff member has different roles at 
multiple sites, they will need different log -in credentials in order to access each site separately.  
 
Live Site:  https://ncgenes2.sirs.unc.edu/  
The live site is the main hub for study operation.  
 
Demo Site  I: https://ncgenes2.sirsdemo.unc.edu/   
This demo version of the site was used for development  of pre -visit and visit 1 tasks  and can be used for training 
purposes.  Data input here does not enter the study record.  Additionally, alert protocols created  by the Demo Site will not 
trigger emails to the clinical project director.  
 
Demo Site II:  https://ncgenes2 -ror.sirsdemo.unc.edu/  
This demo version of the site is used for development of return of results tasks and can also be used for training purposes.  
Data input here does not enter the study record.  Additionally, alert protocols created by the Demo Site will not trigger 
emails to the clinical project director.  
 
Survey Site: https://ncgenes2.sirs.unc.edu/surveys  
The survey site is used to complete parent surveys. Each survey requires a unique code and parent’s completing surveys 
using this site cannot access other data in the tracking system.  
 
Provider Site:  https://ncgenes2.sirs.unc.edu/  
Provider’s share a log -in page with other study staff but  see a unique version of the site . Provider’s only access surveys 
and result information for their patients.  
 
This section covers the basic functions of the tracking system , key terminology, important tools within the tracking system  
and tracking system roles. Later on, the protocol provides  more detailed instructions for completing specific tasks within 
the tracking system.  
  
 
 Logging In  
The following covers logging in to the live tracking site with appropriate screenshots. The same procedures can be used to 
access either demo version of the site.  
 
1. In a web browser , navigate  to https://ncgenes2.sirs.unc.edu/ . The following page will appear:  
 
2. If this is your first time accessing the system, you’ll need to create a password. Steps 3 through  7 will cover this 
process. If you already have a password, simply enter your email and password in the appropriate  boxes and click 
the blue “Login” button to log in.  
 
3. If you  need to create a password, or if you cannot remember your password, click the “Forgot Your Password?” 
link just to the right of the “Login” button. The following page will appear:  
 
4. Enter your email address into the appropriate box, and click the “Send the Password Reset Link.” One of two 
things will happen at this point.  
 
a. If the following screen appears  (next page) , you may not have been added as a user to the tracking 
system. If you receive this message , contact the project coordinator ( pnewmatt@med.unc.edu ) or study 
director ( jeannette_bensen@med.unc.edu ) to resolve the issue . 
 

 
 b. In most cases, the following screen will appear : 
 
5. If you receive this message, proceed to your email inbox and look for an email from jknop@unc.edu . The email 
should look like this:   
 
6. Click the blue “Rest Password ” button, which will open a new browser window (or tab) displaying the following 
page:  
 
7. Enter your email, new password twice in the appropriate boxes. Then press the blue “Reset Password” button. 
You will be automatically logged  in at that time. Remember to keep track of your password for future logins.   

 
 Key Terminology: Task v. Status  
Two terms, task and status, are central to the functioning of the tracking system . Unfortunately, these terms are also easily 
conflated.  
 
Tasks  
Study activities are captured in the tracking system as tasks. A task is completed by study staff in accordance with wider 
protocol. For example, the study coordinator will complete the “Enrollment Call” task while they call a parent and attempt 
to enroll them. As a participant moves through the study , the completion of tasks  will trigger subsequent tasks . At a given 
time, a participant may have several tasks pending . A participant’s task s are listed on their individual page  (see page 67). 
 
Statuses  
Unlike tasks, a participant can only have one status at a time. Statuses capture a participant’s progress through the study. 
For instance, a participant whose parent has completed the enrollment call and consented will have the status of “Parent 
Consented.” Participants with similar status es are in the same  phase of the study. Several statuses in the study are final 
statuses . As the name indicates, final statuses do not change and indicate a participant’s final state in relationship to 
NCGENES. Appendix II contains a full diagram of study statuses.  A participant’s current status  is listed on the 
Participants List (see page 62) or on the participant’s individual page  (see page 67).  
 
Status v. Assignment  Statuses are distinct from selection and randomization assignments. NCGENES 2 has 1 selection 
and 2 randomizations. For each participant that reaches th ose points of the study, their selection or randomization 
assignment will appea r to the right of their name on their individual page  (see page 67). A participant can have more than 
one assignment at one time  (in addition to their status)  and keeps any assignment throughout the study.   
 
 Main Tracking System Pages  
Every tracking system user will frequently encounter  a few main  pages. I n order to orient a potential user, this section 
contains a screenshot of each page with detailed breakdown of their components. The pages covered are the homepage , 
participant list, mailings page, documents page, and individual participant interface.  
 
Homepage  
Upon logging in to the tracking system , users are directed to the homepage. The homepage  lists incomplete study tasks by 
order of their due date.  All study activities logged in the tracking system are captured as tasks . As tasks are completed, 
new tasks are assigned and given due dates by the system based on study protocol.  
 
  
Click here to log out 
of the tracking system  
Toggle between these icons to sort 
the list by different categories.  
Clicking an “Action” button will pull 
up the corresponding task within the 
tracking system. There are two 
possible options for this button, 
highlighted here. Completed tasks 
will not appear on the homepage  
Navigation Header: Visible on all pages. Used to move between pages. 
Gray circle indicates the current user’s study location.  
On the homepage, participants are listed by first and last 
name separately. Clicking on either first or last name will 
take you to that individual participant’s page.  
 
 Participants List  
The P articipants List is accessible from the Navigation Header. As opposed to the homepage, the Participants List 
displays each participant by order of their ID number . In addition, the Participants List shows each participant’s most 
recent status. Importantly, the “New Participant” button is accessed from the Participant List , which allows for the manual 
entry of new participants.  
  
The “New Participant” Button opens a separate form for 
entering data manually. See next page for instructions 
on manually entering a participant.  
Participant names link to individual 
participant pages.  
Click on “Participants” in the Header 
to access this page.  
 
 Manually Adding a Participant  
1. After clicking the “New Participant” button (see above ), the following dialog box  will appear.  
  

 
 2. On this form, enter in as much information as possible about the participant. At minimum, the following fields are 
required : 
a. Name  
b. DOB  
c. Clinic  
d. Provider  
e. Gender  
f. Race  
g. Ethnicity  
 
3. Once all availa ble information has been input, click the blue “Save” button in the bottom corner of the form to 
enter the participant.  
 
Need to edit information on an automatically referred participant?  Once a participant  has been referred , demographic and 
contact information can be edited from that participant’s individual page. For more see the Changing Participant Info  
section . 
  
 
 Mailings Page  
 
The Mailings Page provides lists, organized by mailing, of which participants are due to receive each mailing. This page 
can be accessed from the Navigation Header  and by starting any mailing task.  
  
The name of each mailing 
is followed by the number 
of participants currently 
due for that mailing.  
Clicking “Show Participants” expands the 
selected mailing to list all participants due 
for that mailing.  
Some or all participants can be 
selected by checking the boxes 
next to their name or the box 
next to “Select All.”  
Clicking the “Generate Mail Merge” button 
will automatically download an excel file 
with address information for all the 
participants selected.  
Click on “Mailings” in the 
Header to access this page.  
 
 General Documents Page  (Not Participant Specific)  
The Documents Page houses all the audio files and transcripts  generated by audio -recorded clinic visits. Files can be 
uploaded and downloaded from this page , which is accessed using the Navigation Header . Apart from audio files , all 
participant files should be uploaded  on the individual participant ’s page at the  Documents  tab (See page 74). 
  
Clicking the “View” button automatically 
downloads the corresponding document/file.  
The “New File Upload” Button opens a 
dialog box. Here you can select a file using 
the “Choose File” button and name it 
according to relevant conventions. Clicking 
the “Upload” button completes this process.  
When uploading audio recordings of clinic visits, the  file should be named using the 
following nomenclature: “(NCGENES 2 ID )_audio (# of recorder)_YYYY_MM_DD” . 
Example: NCG20001_audio1_2018_07_11.  
Click on “Documents” in the 
Header to access this page.  
 
 Individual Participant Page 
 
Each participant that is referred as potentially eligible or manually entered into the tracking system has an individual page  
which tracks all the data regarding that participant. This page also contains several tools for completing study tasks  or 
logging contact with the participant.  It can be accessed from the Homepage  or Participants List . 
 
Participant Tasks  
 
The standard view of the participant page displays all pending and completed tasks associated with that participant  listed 
by their order in study protocol.   
Participant Name  
Action buttons and Tabs navigate 
between tools and pages in the 
participant interface.  
Survey codes for use in 
administering Parent 
Questionnaires are 
located here.  
Yellow pill displays current/final 
status of the participant.  
Parent name and 
contact information  
Cool -colored pills display selection 
and randomization statuses.  
Pending tasks can be opened by clicking the “Get Started” 
or “Continue” button. The information on Completed 
tasks can be viewed and edited by selecting “See data.”  
 
 Communication Log  
The study tracking system has a built -in communication log. Communications with participants (calls, mailings, emails, 
etc.) should be tracked in the communication log.  
 
  
The Communication Log is accessed by 
selecting its tab on the Sub -menu  
Existing logs will be displayed by date and 
can be edited or deleted using the pen or 
trash buttons respectively  
New Communication Logs can be 
created by clicking the “Log 
Communication” button. See next 
page for step -by-step instructions 
for logging communication.  
The Communication Log is ordered in reverse -
chronological order with the most recent log 
appearing at the top of the list.  
 
 To log a communication : 
1. After clicking the “Log Communication” button on the appropriate partic ipant’s page, the following dialog 
box will appear:  
 
2. Enter the following data in the communication:  
­ Date  & Time: These fields will auto -populate to the time you log the communication  
­ Subject: Recruitment, Scheduling, Compensation, Contact Check, Birthday  
­ Channel: In -Person, Phone, E -mail, Mailing Address  
­ Status: Reached, Left Message, Bad Contact Information, No English, No Answer  
­ Notes  
 
3. If necessary , select the “Create Appointment”  button  to set an appointment in conjunction with th e 
communication log.  
 
4. In either case, click the “Save changes” button at the bottom of the box. The communication will then be 
saved and visible  from the Communication Log  tab on the participant’s page.  
  

 
 Status Dates  
The Status Dates tab displays all the statuses associated with the study. If a participant currently has or has previously had 
that st atus, the date of that status will be displayed. Otherwise, the status will display as “blank.”  
 
 
 
  
Once a status has 
been changed, that 
change will be 
reflected in the 
status date tab and 
in the yellow pill 
beneath the 
participant’s name.  
A participant’s status can be 
changed manually by clicking 
the “Change Status.” This will 
open a drop -down menu.  
For whichever option is 
selected, a dialog box 
will appear. Select the 
appropriate sub -type of 
status change and type 
in a reason. Click “Save 
Changes” to complete 
the status change.  
Apart from “Force Set…,” all these 
statuses are final and cannot be 
changed.  “Force Set...” returns 
participants to  initial “Referred” 
status and resets all data.  
 
 History  
The History tab displays all the tracking system activity for a given participant . Most changes to participant data, 
including participant status, are captured here. This tab is useful for reviewing a participant’s  case in more depth than 
might be afforded by the task page . 
 
  

 
 Notes  
Notes are used for participant -specific internal communication between NCGENES study staff.  There are two types of 
notes in the system: 1) Information notes and 2) Alerts.  
 
  
When an alert is no longer necessary  
or a note needs to be changed , a 
note can be edited by clicking the 
“edit” button on that note and 
updating its text and/or changing its 
type using the dropdown menu and 
clicking “Save.”  
New Notes are created by click the “New Note” button on the Notes tab. This opens a dialog 
box shown on the next page.  
Alerts are used for time -sensitive/important 
information that study staff should know about the 
participants. Different from an information note, alert 
notes appear on the Participant’s Individual Page 
above the participant’s name.  
Information notes remain in 
the notes tab and should be 
used for general and internal 
communication/reminders 
between study staff.  
Notes are ordered in 
chronological order with the 
most recent note appearing 
at the bottom of the list.  
 
 To create a note:  
1. After clicking the “New Note” button on the Notes tab o f a participant ’s page  (see previous page) , the following 
dialog box will appear:  
2. Enter the Content, and select your Username and desired note type from the corresponding dropdown menus  
(Second dropdown shown here).  
3. Click the “Save” button  
4. Check that the note has saved in the Notes tab  
 
  

 
 Participant Documents  
The Participant Documents tab houses electronic copies of any forms or surveys completed by the participant on paper.1 
While many forms and surveys can be completed within the tracking system, technical disruptions or other extenuating 
circumstances may require the participant or parent complete forms on paper. Such forms should be uploaded into the 
system at the participant’s Documents tab.  
  
 
1 Audio recordings and transcripts will be found on the main documents page accessible from the Navigation Header. See Documents 
Page  
Files can be added to a participant’s Documents 
tab by clicking the “Upload Document” tab, 
which opens the following dialog box. After 
naming and selecting the file to upload, click 
the “Upload” document to upload the file.   
Clicking the “View” button will 
automatically download a copy of 
the corresponding document. 
Documents can also be deleted by 
clicking the “delete” button.  
 
 Other Items on the Individual Participant Page  
The Individual Participant Page contains  some features in addition to the tabs and functions already mentioned. These are 
addressed here .  
  
The “Schedule Reminder” button is not 
currently part of study protocol. See 
Calendaring  
The “Edit Info” button allows 
the user to edit any 
demographic information 
about the participant in the 
dialog box it opens. See below.  
The “Molecular Analysis” button opens a 
separate page which displays results of a 
participant’s exome sequencing.  
The “More” button opens a dropdown menu. The options of this 
menu will change depending on various participant data. All 
possible options are depicted here. The first two options 
download a excel document with the participant’s address and 
NCGENES2 barcode, respectively. The last two create the listed 
task in the tracking system.  
 
 Changing Participant Info  and Contact  
As mentioned above , participant info can be changed by clicking the “Edit Info” button on an individual participant’s 
page.  This opens a new page where the participant  information  can be edited/updated.  
 
If a participant’s contact information needs to be edited/added, the user should instead click on the “See all”  located 
within the parent contact box in the upper -right corner of the individual participant’s page.  
 
This will open the dialog box shown below.  All contact channels currently listed in tracking will appear in this box.  
 
Primary channels will be tagged as shown.  
  

 
 To add a new contact channel, click the “Add” button in the bottom right of the box shown above. This will open the 
following  dialog.   
Select the appropriate channel type from the dropdown list shown below.  
Then, enter in the name of  the channel (e.g. Home Phone), “Address” (e.g 123 -456-7890), and any notes as appropriate. If 
the channel is the primary contact of that type  or if the channel is defunct, indicate this by checking the appropriate boxes . 
  

 
 Any existing contact information can be edite d by selecting it in the dialog box and clicking the pencil icon  as show 
below.  A contact channel can also be deleted by clicking on the trash icon, if necessary.  
 
Conventions for Contact Information  
If the contact information for the parent is entered correctly, the parent info box in the top right corner to the participant’s 
individual page should appear as shown below. Two common errors may skew the appearance of this box.  
Parent Info Missing : If the “Name:” and “Relationship:” fields do not appear  AND the primary guardian is known , ensure 
the “Primary Guardian Relationship” dropdown has a value selected using the “Edit Info” button .  
Name listed before Contact Inf o: If one of the contact fields (e.g. Phone, Mailing Address) is instead listing the legal 
guardian or participant name, this is a misnomer . In order to resolve this issue, that contact channel’s info should be edited 
so that the “Name” field lists the name of the contact channel, rather than the name of the legal guardian or participant.   
Fields should 
appear. If not, 
“Edit Info.”  Fields should not 
display parent or 
child name. If so, 
edit contact info 
(see above).  
 
 Tracking System Roles  
Each use in the tracking system is assigned a role that determines what pages and data that user can access. These roles 
are related to clinical study roles , but are not identical.  
 
id name  Description  
1 Programmer  Programmer working on the system. Has all privileges.  
2 Study Manager  Study Manager has administrative permissions, but should 
not be able to make configuration level changes  
3 Primary Investigator  Primary investigator has full access to the system.  
4 Interviewer  This role is blinded for randomization groups across the 
whole system . 
5 Provider  Provider doing select surveys.  
6 Interviewer Transcriber  This role is blinded to randomization groups for participant s 
until Visit 1 is completed. This role is unblinded to 
randomization groups for participant s after post visit 1 is 
completed . 
7 Transcriber  This role only has access to documents screen . 
8 CLIA  CLIA labs  
 
 
 TRACKING SYSTEM TASKS: STEP -BY-STEP GUIDE S 
 
For every study activity, there is a corresponding task in the tracking system. Some tasks, such as mailings, originate in 
the tracking system and are completed in paper form. Others, such as enrollment calls , are conducted in concert with the 
tracking system. In this section of the protocol, we provide step -by-step instructions for completing every task within the 
tracking system. These guides will omit explanations of exceptiona l situations which might require deviation from 
standard procedures . Such explanations are address ed in the narrative section of the protocol.   
 
Patient eligibi lity and selection  
1. From the  Homepage  (Fig. 1) or an Individual Participant’s  Page (Fig. 2) , find the “Patient eligibility and 
selection” task and select the “Get Started” or “Continue” button.1 
 
2. The dialog box pictured below will a ppear. DOB, Clinic, Provider, Appointment Date and Time, should be pre -
populated on the E ligibility Page. Any missing information should be entered.  
 
3. Based on etiology criteria ,2 click “No” or “Yes” for the question: “Is the cause of this child’s condition unknown 
but likely genetic?”  If “No” the following question will appear . Select the appropriate reason for ineligibility from 
the dropdown.  
 
1 At any point, clicking “Save” or “Save & Exit” allows the user to leave the task and return later to continue.  
2 A list of inclusion and exclusion clinical criteria has been developed by the NCGENES 2 physician team and should be referred  to 
when evaluating a participant’s eligibility Appendix I. Etiology Criteria.  
Fig. 1  
Fig. 2  
FIRST NAME  LAST NAME  
NAME  
 
  
4. In either case, input the referral reason/clinical information/diagnosis  under “Describe the Condition.”  
 
5. Once all data has been entered, click the “Next” button to proceed.  If the participant  is ineli gible, this action will 
take the user to the participant’s individual page and the task will be complete. Otherwise, the following page will 
appear for participant selection.  
 
6. Choose the pediatric participant ’s status for each of the following : race, ethnicity , and t ype of insurance . This 
information , if available,  should be prepopulated from the auto -feed or manually entered patient data . 
 
7. Even if all fields cannot be completed, click the blue “Finish & Finalize” button. This will complete the task and  
redirect the user to the participant’s individual page.  This step is critical because it triggers the task to mail the 
Introductory Letter and Brochure . 
  
NAME  
 
 Intro Letter and Brochure  
The “Intro Letter and Brochure” task is a mailing task. This (and all) mailing task (s) can be started from the homepage  
(Fig. 1)  or individual participant page  (Fig. 2)  by clicking the “Get Started” button for the appropriate participant .  
Either action will redirect the user to the “Mailings” page , where they can generate a mail merge document for a particular 
participant. The “Intro Letter and Brochure” task will be marked complete in the tracking system when this mail merge is 
generated.  
Mailings should be completed  on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 1  section under Mailings . 
 
Enrollment Call (with Selection ) 
Introduction  
 
1. To begin the enrollment call, select the “Get Started” or “Continue” button next to the “Enrollment Call” or 
“Enrollment Call with Selection” task for the appropriate participant. This can be done from either the Home Page  
(Fig.  3) or the Individual Participant Page  (Fig. 4).  
 
  
Fig. 4 
Fig. 5 
Fig. 1  
Fig. 2 
Fig. 3 
 
 2. The dialog box shown below will appear. Throughout the call the script will displayed in a series of dialog boxes. 
The user  should follow along with the script in each dialog box. Actions and reminders will be bolded and 
bracketed  and should not be spoken aloud . Call the parent and walk through the scripts, following prompts 
appropriately. Under “Available ,” select whether the parent  is available and willing to speak over the phone at 
that time.1 
  
 
1 At any point, clicking “Save” or “Save & Exit” allows the user to leave the task and return later to continue.  

 
 a. If the parent is not available, the following section will expand within the dialog box. Enter a date, time, 
and phone when the parent will be available. After concluding the call, click the blue  “Next” button. This 
will end the task for the time being, which can be restarted when the parent is called back . (See step 1)  
b. If the parent declines, the following section will expand within the dialog box. If the parent gives a 
reason, enter it here . After concluding the call, click the “Next” button. This will complete the task and 
the participant ’s status wi ll be changed to “Refused.”  
  

 
 c. If the parent is available, the following section will expand within the dialog box. Continue with the call.  
 
i. If the parent is interested in the study, select “Yes”  under “Interested .” Then, click the blue 
“Next” button. The user will be directed to the Selection  page.  
 
ii. If the parent is not interested in the study, select “No” under “Interested.”  The dialog box will 
expand as shown below. If the parent provides a reason for their lack of interest, enter it here . 
Then, after concluding the call , click the blue “Next” button. This will close the dialog box, 
complete the task , and change the participant’s status to “Refused.”  

 
 Selection  
 
1. If a participant ’s selection was completed at the time eligibility was determined, the following dialog box will 
appear . Click the blue “Next” button and proceed to Parent Eligibility . 
 
2. If, however, the  participant ’s selection has not occurred, the following dialog box will appear.  After re ading the 
script, enter the parent’s answers to the child’s DOB, race, ethnicity , and health insurance. Once all fields are 
entered, click the blue “Next” button . 
 
  

 
 a. If the participant is not selected , the following dialog box will appear. Conclude the call with the parent 
and click the blue “Next” button. This will complete the task and change the participant’s final status to 
“Participant Not Selected.”  
 
b. If the participant is selected, the following dialog box will appear. After reading the script, click the blue 
“Next” button . The system will automatically proceed to Parent Eligibility.  
  

 
 Parent Eligibility  
 
1. When  the Parent Eligibility  page is reached, read through the script and record the parent’s answers to each 
question where appropriate . Once every question has been answered,  click the blue “Next” button.  
 
a. If the parent answers “No” to any of the questions, they will be ineligible. The following dialog box 
will appear. Read the script, conclude the call, and click the blue “Next” button. This will complete 
the task and change the participant’s status to “Parent Ineligible – [Reason for Ineligibility].”  
  

 
 b. If the parent answers “Yes” to all questions, they will be eligible. The following dialog box will 
appear. If the parent cannot continue the call, record a call -back time, c onclude the call,  and click 
“Save & Exit ” in the bottom right corner of the box. If the parent can continue the call, click the blue 
“Next” button to proceed to Consent.  
  

 
 Consent  
 
1. The consent page (shown below) is the m ost extensive of any page during the enrollment call. After carefully 
explaining the study to the participant following the script, ask the par ent if they agree to the first part of the 
study.  
a. If the parent declines, select “No.” The following section will expand. If the parent offers a reason for 
declining, enter it here. Conclude the call and press the blue “Next” button.  This will complete the task and 
give the participant a status of “ Refused .” 
 
b. If the parent agrees to join the study, select “Yes” and click the blue “Next” button. The system will 
automatically continue to Randomization.  
  
[SCRIPT COMPRESSED]  
 
 Randomization  
 
1. The Randomization pa ge has two versions , with (Fig. 1) and without (Fig. 2) pre-visit education.  Read through 
the script and ver ify the mailing address for the parent.  
  
Fig. 1  
Address  
Fig. 2 
Address  
 
 2. If the parent indicates the address is incorrect, click “No.” The box will expand as shown below. Enter the 
parent’s corrected address  and continue with the call.  
3. Once the script is concluded, end the call with the parent and click the blue “Finish & Finalize” button. This will 
complete the task  and automatically redirect the user to the individual participant’s page.  
  

 
 Visit 1 Appointment Packet – with(out) Pre -Visit Pre p 
The “Visit 1 Appointment Packet – with(out) Pre -Visit Prep” task is a mailing task. This (and all) mailing task (s) can be 
started from the homepage  (Fig. 1)  or individual participant page (Fig. 2) by clicking the “Get Started” button for the 
appropriate participant . 
Either action will redirect the user to the “Mailings” page, where they can generate a mail merge document for a particular 
participant. The “ Visit 1 Appointment Packet – with(out) Pre -Visit Prep ” task will be marked complete in the tracking 
system when this mail merge is generated  (Fig. 3) . 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 2  section under Mailings . 
  
Fig. 1  
Fig. 2 
Fig. 3 

 
 Reminder Call for Visit 1  
1. To begin the Reminder call, select the “Get Started” button next to the “Reminder Call for Visit 1” task for the 
appropriate participant. This can be done from either the Home Page (Fig. 1) or the Individual Participant Page 
(Fig. 2).   
2. Walk through the script  as prompted. If the call cannot be completed, click the “Save & Exit” button and log the 
communication  as directed. If the call is completed, click the blue “Finish & Finalize” button to complete the 
task. 
  
Fig. 1  
Fig. 2 
 
 Confirm Visit 1 Appointment Date and Provide r 
1. To confirm the visit , select the “Get Started” button next to the “Confirm Visit 1 Appointment Date and Provider” 
task for the appropriate participant. This can be done from either the Home Page (Fig. 1) or the Individual 
Participant Page (Fig. 2).   
2. Confer with the participant to confirm all the appointment details auto -populated by the tracking system are 
correct. If necessary, change the clinic, provider, appointment date, and time. Once this has been confirmed with 
the participant in the clinic, click the blue “Finish & Finalize” button. This will complete the task.  
  
Fig. 1  
Fig. 2 
 
 Pre-Visit 1 Parent Questionnaire  
The Pre -Visit 1 Parent Questionnaire will in most cases be administered in the clinic and completed by the parent 
themselves. In cases where the tracking system is not accessible in clinic, the parent may fill out the survey on paper and a  
study staff memb er, usually the RA, will enter the survey information into the tracking system after the fact. This step -by-
step guide covers both scenarios.  
 
Completion in the Tracking System  
1. First copy the “Pre -Visit 1 Parent Questionnaire” code from the individual participant’s page (Shown Below).  
2. In a new window, navigate to the surveys version of the tracking system: https://ncgenes2.sirs.unc.edu/surveys . 
The following screen will appear.  
3. Paste the code into the text box, click the blue “Submit” button. Ensure any other tracking system windows in the 
browser are closed and hand the tablet over to the parent.  When the parent finishes the survey, ensure that the blue 
“Finish & Finalize” button has been clicked. This will complete the task and redirect to the survey login page.   

 
 Entry of Paper Form in the Tracking System  
 
If the parent completes the Pre -Visit 1 Questionnaire on paper, it should be entered into the tracking system within 24 
hours. The survey must be scanned and uploaded as well as entered via the task.1 
 
1. First, upload a scan of the paper questionnaire to the participant documents  page and label it “Pre -Visit 1 Parent 
Questionnaire _ID# ” 
 
2. From the individual participant’s page, click “Get Started” next to the Pre -Visit 1 Parent Questionnaire task, as 
shown below.  
 
3. The following pages will appear in succession. After entering the parent’s answers at each page, click the blue 
“Next” and repeat for subsequent pages. When all data is entered, click the blue “Finish & Finalize” button to 
complete the task (See Page 11 ). 
 
Page 1  
 
 
1 If you encounter any ambiguity in an answer to one of the survey questions that requires interpretation, please consult with the 
Clinical Study Director, Jeannette Bensen, by emailing her at Jeannette_bensen@med.unc.edu.  

 
 Page 2  
 
Page 3  

 
 Page 4  
  

 
 Page 5  
  

 
 Page 6  
 
Page 7  

 
 Page 8  
 
Page 9  
  

 
 Page 10  
 
Page 11  
 
  

 
 Visit 1 – Collect Info about Intake Completion  
1. To begin the “Visit 1 – Collect Info about Intake Completion” task, click the “Get Started” button next to the task 
on individual participant’s page. (Shown below)  
2. The following page will appear.  
a. If the parent has their completed Intake Survey, select “Yes” for Question 1 and then complete the task by 
clicking the blue “Finish & Finalize” button.  
 
b. If the parent does not have the intake survey, select “No” for Question 1. The dialog box will expand as 
shown below.  
 
i. If the parent completed their survey, but left it at home, select “Yes” for Question 2. A reminder 
to provide the parent with a prepaid envelope will appear. Click the blue “Finish & Finalize” 
button to complete the task.  
  

 
 ii. If the parent has not completed the survey, select “No” for Question 2. The dialog box will 
expand as shown below.  
 
iii. Indicate whether the participant will complete the survey at the clinic or at home. If at home, 
provide the parent with a prepaid envelope as prompted. In any case, click the blue “Finish & 
Finalize” button to complete the task.   

 
 Baseline Intake  
The Baseline Intake will in most cases be completed by the parent on paper before they arrive to Visit 1. After collecting 
the paper copy, a study staff member, usually the RA, will enter the survey information into the tracking system after the 
fact. In c ases where the parent has not yet completed the Intake and time allows, the parent may fill out the survey on the 
tablet in the clinic before their visit. This step -by-step guide covers both scenarios.  
 
Completion in the Tracking System  
1. First copy the “Baseline Intake” code from the individual participant’s page (shown below).  
 
2. In a new window, navigate to the surveys version of the tracking system: https://ncgenes2.sirs.unc.edu/surveys . 
The following screen will appear.  
 
3. Paste the code into the text box, click the blue “Submit” button. Ensure any other tracking system windows in the 
browser are closed and hand the tablet over to the parent.  When the parent finishes the survey, ensure that the blue 
“Finish & Finalize” button has been clicked. This will complete the task and redirect to the survey login page.   

 
 Entry of Paper Form in the Tracking System  
 
If the parent completes the Baseline Intake on paper, it should be entered into the tracking system within 24 hours of 
receipt. The survey must be scanned and uploaded as well as entered via the task.1 
 
1. First, upload a scan of the paper questionnaire to the participant documents  page and label it “Baseline Intake.”  
 
2. From the individual participant’s page, click “Get Started” next to the “Baseline Intake” task, as shown below.  
 
3. The following pages will appear in succession. After entering the parent’s answers at each page, click the blue 
“Next” and repeat for subsequent pages. When all data is entered, click the blue “Finish & Finalize” button to 
complete the task (See Page 15 ). 
 
  
 
1 If you encounter any ambiguity in an answer to one of the survey questions that requires interpretation, please consult with the 
Clinical Study Director, Jeannette Bensen, by emailing her at Jeannette_bensen@med.unc.edu.  

 
 Page 1  
 
  

 
 Page 2  
  

 
 Page 3  
  

 
 Page 4  
 
**Question 14 refers to all persons the respondent considers to be their c hild, biological or otherwise .  

 
 Page 5  
  

 
 Page 6  
Page 7  
  

 
 Page 8  
  

 
 Page 9  
 

 
 Page 10  
  

 
 Page 11  
  

 
 Page 12  
  

 
 Page 13  
  

 
 Page 14   

 
 Page 15  
 
  

 
 Parent Permission to Audio Tape Clinic Visit  
1. To begin the “Parent Permission to Audio Tape Clinic Visit” task from the participant page, click the “Get 
Started” button next to the task (shown below).  
 
2. After reading the initial prompt on the page shown below, record the parent’s response (“Yes” or “No”) to the 
request to audiotape.  
 
a. If the parent declines, skip the signatures and click the blue “save” button to complete the task.  
 
b. If the parent consents, the parent and study staff should sign in the appropriate boxes, and the names of 
each should be printed below each signature. Once this is done, click the blue “save” button to complete 
the task.   

 
  
Post-Visit  1 Parent Questionnaire  
The Post -Visit 1 Parent Questionnaire will in most cases be administered in the clinic and completed by the parent 
themselves. In cases where the tracking system is not accessible in clinic, the parent may fill out the survey on paper and a  
study staff mem ber, usually the RA, will enter the survey information into the tracking system after the fact. This step -by-
step guide covers both scenarios.  
 
Completion in the Tracking System  
1. First copy the “P ost-Visit 1 Parent Questionnaire” code from the individual participant’s page (Shown Below).  
2. In a new window, navigate to the surveys version of the tracking system: https://ncgenes2.sirs.unc.edu/surveys .  
 
The following screen will appear.  
 
3. Paste the code into the text box, click the blue “Submit” button . Ensure any other tracking system windows in the 
browser are closed  and hand the tablet over to the parent. When the parent finishes the survey, ensure that the blue 
“Finish & Finalize” button has been clicked. This will complete the task and redirect to the survey login page.   

 
 Entry of Paper Form in the Tracking System  
 
If the parent completes the Post -Visit 1 Questionnaire on paper, it should be entered into the tracking system within 24 
hours. The survey must be scanned and uploaded as well as entered via the task.1 
 
1. First, upload a scan of the paper questionnaire to the participant documents  page and label it “Post -Visit 1 
Parent Questionnaire.”  
 
2. From the individual participant’s page, click “Get Started” next to the Post -Visit 1 Parent Questionnaire task, as 
shown below.  
 
3. The following screens will appear in succession. After entering the parent’s answers at each page , click the blue 
“Next” and repeat for subsequent screens. When all data is entered, click the blue “Finish & Finalize” button to 
complete the task (See Page  10). 
 
  
 
1 If you encounter any ambiguity in an answer to one of the survey questions that requires interpretation, please consult with the 
Clinical Study Director, Jeannette Bensen, by emailing her at Jeannette_bensen@med.unc.edu.  

 
 Page  1 
  

 
 Page 2  

 
 Page 3 
  

 
 Page 4  

 
 Page 5 
  

 
 Page 6 
  

 
 Page 7 
  

 
 Page 8  

 
 Page 9 
 
Page 10 
 
  

 
 Post-Visit 1 Clinician Questionnaire  
The Post -Visit 1 Clinician Questionnaire should be completed by the relevant clinician after Visit 1. Study staff will, in 
most cases,1 not be involved in the completion of this task. The following guide will serve as a reference for clinicians 
completing the Post -Visit 1 survey.  
 
1. To begin the “Post -Visit 1 Clinician Questionnaire ,” click the appropriate “Go to Survey” bu tton for the 
participant as it appears on the MD Surveys tab (shown below).  
 
2. The survey consists of a series of pages (shown below). After completing the questions on each page, click the 
blue “Next” button  in the bottom left -hand corner of the page. When you reach the final page , click the blue 
“Finish & Finalize” button  to complete the survey.  
 
  
 
1 In extremely rare situations, the clinician may complete the Post -Visit 1 Questionnaire on paper. In such scenarios, the paper form 
should be scanned and uploaded at the participant documents  page, and the answers should be copied into the tracking system by 
completing the task from the individual participants page. See instructions for the Parent Post -Visit 1 Questionnaire  for comparison.  

 
 Page 1  
 
Page 2  
  

 
 Page 3  
  

 
 Page 4  
  

 
 Page 5  
  

 
 Page 6  
  

 
 Page 7  
 
Page 8   

 
 Page  9 
  

 
 Page 10  
  

 
 Page 11  
  

 
 Page 12  
 
Page 13   

 
 Questionnaires – Collection Method  
1. Begin the “Questionnaires – Collection Method” task by clicking the “Get Started” button next to the task on the 
individual participant’s page.   
 
2. The following dialog box will appear. For each questionnaire, select from the dropdown whether that 
questionnaire was completed by phone, tablet (or computer), or paper. Once all four questions are answered, click 
the blue “Finish & Finalize” button to com plete the task.   

 
 Collect Developmental Age  
1. To complete the “Collect Developmental Age” task, click the “Get Started” button next to the task on the 
individual participant page.   
 
2. The following screen will appear. From the dropdown menu, select the developmental age of the participant as 
provided by the child’s provider.  
 
3. Once the age has been selected, click the blue “Finish & Finalize” button to complete the task.  
  

 
 Randomization to Genome Sequencing  
1. To complete the “Randomization to Genome Sequencing” task, click the “Get Started” button next to the task on 
the individual participant page.   
 
2. The screen to the right will appear. This screen is 
the consent form for this randomization. The user 
should read through and discuss the form with 
the parent in detail.  
 
3. Indicate whether the parent consents for their child’s 
data to be used in future studies.  
 
4. If the parent does not  consent to randomization, click 
the blue “save” button to complete the task.1 
 
5. The date and time will auto -populate above both 
signature fields. If the parent consents, direct them to 
sign in the appropriate gray box.  
 
6. Record the parent’s name, their relationship to the 
participant, and the participant’s name in the 
appropriate boxes below the signature.  
 
7. Sign and print your name in the second set of boxes.  
 
8. Click the blue “save” button to complete the task.   
 
1 Making ANY mark in EITHER signature field will cause the system to register the parent as consented. If the parent does not 
consent, be particularly careful to not make any mark in these fields.  
[CONDENSED]  
 
 Visit 1 Parent HIPAA  
1. Begin the “Visit 1 Parent HIPAA” task by clicking the “Get Started” button next to the task on the individual 
participant’s page.   
 
2. The screen on the right will appear. This 
screen is the HIPAA form for this study. 
The user should read through and discuss 
the form with the parent in detail.  
 
3. If the parent agrees to sign the HIPAA 
consent form, record their child’s preferred 
name, their name, and their relationship to 
the child in the appropriate boxes. Then, 
have the parent sign within the gray box. To 
complete the task, click the blue “save” 
button.  
 
4. If the parent does not  consent to HIPAA, 
skip all data entry (including signature1) and 
click the blue “save” button to complete the 
task.  
 
1 Making ANY mark in EITHER signature field will cause the system to register the parent as consented. If the parent does not 
consent, be particularly careful to not make any mark in these fields.  

 
 Genome Sequencing Consent  
1. To complete the “Genome Sequencing Consent” task, click the “Get Started” button next to the task on the 
individual participant page.   
 
2. The screen to the right will appear. This screen is the 
consent form for undergoing exome sequencing. The 
user should read through and discuss the form with 
the parent in detail.  
 
3. Indicate whether the parent consents to secondary 
analysis of their child’s genes.  
 
4. Indicate whether the parent consents for their child’s 
data to be used in future studies.  
 
5. If the parent does not  consent, click the red “Declined” 
button to complete the task.  
 
6. If the parent consents, direct them to sign in the 
appropriate gray box. The date and time will auto -
populate above both signature fields. Record the 
parent’s name, their relationship to the participant, and 
participant’s name in the appropriate boxes below the 
signature.  
 
7. Sign and print your name in the second set of boxes.  
 
8. Click the blue “Save” button to complete the task.   
[CONDENSED ] 
[CONDENSED ] 
 
 Randomization 2 Assent  
1. To complete the “Randomization 2 Assent” task, click the “Get Started” button next to the task on the individual 
participant page.   
 
2. The screen to the right will appear. This screen is the 
assent form for Randomization 2. The user should 
read through and discuss the form with the 
participant in detail.  
 
3. If the participant does not  assent, click the blue “save” 
button to complete the task.1 
 
4. If the participant assents, direct them to sign in the 
appropriate gray box. The date and time will auto -
populate above both signature fields. Record the 
participant’s name in the appropriate box below the 
signature.  
 
5. Sign and print your name in the second set of boxes.  
 
6. Click the blue “save” button to complete the task.   
 
1 Making ANY mark in EITHER signature field will cause the system to register the parent as consented. If the parent does not 
consent, be particularly careful to not make any mark in these fields.  
[CONDENSED ] 
 
 Genome Sequencing Assent  
1. To complete the “Genome Sequencing Assent” task, click the “Get Started” button next to the task on the 
individual participant page.   
 
2. The screen to the right will appear. This screen is the 
assent form for undergoing exome sequencing. The 
user should read through and discuss the form with 
the parent in detail.  
 
3. If the participant does not  assent, click the red 
“Declined” button to complete the task.  
 
4. If the participant assents, direct them to sign in the 
appropriate gray box. The date and time will auto -
populate above both signature fields. Record the 
participant’s name in the appropriate box below the 
signature.  
 
5. Sign and print your name in the second set of boxes.  
 
6. Click the blue “Save” button to complete the task.   
[CONDENSED ] 
 
 Visit 1 – Parent Reimbursement  
1. From the individual participant page, click “Get Started” next to the “Visit 1 – Parent Reimbursement” task.  
 
2. The page shown below will appear. Enter the amount of compensation and allow the parent to sign within the 
gray box for their receipt. (Date and time will auto -populate). When this is complete, click the blue “save” button 
to complete the task.  
  

 
 Parental Distress Followup  
1. Begin the “Parental Distress Followup” task by clicking the “Get Started” button next to the task on the individual 
participant’s page.   
2. The following screen will appear. Record the date that the psychologist and PIs were informed, as well as the date 
the psychologist responded and any notes in the appropriate spots. Then, click the blue “Finish & Finalize” button 
to complete the task.  
  

 
 Visit 1 Biospeciman Collection  
1. Begin the “Visit 1 Biospeciman Collection” task by clicking the “Get Started” button next to the task on the 
individual participant’s page.   
2. The following screen will appear. If the blood collection is not complete, click “No” and then the blue “Finish & 
Finalize” button to complete the task.  
3. If the specimen collection is complete, click “Yes.” The screen will expand as shown below. Answer the 
subsequent questions “Yes” or “No” as applicable and then click the blue “Finish & Finalize” button to complete 
the task.  
  

 
 Saliva Kit Tasks  
Visit 1 CLIA Saliva Kit Due to No Blood Drawn  - Mailing  
The “Visit 1 CLIA Saliva Kit Due to No Blood Drawn  - Mailing ” task is a mailing task. This (and all) mailing task(s) can 
be started from the individual participant page  by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 CLIA Saliva Kit Due to No Blood Drawn  - Mailing ” task will be marked complete in the tracking system when 
this mail merge is generated.  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 5  section under Mailings .  

 
 Visit 1 BSP Saliva Kit Due to No Blood Drawn  - Mailing  
The “Visit 1 BSP Saliva Kit Due to No Blood Drawn - Mailing” task is a mailing task. This (and all) mailing task(s) can 
be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to No Blood Drawn - Mailing” task will be marked complete in the tracking system when 
this mail merge is ge nerated.  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For detailed 
instructions on completing this mailing, go to the Mailing 5  section under Mailings .  

 
 Visit 1 CLIA  Saliva Kit Due to Insufficient Sample  - Mailing  
The “Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Mailing” task is a mailing task. This (and all) mailing task(s) 
can be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Mailing” task will be marked complete in the tracking system when 
this mail merge  is generated.  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 5  section under Mailings . 
  

 
 Visit 1 BSP Saliva Kit Due to Insufficient Sample  - Mailing  
The “Visit 1 BSP Saliva Kit Due to Insufficient Sample - Mailing” task is a mailing task. This (and all) mailing task(s) 
can be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to Insufficient Sample - Mailing” task will be marked complete in the tracking system when 
this mail merge is generated.  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 5  section under Mailings . 
  

 
 Visit 1 CLIA Saliva Kit Due to Failed Results  - Mailing  
The “Visit 1 CLIA Saliva Kit Due to Failed Results  - Mailing ” task is a mailing task. This (and all) mailing task(s) can be 
started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 CLIA Saliva Kit Due to Failed Results  - Mailing ” task will be marked complete in the tracking system when this 
mail merge is generated (see below).  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 5  section under Mailings .  

 
 Visit 1 BSP Saliva Kit Due to Failed Results  - Mailing  
The “Visit 1 BSP Saliva Kit Due to Failed Results  - Mailing ” task is a mailing task. This (and all) mailing task(s) can be 
started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to Failed Results  - Mailing ” task will be marked complete in the tracking system when this 
mail merge is generated (see below).  
 
Mailings should be completed on the same day they are originated to ensure accurate tracking of this task . For 
detailed instructions on completing this mailing, go to the Mailing 5  section under Mailings .  

 
 Visit 1 CLIA Saliva Kit Due to No Blood Drawn - Recei ved 
The “Visit 1 CLIA Saliva Kit Due to No Blood Drawn  - Received ” task is a mailing task. This (and all) mailing task(s) 
can be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant.  The 
“Visit 1 CLIA  Saliva Kit Due to No Blood Drawn  - Received ” task will be marked complete in the tracking system when 
this mail merge is generated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used . 
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings . 
  

 
 Visit 1 BSP Saliva Kit Due to No Blood Drawn  - Received  
The “Visit 1 BSP Saliva Kit Due to No Blood Drawn - Received” task is a mailing task. This (and all) mailing task(s) can 
be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to No Blood Drawn - Received” task will be marked complete in the tracking system when 
this mail merge is g enerated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used.  
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings .  

 
 Visit 1 CLIA Saliva Kit Due to Insufficient Sample  - Received  
The “Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Received” task is a mailing task. This (and all) mailing task(s) 
can be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 CLIA Saliva Kit Due to Insufficient Sample - Received” task will be marked complete in the tracking system 
when this mail merg e is generated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used.  
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings . 
  

 
 Visit 1 BSP Saliva Kit Due to Insufficient Sample  - Received  
The “Visit 1 BSP Saliva Kit Due to Insufficient Sample - Received” task is a mailing task. This (and all) mailing task(s) 
can be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to Insufficient Sample - Received” task will be marked complete in the tracking system when 
this mail merge  is generated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used.  
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings . 
  

 
 Visit 1 CLIA Saliva Kit Due to Failed Results  - Received  
The “Visit 1 CLIA Saliva Kit Due to Failed Results - Received” task is a mailing task. This (and all) mailing task(s) can 
be started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 CLIA Saliva Kit Due to Failed Results - Received” task will be marked complete in the tracking system when this 
mail merge is generated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used.  
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings . 
  

 
 Visit 1 BSP Saliva Kit Due to Failed Results  – Received  
The “Visit 1 BSP Saliva Kit Due to Failed Results - Received” task is a mailing task. This (and all) mailing task(s) can be 
started from the individual participant page by clicking the “Get Started” button for the appropriate participant.  
 
This will redirect the user to the “Mailings” page, where they can generate a mail merge document for a participant. The 
“Visit 1 BSP Saliva Kit Due to Failed Results - Received” task will be marked complete in the tracking system when this 
mail merge is g enerated (see below).  
 
While the Saliva Kit receipt tasks are technically mailing tasks, they are not completed in conjunction with outgoing mail. 
Because of this, the generation of a mail merge document is only for the purpose of completing this task. The mail merge 
document it self will not be used.  
  
This task should be completed on the same day that a kit is reported received by the BSP to ensure accurate 
tracking of this task . For detailed instructions on completing receipt of this mailing, go to the Mailing 5  section under 
Mailings   

 
 Pre-RoR Packet – No GS without Pre -Visit Prep  
Pre-RoR Packet – GS with Pre -Visit Prep  
Pre-RoR Packet – GS without Pre -Visit Prep  
  
 
 CALENDARING  
 
Each NCGENES 2 site will maintain its own system for keeping track of tasks not captured by the tracking system. These 
systems (will be) explained in this section of the protocol.  
  
 
 NCGENES 2 BIOSPECIMEN PROTOCOL  
 
Overview  
For participants randomized to genome sequencing as part of the NCGENES 2 study, blood is drawn at the first clinical 
visit (evaluation) for DNA extraction, library preparation, sequencing, identity check genotyping and clinically significant 
genetic varia nt confirmation for positive or uncertain results (with respect to their association with the patient’s clinical 
phenotype).  Specifically, one blood tube is sent to the Biospecimen Processing Facility (BSP) and one is sent t o UNC 
Clinical Molecular Geneti cs Laboratory (CLIA labs) for processing. All laboratories initially extract the DNA.  
 
The CLIA lab will also genotype 8 Single Nucleotide Polymorphisms (SNPs) via Sanger sequencing in all participants, 
which will later be compared to genotypes obtained via research GS. This comparison is used as an identity check to 
identify any potential s ample mix -ups.  The CLIA lab additionally stores the remaining DNA for later confirmation of 
clinically significant research results that may arise during the course of the study.  
 
The BSP sends a portion of the extracted DNA to the Berg Laboratory for library preparation.  The sequencing libraries 
are then sent to the High Throughput Sequencing Facility (HTSF) for research GS.  The genetic data is annotated, 
undergoes molecular anal ysis and is reviewed in conjunction with clinical/phenotypic data at a molecular sign -out 
meeting.   
 
If any clinically significant primary or secondary findings are identified, the CLIA Lab is notified to request confirmation 
and reporting.  Confirmation is conducted via Sanger sequencing.  CLIA confirmed results are placed in the patient’s 
medical record  which automatically notifies the onsite physician.  If the CLIA confirmation is being conducted for an 
offsite institution, then the CLIA lab results will be sent via fax to the ordering physician. Negative research GS results 
cannot be confirmed in the c linical lab.  All results (CLIA confirmed and negative) are reported by the research team to 
the ordering physician via email notification. Additionally, physicians are notified by CLIA confirmed results via the 
electronic medical records (EMR) system.  The research email notification asks the physician to return results of testing 
and complete the NCGENES 2 post return of results (RoR) provider survey (the email subject line indicates “ACTION 
REQUIRED”). A patient friendly research report regard ing the res ults of genomic sequencing is attached to the email 
notification to the physician. Additionally, the physician email notification includes  a link to the patient tracking system 
(for participants in the GS arm).  Once at the physician landing page in tracking, the MD clicks on the ‘ PhenoTips & 
Results’  tab, where there is a link to the ‘ Molecular Analysis ’ tab for each participant who is in the GS arm. Results on the 
molecular analysis tab may indicate that the test results are pending, negative or positive/ uncertain (CLIA confirmed).  
There is also a link on this page to a patient’s research result report (Word document that can be printed).  
 
Remaining DNA can be used for future research with parental consent and in rare cases with required concordant child 
assent (which is obtained at the time of GS randomization consent/assent). DNA will be stored indefinitely, but linked 
data will be destroy ed on the patient’s 18th birthday rendering all remaining samples anonymized.  
 
In some cases, the physician may determine that parental DNA confirmatory testing is needed to interpret the genomic 
sequencing results of the child.  In this case, the genetic counselor or nurse notifies the family and the research team of t he 
need to col lect parental DNA.  The research team contacts the patient’s parent to let them know that parental/relative 
genetic testing consents and saliva kits are being mailed (one for each parent).  The research study coordinator will wait 
approximately one week an d phone the parents to consent them by phone, have them sign the consents and return them 
along with their saliva samples to the BSP lab in an addressed/postage paid envelope. Extra consents will be provided so 
that the parents may keep copy for their records.  In rare cases other adult relatives may need to be tested.  This will be 
determined by the ordering physician.  NCGENES 2 will pay for a dditional confirmatory testing in the CLIA of the 
physician determines that it is necessary for the interpretation  of the results for the child.  
 
 
 FIGURE 1. Overview of sample flow through study laboratories, molecular sign -out, CLIA confirmation, and reporting  
  

 
 Collecting Blood Samples at Visit 1  
NCGENES 2 prioritizes collection of blood for research biospecimens. As often as possible, NCGENES 2 blood 
specimens will be collected immediately following Visit 1 from participants consented to exome sequencing. This section 
outlines the protocol for col lecting blood samples at each NCGENES 2 site.  
 
Pre-Visit 1: Preparation of the Blood Collection Kit  
All sites will use a generally uniform procedure for preparing blood collection kits. A blood kit is created for each 
participant and clipped to that participant’s folder for use in the clinic (see “Preparation for Visit 1 ” on page 22 ). In 
addition, a second blood kit (without forms) should always be brought to the clinic should a redraw become immediately 
necessary due to failed collection.  
 
Kit contents  
Each blood collection  kit will include:  
• 2 biohazard bags  
• 2 purple top 3ml EDTA vacutainers (ALWAYS CHECK EXPIRATION DATE)  
• 5 ID barcode labels (includes 1 -2 extra)  
• 11 CLIA Molecular Genetics Test Request Form signed/provider -specific2 – printed on white paper  (See 
Appendix XXXIV  on page 281 ) 
• 1 BSP Requisition Form printed on blue paper3 (see Appendix XXXIII  on page 279 ) 
 
Kit assembly  before the visit  
Place p rint patient -specific barcode  ID labels , both blood tubes, one folded biohazard bag and a folded Molecular 
Genetics Test Request Form and/or BSP Requisition Form into the second  biohazard bag.  ALWAYS bring a pair of 
gloves should you need to handle the blood tubes.  A biohazard -labeled cooler bag should also be brought to the clinic 
appointment  for transporting/mailing blood tubes to the BSP post -Visit 1 . 
 
After the Visit: Collection and Distribution  
Each site will follow a slightly different protocol for collecting and distributing blood samples. Th is section describes the  
protocol for creating a phlebotomy order , assisting with blood collection, assembling  the blood collection kits, and 
distributing blood samples at each site.  
 
University of North Carolina at Chapel Hill – UNC  
Creating EMR Research Phlebotomy Order  
Following reveal of randomization #2 to receipt of genomic sequencing and completion of GS consent, but prior to 
walking the patient to phlebotomy area, the study coordinator will complete an Epic EMR Research  Phlebotomy blood 
draw order ONLY IF a Clinical Phlebotomy order has NOT been initiated by the physician.  If clinical draw HAS BEEN 
ordered, then the research blood collection is piggybacked  on the clinical draw. Detailed instructions  for creating a blood 
draw order can be found in  Appendix XXVII  on page 263 .4 EPIC orders require a 3 -step process: 1) creation of the order, 
2) approval by the ordering physician, and 3) approval by phlebotomist before the phlebotomist draws the blood.  
 
Blood Collection  
Once an order has been created, the SC should assist the participant and parent with navigating the process of the blood 
draw.  
 
1 ONLY for ECU and UNC. Mission creates Molecular Genetic Test Request electronically  
2 A UNC MGL form will need to be signed by each physician on the study team one time – then these can be photocopied for use 
throughout the study. The study coordinator will select the appropriate MGL/CLIA lab physician's form to include with the blo od kit.  
3 The BSP Requisition Form is printed on blue paper to easily distinguish which form is which when both are folded and placed i n 
separate blood bags  
4 All staff placing orders must comply with Epic training and receive authorization for placing research phlebotomy orders (See  
Appendix XXVI  on page 252 ).   
 
 1. Walk patient and parent/relative to main lab in the UNC Women’s Hospital lobby.  Get a number from the clinic 
dispenser.   
2. The parent will inform the phlebotomy worker at the check -in desk that their child needs labs. The SC  or the 
parent should notify the worker that one of the labs is for research.  
3. Accompany the family to the blood drawing area/station when their number is called.  
4. Provide the phlebotomist with the tubes from the phlebotomy kit.  
5. Put on gloves  
6. Record the time and date blood is drawn on the relevant lab forms.  
7. Receive the blood tubes from the phlebotomist and assemble the blood collection kits (see below ) 
8. Thank the family and guide them to the hospital exit.  
9. Immediately, complete the “Visit 1 Biospecimen Collection” task (see page 154 for more info ) using the tablet 
computer (e.g. indicating successful collection of both tubes and mailing to the labs).  
 
Assembling the Blood Collection Kit for Distribution  
Following the Epic EMR research phlebotomy order placement and blood draw,1 label each blood tube with a  barcode  
label. Label and complete the UNC BSP Requisition Form . Fold and insert  it into one of the biohazard bags along with the 
3ml EDTA vacutainer tube  with greatest blood volume , ensuring that the header of the form is visible through the bag.  
 
Label and complete the UNC Molecular Genetic Lab (MGL) Test Request Form by placing a participant -specific barcode 
label in the upper right -hand corner of the form and record ing the date. Fold and insert the form into the other biohazard 
bag with the other 3ml EDTA vacutainer tube , ensuring that the header of the form is visible through the bag . The 
different colored forms (blue BSP and white CLIA) will facilitate distribution to the correct laboratory.  
  
 
1 Labeling of tubes and forms follows blood collection to avoid wasting pre -labeled tubes and forms if blood collection is declined or 
unsuccessful.  

 
 Blood Sample Distribution  
The blood tubes for the MGL may be tubed/chuted (using the tubing station in the Phlebotomy are a or behind the 
Pediatric Check -out desk (near the pediatric consult room). One specimen within the biohazard bag that includes the 
correct MGL request form should be placed in the tube and sent to the Core lab (tube station #30 ) or delivered to Core 
Lab by hand (they will deliver it to the MGL) .1 
 
Tubes for research exome sequencing should be delivered to the BSP, located on 3rd floor of Michael J. Hooker 
Building/Gilling School of Public Health. Study staff delivering specimens to the BSP  will need access  to this building  on 
their UNC one card. At the BSP, blood samples should be logged in using the LIMS system (for detailed instructions on 
entering blood samples into the LIMS, see Appendix XL  on page 286 ) 
 
How is delivery tracked? The NCGENES 2 study coordinator logs that the samples have been delivered to each lab in the 
Tracking System by completing the “Visit 1 Biospecimen Collection ” task (See page 154 for more info ).  The entry of 
the specimens into the BSP LIMs will be the indication that the BSP lab has received the sample. The entry of the 
specimen into RENCI Genomic Molecular Workbench by the MGL/CLIA lab will indicate that the CLIA lab has received 
the sample.  
 
East Carolina University – ECU  
Creating EMR Research Phlebotomy Order  
Following reveal of randomization #2 to receipt of genomic sequencing and completion of GS consent, but prior to 
walking the patient to phlebotomy area, complete an Epic EMR Research Phlebotomy blood draw order ONLY IF a 
Clinical Phlebotomy order has NOT been initiated by the physician.  If clinical draw HAS BEEN ordered, then the 
research blood collection is piggy backed onto the clinical draw. Detailed instructions for creating a blood draw order can 
be found in Appendix XXVII  on page 263 .2 ECU EPIC orders require a 3 -step process: 1) creation of the order, 2) 
approval by the ordering physician, and 3) approval by phlebotomist before the phlebotomist draws the blood.  
 
Blood Collection  
1. Walk patient and parent to main lab in the UNC Women’s Hospital lobby.  Get a number from the clinic 
dispenser.   
2. The parent will inform the phlebotomy worker at the check -in desk that their child needs labs. The SC  or the 
parent should notify the worker that one of the labs is for research.  
3. Accompany the family to the blood drawing area/station when their number is called.  
4. Provide the phlebotomist with the tubes from the phlebotomy kit.  
5. Put on gloves  
6. Record the time and date blood is drawn on the relevant lab forms.  
7. Receive the blood tubes from the phlebotomist and assemble the blood collection kits (see below ) 
8. Thank the family and guide them to the hospital exit.  
9. Immediately, complete the “Visit 1 Biospecimen Collection” task ( see page 154 for more info ) using the tablet 
computer (e.g. indicating successful collection of both tubes and mailing to the labs).  
  
 
1 The MGL staff enters sample receipt once/week (and other data as sample is processed) into the Genomic Molecular Workbench 
hosted by RENCI (see Appendix XXV  on page 248 ) for details of data entry process and content)  
2 All staff placing orders must comply with Epic training and receive authorization for placing research phlebotomy orders (See  
Appendix XXVI  on page 252 ).   
 
 Assembling the Blood Collection Kit for Distribution  
Following the Epic EMR research phlebotomy order placement and blood draw,1 label each blood tube with a barcode 
label. Label and complete the UNC BSP Requisition Form. Fold and insert it into one of the biohazard bags along with the 
3ml EDTA vacutainer tube with greatest blood volume , ensuring that the header of the form is visible through the bag.   
 
Label and complete the UNC Molecular Genetic Lab (MGL) Test Request Form by placing a participant -specific barcode 
label in the upper right -hand corner of the form and recording the date.  
 
Note: Per CLIA standards, ECU must include ordering physician name and fax# on the Molecular Genetics Lab Test 
Request Form for results reporting.  
 
Fold and insert the form into the other biohazard bag with the other 3ml EDTA vacutainer tube, ensuring that the header 
of the form is visible through the bag. The different colored forms (blue BSP and white CLIA) will facilitate distribution 
to the correc t laboratory.  
 
Blood Sample Distribution  
After collection,  both blood tubes  should be sent in a  mailer to the UNC BSP Laboratory.  The mailer consists of an 
outer box and an inner biohazard bag and a cotton 4 -tube, tube holder.   The tubes will be placed in the tube holder an d 
then this holder placed in the biohazard bag. The biohazard bag containing the blood tubes and the two labeled requisition 
forms (one for BSP and one for CLIA MGL) are placed in the box.   The PRE -CHILLED gel -pack will be placed in the 
foil bubble pouch and placed on top of  the tube containing bag in the box.  This cold gel pack keeps the samples at 
approximately 2 -10 degrees C during shipment. The tubes/forms will be separated and grouped appropriately upon arrival 
in the UNC BSP lab.  A member of the BSP staff will walk the CLIA laboratory sample to the Molecular Genetics 
Laboratory (CLIA lab) drop -off window, indicating to the clerk that ‘the sample is for the DNA Lab’.  No prior 
notification is necessary. The BSP lab will record receipt of the BSP samples in the BSP LIMS and this status can be 
reported by the study analyst on a daily basis.  In this way centers will know when mailed samples have arrived.  
Immediate notification to center -specific study coordinator by the BSP lab is necessary if samples arrive and tubes are 
broken or otherwise produce unsatisfactory DNA yield.  This will initiate the saliva collection  protocol at the 
participant’s  site. The BSP address for shipment is located in Appendix XXX  on page 274 . 
 
Upon mail receipt the BSP will EMAIL notify the UNC Study Coordinator (Tracey Grant) and Co -Investigator 
(Jeannette Bensen) of the receipt, ID# and study site (ECU/Mission) for all NCGENES 2 samples.  The entry of the 
 
1 Labeling of tubes and forms follows blood collection to avoid wasting pre -labeled tubes and forms if blood collection is declined or 
unsuccessful.  

 
 specimens into the BSP LIMS upon arrival will be the indication that the BSP lab has received the sample. The 
entry of the specimen into RENCI by the MGL/CLIA lab will indicate that the CLIA lab has received the sample.  
 
NOTE: UNC staff may assist ECU in the clinic and thus transport all samples back to the respective BSP and CLIA labs 
(therefore mailing of specimens by ECU to UNC BSP may not be required).  
 
Mission Health - Asheville  
Creating EMR Research Phlebotomy Order – Mission Health  
Following reveal of randomization #2 to receipt of genomic sequencing and completion of GS consent, but prior to 
walking the patient to phlebotomy area, complete a Cerner EMR GENE Order with comments of “NCGENES 2 Research 
Phlebotomy blood draw - see kit f or instructions and tubes - genetics to pick up”. Detailed instructions for creating a blood 
draw order can be found in Appendix XXVIII  on page 272 .1   
 
Note: this may not be necessary if a clinical phlebotomy blood draw has been ordered and the research team is allowed to 
piggyback on to the clinical draw to collect the 2 research blood tubes.  
 
Blood Collection  
1. Walk patient and parent to Mission Children’s Phlebotomy Laboratory.   
2. The parent will inform the phlebotomy worker at the check -in desk that their child needs labs. You or the parent 
should notify the worker that one of the labs is for research.  
3. Accompany the family to the blood drawing room when they are called.  
4. Provide the phlebotomist with the tubes from the phlebotomy kit.  
5. Put on gloves  
6. Record the time and date blood is drawn on the relevant lab forms.  
7. Receive the blood tubes from the phlebotomist and assemble the blood collection kits (see below ) 
8. Thank the family and guide them to the hospital exit.  
9. Immediately, complete the “Visit 1 Biospecimen Collection” task (see page 154 for more info ) using the tablet 
computer (e.g. indicating successful collection of both tubes and mailing to the labs).  
 
  
 
1 All staff placing orders must comply with Cerner training and receive authorization for placing research phlebotomy orders (S ee 
Appendix ).   
 
 Assembling the Blood Collection Kit for Distribution  
Following  the Cerner EMR research phlebotomy order placement and blood draw, label each blood tube with a barcode  
label. Label and complete the UNC BSP Requisition Form. Fold and insert it into one of the biohazard bags along with the 
3ml EDTA vacutainer tube with greatest blood volume , ensuring that the header of the form is visible through the bag.   
 
Label and complete the UNC Molecular Genetic Lab (MGL) Test Request Form by placing a participant -specific barcode 
label in the upper right -hand corner of the form and recording the date.  
 
Blood Sample Distribution  
After collection, both blood tubes  should be sent in a mailer to the UNC BSP Laboratory.  The mailer consists of an 
outer box and an inner biohazard bag and a cotton 4 -tube, tube holder.   The tube s will be placed in the tube holder and 
then this holder placed in the biohazard bag. The biohazard bag containing the blood tube and the BSP lab requisition 
form is placed in the box.   The PRE -CHILLED gel -pack will be placed in the foil bubble pouch and pl aced on top of the 
tube containing bag in the box.  This col d gel pack keeps the samples at approximately 2 -10 degrees C during shipment. 
The BSP lab will record receipt in the BSP LIMs system and this status can be reported by the study analyst on a daily 
basis.  In this way centers will know when mailed samples have arrived.  Immediate notification to center -specific study 
coordinator by t he BSP lab is necessary if samples arrive and tubes are broken or otherwise produce unsatisfactory DNA 
yield.   This will initiate the saliva collection  protocol at the participant’s site. The BSP address for shipment is located in 
Appendix XXX  on page 274 . 
 
Upon mail receipt the BSP will EMAIL notify the UNC Study Coordinator (Tracey Grant) and Co Investigator 
(Jeannette Bensen) of the receipt, ID# and study site (ECU/Mission) for all NCGENES 2 samples.  The entry of the 
specimens into the BSP LIMs upon arriv al will be the indication that the BSP lab has received the sample.  
 
  
Mission  
 
 Saliva Collection for Child Participants  
Overview  
NCGENES 2 prioritizes collection of blood samples from child participants consented to exome sequencing. A family 
should be offered saliva collection only if one of the following scenarios occurs:  
1. No Blood  was collected at visit 1 : Neither tube of blood was able to be collected  
a. Attempted b lood collection was not successful1 
b. Parent refused blood collection for child  
2. Insufficient blood  was collected at visit 1 : One or both tubes have < 1ml of blood (1 ml is minimum volume for 
each lab) at collection  
3. Samples failed processing  (FAILED RESULTS) : One or both labs (BSP & CLIA/MGL) notify NCGENES 2 
Study Coordinator/Co -Investigator that  completely or partially and saliva kit(s) are needed to obtain DNA for 
testing  
a. Sample tube(s) arrive broken  
b. A sample is dropped in the processing lab  
c. The volume is 1ml or more at collection but yields an insufficient amount of DNA  
 
Scenarios 1 and 2 should be identified by the SC at the time of the blood draw. Scenario 3 will occur after the conclusion 
of Visit 1. The protocol in each scenario is described below.  
 
Saliva Collection Initiated at Visit 1 Phlebotomy  
Scenario 1: No Blood Drawn  
The Study Coordinator may encounter a scenario  in which blood collection fails entirely at phlebotomy or the parent 
declines blood draw for the child at Visit 1. In these cases, the parent is offered the option of saliva collection by mail. In 
the tracking system, this will be recorded in the “ Visit 1 Biospecimen Collection ” task (see page 154) with “Question 1. 
Blood collection Complete? ” Answering this question “No” will autogenerate  two tasks : “V1 BSP Saliva Kit Due to No 
Blood Drawn ” (see page 156) and “V1 CLIA Saliva Kit Due to No Blood Drawn ” (see page 155). Because DNA will 
be need ed for both labs, two saliva kits are mailed to the parent . 
 
Scenario 2: Insufficient Blood Collection at Visit 1  
The Study Coordinator may encounter  a second scenario  of insufficient sample collection (<1ml in either tube).  If this 
occurs the Study Coordinator will ask the phlebotomist to attempt to draw an additional tube (or attempt a second stick if 
the parent agrees) to see if enough blood may be collected to satisfy each lab ’s requirements  (at least 1 ml for each lab).  If 
the phlebotomist is unable to obtain two 3ml tubes (or a set of 3 tubes that provides at least 1 ml for each lab), the Study 
Coordinator will  inform the family that they will receive 1 -2 saliva kits by mail depending on the nee d, e.g.  if enough 
blood was collected (1 ml) to satisfy the needs of one of the labs, then only 1 kit would be needed (see Saliva Collection 
section  on page 178 ). In the tracking system, this will be recorded in the “ Visit 1 Biospecimen Collection ” task (see page 
154) with Question s 2-3. Answering Question 2 “No” will autogenerate  the “V1 BSP Saliva Kit Due to No Insufficient 
Sample ” task (see page  158) and  answering Question 3 “No” will autogenerate  the “V1 CLIA Saliva Kit Due to 
Insufficient Sample ” task (see page  157).  
 
Scenario 3: Saliva Collection Initiated by Lab (BSP/CLIA/Mission CLIA)  
Failed Results  
If insufficient specimen is received by mail (either blood (<1ml) or saliva (<0.5ml)) in the lab(s) OR if DNA extraction 
fails to produce sufficient quantities of DNA for study needs  at either lab , then the lab staff must notify Jeannette Bensen, 
jbensen@med.unc.edu  AND 919 -801-9267) and the Study Coordinator by email and phone  (Tracey Grant 
(traceyg@unc.edu  AND 919 -306-1410) within 24 business hours of sample receipt/sample extraction failure to allow for 
recollection by saliva kit mailing. The UNC research team will notify the partner site if relevant and work together to 
ensure that the tracking system is updated and the saliva kit(s) are prop erly mailed (in most cases the UNC staff will be 
 
1 In some cases an extra tube or second stick (after the clinical draw) may be necessary to acquire a sufficient volume of bloo d, so the 
SC should always have an extra set of tubes/labels should this be necessary at blood draw  
 
 responsible for mailing saliva kit(s) to collect a pediatric patient’s (Child’s) specimen).1  If the need for saliva collection 
arises after the conclusion of Visit 1, the study coordinator or other study staff under the direction of the study coordinat or 
will notify the parent by phone of the need for a saliva kit collection.  This contact is reco rded in communication log  in 
the tracking system. Additionally, the local Study Coordinator must record the failed results  from blood collection (failed 
extraction/insufficient blood) reported by the lab(s) by creating  “V1 BSP/CLIA Saliva Kit Due to Failed Results ” task for 
one or both labs.  For detailed instructions on how to create these tasks, see the “ Using the Tracking System ” section on 
page 75 .  
 
Note:  ALL POST -VISIT 1 Phlebotomy sample scenarios such as insufficient samples received by mail and failed 
extractions are designated in the patient tracking system as FAILED RESULTS by Creating the V1 lab – saliva kit due to 
failed results task.  Note to comp lete that task go to the task list for the patient and click ‘pending’, this will take you to a 
mail merge to create the label for the kit.  Once the mail merge is completed the date associated with this task will be the 
date the kit was mailed.  
 
Sample Fails Identity Check  
If the identity check genotypes assayed in the CLIA Lab do not match the identity genotypes assayed by the High 
Throughput Sequencing Facility , a recollection of DNA via mailed saliva kit will be required. The Molecular Analysis 
group (Bradford Powell, bradford.powell@unc.edu ) will notify the study coordinator if discordance in identity 
genotyping occurs. In the event of failed identity check, one or two DNA saliva kits will be mailed, one for DNA 
extraction in the UNC CLIA laboratory and possibly one for DNA extracted in the BSP (the need for one vs. two saliva 
kits will be determined by the molecular analysis team at the time of identify check discordance). Upon receipt, the CLIA 
laboratory will perform genotyping of t he identity -check SNPs on their received sample, and the decision for additional 
processing of the BSP sample will depend on whether the new CLIA genotyping establishes sample identity.  
 
Saliva Kit  Mailing  Preparation  
A patient saliva kit2 includes: one large bubble mailer with one or two saliva kit(s) (swab and case), one or two Ziploc 
bag(s), and one folded, pre -posted and addressed bubble mailer (this bubble mailer will be smaller than the larger one that 
the rest of the supplies are mai led in). One saliva kit is mailed if only one lab needs a sample, but 2 kits are mailed if both 
BSP and CLIA lab s need samples. Sample collection swabs/swab tubes are removed from the plastic kit box(es) and are 
labeled with patient -specific barcode labels (generated from tracking system) and then replaced back into the plastic kit 
box(es) prior to mailing.   An example of a pediatric participant (child) ID barcode label is shown below:  
Patient barcodes will always end with -00.   
 
1 If insufficient sample is identified by one lab, the UNC Study Coordinator should email the other study lab to confirm that t he other 
sample is sufficient prior to mailing the saliva collection kit in case 2 saliva kits are needed.  
2 See Appendix XXXII  on page 268  for information on ordering supplies  

 
 One plastic box/kit will go inside each provided Ziploc bag to prevent leakage during transport. The large bubble mailer 
will also include three sheets of paper:  
1. an NCGENES 2 participant saliva letter (see Appendix VIII  on page 203 ) 
2. an NCGENES 2 saliva kit mailing instructions sheet that outlines how to return the saliva back to the BSP (see 
Appendix IX  on page 204 ) and  
3. enlarged Oragene OG 575 saliva kit instructions printed on a colored sheet of paper (yellow; these instructions are 
the same as the ones inside the saliva kit, however this form additionally collects the data and time of saliva 
collection and is returned t o UNC along with the saliva samples.  (see Appendix X  on page 205 )  
*All relevant paperwork can be found on IRBIS.  
 
Example return labels1 and saliva mailing contents/package for 2 kits shown here.  
 
For Mission saliva samples , the Mission SC will address the return envelope to the UNC BSP.  
 
Mailing and receipt of saliva kits as well as distribution to relevant lab(s) is recorded in the patient tracking system by the  
Study Coordinator. Routine reports are run by the study analyst to ensure that the loop is closed from sample collection to 
receipt and processing.  
 
The participants will be instructed on the NCGENES 2 saliva kit collection process and how to return the completed 
saliva kit(s) by mail to the UNC BSP. The parent will include the following in the returned pre -posted and addressed 
bubble mailer:  
1. NCGENES 2 saliva kit mailing instructions with the date and time of the saliva collection completed by the 
parent,  
 
1 Use the Dymo label maker to print the return address and the 5264 shipping labels to print the BSP address  

 
 2. the Ziploc bag with one or two saliva tube(s).  
Example return mailings shown here.  
 
Upon receipt of returned saliva kits to the lab, the BSP staff will notify Jeannette Bensen ( jbensen@med.unc.edu /919-
801-9267) and Tracey Grant (traceyg@unc.edu). Returned kits will follow the same sample distribution as outlined for 
blood specimens above and will depend on site (UNC, ECU, Mission Health) and the lab reporting the sample failure 
(UNC BSP lab, UNC CL IA/MGL lab, Mission Health CLIA lab). The UNC Study Coordinator/staff will go to the BSP 
when notified of saliva sample receipt and will take the appropriate request forms and ensure distribution to the correct 
labs:  
1. Blue BSP request form – be sure to indicate that saliva is the “TYPE” of sample on the form and place an 
appropriate label on the form  
2. MGL/CLIA request form – be sure to complete the signed version (correct ordering physician) of the appropriate 
child/pediatric patient saliva request for exome sequencing form.   

 
 Saliva Collection For Parent s/Relative s 
Overview – Parent/Relative  
To initiate the parent/relative saliva kit collection the clinical team (MD/G C) must contact the local SC, who must in turn 
notify the UNC SC (Tracey Grant) and Jeannette Bensen of the need to collect a DNA sample  from parents /relatives  to 
resolve interpretation of the child’s exome sequencing results. Confirmatory DNA tests will be paid for by NCGENES 2 
research funds , performed in the MGL/CLIA lab (UNC) , and reported to the child’s  medical record. Any adult relatives 
(e.g. parents)  must be consented in advance of saliva collection.  The general procedure for this will be to mail the 
consents (2 copies of each for each parent so that one can be signed and returned to UNC/Mission and one kept by the 
parent).1 This can be done in conjunction with the saliva kit mailing , i.e. each parent is mailed 1 saliva kit with an 
accompanying consent and other standard documents that are contained in the saliva kit (described below).  The Study 
Coordinator/Genetic Counselor who typica lly consents the participants to genomic sequencing should call the parent to 
consent them to the parent/adult relative DNA testing. Following this phone consent,  the parent signs and dates the form 
and places it in the addressed/postage paid envelope.  
 
DNA Sample needed from child relative? Relatives under the age of 18 must provide assent and have a parent/legal 
guardian consent in advance of saliva collection. Assenting by phone is not approved.  All assents to relative testing must 
be made in person for NCGENES 2 to cover family testing.  
 
Saliva Kit Mailing Prepar ation  
A parent/relative saliva kit2 includes: one large bubble mailer with one saliva kit (swab and case), one Ziploc bag, and one 
folded, pre -posted and addressed bubble mailer (this bubble mailer will be smaller than the larger one that the rest of the 
supplies are mailed in). The saliva tube is removed from the kit and the appropriate participant label is placed directly 
on the tube. Labels are generated from the tracking system . The labeled tube is then replaced back inside its plastic kit 
box. Examples of participant ID barcode labels for mom and dad are shown below:  
Mom – 01 Dad – 02  
 
Parent barcodes will always end with -01 for mom/parent 2 and -02 for dad/parent 2. The indication that the saliva kit is 
for -01 mom/parent 1 and -02 dad/parent 2 should be explicit, with a barcode on the saliva tube, a label that says “mom - 
01” or “dad - 02” on the outside of the plastic casing holding the saliva kit, and a label that says “mom - 01” or “dad - 02” 
on the outside of the plastic Ziploc bag.3 
 
The plastic box/kit will go inside the Ziploc bag to prevent leakage during transport. The saliva tube will be pre -labeled 
with a parent appropriate barcode with the correct participant ID ending in “ -01” for mom/parent 1 and “ -02” for 
dad/parent 2.  Insid e the large bubble mailer will also include four sheets of paper:  
1. an NCGENES 2 parent saliva letter (see Appendix XI  on page 206 ) 
2. Parent/Relative DNA testing consent ( two copies per parent, one to return and one to keep ) 
3. an NCGENES 2 saliva kit mailing instructions sheet that outlines how to return the saliva back to the BSP4 (see 
Appendix XII  on page 207 ), and  
 
1 In some cases, consent and/or saliva collection can occur in the clinic should the family be returning for another reason. A clinic visit 
should not be scheduled solely for the purpose of parent or relative consent/collection.  
2 See Appendix XXXII  on page 268  for information on ordering supplies  
3 Note: -03 will designate other relatives as needed – the relative type (mom, dad, maternal aunt, etc should be written on the MGL 
forms that go to the CLIA lab)  
4 These instructions are the same as the ones inside the participant saliva kit outside of additionally recording the data and time of 
saliva collection. These should be returned to UNC along with the saliva samples.  

 
 4. enlarged Oragene OG 575 saliva kit instructions printed on a yellow sheet of paper (see  Appendix X on page 
205)  
*All relevant paperwork can be found on IRBIS.  
 
Parents/relatives will be instructed on the NCGENES 2 saliva kit collection process and how to return the completed 
saliva kit by mail to the UNC BSP. The parent will include the following in the returned pre -posted and addressed bubble 
mailer:  
1. NCGENES 2 saliva kit mailing instructions with the date and time of the saliva collection completed by the 
parent,  
2. the Ziploc bag with one or two saliva tube(s).  
 
Upon receipt of returned saliva kits to the UNC lab, the BSP staff will notify Jeannette Bensen ( jbensen@med.unc.edu ; 
919-801-9267 ) and Tracey Grant (traceyg@unc.edu). Samples collected from Mission participants may be mailed to the 
UNC BSP and then brought  to the UNC CLIA lab  if necessary . The UNC RA will go to the BSP   lab when notified of 
saliva sample receipt and will take the appropriate request forms OR actions (enter into an electronic system) and ensure 
logging of sample receipt and distribution (UNC MGL CLIA lab). Two forms for parental/relative collection are needed 
by the UNC MGL CLIA lab (2 below):  
1. MGL/CLIA request forms:  
a. Be sure to complete (label, etc.) the signed version (with correct ordering physician) of the appropriate 
child/pediatric patient saliva request for exome sequencing form.  
b. Label the Phenotypic information MGL request form with a parent -specific bar code (generated from the 
tracking system). Ask the genetic counselor to complete the MGL request form with phenotypic 
information on each parent when the initial request for paren tal saliva kits is made.  Hold the form until 
sample arrival and then combine it with the first form/MGL confirmatory testing request form (custom 
seq family variant) and send it with the sample to the MGL/CLIA lab.  
 
Mailing and receipt of the saliva kit is tracked in  the communication log  of the tracking system by the SC or designee. 
Any consents should be uploaded to the appropriate participant’s document tab. Receipt of the sample is also tracked in 
the RENCI molecular workspace and in the MGL/CLIA laboratory LIMs. Routine reports are run by the study analyst to 
ensure that the loop is closed from sample collection to receipt and processing.  
 
 
Mailed Saliva Kit Tracking – for samples processed and logged into the BSP LIMs  
The UNC BSP will notify a member of the NCGENES 2 team when saliva samples have arrived to the BSP. The 
NCGENES SC/RA will transport the saliva kit to the CLIA lab along with the appropriately completed MGL forms .  For 
returned parental saliva kits, an additional MGL form titled, “NCGENES Request for Family Studies: Molecular Genetics 
Laboratory” will be completed by the participant’s physician or more likely genetic counselor. The study team will 
request that this form be completed when the request is made for parental testing.  The genetic counselor will return the 
completed form to the study team who wi ll hold it until sample arrival in BSP.  At that time the study team will complete 
the MGL request form (pre -signed by the relevant ordering physician) for parental saliva confirmatory testing and will 
combine that form with the Family Studies form complet ed by the counselor.  Both forms will be sent with the saliva 
sample to the MGL/ CLIA lab by the hospital tube system. Each parent’s saliva sample will have their own set of 2 MGL 
forms.  The MGL will log receipt of saliva kit in the RENCI workflow system, extract DNA from the saliva kit (See 
Appendix XXII  on page 238 ), and perform the requested confirmatory testing . 
  
ECU – Saliva Sample Request/Need  
The local Study Coordinator is responsible for coordinating saliva kit mailing for the UNC MGL Lab. The saliva kit  is 
mailed from the UNC Study Team (including appropriate lab request forms) for ECU to the family and is/are returned to 
the UNC BSP.  If two kits are mailed both are returned to the UNC BSP lab return address. The BSP will notify the study 
team who will be responsible for completing appropriate forms and distributing the saliva samples to the appropriate UNC 
lab for processing. The UNC Study C oordinator records and logs the contact with the parent, as well as the kit 
mailing/blood recollection and receipt and distribution of the sample in the patient tracking system.  
 
  
Mission Health – Saliva Sample Request/Need  
The Mission  Study Coordinator is responsible for coordinating saliva kit mailing.  The saliva kit is mailed from the 
Mission Health team to the family and is returned to the Mission Health Study Coordinator . The kit will have the Mission 
health CLIA Lab return address. The Mission Study Coordinator records and logs the contact with the parent, as well as 
the kit mailing and receipt and distribution of the sample in the patient tracking system. The Mission team will also 
perform  the phone consent and  upload  signed consent forms  to the tracking system . The MGL will log receipt of saliva kit 
in the RENCI workflow system and extract DNA from  the saliva kit (See Appendix XXII  on page 238 ). As with blood 
DNA, the CLIA MGL will perform identify check genotyping and store/hold remaining DNA for confirmation of positive 
findings if needed.  
 
Note: Saliva collection kits will be order ed centrally by the Biospecimen Processing Facility.  Saliva kits will be supplied 
to Mission Health. 1  
 
Biospecimen Processing, Distribution and Reporting  
All specimen processing protocols are available in the Appendix.  This section  provides  an overview of the general 
process:  
 
Samples processed and distributed by the UNC Biospecimen Processing Facility (BSP)  
Blood or Saliva Specimen Processing  
For pediatric participants enrolled at either UNC, ECU or Mission Health in  the genomic sequencing arm of the clinical 
trial, either a 3ml blood specimen or saliva swab kit is sent to the UNC BSP laboratory where DNA is extracted and 
quantitated.  The UNC BSP Lab sample flow overview and blood and saliva DNA extraction and quantitation protocols 
are available in the appendix.  F ollowing DNA extraction and quantitation, the sample is sent to the Berg Lab for library 
preparation prior to high -throughput seque ncing.  
 
Distribution of blood or saliva DNA to Berg Lab  
After BSP processing (DNA extraction), quantitation and aliquoting the samples are placed into the protocol 
“BSP_TO_BERG”.   The BSP lab staff will send the Berg lab (specifically Alicia Brandt) an email indicating that a set of 
samples is ready and provide  the list of sample IDs in the batch.  Batches are approximately 10 or more samples per 
transfer.   Berg lab staff (Alicia Brandt or technician TBD) pick up the samples in the BSP and sign a copy of the sample 
manifest (hard copy of the BSP_TO_BERG works heet).  This signed copy goes into the BSP transfer log and the Berg lab 
takes a second copy.   The BSP staff input the pickup information (courier, date, time) into the BSP LIMS and then close 
out the works heet.  This then allows the Berg lab to perform a core transfer of the samples into their (Berg) LIMS.  
 
Samples processed and POSITIVE OR UNCERTAIN RESULTS reported by the UNC 
Molecular Genetics CLIA Lab (UNC MGL)  
Blood or Saliva Specimen Processing  
For pediatric participants in the genomic sequencing arm of the clinical trial enrolled at UNC , Mission , or ECU either a 
3ml blood specimen or saliva swab kit is sent to the UNC Molecular Genetics Lab (UNC MGL) where DNA is extracted, 
quantitated and identity check genotype completed (used to resolve potential sample mix -ups).  The UNC MGL blood and 
saliva D NA extraction, quantitation and identity check protocols are available in the appendix.  Following DNA 
extraction and quantitation, the DNA sample under goes genotyping for 8 single nucleotide polymorphisms to be used for 
comparison to data obtained through GS. The remaining DNA sample is held until notification at the molecular sign -out 
meeting that positive or uncertain research findings must be confirme d.   
 
Confirmation of Positive or Uncertain Research Genomic Sequencing Findings  
 
1 See the Supplies list in Appendix XXXII  on page 268 . 
 
 Research sequencing confirmation is conducted via Sanger sequencing in the UNC MGL CLIA lab (protocol available in 
the Appendix).  CLIA confirmed results are placed in the patient’s medical record which automatically notifies the UNC 
ordering physician.  I f the CLIA confirmation is being conducted for an ECU  or Mission  study participant, then the CLIA 
lab results will be sent via fax to the ordering physician. Negative research GS results are NOT confirmed in the CLIA 
clinical lab. Negative results notifica tion is done by the NCGENES 2 Patient Tracking System that generates an email 
notification to the ordering physician indicating results are available.  This notification include s a patient friendly research 
result report and points the MD to the molecular analysis tab to see the negative result report and requests the physician to  
complete the physician post -RoR survey.  All results (positive, negative or uncertain) are reported t o the family by the 
clinical  genetic counselor or ordering physician by phone or in-person.   
 
Sample reporting of NEGATIVE RESULTS by UNC NON -CLIA RENCI System - All Sites  
Return of NEGATIVE RESEARCH results to NCGENES 2 patients (All Sites)  
Negative research results cannot be confirmed , thus negative results will not be confirmed by either UNC CLIA 
Molecular Genetics Labs.   
Instead negative results notification is done by the NCGENES 2 Patient Tracking System that generates an email 
notification to the ordering physician indicating results are available.  This notification includes a patient friendly resea rch 
result report an d points the MD to the molecular analysis tab to see the negative result report and requests the physician to 
complete the physician post -RoR survey.  All results (positive, negative or uncertain) are reported to the family by the 
clinical  genetic counselo r or ordering physician by phone or in -person.   
 
Final Genomic Sequencing Report to Parent/Caregiver  
At the end of the study, after the final 12 -month telephone survey, parents will be mailed a final thank you letter for their 
participation (a copy of the final genomic sequencing results for their records MAY accompany their thank you note).  
 
 APPENDICES  
 
Appendix I.  Etiology Criteria  
CLINICAL CRITERIA  
Research Project: NCGENES 2  
Updated 2/21/2020    
 
Clinical screening criteria to determine pediatric patient NCGENES 2 eligibility  
 
Instructions: Eligibility screening has two phases. First, use the “Initial (Non -Phenotypic) Eligibility Criteria” (Page 1) 
to determine if the patient should be screened by phenotype. Then, if the participant meets the first set of criteria, use th e 
“Phen otypic Eligibility Criteria” (Page 2 -3) to determine whether the patient qualifies by phenotype. Both sets of criteria 
include separate inclusion and exclusion criteria.  
 
It is anticipated that this document will evolve as the study unfolds.  Likely new criteria both inclusion and exclusion will  
emerge as we begin to screen potential patient records at all sites.  
    
Contact person for questions:  Jeannette Bensen, PhD ( jbensen@med.unc.edu , 919 -801-9267 (cell))  
 
Initial (Non -Phenotypic) Eligibility Criteria  
 
1. Inclusion criteria:  
a. Age at the initial evaluation: less than 16 years old at NCGENES 2 study eligibility determination.  
b. The following types of pediatric patients with first visit  to either outpatient Pediatric Neurology or Pediatric 
Genetics and Metabolism clinic will be are considered eligible for phenotypic screening and if phenotypically 
eligible are invited to enroll in NCGENES 2:  
i. Patients who have never been worked up and who do not currently have a known etiology for their condition 
but it is suspected to be genetic  
ii. Patients who are referred from an outside UNC/NCGENES 2 Study Site neurologist - ‘second 
opinion’/patient has had some work up  
iii. Patients initially seen as an inpatient at UNC/NCGENES 2 Study Site, with subsequent first visit to Pediatric 
Neurology or Pediatric Genetics and Metabolism clinic  
iv. Patients who have previously been seen in Pediatric Neurology (1 or more times) and are referred as a New 
patient to Pediatric Genetics are considered eligible for phenotypic screening and if phenotypically eligible 
are invited to enroll in NCGENES 2  
 
2. Exclusion criteria:  
a. Patients who are 16 years or older at NCGENES 2 study eligibility determination  
b. The following types of pediatric patients with a ‘New’ visit to either outpatient Pediatric Neurology or Pediatric 
Genetics and Metabolism clinic are considered NOT eligible for phenotypic screening:  
i. Patients designated as ‘New visit’ to either (Peds Genetics or Peds Neuro) clinic because it has been > 3 
years since their last visit to the clinic (essentially, they are a return patient to the same clinic)  
ii. Patients designated as ‘New visit’ to either (Peds Genetics or Peds Neuro) clinic but have been seen in <=3 
years ago in that same clinic.  This can be determined by a review of the medical record where it can be 
clearly seen that this patient has been see n by the same or a different doctor in that same clinic in the past.  
For example, a patient has been seen 2 times in a clinic and then calls needing an immediate appointment and 
the MD tells the scheduler to put them in ANY type of clinic appointment avai lable and the scheduler places 
the return patient in a “New visit’ slot.  
Phenotypic Eligibility Criteria  
 
1. Inclusion Criteria  
a. One of the following conditions/initial referral reasons:  
 
 i. Epilepsy and seizures (Any seizures if with developmental delays. Any seizures onset prior to 6 months old. 
But not for example febrile seizures or a single afebrile seizure in a child with typical development).  
ii. Neuromuscular disorder (this may include muscle weakness,  elevated CKs, neuropathies, arthrogryposis, 
etc) 
iii. Brain malformation (this includes lissencephaly, schizecephaply, megaencephaly, polymicrogyria, 
pachygyria, etc)  
iv. Intellectual disability/autism spectrum disorder with intellectual disability/developmental delay  
v. Hypotonia (unexplained)  
vi. Inborn errors of metabolism suspected  
vii. Movement disorder (dystonia, ataxia, etc)  
viii. Other conditions that are considered have a genetic etiology (such as severe congenital central 
hypoventilation syndrome).  
ix. Microcephaly/Macrocephaly with developmental delays or any that are >2.5 SD from normal.  
x. Metabolic indications that WILL be included [represents 30% of metabolic patients] are:  
1. R/O mitochondrial disorder  
2. R/O metabolic with neurologic component like;  
a. Hypotonia  
b. Ketosis  
c. Hypoglycemia  
d. Hepatomegaly  
e. Cyclic vomiting  
f. Splenomegaly  
xi. Chromosome Abnormality (some select cases see below)  
1. Note: A microarray VUS would still effectively be in a “diagnostic odyssey” and be eligible, however it 
could also be a real “positive” in which case the referral would be for post -test counseling and the case 
would be ineligible.   
xii. Hearing loss  
xiii. Dysmorphic features  
xiv. Skeletal Dysplasia (e.g., achondroplasia, OI, Unknown)  
xv. Multiple congenital anomalies  
1. Includes multiple congenital anomaly syndromes with no etiology (e.g., VATER, CHARGE (make sure 
not related to CHD 7 gene mutation), Pierre Robin  
xvi. Rhabdomyolysis  
xvii. Hereditary/Childhood Cancer while typically out of scope for NCGENES 2, should not be an absolute 
exclusion criterion.  There are some multisystemic genetic syndromes where cancer can be seen (e.g., Wilms 
tumor in the setting of overgrowth, neonatal hypogl ycemia, and exomphalos would suggest Beckwith -
Wiedemann syndrome).  When such a condition is described provide as much detail as possible related to 
any other clinical findings, path report and send to Jonathan for determination of eligibility.  
xviii.  Fetal Alcohol Syndrome – while an entirely non -genetic disorder BUT may be confused with other genetic 
syndromes.  Many cases of FAS are challenging for referring pediatricians to diagnose and thus in some 
cases these referrals will be considered eligible.   Specifically, if developmental delay  is included as a finding 
in the child with FAS referral we will consider them ineligible.  We will let the geneticist rule the child in or 
out during the clinic visit.  If the clinical geneticist diagnosis FAS then this will be a ‘diagnosis at visit 1’ an d 
thus these patients will be investigator withdrawals with the typical ineligibility status sentence.   
 
  
 
 2. Exclusion criteria  
a. Any known history of the following acquired conditions such as ischemic encephalopathy (including perinatal 
stroke), CNS infection (such as meningitis or encephalitis), brain trauma, autoimmune/inflammatory disorder or 
other acquired injury to brain/nerve/muscle.  Macrocephaly in a patient with known hydrocephalus/shunt.  
b. Patients who have a known genetic diagnosis that explains the clinical presentation.  
c. Most metabolic will NOT be included (e.g., abnormal newborn screen) [represents 70% of metabolic patients]  
d. Café au lait (isolated)  
e. Trisomy 21, 18, 17, 16p  
f. Microdeletion 22q  
g. Family history of a known genetic condition (e.g., CF, being referred for genetic counseling)  
h. Short stature (isolated)  
i. Obesity (isolated)  
j. Failure to thrive (isolated)  
k. Cleft lip and/or cleft palate (isolated - not part of a syndrome)  
l. R/O connective tissue disorder/hypermobility  
i. R/O Ehlers -Danlos Syndrome  
ii. R/O Marfan Syndrome  
m. Congenital nevus (isolated)  
n. Congenital scoliosis (isolated)  
o. Isolated Attention Deficit/Hyperactive Disorder (ADHD)  
  
 
 Appendix II. Study Statuses   

 
 Appendix III. Randomized Recruitment  
Recruitment sampling and randomization in NCGENES  
2/14/2018  
 
1. Recruitment Sampling  (randomization recruitment) – Using the last full year (2016) of patients coming to 
relevant UNC clinics where NCGENES2 patients are seen identify the frequency of the following groups (% of 
total patients). Operationally recruit all African Americans/His panic/Medicaid (under -served/under -represented) 
patients and calculate sampling proportions for the remaining group (served). Randomly assign a sample weight 
to patients in this group and recruit only if the randomly assigned proportion  is at or below the sampling weight.  
 
 
2. Study intervention randomization #1 (Pre vs. No Pre -visit prep) – Create randomly permuted blocks of size 2 -8 
for each of the 4 sample groups above until the targeted number of enrolled is achieved.  
3. Study intervention randomization #2 (Genomic Sequencing (GS) vs. No GS) – Should make sure that those in pre 
vs No pre -visit prep are equally distributed into +/ - GS groups  
a. I agree – per Fang -Chang Lin  
4. Both interventions are randomized 1:1  
5. Concern and Question:  
a. While we will apply randomized recruitment (sampling/selection) to balance proportion of underserved to 
served at enrollment this will not ensure balance of served and underserved within intervention arms, 
true? Is there any way to ensure balance of served  underserved within intervention arms?  
i. I thought it would be balanced. If I understand it correctly, we are going to randomize 
intervention/control assignments 1:1 ratio in each of the 4 groups above. Therefore, the 
underserved and served ratio is still 3:2 in the intervention group, as well as  in the control group. 
Per Feng -Chang Lin  
b. Should subjects be randomized to both arms at the same time. Concern that some participants in arm 1 
with pre -visit prep of certain demographic group will be burdened and drop out before GS randomization.  
Randomized Recruitment Charts for UNC NCGENES 2 Clinics 
Pediatric Genetics and Metabolism Clinic
Per yr*Project 
number 
in UNC 
clinics% 
selected 
randomly 
for studyNumber 
selectedMinus 
10% 
ineligibleEligibleMinus 30% non-
responders or 
refusalsProjected cases 
enrolledProportion
AA -Hispanic-Medicaid 1438 100% 1438 144 1294 388 906 60%
Non-AA - Non-Hispanic - Non-Medicaid 1500 64% 960 96 864 259 605 40%
ALL 1511 100%
Pediatric Neurology Clinic
AA -Hispanic-Medicaid 3035 100% 3035 304 2731 819 1912 60%
Non-AA - Non-Hispanic - Non-Medicaid 2640 77% 2033 203 1830 549 1281 40%
ALL 3193 100%
Both Clinics Combined
AA -Hispanic-Medicaid 4473 100% 4473 447 4025 1208 2818 60%
Non-AA - Non-Hispanic - Non-Medicaid 4140 71% 2993 299 2694 808 1885 40%
ALL 4703 100%
**Assumes proportions (served/under-served) of ALL clinic cases (shown here) is equal to the proportion of cases who fit clinical criteria
*** Likely non-response rates will differ by group and will need to be adjusted over time to allow better % selected estimates
 
 i. I feel drop -out is probably the main reason for unbalance. If we do have the same drop -out rate 
between underserved and served, then 3:2 ratio remains, as shown in your table. If we have the 
same drop -out rates between intervention and control, then 1:1 ra tio between intervention and 
control remains, as well as the 3:2 ratio between underserved and served. - per Dr. Lin  
c. Should we do something at block randomization to account for these concerns. Dr. Lin would not 
recommend any other adjustments at randomization to address this Indeed. The block randomization can 
guarantee the balance between intervention and control, but without balanced drop -out, the final sample 
cannot reach the ideal ratio. However, we will do intention -to-treat analysis, so the intervention and 
control ratio should still be balanced. -per Dr. Lin  
d. Per Dr. Lin, he will generate trial randomization list but wants to be sure that the numbers on the list are 
assigned sequentially and matched to a specific ID#. The patient tracking system will handle this. He will 
send randomization list when we let him know that we are ready to go. The randomization scheme will be 
applied to individuals in the study as they enrolled. There will be a different randomization list for each 
site. 
 
REFERENCES:  Weinberg CR1, Sandler DP . Randomized recruitment in case -control studies.  Am J Epidemiol.  1991 
Aug 15;134(4):421 -32. 
 
 
  
 
 Appendix IV. Pre -Clinic and In -Clinic Activities list for Research Assistant and Study 
Coordinator  
RA Pre -Clinic and In -Clinic Activities  
(updated 10/7/2019)  
 
Before clinic visit  
1. Check NCGENES calendar for clinic location and study ID of scheduled participants  
2. Obtain clinic consult room  
3. Charge all electronic devices (audio recorder, iPad, tablet)  
4. Be sure that all movies and cartoons on Netflix have been refreshed each week  
5. Pack the following:  
• All chargers for electronic devices  
• All electronic devices (tablet should have stylus)  
• Create participant study folders (see chart order document)1  
• Pen 
• Laminated instructions for physicians  
• Laminated sheet with MDs and genetic counselor names  
 
To do in clinic  
1. Sit outside Pediatrics  clinic to look for relevant patient check in2 
2. Correspond with the study coordinator by text regarding arrival of patient noted in the EMR  
3. Login to UNC -guest /relevant hospital internet access  (set up so automatic)  
4. Open VPN and connect, which ensures secure access  
5. Once connected, open Chrome and click on NCGENES tab  
6. Click on 'participants' and in the URL line enter participant ID number or order participant list by ID and click on 
participant’s name to open  task list  
7. Approach patient in clinic waiting area , confirm parent’s/patient’s name and introduce yourself and your 
relationship to the NCGENES  
8. Confirm appointment in tracking system  
9. Collect intake from parent, place in participant’s folder and indicate receipt of form in tracking . 
a. If patient doesn't have form, provide paper intake with postage paid return envelope and complete necessary 
items in the tracking system for that scenario  
b. If there is 45 minutes prior to the clinic appointment AFTER completion of all pre -clinic visit research and 
clinical activities (e.g. height and weight), the parent can complete the intake form on paper in the clinic room  
c. A note must be made in the participant’s chart in the tracking system if any part of the Intake form is 
completed AFTER the clinic visit  
10. Open a second web page and navigate to https://ncgenes2.sirs.unc.edu/surveys3 
11. Go back to specific patient's 'task' page and copy the survey code for pre -visit survey and go to second page and 
paste in survey code  
12. Go back to patient task page and close it - leaving only the survey page open . This ensures that the parent cannot 
see other study participant’s details/files  
13. Open survey on tablet and hand to parent for completion (with or without stylus or touch). Let parent know to 
hand you the tablet when done . Stay nearby  for questions/tablet challenges . 
14. Obtain tablet from parent (click finish, if needed)  
15. Re-open a patient specific ‘task’ page and confirm pre -visit 1 parent survey now has a ‘completed’ status  
16. Click on parent permission to audiotape task and read/state that study is trying to learn about parent and physician 
communication and would like to audiotape the clinic visit and that if the parent consents they will check “yes” 
and sign  
17. Hand the tablet to the parent to indicate “yes” or “no” and sign  
 
1 SC or unblinded member of the study team will provide RA with the appropriate post -visit survey for each participant.  
2 If the patient is approached prior to check in , just do a brief introduction and inform them you will speak with them after check -in - 
do not want to delay check -in process ) 
3 Tasks 10 -18 may be completed after patient has been weighed, etc. by nurse and placed in exam room.  
 
 18. When they return tablet to you, type in the parent’s name, then sign and date and type your name as witness 
before clicking “Finish and finalize”  
19. Prior to genetic counselor (or physician) entering the room, turn on audio recorder (side bar), then press record  
and say the recorder number and participant ’s study ID  number1  
20. Set recorder and case on shelf in clinic room  out of reach of patient  
21. When done, let the genetic counselor  or physician (they sit in work room ) know that you are finished, and the 
patient is ready for clinical visit to begin2 
(Both the counselor and physician will need to see patient next)  
22. Go to waiting area/consultation room and, if possible, enter the paper intake form into the tracking system,3 while 
monitoring  whether the clinician has concluded their visit   
23. At the end of the visit, turn off and collect tape recorder and provide post -visit survey (ideally in the exam room , 
though the post -visit survey can be administered in the waiting/ consultation room if needed)  
24. Provide the post -visit parent survey as you did pre -visit survey via a new surveys tab, BUT use the appropriate 
survey code for the post -visit survey on the participant page  
25. While parent is doing post -visit survey, consult with the physician regarding developmental age of child (only if 7 
years of age or older chronologically) and any planned blood orders. Also identify if any time sensitive blood 
collections are needed (e.g., those needed by 3pm, etc.). Relay this information to the Study Coordinator  in-
person or by text.  
26. When parent is done with the survey let them know that you will now take them to the Study Coordinator  (who 
they may have spoken with by phone before today’s visit) who will talk to them about a potential next test and 
provide snacks/reimbursement. When the SC is finished seeing the parent they will direct them to the check -out 
area and then take them to the phlebotomy area if their child needs to have any blood drawn.  
27.  Collect the iPad and walk patient and parent to consultation room and hand off folder and patient to Study 
Coordinator4 
28. Double check to be sure that you have all tablets, iPads and audio recorders that were brought to the clinic  
29. Return to the office and place all electronic devices on chargers in preparation for the next clinic   
 
1 If unable to record the study ID number, then on the intake form, you received from the parent, write the number of the recor der that 
was placed in the room.  
2 NEVER unblind the physician or genetic counselor to the randomization status of the patient (either pre -visit prep or genomic 
sequencing). If this happens a NOTE should be placed in the participant’s tracking system record. The physician and genetic 
couns elor can ONLY be unblinded to patient’s randomization status AFTER the physician has completed the post -visit 1 physician 
survey  
3 If the Intake form was not entered by the RA during the clinic visit, it should be entered after the Study Coordinator return s with the 
folder from the clinic or immediately the next morning. Intake forms should be entered within 24 hours of collection.  
4 To date we have used the UNC consultation room in Pediatrics  clinic (behind check out) primarily, but have also used the cardiology 
conference room  
 
 Study Coordinator Pre -Clinic and In -Clinic Activities  
(10/7/2019)  
 
Before clinic visit:  
• Log into the NCGENES tracking system1 to review potential study participants  
• Once in tracking, select a referred patient scheduled to visit the clinic three or more weeks from the date of 
review, starting with the closest appointment date  
• Log into EPIC and navigate to the selected patient’s medical record information.  
• Review this information to confirm the patient’s DOB, MRN#, appointment information, and language spoken is 
the same as that listed in the tracking system.  
• If any of the data is different, revise the tracking system to contain the same information that is listed in EPIC and 
as necessary add a note in tracking to document any changes.  
• Review the patient’s medical record information in EPIC to determine if the patient meets study’s clinical 
inclusion criteria.  
• Make appropriate selections in the tracking system to indicate the patient’s study eligibility, per the above EPIC 
review.  
• For ineligible patients, no further action is needed  
• For eligible patients:  
o Ask an RA to send the study introduction letter (SC will serve as their back -up) 
o Make enrollment calls  
o Update tracking system to reflect the outcome of enrollment calls  
• For participants that agree to be in the study:  
o Based upon randomization for intervention 1, have an unblinded RA create and mail enrollment packet 
(SC will serve as their back -up) 
o Add participant to NCGENES calendar  
o For participants attending the genetics & metabolism clinic, make a note in MEDGIS that patient is an 
NCGENES participant  
o For patients attending the neurology clinic, email Betty to inform her of their participation2 
o Inform RA, student volunteer, and Jeannette of upcoming clinic dates and times  
o Make reminder calls and update tracking system to reflect call outcomes  
• 1 to 2 days before clinic:  
o Provide RA attending clinic with the appropriate post -clinic visit survey for each participant  
o Check SC clinic bag to ensure it contains all needed supplies and age appropriate participant gifts 
(generally there are 2 gift choices per participant)  
  
 
1 All actions before and during clinic are in the production version of the NCGENES tracking system.  
2 The email should contain the patient name, MRN#, appointment date & time, and provider name (generally, SC sends Betty an ema il 
twice a month regarding study participants)  
 
 To do in clinic:  
During initial meeting:  
• Introduce yourself  
o Typically, parents are told on the phone that they will meet with Tracey or another member of the team in 
clinic. If you spoke with the family on the phone, introduce yourself accordingly  
o If not, tell the parent you work with Tracey  
• Tell them what will happen during this time (i.e. discuss the second part of the study, take them to check -out 
/blood draw). Also tell them at check -out they can get a note for school or work if needed.  While the parent is at 
check -out the SC should stand  either outside the consult room door or by the tiles with handmade pictures, etc., to 
meet the parent and take them to phlebotomy/direct them how to exit the hospital.  
• Remind they will receive a copy of the forms discussed (also remind them of this point during/at the end of each 
consent discussion, depending upon how overwhelmed they seem)  
• If assent is needed:  
o Tell parent you will need to talk to their child about the study, since they are at least 7 years old. Also, 
because of this, both parent and child must agree to participate. Generally, try to say this without the child 
hearing as they may get excited/make a comment that they don’t want to participate (and at this point they 
have not heard anything about the study). Also, this facet of the study tends to m ake parents tense up. If 
so, explain to the parent that this is part of standard practice, is required, and is a way to ensure that kids 
understand what is taking place.  
o Explain to the parent that you’ll discuss the study with them first and then their child, and that they will 
get a copy of everything that is discussed with them and their child.  
Consent form 1:  
1. At the top of the form and on all the forms we discuss today is the name of the study investigators and contact 
information. Pointing out that the phone number is the same one that they have received before in the packet. And 
that this number and email is what they can use to reach members of the study team.  
2. They can decline at any time and that it will not impact their care. Whatever was decided/is done during the study 
will not change what the Dr. (say provider name) wants to have done.  
3. If they decide to continue in the study, regardless of if they are assigned to GS or no GS that we will study their 
child until they are 18 by looking at their medical records and insurance information. Once they turn 18 the link 
between their name and stu dy ID number will be removed.  
4. We are looking at medical records and insurance information for items around why they came to clinic today. 
That when we use this information to report on study findings, we report in generalities, like for example we saw 
850 families and from 50 we learne d X and from 150 we learned Y. Also mention that we place information in 
public databases, which is something that researchers do to learn from each other, but this information is included 
without any personal information on study participants.  
5. Participation will not involve an additional trip to UNC, we understand that no one lives close, so the study was 
designed in such away as to not have them make a trip to UNC only for the study. Which is why we try to have 
study activities done when they a re already coming.  
6. What will happen today is, if they are assigned to have testing and they decide to do so, that for their child 
participation means giving a little extra blood today. For them it means doing a phone interview about 6 -8 months 
from today and then another pho ne interview about 6 -months after that. If they are assigned to no GS or decide 
not to have testing, then there are no activities for their child, but that they will still have the phone interviews.  
7. The study’s funder is part of the NIH (the part of government that funds most research).  
8. The IRB is the Institutional Review Board, which is the organization that approved us to do this study and that 
they make sure researchers do what they say they will do. If they do not think this has occurred, they can contact 
the IRB with or without givin g their name to discuss the issue.  
9. The IRB’s number is included in the consent, and that they will get a paper copy of the consent after signing.  
10. The IRB requires that we have information in the consent about future use of the data, so this section discusses 
this use and that they can still be in the study regardless of if they decide to have or not have their information 
stored in the separate data base.  
11. Discuss the future use section of the consent and offer to let the parent read it on the screen.  
 
 12. At the end of reviewing consent form, inform the parent that in by signing this form they are agreeing to allow us 
to  
o 1) flip the coin to see if they are or are not offered GS testing  
o 2) to look at their child’s medical and insurance information regarding information around why they came 
to clinic today, until their child is 18  
o 3) that we will have to obtain HIPPA consent, since this consent is what allows us to look at their child’s 
medical and insurance records.  
13. Ask if they will sign consent form 1.  
HIPPA Consent:  
1. Acknowledge they are likely familiar with HIPPA due to previous trips to the doctor/hospital.  
2. Their signature is needed because it allows us to receive and share information with other HIPPA covered entities.  
3. Point out below differences with giving us HIPPA consent versus other times they typically encounter HIPPA:  
o Although they can withdraw from the study at any time by calling, that to withdraw HIPPA authorization 
requires notification in writing by email or letter, because it involves medical records, etc. The phone 
number and email address are at the top of the consent forms.  
o Because of the role of NIH and the IRB they can audit the project and that during this audit they may look 
at their child’s research records. This look may reveal some of their child’s medical/insurance information 
or they may ask to see this information t o clarify a question. They are not HIPPA covered entities, but we 
expect them to treat the information in the same manner as HIPPA entities. Records chosen for an audit 
are random, and that their child’s record may or may not be selected.  
o If they give HIPPA authorization to others, after this project, and there is project information in their 
child’s medical record, that these others will have the project information (unless they restrict access)  
4. Offer to let parent read HIPPA consent on the screen  
Informed consent 2:  
1. GS testing is not a new test, but we are trying to determine if having the test sooner rather than later in the process 
of learning a reason for why their child came to clinic today, impacts care they receive down the road. For 
example, if they have more o r less additional test then children who do not have GS testing.  
2. Test results typically come back into one of three categories:  
o Positive, meaning the change we see is the cause for why their child came to clinic today.  
o Uncertain, means that there is not enough data yet to know if the change we see causes health issues or is 
part of the many changes that people just have.  
o Negative, means at this time we did not find a change that is related to why their child came to clinic 
today.  
o As more research is done, an uncertain or negative result could change to something else. And if we learn 
of a change, or of a reason that may impact their wanting to continue study participation that we will 
contact them.  
3. If the results are positive or uncertain, the test is confirmed in the hospital lab, and this confirmation allows the 
results to become part of their child’s medical record.  
4. Once information is placed in the medical record it cannot be removed. So, if they call after this has occurred, we 
can stop research but cannot remove the information from their child’s medical record. Usually give an example 
of what happens if they withd raw before and after the 6 -month time point of receiving results.  
5. When discussing medically actionable items:  
o Remind them that since this GS test is not new, there are some changes that we know cause health issues 
and that these issues are typically something that happens as an adult.  Therefore, the professional 
genetics organization, has made it optional for par ents to learn this information. Regardless of what they 
decide, it will not change the care they receive or what happens to study participation (i.e. We still follow 
until their child is 18, phone interviews still occur.  
o Because these conditions usually happen as an adult, finding them may mean that they, the child’s other 
parent or other family members may need to be tested. The study does not cover these tests; the cost is 
billed to them/their insurance.  
o Offer to let parent read this section of the consent on the screen  
 
 6. Ask if they will sign consent form 2.  
Assent form 1 and 2:  
1. Intro yourself again to the child  
2. Tell them you’re going to talk to them about the study, but first you would like to know if they have any questions 
about what they overheard you telling their parent  
3. Tell them their parent will get a copy of what we talk about and that a phone number is on it. So, if they have a 
question later, they can ask their parent to call and their question(s) will be answered.  
4. That although you may like too, you can’t change anything that the Dr. (state their name) wants to happen.  
5. Tell them that like in school they have to study to learn things, that we are doing this study to learn if a test, will 
help doctors learn why they and other kids have to come see them.  
6. That we are seeing 850 kids and that we ask half the kids if we can look at their medical records until they are 18, 
and the other half of the kids we ask if we can look at their medical records and that they give a little extra blood 
(like 1 -2 teaspoons).  Giving this extra blood just means adding small tubes to the ones the doctor wants. They will 
not get stuck another time.   
7. Us looking at their records does not mean they have to come back to see us, it just means work for us to do.  
8. Ask if it’s okay for you to flip the coin to see which group they are in  
9. Pause and tell them which group they are in  
10. Tell them the test is looking to see if there is a change in their genes that is the reason for why they came to clinic 
today.  
11. The test will either say “yes” we see a change that is the reason, “no” we don’t see a change that is the reason, or 
“we see a change” but don’t know what it means. That we all have changes, and some cause people to come to the 
doctor and others don’t.  
Blood Draw:  
• On side pocket of red bag are gloves and extra blood supplies.  
• While family is waiting for blood draw to occur (or sooner if possible), do the following:  
o Label the tubes  
o In upper right - hand corner of the white provider signed MGL form, place study label and hand write date 
and time of blood draw  
o After tubes are obtained, complete the BSP form  
o After blood draw is done, walk them back to the area outside of phlebotomy and give them directions on 
how to exit the hospital.  Then prepare the biohazard bags as below.  If they valet parked, they go to either 
the hospital staff member at the front of t he phlebotomy section or the information desk and they contact 
the valet service.  
o In one biohazard bag place the MGL form and the blood tube with the smaller amount of blood and send 
this bag to the CORE lab via the shoot system. Number for the core lab is 30.  There is long delay 
between when select enter, for the tube to be sent and i t actually goes. Stay there until the tube is gone 
and the screen is as it was before you sent the tube.  
o In the other biohazard bag, place the tube with the higher amount of blood and the completed BSP form 
into the red biohazard bag and take it to the BSP.  
o If needed  help the parent hold/calm the child during blood draw.  
In the phlebotomy area, take the family to the desk area closest to where you enter the phlebotomy section. The 
parent gives the child’s name and DOB and the name of the doctor who saw them. They do not need to take a 
number or see someone in the glass off ice area, because they have already checked into clinic.  
  
 
 Appendix V. Address , Barcode , and Shipping  Label Information and Instructions  
Required l abel printer s and labels1 
Each product name links to the manufacture for specifications. Choice of vendor depends upon the preference of the buyer 
and available prices. Suitable alternatives may be substituted  at buyer’s  discretion.  
 
Printer Hardware:  
For Barcodes and Address Labels:  LabelWriter®  450 Twin Turbo    SKU: 1752266  
For Barcodes   or  Address Labels :  LabelWriter® 450 Turbo    SKU: 1752265  
For Large Shipping Labels:   Any Standard Printer  
 
Labels:  
For Address  Labels :   LW Address Labels 1 1/8" x 3 1/2"   SKU: 30252   
For Barcode s:    LW Multi -Purpose Labels, Small 1" x 2 1/8"  SKU: 30336  
For Large Shipping Labels:   Avery® Shipping Labels, 3 -1/3" x 4"   Prod  #5264  
 
Printer Software:  
For Dymo Printers:  Mac:  DYMO Label v8 .7.3  Downloa d   Windows:  DYMO Connect for Desktop v1.2  Downloa d 
All other printers:  Contact your institution ’s IT/Helpdesk  
 
DYMO LabelWriter  Setup Instructions  
Follow these steps to configure a DYMO LabelWriter for printing.  
1. Download the software for your computer by clicking the appropriate link  above  and obtaining IT approval as 
necessary . 
2. Download the following documents and store them somewhere on your PC.  These files are available in Teams or 
Sharepoint. You may also contact Peter Newman -Matthews if you have trouble locating these files.  
a. NCGENES 2 Barcode.label  
b. NCGENES 2 Address.label  
c. Barcode Data Template.xlsx  
d. Address Data Template.xlsx  
3. Load your Dymo printer with the appropriate size labels per the above specifications. If using a twin turbo, load 
one type of label in each spool.  
 
  
 
1 Ordered by clinical team, not lab  
 
 Printing  Barcode Labels  
(If using  a single DYMO, make sure to spool LW  Multi -Purpose Labels, Small 1” x 2 1/8” ) 
1. Open “NCGENES 2 Barcode .label ” using the DYMO Connect application.  
2. Click  the purple “Import Data” button on new the top of the window.  
 
3. Find the  barcode excel merge document  (use “Browse…”) an d then import the desired records. Settings should be 
preset. If not, mirror  the image below.  
4. If necessary, adjust the fields on the barcode (this should not be necessary). If you need to print multiple copies of 
a barcode, first select the settings icon next to the print button and indicate the number of copies you wish to print. 
Then, click the blue “Print” button in the bottom right -hand corner.  
 
  

 
 Printing Address  Labels  
(If using a single DYMO, make sure to spool LW Address Labels 1  1/8” x 3 1/8”)  
1. Open “NCGENES 2 Address .label ” using the DYMO Connect application.  
2. Click the purple “Import Data” button on new the top of the window.  
 
3. Find the address  excel merge document (use “Browse…”) and then import the desired records. Settings should be 
preset. If not, mirror the image below.  
4. If necessary, adjust the fields on the address label  (this should not be necessary). If you need to print multiple 
copies of a barcode, first select the settings icon next to the print button and indicate the number of copies you 
wish to print. Then, click the blue “Print” button in the bottom right -hand corner.  
  

 
 Appendix VI.  Shopping List for ECU and Mission   
Shopping Lists for ECU and Mission  
(May 24, 2019)  
 
1. Lenovo study tablet computers…THEY ARE HAVING A SALE IN MARCH SO ORDER SOON:  
a. See specification on next sheet/back sheet.  You will need to purchase 2 one will be used for recruitment 
and one for clinic activities.  You will not be able to see 2 participant s at the same time unless the Study 
Coordinator who is recruiting is willing to give up the tablet to the clinic staff (RA and Genetic 
Counselor).  
2. Additional Tablet ThinkPad Pro pens (in case they get lost) – ONLY if using a tablet -otherwise use mouse  
3. Two audio recorders and cases (For UNC four Olympus DS -2500 recorders were purchased.:  (get box Link to 
recorder instruction manual: 
http://www.olympusamerica.com/cpg_section/cpg_support_product.asp?id=1620  
4. Two double port USB wall charger (for UNC Staples Dual USB wall charger were purchased at a cost of $13.19 
each)  
5. Need one iPad AND cases – via Netflix download free movies and cartoons onto the iPads for kids to view during 
the visit (optional – only if institution allows purchase)Two  
6. Two rolling carts (the carts for UNC were purchased from Staples, the specific item information is: GP 80783 
Embassy Plus Rolling Briefcase for 16” Laptops, Black. Cost $57.96.)  
7. Printer with the ability to print in black and white and in color, and on dual sides  
8. See Supplies and Ordering Information section of the Biospecimen Protocol for descriptions/specifications of 
items that need to be purchased for both blood and saliva collection, as well as, materials needed to mail samples 
to UNC. Note:  Due to expiration dates ordering blood tubes and saliva collection kits should occur a month 
before the first participant  is seen in clinic. This will allow for maximum self -life. Also, once materials are 
received confirm expiration dates are at least 12 -months from the date of receipt.  
9. One biohazard transport bags (For UNC these were purchased from Amazon. Product: Biohazardous Transport 
Insulated bag. Brand name: Hopkins Medical Products Part #: Ho539656. Cost: $7.95)  
10. Gloves for handling blood and possibly saliva samples (if your hospital allows you to collect them onsite)  
11. Snacks for participant s and other children with the family (fruit gummies and animal crackers go over big with 
families)  
12. File folders and related labels (Avery labels were purchased for UNC with the following dimensions:  
a. Mailing introduction letter: Avery #5160  1” x 2 5/8”  
b. Mailing enrollment packets: Avery #5264  3 1/3” x 4”  
c. For file folders: Avery #8366 1/3 Cut 2/3” x 3 7/16”  
13. Thank you and birthday cards  
14. Non-monetary child compensation gifts (and storage container if they do not have a locked storage area). (For 
UNC all of these gifts contained the school logo, footballs and water bottles were the family preferred items 
however, it was difficult to include a football in the rolling cart.)  
15. Laptop protector for each laptop (for UNC Belkin Notebook Sleeve for 14” Laptop/Chromebook, black were 
purchased at a cost of $16.49 each)  
16. Lock box to store cash/gift cards for study visits and phone interviews (For UNC a Barska extra small cash box 
with combination lock was purchased at a cost of ($26.61)  
17. Barcode label printer and labels (For UNC these items were purchased at Staples and the specifications are: 
printer: DYMO Label Writer 450, labels: DYMO 45010 ½ -inch high -performance permanent self -adhesive 
polyester label tape for label makers, black on c lear (sold by the role).  
 
 
  
 
 Item:  
ThinkPad X1 Yoga 3G   
   Part No: 20LDCTO1WW  
 Ships In:  
Ships in 5 -7 
business days  
 Qty: 
1  
 Price:  
$1,701.00  
 
    
● 8th Generation Intel® Core ™ i5-8250U Processor (1.60GHz, up to 3.40GHz 
with Turbo Boost, 6MB Cache)   
● Windows 10 Pro 64   
● Windows 10 Pro 64 English   
● 14.0" FHD (1920 x 1080) IPS anti -reflective, anti -smudge, multi -touch, 270 
nits  
● 8 GB LPDDR3 2133MHz (Onboard)   
● Integrated Intel® UHD Graphics 620   
● 256 GB Solid State Drive, PCIe -NVMe OPAL2.0 M.2   
● Black   
● 720p HD Camera with ThinkShutter and microphone   
● ThinkPad Pen Pro (Garaged)   
● Backlit Keyboard - US English   
● Fingerprint Reader   
● Hardware dTPM   
● Hardware dTPM2.0 Enabled   
● 4 cell Li -Ion 54Wh   
● 65W AC Adapter (2pin) - USB Type C   
● Intel Dual Band 8265 Wireless AC (2 x 2) & Bluetooth 4.1 with vPro   
● 14.0" FHD (1920x1080), IPS, 300nits, Touch, WLAN, No WWAN, 720p HD 
Camera with shutter, Mic, Black   
● Intel UHD Graphics 620   
● Publication -English   
● Retail Packaging   
● 1 Year Depot or Carry -in  
  
  
 
 
 Sub total:  
Estimated total:  
You Saved:  
 $1,701.00  
$1,275.75  
-$425.25  
 
 
 
  

 
 
NCGENES PARTICIPANT DISTRESS CALL FORM  
CONFIDENTIAL  
 
These forms include protected health information (PHI) as defined by the Privacy Rule of the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA). The forms and the information on them should be stored 
and transmitted in accordance with HIPAA rules regarding  Confidentiality  (PHI should not be available or 
disclosed to unauthorized people) and  Integrity  (PHI should not be altered or destroyed in an unauthorized 
manner).  
*********************** ****** ** To be completed by study team  ******* ************** ************  
 
Date of referral:  ______________________________________  
Participant name:  _____________________________________ _ 
Participant phone numbers:  
 Cell: ________ ________________________  
 Home: ______ _________________________  
 
Participant address: ___________________________________  
 ___________________________________  
  
Reason for referral  (check one):  
□ Anxiety/GAD7 score above 15  
□ Depressive symptoms/PHQ8 score  above 20  
 
********** ******** ************  To be completed by study psychologist  ******* ***** ****** **** ***** 
 
INSTRUCTIONS: Please contact participant  within 2 weeks, making a minimum of 3 call attempts. If possible, 
try both weekdays and weekends at different times of day. Regardless of whether you were able to contact the 
participant after 2 weeks, complete this form and return it to the study team.  
 
Contacted participant?  (check one):  □ Yes     □ No 
Date  contact made : __________________________  
Wanted referral?    □ Yes     □ No  
Brief description of problem and action taken during contact: ___________________________ _______________  
_________________ ____________________________________________________________ ______________  
_____________________________________________________________________________ ______________  
_____________________________________________________________________________ ____________ __ 
_____________________________________________________________________________ ______________  
_____________________________________________________________________________ ______________  Appendix VII. Par ticipant  Distress Call Form  
This is a study document and  should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS . 
  
 
 Appendix VII I. NCGENES 2 Participant Saliva Letter  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS . 
  

 
 Appendix IX. NCGENES 2 Saliva Kit Mailing Instructions  (Part icipant)  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS.  
 
  

 
 Appendix X. Enlarged Oragene OG 575 Saliva Kit Instructions  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS  
  

 
 Appendix XI. NCGENES 2 Parent Saliva Letter  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS.  
  

 
 Appendix XII. NCGENES 2 Saliva Kit Mailing Instructions  (Parent)  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS  
 
  

 
 Appendix XII. Parent Consent to DNA Collection  
This is a study document and should be downloaded directly from IRBIS  to ensure that the most recent edited and 
authorized document versions is being used. This form is reproduced here as a reference only and should not be copied for 
use in the study.  
 
The UNC Study Coordinator is responsible for ensuring that all other sites (ECU/Mission) have access to IRBIS.  
 
  

 
 Appendix XIII. Biospecimen Processing Facility (BSP) – NCGENES 2 Overview  
 
  

 
 Appendix XI V. BSP Blood Processing for NCGENES 2 – includes DNA Extraction  
 
 
BSP Facility Autopure Automated Whole Blood Plasma and DNA two step extraction.       
   protocol ver. 04_25_18  
 
I Purpose: To insure high molecular weight DNA that is free from contaminants and suitable for sequencing and 
genotyping.  
 
II Materials:  
▪ Field sample  delivered either by study staff or overnight courier  
▪ Gloves  
▪ 50 ml Autopure input qubes (pink caps)  
▪ 50 ml Autopure output qubes (blue caps)  
▪ Auotpure and all Puregene reagents   
▪ 5 ml serologic pipettes  
▪ Screw top 1.5 -2.0ml microcentrifuge tube  
▪ -80º C freezer  
 
III Procedure:  
Collection  
▪ Universal precautions for working with human specimens should be followed during all stages of specimen 
handling. Universal (or Standard) precautions such as hand washing, contaminated needle and sharps disposal, 
use of personal protective equipment, decon tamination of equipment and work surfaces, and labeling of specimen 
containers are described in the UNC Laboratory Safety/Exposure Control Plan (located on lab bookshelf).  
▪ Receive whole blood into the BSP facility by courier or overnight carrier and log into BSP facility’s Laboratory 
Information Management System (LIMS).  
▪ Blood tubes will automatically be planned into the LYS_PL_EXT general or equivalent study -specific protocol. If 
plasma is not required for the project blood tubes will be routed to a Cell lysate preparation in the LIMS. The 
specific protocol will depend on  the blood volume and whether manual or an automated protocol will be used.  
 
Plasma Extraction  
▪ Within 0.5 hours, begin processing sample.  
▪ Process each blood tube per lab/specimen ID separately.  
▪ Open LYS_PL_EXT protocol in the LIMS and create a workset.  
▪ Follow LIMS directed protocol which is summarized below  
▪ Spin blood tube using Program1 (3250 x g for 10 minutes at 15°C) in the Sorvall centrifuge in the tissue culture 
area using bucket covers.   
▪ In a biological safety cabinet remove the plasma without disturbing the buffy coat layer with a 5ml serological 
pipette, with the pipette aid set on low.  
▪ Aliquot plasma equally into four pre -labeled Screw top 1.5 -2.0ml microcentrifuge tubes. Note some study -
specific protocols may require more than four aliquots, which will be noted in the LIMS protocol.  
▪ Place aliquots into their LIMS directed redundant storage locations.  
 
Cell Lysate Preparation  
▪ The remainder of the whole blood  after removal (or the entire blood tube if plasma was not collected) is then 
processed to cell lysate either in an automated fashion on the Autopure LS, (if either 8 or 16 samples are ready for 
processing) or manually perf ormed using the same procedures that the Autopure uses. These procedures are 
briefly described below.  

 
  
Manual Lysate Preparation  
▪ Note manual lysate preparation was performed in the LIMS  
▪ Pour remainder of the whole blood after plasma removal (or the entire blood tube if plasma was not collected) 
into a pre -labeled Pink qube.  
▪ Add 30mls (for 5 -10 ml of whole blood) or 15mls (for 1 -5mls of whole blood) of Puregene RBC lysis, close tube 
and invert slowly 50 times.  
▪ Incubate at room temperature (RT) for 6.5 minutes  
▪ Spin on protocol 2 (3,000 x g for 5 minutes at 15°C) in Sorvall centrifuge in the tissue culture area using bucket 
covers.  
▪ Remove PinkQube(s) from centrifuge; note the size of the WBC pellet. If there is no pellet or the pellet is 
extremely small, make a comment in the open protocol in the LIMS.  
▪ Pour supernatant into biohazardous waste. Place cap back on tube and briefly vortex pellet to loosen.  
▪ Add 10 ml of Puregene cell lysis solution to loosened pellet. Replace top, vortex, and place into LIMS directed 
RT lysate storage. Store lysate for at least 1 day and up until 1 month before proceeding to the DNA lysate 
preparation.  
 
Automated Lysate Preparation  
▪ Enter rack set -up menu.  
▪ Choose the “lysate prep” protocol.  
▪ Choose number of tubes (8 or16).  
▪ Enter run name date.run#of the day  
▪ Enter rack number  
▪ Enter Qube lot #  
▪ Scan PinkQubes  
▪ Place rack on machine  
▪ Press start run  
▪ At end of run, vortex PinkQubes and place into LIMS directed room temperature lysate storage. These container 
IDs will be automatically placed in the next appropriate protocol in the LIMS. Store lysate for at least 1 day and 
up until 1 month before proceed ing to the DNA lysate preparation.  
 
DNA Extraction Autopure Run  
▪ Add glycogen to BlueQubes if samples arrived >4 days after collection or if original sample was frozen. Note 
some studies may not request this step because of cost and will accept a lower DNA yield.  
▪ If multiple tubes arrive for one lab/specimen ID, process these lysate tubes on separate DNA extraction Autopure 
runs 
▪ Enter rack set -up menu.  
▪ Choose the “Cell lysate 3X spin EtOH stop” protocol.  
▪ Choose number of tubes (8 or16).  
▪ Choose re -hydration volume (500ul for a 1 -5ml blood prep or 1000ul for a 5 -10ml blood prep).  Choose 0 for 
hydration volume and manually add specific volumes when the run is finished.  
▪ Enter run name  
▪ Enter rack number  
▪ Enter Qube lot #  
▪ Scan input and output Qubes  
▪ Place rack on machine  
▪ Press start run  
 
Post Autopure Run  
▪ Run ends with DNA spun in 70% ethanol, this needs manual finishing. Carefully pour off ethanol and leave tube 
to air dry upside down for 10 minutes. Then add hydration solution . Unless otherwise specified by the project use 
500ul of hydration buffer for 1 -5ml starting blood tube or 1000ul for 5 -10ml starting blood tube.  
▪ After manual resuspension of hydration buffer incubate Pink qubes at 65°C for 1 hour (30min for a 500ul prep). 
Samples must be vortexed thoroughly (at least 1 minute), prior to being placed in the water bath and at least 1 
time during the hour incubation, and at the end of the incubation.  
 
 ▪ After incubation in the water bath samples are placed on the Fisher Scientific multi -tube shaker, set at 2500 RPM 
for 1 hour.  
▪ After shaking leave DNA on bench at RT overnight.  
▪ Evaluate DNA solution after overnight incubation, if DNA is not in solution more rehydration buffer may be 
added followed by additional incubations at 65ºC and/or RT.  
▪ After hydration combine any samples that had been placed into multiple Qubes prior to Autopure run.  
▪ Place DNA at 4°C prior to quantitation, gel analysis (if requested by project), and aliquoting.  
 
DNA Quantitation  
▪ DNA extracted from either blood is quantitated using UV absorbance on either the Denovix instrument or the 
Dropsense. Project specific needs may require Picogreen quantitation also. See specific SOPs for the use of these 
pieces of equipment.  
▪ Prior to quantitation and/or aliquoting, mix samples on the multi -tube shaker set at 2500 RPM for 5 minutes, 
briefly spin DNA and proceed to next LIMS -directed procedure.  
  
 
 Appendix X V. BSP Saliva Processing – DNA extraction  
 
Procedure:   MSMI 2ml Saliva Protocol  
Version: 04.27.18  
 
Prepared By:   Hendrick DeJong                      6/12/2014  
                                                                               Author’s name    Signature   Date  
Preparer’s Title:   Lab Manager  
          
Adopted:         
          Date  
Updated:             4/27/2018  
          Date  
 
BSP Sign Off  
Reviewed:   
     Signature    Date  
      
     Signature    Date 
     
     Signature    Date 
     
     Signature    Date  
   
 
Signature    Date  
  

 
  
      
PROCEDURE  CHANGE LOG   
 
Procedure:   MSMI 2ml Saliva Protocol  
                                                                                   
 
Date  Version  Changes Made  Edited  
By 
(initials)  Reviewed 
By 
(initials)  Date 
Reviewed  
1/12/14  1.12.14  Changed elution volume to 
300 µl (from 500 µl) to 
increase concentration.  
Incorporated spin step 
immediately after MSM1 
elution. Added 20 µl elution 
buffer to final elution volume 
to account for transfer loss.  HD   
3/3/16  3.3.16  Added cover sheet, procedure 
change log, reference, safety, 
and change log sections.  
Added footer (File Name)  AR   
6/14/17  06.14.17  Minor procedural additions 
and clarifications  PS   
4/27/2018  04.27.18  Expanded on Supplies, 
Procedure, MSM1 Run (pre -
run checks), and Post Run 
(waste disposal).  PVB    
      
 
  

 
  
 
MSMI 2ml Saliva Protocol - Ver. 03.03.16  
Purpose  High throughput isolation of nucleic acid from 2ml Oragene saliva samples or buccal swabs using the 
Magnetic Separation Module I  
Equipment and Supplies  
▪ Magnetic Separation Module I (MSMI)  
▪ Dedicated PC with Chemagic software with Code II scanner  
▪ Positioning frame for Block 8  
▪ Gloves  
▪ Tissue Lysis Buffer – Perkin Elmer Art No. 805  
▪ Chemagic Saliva Kit Number CMG -1081  
▪ 4 ml MSMI elution tubes  
▪ 24 well deep -well blocks  
▪ 24 rod sheaths  
▪ Snapcap 1.5 ml microcentrifuge tubes  
▪ Screwtop 1.5 microcentrifuge tubes  
▪ Microcentrifuge  
▪ Pipettors:20ul, 200ul, 1000ul pipette and tips  
▪ -80° Freezer  
Reference   
▪ Purification Protocol for 2ml of Oragene Saliva Using the Chemagic Magnetic Separation Module I  
▪ M:\epid_bsp \BSP Administration \Maintenance \MSMI \Chemagic Protocols \ Microsoft Word - US - 
chemagic DNA Saliva Kit special 2 ml H24 VD120214.doc  
www.chemagen.com  
 
▪ Oragene • Discover DNA Collection Kits  
OGR -675 for assisted collection  
OGR -575 for assisted collection  
OGR -250 2ml sample volume  
OC-175    for assisted collection  
www.dnagenotek.com  
 
Safety Precautions  
▪ Wear appropriate Personal Protective Equipment whenever handling chemicals or human body fluid  
▪ CDC Universal precautions should be used when working with any human specimen. Precautions 
such as hand washing, contaminated needle and sharps disposal, decontamination of equipment and 
work surfaces, and labeling of specimen containers are described in t he UNC Laboratory 
Safety/Exposure Control Plan (located on bookshelf in MHRC Room 3213)  

 
 ▪ Read and understand the MSDS sheets for all of the reagents  
 
Procedure  
 
Collection  
 
▪ Receive Sample into the BSP facility by courier or overnight carrier and log into BSP facility’s 
Laboratory Information Management System (LIMS)  
▪ Prior to extraction on the MSMI, saliva samples need to be incubated at     55º C for at least 1 hour 
(Following instructions from DNAgenotek)  
▪ If the volume is less than  1mL, bring total volume up to 1.5mL by adding tissue lysis buffer 
(Perkin Elmer Art. No. 805)  
▪ Samples with volumes up to 2.5mL can be processed with this protocol.  
▪ Place frozen ( -80º C) samples on bench for 5 minutes, and then thaw immediately in a 37º C water 
bath for 3 minutes  
▪ Duplicate samples should be processed in separate runs to avoid loss through machine failure  
 
Pre MSMI Run  
 
          LIMS Protocol: DNA_MSM1_Saliva_Small  
 
▪ Turn on MSMI and Computer  
▪ Open Chemagic software  
▪ Connect lines for reagents 2 -6 and verify sufficient volume for run (~250ml)  
▪ Select protocol “Prime Lines 1 -6” and verify that liquid is being dispensed correctly.  
o If nozzles are clogged, use Kimwipe or remove nozzle and clean with warm water.  
▪ Select protocol “Check Manifolds 1 -6” and verify that liquid is being dispensed correctly.  
▪ Check waste container and empty if needed  
 
MSMI Run  
 
▪ Select protocol “8 saliva 2ml autofill h24 4ml.che”  
▪ Place 24 disposable rod sheaths in the 24 Tip Rack and place in Position 1  
▪ First pipette up and down to homogenize samples, then transfer saliva samples into deep well block in 
Position 2  
▪ Mix magnetic beads by shaking bottle or gently vortex for 1 minute  
▪ Pipet 240 µl magnetic beads in the deep well block in Position 3  
▪ Place empty deep well racks in Position 4, 5 And 6  
▪ Place elution tubes in tube holder in Position 7  
▪ Fill elution tubes with 170 µl elution buffer (assuming 20 µl loss)  
▪ Place empty deep well plate in positioning frame  in Position 8 for waste collection  
▪ Scan input and output tubes  
▪ Start run (run time approximately 1hr. 15mins.)  
▪ Disconnect lines from reagents 2 -6 after dispensing in completed  
 
Post MSMI Run  
 
▪ After run has finished, remove elution tubes  
▪ Transfer samples to 1.5ml snapcap tubes  
 
 ▪ Spin the tubes for 5 minutes at 14000xg  
▪ Transfer supernatant to a sterile 1.5ml screwcap tube (Do not transfer pellet)  
▪ For short term storage: Place DNA at 4°C in coldbox until OD readings are taken in the next protocol  
▪ For long term storage: Store sample in LIMS assigned -80°C storage  
▪ WASTE DISPOSAL:   
o P2 (binding buffer) and P6 (mag beads) - MSM1 waste container  
o P3, P4, P5 - down sink with lots of water  
o Empty P8 (waste tips) and place used deep well blocks from P2 -P6 into biohazard waste 
container.  
 
DNA Quantitation  
 
▪ Extracted DNA from Oragene saliva or buccal swabs is quantitated using UV absorbance on either 
the DeNovix instrument or the Dropsense. See specific SOPs for the use of these instruments  
▪ After ODs are uploaded into LIMS, follow study -specific protocols for either aliquoting, additional 
quantification, or storage.  
 
Change Log  
▪ Ver. 01.12.14  
▪ Ver. 06.12.14  
▪ Ver. 03.02.15  
▪ Ver. 03.03.16  
▪ Ver. 06.14.17  
▪ Ver. 04.27.18  
  
 
 Appendix XVI. CLIA Clinical Lab – Processing, Storage, Genetic Analysis and Reporting  
UNC Molecular Genetics Laboratory  
l.  Procedure for Receipt of Samples for NCGENES2  
1. NCGENES2 is a research study on the implementation of genomic sequencing. Samples are sent to the 
clinical laboratory for Research DNA Extraction and will be used for CLIA confirmation of mutations 
identified on a research basis. Samples (primarily blood, although saliva is a secondary option if blood 
collection or DNA extraction fail – see Insufficient Blood Sample Protocol) are collected from patients 
enrolled at three sites (UNC, ECU and Mission Health).  The UNC MGL acts as the CLIA confirmatory 
lab for  any positive findings (per research protocol, positive or uncertain findings potentially 
contributing to the child’s disorder are confirmed as are any clinically actionable secondary sequencing 
findings) for both UNC and ECU.  Mission Health will perform its own confirmatory testing in its own 
CLIA -certified lab.   
2. One 3mL tube of blood will be sent with a Molecular Genetics Test Request Form. Under Patient 
Information there should be a unique NCGENES number (NCG_2XXXX), and a test request for “other” 
with Whole Exome Sequencing written in.  
3. Confirm the number on the requisition is the same as the number on both tubes.  Write the date received 
on the requisition.   
4. Accession in EPIC for tests: Research Extraction (LAB13783) and Research Identity Genotyping 
(LAB13803) using the “Requisition Entry” function.  
a. Use  “Genetics department -participating” as the submitter  
b. Click on the “Patient” Box. Close the patient demographic window that opens up. Then click on 
“Non - Human” button on the tool bar.  
c. Go to the  “Patient” box again and  Enter the name as the described format :  “NCG, 20046 -00”  
d. Use Z13.79 as the Diagnosis code  
e. Order both tests on the same Case#  
5. Perform two DNA extractions of 100 uL each on the QiaSymphony. Label the two tubes of extracted 
DNA with the NCG number plus A or B (example: NCG_00001A and NCG_00001B).  Nanodrop both 
DNA extractions and staple the results to the requisition.  Freeze both DNA tubes at -70oC. 
6. Add the sample information to the spreadsheet found on the L drive at 
Molecular>NCGENES>NCGENES sample log.xls.  
7. Make a new folder for the requisition/paperwork and place it in the NCGenes file cabinet.  
8. The research specialist (Sayanty Roy) will Login to the RENCI system and record sample receipt, date 
and time.  
9. When a batch of 12 samples is available, the research specialist (Sayanty Roy) will perform identity 
genotyping and enter the results in the MGL NCGENES2 database and Login to the RENCI system to 
enter the results of the identify check.  
 
10. Insufficient Blood Sample Protocol   If the UNC MGL determines that insufficient sample has been 
provided they are to notify the UNC study coordinator at 919-801-9267 .  The study coordinator will 
contact the family and mail a saliva collection kit (one per lab that reports insufficient sample).  The 
saliva kit will be returned to the UNC BSP research lab where it will be couriered to the UNC MGL, 
along with a MGL test request form, for DNA extraction, identity genotyping and potential mutation 
confirmation. The research specialist (Sayanty Roy) will complete DNA extraction and items 6 -9 above.  
 
II. Receipt of Samples for NCGENES2 Family members ( NCG_2XXXX -1,-2, etc.)  
When a sample arrives from a family member of an NCGENES participant (labeled NCG_2XXXX -1,-2, 
etc.):  
1. Follow steps 1 -6 above.  
 
 2. Give the paperwork to Dr. Weck so that she can assign variant confirmatory testing immediately.  
 
III. Accessioning NCGENES2 samples with positive results for UNC  Patients into Medical Records 
(EPIC)  
1. For all patients with positive or uncertain research results, confirmatory sequence testing will be 
performed by the research specialist (Sayanty Roy) in the CLIA -certified MGL. After confirmatory 
testing is complete, these samples will be re -accessioned i nto EPIC/ beaker using the patient’s MR# so 
that the results can be transmitted to EPIC and become part of the patient’s medical record.  
2. Dr. Weck will provide the necessary paperwork with all of the patient information needed for 
accessioning (this information will be retrieved from the RENCI system and will include the patient’s 
name, MRN and DOB).  A medical record number is required.  If  one cannot be found within this 
paperwork, notify Dr. Weck so she can ask the study coordinator to provide one.  
3. If a medical record number is provided but the patient is not found in the EPIC/Beaker system, notify 
Valerie in the LIS department to update this patient into the system.  
4. Accession the specimen using the Requisition Entry function, with “Genetics department -participating” 
as the submitter.  
5. Select blood as the specimen type.  Select NCGENES research sequence confirmation as the procedure 
(LAB13793).  Use the ordering physician listed on the MGL Test Request Form as the Ordering 
provider and Dr. Jonathan Berg as the Authorizing provider. Use D r. Weck as the case pathologist.  
6. Ensure that the Bill to box is selected Client Bill and not Patient Bill.   This is important so that the 
NCGENES2 study will be billed for the testing and not the patient (this will be the case for all tests both 
at UNC and ECU – they will be paid centrally at UNC by the study).  
7. Save the changes and be sure to indicate the Case# (i.e. MLM #) -number on the paperwork.  Return all 
paperwork to Dr. Weck and let her know that the accessioning is complete.  
8. Sayanty will perform Sanger research confirmation and Dr. Weck will sign out the case in EPIC  
9. Dr. Weck will log in to RENCI System and enter the research results category.  
 
IV. Reporting positive clinical results for NCGENES2 ECU Patients and Faxing to the Ordering 
Physician  
1. For all ECU patients with positive or uncertain research results confirmed in the UNC MGL, it will be 
necessary to fax (using the fax number on the request form) the generated report to the ordering 
physician listed on the MGL Test Request Form received with the sample.  
  
 
 Appendix XVII. UNC MGL – Blood DNA Extraction for NCGENES 2  
Molecular Genetics Laboratory Department  Manual  
 
  Policy Name/Procedure Name  DNA Extraction using QIASYMPHONY DNA Mini 
Kits  
Author/ Revision Date  Sherry Nelson, Revision date 07/01/17   
Date this Version Effective  July 2017   
 
SPECIMENS:  
 
DNA can be extracted from whole blood, stem cells, cultured cells, and CD3 fractionated cells.  Whole blood is 
collected in pale yellow -top ACD or purple -top EDTA tubes.  Other anticoagulants such as heparin should be 
used only with the knowledge and consent of the directors, and documented on worksheets. Cultured cells such as 
amniocytes are processed by centrifugation at 3000rpm for 5 minutes.  RPMI buffer is then removed by pipette. 
The cell pellet is re-suspended with 800 -1000 uL PBS buffer.  Excess sample not used for extraction is stored at –
20°C until final reports are generated and then it is discarded.  Extracted DNA not used for requested testing is 
stored at 4°C short term and then at –20°C f or a minimum of two years.  
 
APPARATUS/REAGENTS:  
 
1. QIAsymphony DSP DNA mini kit – Qiagen (937236)  
2. Sample Prep Cartridges, 8 well – Qiagen (997002)  
3. 8 Rod Covers – Qiagen (997004)  
4. Filter Tips, 1500 uL – Qiagen (997024)  
5. Filter tips, 200uL – Qiagen (990332)  
6. 1.5mL and 2.0mL Sarstedt tubes  
7. 01, 02 and 3B tube adaptors  
 
PROCEDURE:  
 
System Set -Up 
 
1. Turn on the instrument - the power button is located on the lower left side of the machine, in the front.  
 
2. Log in on the main screen.  
 
Preparation for Operation  
 
1. Prepare the reagent pack:  
a. When opening a fresh extraction kit:  
Remove the reagent pack from the pre -packaged white base and insert the reagent pack into the grey 
support base. Attach the Proteinase K rack to the side of the reagent pack. Place the piercing lid on top of 
the reagent pack and push down lightly until bot h ends make a snapping sound. Remove and vortex the 
magnetic bead cartridge for approximately 1 minute. Place the magnetic beads cartridge back onto the 
reagent pack and peel back the foil cover. Uncap both Proteinase K vials.  
b. When using a pre -opened extraction kit:  
Remove and vortex the magnetic bead cartridge for approximately 1 minute. Remove the seal lids from 
each position and place on a clean absorbent pad. Uncap both Proteinase K vials. Place the caps on a 
clean absorbent pad.  

 
  
2. Open the reagents and consumables drawer and slide the reagent pack into either the front or back slot 
with the magnetic beads facing outward.  
 
3. Fill Sample Prep Cartridges and 8 Rod Covers as necessary.  
 
4. Close the reagents and consumables drawer and, when prompted, select “Yes” for all components of the 
drawer and then select “Scan” at the bottom of the window to start a full inventory scan.  
 
5. Extractions are maximized by processing samples in groups of 8. Gather all samples to be extracted and 
print labels using the Labjet printer.  
 
6. Print out a Qiasymphony set -up worksheet from the L drive and place the labels in the appropriate spots 
on the worksheet template. Fill in the technologist’s initials, extraction date and DNA Mini Kit lot 
number on the worksheet.  
 
7. While referencing the Qiasymphony set -up worksheet, uncap each blood tube and place it in the 
corresponding slot on the sample rack. For collection tubes that are not 16 X 100 in size, place 3B 
adapters containing 2mL sarstedt tubes into the appropriate po sition in the sample rack. Pipet 500uL of 
blood (a minimum sample volume of 400uL is required) into each 2mL tube. NOTE: If for any reason a 
space in the sample rack is skipped, a tube must be placed in that position to prevent throwing off all the 
followi ng samples.  
 
8. For the pediatric ACD tube (3mL yellow top), place a 3B adaptor into the appropriate position on the 
sample rack. For the 3mL EDTA tube, place a 01 adaptor; and if there are any 6mL ACD or EDTA tube 
(s), place a02 adaptor into the appropriate position(s) o n the sample rack.  
 
9. Pull down to open the sample drawer, and slide the sample rack up to the black line of any slot labeled 1 -
4. 
 
10. Wait for the barcode reader to move out into position near the sample rack, and then in one continuous 
motion, slide the sample rack completely into the slot.  
 
11. If the rack was successfully inserted, the green indicator light of that slot will turn an amber color. A light 
blue “Batch” button will also light up on the main screen in the corresponding slot. The status line, to the 
right of the batch button, should u pdate to “Loaded”. If the slot turns a red color, an error message will 
pop up on the main screen. If this happens, pull the sample rack completely out of the slot, touch “OK” on 
the main screen, and repeat steps 8 -9.  
 
12. Touch the light blue “Batch” button on the main screen.  
 
13. The sample tube selection screen will appear, and a dark blue “Sample Tubes” button should be lit on the 
right side of the screen. All positions occupied by blood tubes should also be lit. If a barcode was 
scanned, the position will be light blue, and if n o barcode was scanned, it will be orange.  
 
14. Samples requiring a 3B adapter were scanned as the sample rack was inserted into the instrument and 
should have the appropriate tube size listed on the sample selection screen. All 16X100 collection tubes 
should also have the appropriate tube size listed on the sample selection screen.  
15. Touch the space for slots where a 3B adaptor was placed for the pediatric ACD tubes.   
 
 
 16. Touch the “ID/Type” button on the right hand side of the sample tube selection screen. Choose Tube 3B 
option. From the drop down menu, select “BD#364012 T2.6 glass 10.25x64”.  
17. Touch “Next” when finished.  
 
18. On the next screen, highlight all samples.  On the right side of the screen, touch the “DNA Blood” 
protocol button. From the drop down menu, select “Blood_200_V7_DSP_100 Elution”, then touch 
“Next”.  
 
19. Label one 1.5mL Sarstedt tube for each sample. Remove tube caps and using the set -up worksheet as a 
reference, place each tube in the correct position in the cooled elution rack.  
 
20. Open the Qiasymphony elution drawer and place the elution tube rack in position 1.  
 
21. Close the elution drawer, and touch slot 1 on the elution screen. A 
  icon will appear to the left of slot 1 
indicating the elution rack is cooled.  
 
22. On the right side of the elution screen, touch “Tube_1.5mL AdapterV1 (no BC)”. On the drop down 
menu, select “SAR#72.607 **T1.5 Screw”. Touch “OK” and an inventory scan of the elution drawer will 
begin.  
 
23. Touch the “Queue” button on the right side of the screen.  
 
24. Open and close the waste drawer, and when prompted, touch “Scan” to start an inventory scan of the 
waste drawer.  
 
25. When the inventory scan is complete, touch “Run” on the main screen.  
 
26. When the run is complete, a blue status bar will flash on the front of the instrument. Open the sample 
drawer and slide the sample rack out to remove it from the slot. The “Batch” button will disappear from 
the main screen.  
 
27. Cap each blood tube and store appropriately.  
 
28. Open the elution drawer, and remove the elution rack from slot 1. Touch slot 1 on the elution screen, and 
select “Remove” and then “OK”. Close the elution drawer and wait while the instrument performs an 
inventory scan.  
 
29. Open the reagents and consumables drawer and slide out the reagent pack. Cap each reagent using the 
seal lids. Cap the Proteinase K vials as well. The reagent pack can be stored at room temperature until 
next use.  
 
Procedure Revisions:  
January 2015: added that a sample must not be skipped in the rack.  
July 2016: No changes made  
July 2017: No changes  
 
 Appendix XVIII. UNC MGL – Saliva DNA Extraction for NCGENES 2  
            Molecular Genetics Laboratory Department  Manual 
 
  Policy Name/Procedure Name  Newborn Saliva DNA Extraction using the  
Qiagen BioRobot® EZ1  
 Author/ Revision Date  Kay Chao, 08/20/15  
Date this Version Effective  September 2015  
 
REFERENCES:  
 
1. BioRobot EZ1 User Manual,   Version 1.1, July 2005  
 
2. EZ1 DNA Handbook, 3rd Edition, February 2008  
    (EN-EZ1-DNA -Blood -Handbook, April 2010)  
 
 
PRINCIPLE:  
 
Magnetic particle technology combines the speed and efficiency of silica -based DNA purification with the 
convenient handling of magnetic particles.  DNA is isolated from lysates in one step through its binding to the silica 
surface of the particles in the presence of a chaotrophic salt.  The particles are separated from the lysates using a 
magnet.  The DNA is then efficiently washed and eluted in elution buffer.  
 
SPECIMENS:  
 
DNA is extracted from newborn saliva sample collected from prototype P -118 (DNA Genotek, Inc. Ottawa, ON, 
Canada) with swabs and preservation buffer in collection tube. After collection, ensure the collected sample is in 
an upright position to keep swab in  the preservation solution and store at 15oC to 25oC.  
Extracted DNA not used for requested testing is stored at 4°C short term and then at –20°C for a minimum of two 
years.  
 
 
 
APPARATUS/REAGENTS:  
 
1. BIOROBOT® EZ1 – Qiagen  
2. EZ1 DNA Blood 350 µl Kits – Qiagen (cat# 951054)  
 
PROCEDURE:  
 
Proteinase K pretreatment:  
Add 10 µl of 20 mg/mL Proteinase K solution to 350 µl of saliva sample. Mix the sample by inverting the sample tube 5 
times and incubate at 56OC hybridization oven for overnight.  Proteinase K -treated samples may be stored at room 
temperature until ready for purification.  
 
 
EZ1 purification:  
 
  1. Insert the appropriate EZ1 Card (EZ1 DNA blood card) completely into the EZ1 Card slot.  
  2. Switch on the BioRobot EZ1.  
3. Press “Start” to display the “Protocols” menu.  

 
 4. For worktable setup, press “ 2” to start for the 350 µl sample protocol . Select“ 2” to elute in 100 µl 
elution volume. Pure ethanol wash, select  “2” Yes. 
5. Press any key to proceed through the text displayed in the LCD.   
6. Open the workstation door.  
7. Invert 1 -6 reagent cartridges twice to mix the magnetic particles.  Then tap the cartridges to deposit the 
reagents at the bottom of their wells.  
8. Load the reagent cartridges into the cartridge rack.  
 
Note:   After sliding a reagent cartridge into the cartridge rack, ensure that you press down on the 
cartridge until it clicks into place.  
 
9. Load 1 -6 opened elution tubes in to the first row.  
10. Load 1 -6 tip holders containing filter -tips into the second row.  
11. Load 1 -6 each of 2 mL tube with 1800 µl of 80% Ethanol  (1440 µl of 100% Ethanol and 360 µl of 
molecular grade water) into the 3rd row.  
12. Load 1 -6 opened sample tubes containing 200 µl l saliva samples into the fourth row. 
13. Close the workstation door.  
14. Press “Start” to start the protocol.  
15. When the protocol ends (~20 min), the LCD displays “Protocol Finished”.  Open the workstation door.  
16. Remove the elution tubes containing the purified DNA.  Discard the sample preparation waste.  
17. To run another protocol, press “ESC”, prepare samples as described in step 1, and follow the procedure 
from step 5 onward.  Otherwise, press “Stop” twice to return to the first screen of the LCD, close the 
workstation door, and switch off the BioRobot EZ1.  
18. Clean the BioRobot EZ1with Sani wipes.  
  
 
 Appendix XIX. UNC MGL - Identity Testing Protocol for NCGENES 2  
STEP 1: PCR  
REAGENTS:  
Platinum Blue PCR SuperMix (Invitrogen)  
 PCR primers (10µM working stocks):  
 
SNP  Oligo  Sequence 5' -3' 
rs600859  rs600859_for  GGGATTCATCTCCCACAAAA  
 rs600859_rev  CCCAGCAGATGACTTCTTCC  
rs1800351  rs1800351_for  TTCCAGGATCTGTAACAATGGA  
 rs1800351_rev  ATGCAAAGCACCATGATGAA  
rs3746438  rs3746438_for  GACTCACGTCCTCCACCTGT  
 rs3746438_rev  GGTGAAGAACCTGACGGAAG  
rs2236181  rs2236181_for  TTGAGGGATTCGGGACAATA  
 rs2236181_rev  ACAGGCCATCCTCACTGTTC  
rs11734372  rs11734372_for  CACAAAATTGGTTTAAAGCTGATG  
 rs11734372_rev  ACCCGGCCTGAATACTCTTT  
rs2229992  rs2229992_for  TTGGTACCAGTTTGTTTTATTTTAGA  
 rs2229992_rev  CCTTGTTGGCTACATCTCCA  
rs10835051  rs10835051_for  GGGCCTCCACTCTTTGATCT  
 rs10835051_rev  CTGATTTCAAAGAGGCAACTGA  
rs12129650  rs12129650_for  GCATCATAGGAAACCACAGG  
 rs12129650_rev  GAGAAATTGTAGCCGTATGAAGC  
   
PCR AMPLIFICATION  
1. For high -throughput workflow (i.e., runs of multiples of 12 samples), for each SNP, combine the For & 
Rev oligos to a final concentration of 10uM each. Plate 1uL of mixed primers in a 96 -well plate, so that 
each column of 8 wells contains each primer pair, cover with a kimwipe and dry overnight. Dried primer 
plates can be stacked and stored in plastic bags at 4C for at least 6 months.  
 
2. For each sample, create the following PCR mix:  
Platinum Blue SuperMix   118µL  
DNA (10 -50ng/uL)    9uL 
 
3. Add 15uL of PCR mix to each well in a column on the PCR plate.  
 
4. Vortex briefly, buzz spin to ~1200rpm, and incubate the samples in the thermocycler using the 
following conditions:  
94°C, 2:00  
 
94°C, 0:30   ( 
55°C, 0:30  (35 cycles of these 3 steps)  
72°C, 1:00   ( 
 
72°C, 3:00  
 
 
 4°C, ∞  
 
When finished, perform check gel with 5uL product if desired.  
 
PCR CLEANUP  
Use AMPure PCR cleanup according to manufacturer’s instructions  
 
STEP 2: CYCLE SEQUENCING  
REAGENTS:  
 Lab-grade water  
 Big-Dye Terminator  
 
SEQUENCING AMPLIFICATION  
1. For high -throughput workflow, create sequencing plates by plating 1uL of FOR primer (10uM working 
stock) in a 96 -well plate, so that every column contains 1 well for each of the 8 FOR primers, cover with 
a kimwipe and dry overnight. Dried primer plates can  be stacked and stored in plastic bags at 4C for at 
least 6 months.  
 
2. Create BigDye master mix, multiplying the values below by the number of samples:  
Reagent:   Volume per sample (8 reactions):   For 12 samples:  
 BigDye    42µL       504µL  
 Water     52.8µL       634µL  
 
3. Using an 8 -channel pipet, add 10µL to each appropriate well of the sequencing plate.  
4. Using an 8 -channel pipet, transfer 1uL of the cleaned PCR amplicon to the sequencing plate. Apply 
adhesive plateseal.  
 
5. Vortex briefly, buzz spin to ~1200rpm, and incubate the samples in the thermocycler using the 
following conditions:  
 
96°C, 0:05  
96°C, 0:10   ( 
50°C, 0:05   (25 cycles of these 3 steps)  
60°C, 4:00   ( 
 
60°C, 10:00  
4°C, ∞  
 
SEQUENCING CLEANUP  
 Purify sequencing reactions with Centrisep columns or plates according to manufacturer’s instructions.  
PERFORM SANGER DIDEOXY SEQUENCING PER PROTOCOL  
 
ENTER IDENTITY CHECK GENOTYPE DATA INTO GENOMIC MOLECULAR WORKBENCH  
The resulting genotype data from the identity testing protocol described above is entered into the Genomic Molecular 
Workbench hosted by RENCI (see Appendix section: CLIA Lab Tracking in NCGENES 2 Genomic Molecular 
Workbench (GMW) for details of data entry  process and content)  
 
 Appendix XX. UNC MGL - CLIA Confirmation of Genetic Variant for NCGENES 2  
            Molecular Genetics Laboratory Department  Manual 
 
  Policy Name/Procedure Name  Custom DNA Sequencing  
Author/ Revision Date  Ferrin Wheeler, Review date 12/5/17  
Date this Version Effective  December 2017  
 
This is a general procedure for sequence -based testing of a known/familial mutation.  
 
Assay Design  
 
Identify the exon and flanking intronic sequence that harbors the known mutation using Ensembl, UCSC Genome 
Browser or NCBI. Typically, amplification of the entire exon will be the best assay design, with primers placed in the 
flanking introns.  Choose pri mers by hand or use a primer design website such as Primer3 (http://bioinfo.ut.ee/primer3/). 
Ideal amplicon size is between 200 and 400 bp.  In most cases, PCR primers will also be used as sequencing primers. 
Ideal primer Tm values are 55 -60 oC, with GC co ntent of 50%.  
 
PCR Amplification  
 
For previously unanalyzed specimens: In addition to the patient sample, include a positive control (family member with 
mutation, when available), normal, and no template control in every run.  
 
For specimens run to confirm the presence of a previously identified mutation (such as information from a research 
assay): In addition to the patient sample, include a no template control in every run.  
 
 
 
PCR Master Mix  1 Reaction (in µl )  
Platinum Blue PCR Master mix  22 
Forward Primer (10 
  ) 1 
Reverse Primer (10 
  ) 1 
DNA or Water  1 
 
   94oC for 2 min.      
 
   94oC for 30 sec.         
   55oC for 30 sec.       X 35     
   72oC for 1 min.      
 
   4oC hold      
 
Check Gel  
 
Run 5 µl of PCR product on an e -gel and proceed if DNA samples amplified and the water control is blank.   
 
Purification of PCR Product  
 

 
 Add 2 µl l of ExoSAP -IT to 5 µl of PCR product.  
 
Incubate in PE 9700 or MJ thermocycler using  EXOSAP -IT program:  
37 oC for 30 minutes, then 80 oC for 15 minutes.  Product can be stored at –20oC if necessary.  
 
Cycle Sequencing Reaction  
1.  The sequencing reaction is set up on ice as follows:   
* All volumes are in microliters.  
 
 
 
 
 
 
 
2.  Amplify in 9700 thermocycler using the following program:  
 9700 user:  cx; program: cx26 -seq 
 
96oC for 5 sec.  
 
  96oC for 10 sec.  
50oC for 5 sec.           X 25  
60oC for 4 min.  
 
60oC for 10 min.  
 
4oC hold  
  
 Samples can be stored at –20oC if not used immediately  
 
Purification of Cycle Sequencing Product  
 
1. Separate the required number of 8 -well strips from the package, cut the bottom plugs and remove the foil covers.   
 
2. Place the strips in the wash trays, making sure to balance the trays, using old strips if  
necessary. Centrifuge at 750 g for 2 minutes.  
 
3. Place the strips into the ABI 3130 Genetic Analyzer 96 -well plate, in the wells to be used for the run. If the run is 
larger than 16 samples, use two plates for the run so the spins are balanced.  If not, use old columns for the 
balance plate in the centri fuge.  
 
4. Using a P20 pipette set at 15 µl, add the sequencing reaction to the center of the column.   
Be careful to keep track, taking care to add one sample to each tube, in the correct order.  Keep the empty reaction 
tubes in the order used to set up the sample sheet.   
 
5. Secure samples with parafilm and centrifuge at 750g for 2 minutes.   
 
6. Runs are done in groups of 16 (two rows of 8 from the 96 -well plate).  If fewer than 16 samples are to be run, the 
remaining wells are filled with 20 µl of water.  Add the water to the side of the well, to avoid having air trapped 
below.  
 
7. Cover the plate(s) with the 96 -well septa and place the sample tray(s) in a 9700 thermocycler at 95 oC for 3 
minutes to denature the samples.  Sequencing Reaction  12.5 uL reaction*  
ExoSAP -IT treated PCR product  1.125  
Primer (10 µM)  0.75  
Autoclaved ddH 20 5.625  
BigDye Terminator  5  
 
  
 
ABI 3130 Operation  
 
1. Turn on the computer before turning on the instrument.    
 
2. Open 3130 Data Collection from the desktop, click the Plate View  tab and click New or Edit.  This process is 
analogous to creating a sample sheet and will identify which sample is in each well.  Name the plate with the date 
followed, if necessary, by a letter suffix (a, b, c, etc.), and select Sequencing . 
 
3. Use the Plate Editor  as a template for the plate and enter sample information for the wells containing samples.  If 
a full plate is not needed, mark on the plate which wells have been used so the remaining wells can be used for 
subsequent runs.  Enter the following informatio n using the pull -down window when present:  
 
Sample Name:   Sample and primer (i.e., MLM# -exonF).  Spaces are not allowed in this window.  
Comment:   Gene name and exon number  
Results Group:   Whatever folder you want the results to be saved to  
Instrument Protocol:   SeqE  
Analysis Protocol:      SeqE  
 
When the plate record is complete, click OK.  The plate record will now appear in the Plate View  tab as a 
Pending Plate Record.  
 
4. Place the 96 -well plate, with the 96 -well septa in place, into the plate base and fit the plate retainer over the top.  
Make sure the plate retainer holes are aligned with the holes in the septa.  Place the entire plate assembly onto the 
autosampler.  
 
5. When the plate is in place, the plate position indicator in the Plate View will change from gray to yellow, 
indicating it is ready to be linked to a pending plate record.   
 
6. Click on the appropriate plate record in Pending Plate Records and then click the plate position indicator that 
contains the plate to be linked.  
 
7. Once the plate has been linked to a plate record, the green Run Instrument button on the toolbar is enabled.  
Click the Run button to start run.  The run will be separated into groups of 16.  
 
8. During a run Status View can be used to monitor the run.  Array View and Capillary View  can be viewed but 
these windows should not be left open as they can cause unrecoverable screen update problems.  
 
 
 
Run Analysis  
 
1. Open ABI Sequencing Analysis Software from the Start  menu:  
  Start  
      Applied Biosystems  
            Sequence Analysis 5.2  
               Sequencing analysis  
 
2. In the Sample Manager window, click Add Files .  Under Desktop, select Shortcut to Data Extractor .  Select 
the appropriate run and select Add All .   
 
3. Individual files can be viewed and printed.  
 
 
 Procedure Revisions  
November 2016: Replaced the MO# with MLM#  
December 2017: Procedure reviewed, no change made  
 
ENTER CLIA GENETIC VARIANT RESULTS INTO GENOMIC MOLECULAR 
WORKBENCH The resulting genotype data from the identity testing protocol described above is entered into the 
Genomic Molecular Workbench hosted by RENCI (see Appendix section: CLIA Lab Tracking in NCGENES 2 Genomic 
Molecular Workbench (GMW) for details of data entry  process and content)  
 
  
 
 Appendix XXI. Mission Health MGL – Blood DNA Extraction for NCGENES 2  
POLICY: ML606 NUCLEIC ACID ISOLATION USING MAXWELL RSC  
POLICY VERSION: D  
POLICY EFFECTIVE DATE: 6/6/2018  
 
 
SCOPE  
For use in the Molecular section of the Fullerton Genetics Laboratory  
 
PRINCIPLE  
The Promega Maxwell® Rapid Sample Concentrator (RSC) Instrument provides automated nucleic acid purification for a range of 
sample types. The purification methods use sample lysis and paramagnetic particles that bind nucleic acids to a solid mobile plunger 
as the primary separation principle. Up to 16 samples can be prepared in a single run using preprogrammed kit specific run me thods 
(approximately 40 minutes).  This approach to magnetic capture avoids common problems such as clogged tips or partial reagent 
transfers, which result in suboptimal purification processing by other commonly used automated systems.  
The automated purification performed by the Maxwell® RSC Instrument include:  
1. Sample lysis in the presence of a specially formulated Lysis Buffer  
2. Binding of nucleic acids to paramagnetic particles  
3. Washing of the bound target molecules away from other cellular components  
4. Elution of the product  
The Promega Maxwell® RSC Instrument is supplied with preprogrammed purification procedures and is designed for use with 
predispensed reagent cartridges.  Four kits are currently being used:  
1. The Maxwell® RSC Whole Blood  DNA Kit is used for purification of genomic DNA (gDNA) from whole blood samples. 
The Maxwell® RSC Whole Blood DNA Kit purifies samples using a silica -based paramagnetic particle, called the 
MagneSil® particle. The Maxwell® RSC Whole Blood DNA Kit is desig ned to purify genomic DNA from 50μl to 500μl of 
whole blood.  
2. The Maxwell® RSC Blood DNA  Kit is used for purification of genomic DNA (gDNA) from samples. The Maxwell® RSC 
Blood DNA Kit purifies samples using a novel paramagnetic particle, called the MagnaCel ™ particle. This particle utilizes 
cellulose -based binding of nucleic acids and provides a higher bind capacity and cleaner eluate than traditional DNA 
purification. The Maxwell® RSC Blood DNA Kit is designed to purify genomic DNA from up to 300μl of whole blood.  In 
addition to whole blood, FGL has validated this kit to isolate DNA from OraCollect Buccal Swabs, Tissues, Amniotic Fluid, 
and Cultured Cells.  
3. The Maxwell RSC DNA FFPE  Kit purifies nucleic acid form FFPE tissue using paramagnetic particles, which provide a 
mobile solid phase to optimize sample capture, washing and purification of gDNA following a manual deparaffinization and 
tissue lysis procedure.  
4. The Maxwell® RSC simplyRNA Blood kit is used for isolation and purification of total RNA from fresh whole blood 
collected in EDTA tubes. Prior to loading the samples onto the Maxwell® RSC, blood samples are preprocessed by selective 
red blood cell lysis, w hite blood cell isolation, followed by white blood cell lysis. The lysed samples are transfered into the 
provided cartridge and RNA is captured using paramagnetic particles that bind RNA and provide a solid mobile phase that 
carries the sample through a se ries of washes for sample purification.  
 
POLICY  
The Nucleic Acid Isolation and Quantitation process is documented in the Laboratory Information System.  
 
SPECIMEN REQUIREMENTS  
 
See appendices for sample specific requirements  
 
EQUIPMENT, REAGENTS, AND SUPPLIES  
 
Equipment and Instrumentation:  
• Maxwell® RSC (Promega)  
 
 • Maxwell®  RSC 16 sample deck tray  
• Lab Armour Bead Bath set to 53°C  
• Microcentrifuge  
• Magnetic microcentrifuge tube rack  
• Vortex  
• NanoDrop® ND -1000 Spetrophotometer  
• P1000, 200, and 20 Pipettes  
• Heat Block  
• Dead Air Box  
• Auto Pipette  
 
Reagents or Media:  
• Maxwell® RSC Blood DNA Kit (Promega)  
• Maxwell® RSC Whole Blood DNA Kit (Promega)  
• Maxwell® RSC DNA FFPE kit (Promega)  
• Maxwell® RSC simplyRNA Blood kit (Promega)  
 
Reagent Preparation: Only the Maxwell® RSC simplyRNA Blood kit. See ML606 Appendix F for instructions.  
 
Storage Requirements: Store the Maxwell® RSC kits at room temperature (15 –30°C). See ML606 Appendix F for instructions and 
Maxwell® RSC simplyRNA Blood Reagent storage requirements.  
 
Supplies:  
1. 1.5 ml screw top microcentrifuge tubes  
2. Filtered Pipette Tips: Long P1000, Standard P1000, P200, P20  
3. 1.5 mL Flip Cap tubes  
4. 10 mL Serological Pipettes  
5. Disposable Transfer Pipettes  
 
QUALITY CONTROL  
 
QC Material:  Nuclease Free Water, Elution Buffer from the Extraction Kit.  
Preparation and Handling:  QC material kept at room temperature.  
Frequency of Performance:  For every sample.  
Acceptable Limits:  OD 260/280  between 1.6 and 2.00 for DNA. OD 260/280 > 1.6  and  OD 260/230 > 1.2 for RNA  
Corrective Action (if fail):  Re-extraction of patient sample if possible. DNA Clean -up protocol.     
Recording QC Data:  The following QC information is documented in the LIS:  
6. Proteinase K added (check if added)  
7. Lot number and Expiration dates of Maxwell kit and dilution solution used   
8. Type of Maxwell kit used    
9. Volume of Elution Buffer used  
10. Initial and final concentration reading of Nucleic Acid  
11. 260/280 Values. 260/230 Values for RNA Isolation  
12. Total yield of Nucleic Acid  
13. Initials of technologist isolating nucleic acid and date performed  
14. Deparaffinization Date (for FFPE tissue)  
15. Reagent Preparation Dates for simplyRNA Blood kit  
 
PROCEDURE  
 
Maxwell® RSC Instrument Operation  
Refer to Appendices for sample specific procedures and preprocessing requirements.  
Refer to the Maxwell ® RSC Instrument Operating Manual for detailed information.  
 
  
1. Turn on the Maxwell® RSC Instrument and Tablet PC. Log in to the Tablet PC, and start the RSC software on the Tablet PC. 
The instrument will power up, proceed through a self -check and home all moving parts.  
2. Press Start to access the extraction method selection screen.  
3. On the extraction method selection screen, select the method that matches the kit being used.  
4. Verify the correct method is selected and press the Proceed button  
5. Use the bar code reader to scan the 2D bar code on the kit box to enter the kit lot and expiration information.  
6. On the cartridge setup screen, touch the cartridge positions to deselect any positions that will not be used. Selecting or 
deselecting any cartridge position is only used for reporting purposes and does not affect the way the instrument processes 
samples.  
7. Enter the Elution tube identifier by scanning the barcode of the corresponding side label (optional).   
8. Press Proceed button to continue  
9. Confirm all checklist items  
a. cartridges are loaded on the instrument with the seals completely removed  
b. samples were added to well #1 of the cartridges  
c. uncapped elution tubes are present with Elution Buffer  
d. plungers are in well #8  
10. Transfer the deck tray containing the prepared cartridges onto the Maxwell® RSC Instrument platform by angling the back of 
the tray into the platform and pressing down on the front until the tray snaps into place.  
11. Ensure the deck tray is placed in the Maxwell® RSC Instrument with the elution tubes closest to the door. If you have 
difficulty fitting the deck tray on the platform, check that the deck tray is in the correct orientation.  
12. Ensure the deck tray is level on the instrument platform and fully seated.  
13. Touch the Start button to begin the extraction run. The tray will retract, and the door will close.  
14. The Maxwell® RSC Instrument will immediately begin the purification run. The screen will display information including 
the user who started the run, the current method step being performed, and the approximate time remaining in the run.  
15. Pressing the Abort button will abandon the run. The samples will be lost for all aborted runs. If the run is abandoned before 
completion, you will be prompted to check whether plungers are still loaded on the plunger bar. If plungers are present on th e 
plunger bar, you shoul d perform Clean Up when requested. If plungers are not present on the plunger bar, you can choose to 
skip Clean Up when requested.  
16. Follow on -screen instructions at the end of the method to open the door. Following the automated purification procedure, the 
deck tray will be warm. It will not be too hot to touch. To remove the deck tray from the instrument platform, hold onto the 
sides of the deck tray  
17. Verify that plungers are located in well #8 of the cartridge at the end of the run. If plungers are not removed from the plun ger 
bar, follow the instructions in the Maxwell ® RSC Instrument Operating Manual #TM411 to perform a Clean Up process to 
attempt to unload the plungers.  
18. Cap the elution tubes  
19. Remove the deck tray from the instrument.  
20. Remove the elution tubes from the tray.  
21. The extraction run report will be displayed. From the report screen, you can print or export this report or both.  
22. Remove the cartridges and plungers from the deck tray and discard as hazardous waste. Do not reuse reagent cartridges, 
plungers or elution tubes.  
 
PROCEDURE NOTES  
• If you are processing fewer than 16 samples, center the cartridges on the deck tray.  
• Specimen or reagent spills on any part of the deck tray should be cleaned with a detergent -water solution, followed by a 
bactericidal spray or wipe, then water. Do not use bleach on any instrument parts.  
• Use only the 0.5ml Elution Tubes provided in the kit; other tubes may be incompatible with the Maxwell® RSC Instrument.  
• If a larger volume of eluate is desired, the chemistry can be eluted in up to 150μl of Elution Buffer. Elution with 60μl of 
Elution Buffer will result in the greatest final concentration of purified nucleic acid, while elution with a higher volume will 
result in higher yield of purified nucleic acid  
• The starting volume of Elution Buffer will not result in the same elution volume after running the method.  Typically, the 
resulting elution volume will be approximately 10 –25μl less than the starting volume.  
• Resin carryover into the Elution Tube is typical. Using a larger starting volume of Elution Buffer and/or a smaller volume of  
sample will reduce this carryover  
 
 • RNA isolation is carried out using equipment and consumables dedicated explicitly for RNA isolation under aseptic 
conditions.  
 
Nucleic Acid Concentration and Working Solution Preparation  
 
Reference Document ML607 - Nucleic Acid Concentration and Working Solution Preparation . 
 
REFERENCES  
 
Promega/Madison, WI, “Operating Manual Maxwell® RSC Instrument Operating Manual”, TM411 Revised 7/16.  
Promega/Madison, WI, “Technical Manual Promega Maxwell® RSC Whole Blood DNA Kit”, TM455 9/15.  
Promega/Madison, WI, “Technical Manual Promega Maxwell® RSC Blood DNA Kit”, TM419 Revised 1/15.  
Promega/Madison, WI, “Technical Manual Promega Maxwell® RSC DNA FFPE Kit”, TM437 Revised 11/17.  
Promega/Madison, WI, “Technical Manual Promega Maxwell® RSC simplyRNA Blood Kit”, TM417 Revised 11/17.  
 
  
 
 POLICY: ML606 APPENDIX A BLOOD  
POLICY VERSION: A  
POLICY EFFECTIVE DATE: 12/15/2016  
 
 
SPECIMEN REQUIREMENTS  
 
Patient Preparation:  No special patient preparation required.   
Specimen Collection Method:  Peripheral blood in lavender top EDTA vacuum tube obtained using standard venipuncture techniques.  
Other anticoagulants may be acceptable, including Sodium Heparin (green top), ACD Solution A (yellow top), and Sodium 
Citrate (light blue top).  A minimum of 1 ml can be drawn, but the optimal a mount is 3 ml or greater.  
Special Handling or Storage Conditions:   Upon receipt, store tube at 4°C until processed.  
 
PROCEDURE  
 
Using Whole Blood DNA Kit for Blood Specimens  
 
1. Open the LIS and build an isolation batch.  
2. Print two labels for the specimens in the batch.  
3. Double check the LIS labels with the specimen container.  
4. Change gloves before handling Cartridge, Plunger and Elution Tube.  
5. Place the cartridge on the deck tray with the printed end opposite the numbers on the tray. Reference the Manufacturer’s 
Quick Start Guide for a visual.  
6. Press down on the cartridge to snap it into position.  
7. Place an empty elution tube into the elution tube position for the cartridge on the deck tray.  
8. Add 125μl (60 – 150μl) of Elution Buffer to the elution tube. Close the lid.  
9. Place a label on the top of the elution tube and the reagent cartridge.  
10. Verify the name on labeled cartridge corresponds to the name on the blood tube. Carefully peel back the seal so that all 
plastic comes off the top of the cartridge. Ensure that all sealing tape and any residual adhesive are removed before 
placing cartridge s in the instrument.  
11. Transfer 500μl (50 –500μl) of mixed blood sample to well #1 of the corresponding cartridge.  
12. Tip-mix the blood sample in Well #1 by pipetting up and down several times.  
13. Verify the number on the specimen container matches the number on the label of the corresponding elution tube.  
14. Refer to ML606 for the Maxwell Instrument Operations.  
15. Label 1.5ml screw -top tube during the Maxwell run.  
16. Upon completion of the run, open the Maxwell and remove the elution tube.  
17. Vortex and centrifuge the elution tube in the microcentrifuge for 1 minute at full speed.  
18. Place the elution tube on the magnetic rack to pull any resin that remains in the tube to one side.  
19. Transfer the supernatant to the labeled screw -top tube that corresponds with the accession number on the elution tube.  
Make note of the elution volume that is recovered from each elution tube.  
20. Enter the actual elution volume in the Elution Volume column on the LIS Isolation worksheet (ex. 125uL elution buffer 
typically gives 109ul after run is complete)  
21. Enter/Verify kit lot number on the LIS Isolation worksheet  
 
Using Blood DNA Kit  for Clotted  Blood Specimens  
 
Pretreatment  
• Mix blood sample for at least 5 minutes at room temperature.  
• Prepare and label 1.5mL flip -top tube  
• Add 300μl of Lysis Buffer to the flip -top tube.  
• Add 30μl of Proteinase K (PK) Solution to flip -top tube.  
• Add liquid blood 50 -300μl to the flip -top tube.  
• Vortex flip -top tube for 10 seconds.  
 
 • Incubate flip -top tube at 56°C for 20 -30 minutes.  
 
Processing  
• Change gloves before handling Cartridge, Plunger and Elution Tube.  
• Place the cartridge on the deck tray with the printed end opposite the numbers on the tray. Reference the 
Manufacturer’s Quick Start Guide for a visual.  
• Press down on the cartridge to snap it into position.  
• Place an empty elution tube into the elution tube position for the cartridge on the deck tray.  
• Add 100μl (range 40 – 100μl) of Elution Buffer to the elution tube. Close the lid.  
• Place a label on the top of the elution tube and the reagent cartridge.  
• Carefully peel back the seal so that all plastic comes off the top of the cartridge. Ensure that all sealing tape and any 
residual adhesive are removed before placing cartridges in the instrument.  
• Verify the number on the specimen tube matches the number on the label of the corresponding elution tube.  
• Transfer the blood lysate sample from the flip -top tube to well #1 of the cartridge.  
• Tip-mix the sample in Well #1  
• Refer to ML606 for the Maxwell Instrument Operations.  
• Label 1.5ml screw -top tube during the Maxwell run.  
• Upon completion of the run, open the Maxwell and remove the elution tube.  
• Vortex and centrifuge the elution tube in the microcentrifuge for 1 minute at full speed.  
• Place the elution tube on the magnetic rack to pull any resin that remains in the tube to one side.  
• Transfer the supernatant to the labeled screw -top tube that corresponds with the accession number on the elution 
tube. Make note of the elution volume that is recovered from each elution tube.  
• Enter the actual elution volume in the Elution Volume column on the LIS Isolation worksheet (ex. 100uL elution 
buffer typically gives 90ul after run is complete)  
• Enter/Verify kit lot number on the LIS Isolation worksheet  
 
  
 
 Appendix XXII. Mission Health MGL – Saliva DNA Extraction for NCGENES 2  
POLICY: ML606 APPENDIX G SALIVA  
POLICY VERSION: A  
POLICY EFFECTIVE DATE: 9/18/2018  
 
 
SPECIMEN REQUIREMENTS  
 
Patient Preparation:   It is preferable that the patient has no food or drink for 30 minutes prior to collection.  
Specimen Collection Method:  
Collection instructions given to physicians/practitioners:  
Step 1:  Gently move sponge along gums and inner cheek for 30 seconds to soak up saliva.  
Step 2:  Wring saliva out of sponge using the v -notch of the funnel. Repeat until liquid saliva reaches the fill line on the 
collection tube.  
Step 3:  Holding the tube upright, close the lid firmly until you hear a clicking sound. The liquid in the lid will then be 
dispensed into the tube.  
Step 4:  Holding the tube upright, unscrew the lid and replace with cap provided.  
Step 5:  Shake the capped tube for 5 seconds, discard the funnel.  
Special Handling or Storage Conditions:   Upon receipt, store tube containing saliva sample at room temperature until processed.  
 
PROCEDURE  
 
Using Blood DNA kit for ORAGENE Discover Saliva Specimens  
Pretreatment  
1. Vortex the ORAGENE Discover Saliva Specimens for 10 seconds  
2. Incubate the ORAGENE Discover Saliva Specimens at 50 -53°C in a bead bath for 1 hour.  
Processing  
3. Change gloves before handling Cartridge, Plunger and Elution Tube.  
4. Center the cartridges on the deck tray. Press down on the cartridge to snap it into position.  
5. Place an empty elution tube into the elution tube position for the cartridge on the deck tray. Label both cartridge and 
corresponding elution tube.  
6. Add 68μl of Elution Buffer to the elution tube. Close the lid.  
7. Verify the name and number on the specimen container matches the name and number on the label of the corresponding 
cartridge.  
8. Carefully peel back the seal so that all plastic comes off the top of the cartridge. Ensure that all sealing tape and any 
residual adhesive are removed before placing cartridges in the instrument.  
9. Transfer all of the sample to well #1 of the corresponding cartridge.  
10. Mix sample in Well #1 by pipetting up and down several times.  
11. Refer to ML606 for the Maxwell Instrument Operations  
12. Label 1.5ml screw -top tube during the Maxwell run.  
13. Upon completion of the run, open the Maxwell and remove the elution tube.  
14. Vortex and centrifuge the elution tube in a microcentrifuge for 1 minute at full speed.  
15. Place the elution tube on the magnetic rack to pull any resin that remains in the tube to one side.  
16. Transfer the supernatant to the labeled screw -top tube that corresponds with the accession number on the elution tube.   
 
REFERENCES  
Promega/Madison, WI, “Operating Manual Maxwell® RSC Instrument Operating Manual”, TM411 Revised 7/16.  
 
Promega/Madison, WI, “Technical Manual Promega Maxwell® RSC Blood DNA Kit”, TM419 Revised 1/15.  
 
ORAGENE DISCOVER Product Insert. PD -PR-00619 Issue. DNA Genetec Inc. Ottawa, Canada. 1/2016 -09. 
 
 
 Appendix XXIII. Mission Health MGL - Identity Testing Protocol for NCGENES 2  
POLICY: ML809 MATERNAL CELL CONTAMINATION TESTING (PROMEGA 
POWERPLEX16 KIT)  
POLICY VERSION: B  
POLICY EFFECTIVE DATE: 6/5/2018  
 
 
SCOPE  
 
This procedure is intended for use by the Molecular section of the Fullerton Genetics Laboratory.  
 
 
PRINCIPLE  
 
STR (short tandem repeat) loci consist of short, repetitive sequence elements 3 to 7 base pairs in length. These repeats are 
well distributed throughout the human genome and are a rich source of highly polymorphic markers. Alleles of STR loci are 
different iated by the number of copies of the repeat sequence. Analysis of STR loci creates a unique genetic profile of an individual 
and can be used in many different human identification applications. Prenatal samples are assessed for maternal cell contamin ation 
(MCC) by comparing the STR profiles of DNA isolates from a fetal sample and a maternal blood sample. MCC occurs from poor 
collection technique of the fetal sample or, in the case of product of conception sample types, the inability to differentiat e fetal t issue 
from maternal tissue during sample processing.  MCC testing ensures that any results from downstream testing are a product of  the 
fetal sample and not of contaminating maternal DNA.   
The Promega PowerPlex® 16 HS System is a kit that is designed to amplify 16 STR loci in a multiplex PCR fashion using 
fluorescently labeled primers. The amplified products are separated by size using capillary electrophoresis and the raw data is 
analyzed o n the GeneMapper Software.  
 
Fluorescent  Dye/Color of peaks  Loci  
Fluorescein (FL)/  
Blue  Penta E  
D18S51  
D21S11  
TH01  
D3S1358  
Carboxy -tetramethylrhodamine (TMR)/  
Black  FGA  
TPOX  
D8S1179  
vWA  
Amelogenin  
6-carboxy -4´,5´ -dichloro -2´,7´ -
dimethoxy -fluorescein (JOE)/  
Green  Penta D  
CSF1PO  
D16S539  
D7S820  
D13S317  
D5S818  
 
 
POLICY  
 
This assay is not considered a diagnostic test. Rather, it is used as a prerequisite for downstream testing of prenatal sample types. All 
patient and assay information is documented and stored in the Laboratory Information System.  
SPECIMEN REQUIREMENTS  
 
Specimen : 
• Prenatal Sample: DNA isolated from Amniotic Fluid, Product of Conception (POC), Tissue, Chorionic Villi, or cultured cells 
in a buffered solution.  
• Maternal Sample: Whole Blood or Buccal Swab.  
 
  
EQUIPMENT, REAGENTS, AND SUPPLIES  
 
Equipment or Instrumentation:  
• ABI 9700 thermal cycler  
• ABI 3500 Genetic Analyzer with POP -7 Polymer (or equivalent)  
• Centrifuge  
• Minicentrifuge  
• Vortex  
• Pipettes (P -2, P-20, P -200, P -1000)  
 
Reagents:  
• Promega PowerPlex® 16 HS System  
Contains:  Water, Amplification Grade  
PowerPlex® HS 5X Master Mix  
PowerPlex® 16 HS 10X Primer Pair Mix  
2800M DNA Control  
ILS 600  
Allelic ladder control  
• HiDi Formamide  
 
Storage Requirements:  
 
All PowerPlex® 16 HS reagents are to be stored at -20
C (no defrost).  
 
Consumables  
• 0.2 ml thin -walled PCR tubes  
• 1.5 mL tubes  
• Half skirted 96 -well reaction plate  
• Clear adhesive film plate cover  
• Aerosol resistant tips for pipettes  
• Septa  
 
Special Supplies:  
 
GeneMapper Software  
 
QUALITY CONTROL  
 
QC Material:  
• Allelic Ladder control (provided with kit)  
• 2800M DNA control (provided with kit), diluted to 0.5 ng/µL in PCR grade water  
• No DNA control run with each experiment.  
• Internal Lane Standard (ILS) 600 (provided with kit)  
 
Frequency of Performance:  
 
Testing of controls is carried out each time an experiment is performed  
 
Acceptable Limits:  
 
• The PowerPlex® 16 HS Allelic Ladder mix contains all possible allele sizes for each marker.  
 
• 2800M Control DNA allele sizes:  
 
 
 
Marker  Expected Size(s)  Marker  Expected Size(s)  
D3S1358  17, 18  D16S539  9, 13  
 
 THO1  6, 9.3  CSF1PO  12 
D21S11  29, 31.2  Penta_D  12, 13  
D18S51  16, 18  AMEL  X, Y  
Penta_E  7, 14  vWA  16, 19  
D5S818  12 D8S1179  14, 15  
D13S317  9, 11  TPOX  11 
D7S820  8, 11  FGA  20, 23  
 
• The No DNA control should only have the ILS 600 visible, no blue, green or black peaks above a peak amplitude of 200.  
 
• The Internal Lane Standard (ILS) 600 contains 22 DNA fragments of 60, 80, 100, 120, 140, 160, 180, 200, 225, 250, 275, 
300, 325, 350, 375, 400, 425, 450, 475, 500, 550 and 600 bases in length  
 
Corrective Action (if fail):  
 
Repeat assay, check DNA quality, if necessary.  
 
PROCEDURE  
 
Refer to ML809F1 Maternal Cell Contamination Worksheet.  
 
Creating GeneMapper Project  
1. Open the GeneMapper program.  Under the File menu, choose New Project.  
 
2. Choose the project type “Generic”.  In the File menu, select “Add Samples to Project”.  When the “Add Samples” window 
opens, choose the “Files” tab and navigate to the samples, typically found in:  Computer/AB SW & Data (D:)/Applied 
Biosystems/3500/Data/(f older containing data).  
 
3. Highlight the samples to be added to the project and click "Add To List" button.  Once samples (or the folder they are in) 
appear in the right side of the window, click the "Add" button.  
 
4. Once the samples open in the window, find the Allelic Ladder on the list.  Ensure the sample type is set to "Allelic Ladder".   
 
5. In the "Analysis Method" column, click on the box for the sample at the top of the list and choose "GM4.1 Analysis Method 
16 HS" analysis method. Click on the heading to highlight the entire column, and press Ctrl D to fill down the column.  
 
6. In the "Panel" column, click on the box for the top sample and open the folder "PowerPlex_16_Panels_v2.0". Choose 
"PowerPlex_16_v2.0" and double click to add it.  Highlight the entire column and fill down.  
 
7. In the "Size Standard" column, click the top sample box and choose "CXR_ILS_600" and fill down the entire column.  
 
8. Locate the green arrow at the top of the GeneMapper window.  Click on the arrow to analyze the samples. Save the project, 
using the experiment number (i.e. MCC -7) as part of the name.  
 
Analysis  
1. Highlight the 2800M control, the allelic ladder and the No DNA to check each control. Go to the "Analysis" menu at the top 
of the GeneMapper window and select "Display Plots" to view the electropherograms. Make sure the Plot Setting on the new 
window is se t at "HID plot setting".  Set the number of panes to view to the desired number. To change the Y -axis, click on it 
when the cursor is a magnifying glass and slide the line down to the desired height.  
 
2. Confirm the run meets the QC requirements as listed in this protocol. Look to be sure each dye has clean peaks.   
 
3. Save an image of the QC sample’s electropherograms. Click out of window.  
 
4. Highlight the fetal and maternal samples and view the electropherograms. Deselect all but one dye color. Adjust image and 
save. In the "View" menu, choose “Zoom” and then “Zoom To Marker” to view each marker individually. View the peaks for 
each marker and  document the alleles for the fetal and maternal samples. Repeat for all dyes.  
a. Off-ladder allele calls (labels OL) can be deleted and not analyzed further.  
b. All on -ladder allele calls should be scrutinized carefully.  Peaks below 1000 may represent artifacts due to stutter 
PCR products, fluorescent background peaks or contaminating maternal alleles in the fetal sample.  If these peaks 
align with either or both  of the maternal alleles then they should be noted and flagged for further review.  
c. Document if the marker is informative. A marker set is informative if there is a unique maternal allele that is not in 
 
 the stutter position of the fetal or shared allele. A marker set is uninformative if 1) alleles are completely shared 
between maternal and fetal samples, 2) if the maternal sample is homozygous (only 1 peak), or 3.) if the maternal 
allele is in the stutter  position of the fetal or shared allele.    
d. Document if there is evidence of contamination. Evidence of contamination includes either the presence of 3 peaks 
in the fetal sample if the fetal sample marker is heterozygous, or if there is a large difference in fetal peak heights of 
a likely homozygous  allele and a maternal allele in the fetal sample.  
e. If an informative marker shows evidence of contamination, determine which of the peaks in the fetal sample fit the 
descriptions of Fetal, Maternal, and Shared allele. Document the marker name, allele identifications, allele sizes (# 
of repeats), and peak h eights.   
f. Calculate estimated % Maternal Cell Contamination for each contaminated marker as well as the Average % 
Maternal Cell Contamination for the fetal Sample (if applicable).  
 
CALCULATIONS  
 
1. The GeneMapper software performs the calculations necessary for viewing the data collected by the Genetic 
Analyzer.  The allele sizes and peak height values are used to estimate the percentage of maternal contamination, if 
applicable.  
2. All other calculations are performed the LIS.  
 
% MCC for a Marker with a Heterozygous Fetal Sample  
 Maternal Allele Peak Height / (Maternal Allele Peak Height + Fetal Allele Peak Height)  
 
% MCC for a Marker with a Homozygous Fetal Sample  
 2 x Maternal Allele Peak Height / (Maternal Allele Peak Height + Fetal Allele Peak Height)  
 
Average % Maternal Cell Contamination of Fetal Sample  
Sum of the % MCC for Contaminated Informative Markers / Total # of Informative Markers  
 
REPORTING RESULTS  
 
Reporting Format :  
 
Results are reported as either “No Contamination” or “Contamination present” and the Average % MCC is given.  
 
Reference Intervals:  
• At least 2 informative alleles must be present for analysis.  
• The lower limit of detection of maternal cell contamination (MCC) using the PowerPlex® 16 HS kit is ~5%.  
• Normal (Uncontaminated) result:  <5% maternal cell contamination detected.  
• Contaminated result:  ≥5% maternal cell contamination detected.  
• FGL has shown that Chromosomal Microarray results for prenatal samples with up to 20% MCC can be distinguished from 
contaminating maternal DNA. Results for such samples may be reported at the Director’s discretion.  
 
Note:  The sensitivity of different test methodologies to MCC varies, and the effects of MCC levels on result interpretation should 
be determined for each test procedure.  
 
 
LIMITATIONS OF PROCEDURE  
 
Interferences:  
The STR loci and primers have been selected to avoid or minimize artifacts. The artifacts often associated with Taq DNA 
polymerase include repeat slippage and terminal nucleotide addition.  
 
Repeat slippage (called stutter or shadow bands) is due to the loss of a repeat unit during DNA amplification, somatic 
variation within the DNA, or both.  The amount of slippage depends on the locus and the DNA sequence.  
 
Terminal nucleotide addition occurs when Taq DNA polymerase adds a nucleotide (usually adenine) to the 3’ ends of 
amplified DNA fragments.  This addition is not dependent on the template sequence.  The efficiency with which this occurs var ies 
with differen t primer sequences, thereby occasionally creating an artifact band that is one base shorter than expected.  Primer 
sequences and a lengthy final extension in the amplification parameters provide conditions to complete the terminal nucleotid e 
addition when the template DNA amounts are optimal.  
 
 
 The presence of microvariant alleles (alleles differing from one another by lengths other than the repeat length) complicates  
interpretation and assignment of alleles. There appears to be a correlation between a high degree of polymorphism, a tendency  for 
microvariants and increased mutation rate.  Thus, FGA and D21S11 display numerous, relatively common microvariants. For reaso ns 
yet unknown, the highly polymorphic Penta E locus does not display frequent microvariants.  
 
See the PowerPlex® 16 HS System technical manual for full explanations.  
 
 
REFERENCES  
 
Promega Corporation/ Madison, WI, Technical Manual "PowerPlex® 16 HS System Instructions for use of products DC2100 AND 
DC2101”, Part # TMD022, Revised 5/16.  
 
www.promega.com  
 
Applied Biosystems/Foster City, CA, “GeneMapper Software Version 4.1, Microsatellite Analysis Getting Started Guide”, Part 
Number 4403672, Rev. A, 04/2009.  
 
Nagan, N., et al., J Mol Diagn. 2011 Jan;13(1):7 -11.  
Lamb, A., et al., Genet Med. 2012 Nov;14(11):914 -21. 
Coleman, WB, Tsongalis, GJ. Molecular Diagnostics for the Clinical Laboratorian. 2nd Edition. Humana Press. New York, New York. 
2006.  
 
 
 
 
  
 
 Appendix XXIV. Mission Health MGL - CLIA Confirmation of Genetic Variant for 
NCGENES 2  
POLICY: ML901 APPENDIX O -WHOLE EXOME SANGER CONFIRMATION 
SEQUENCING  
POLICY VERSION: A  
POLICY EFFECTIVE DATE: 9/30/2017  
 
 
SCOPE  
This document is intended for use in the Molecular section of the Fullerton Genetics Laboratory  
 
PRINCIPLE  
Confirmation testing by Sanger sequencing will be performed after the whole exome sequencing (WES) data are analyzed.  This 
testing is initiated by the director analyzing the WES data via exporting the variants of interest from the Cartagenia Bench Lab NGS 
software (see ML408 -Appendix A) and the SeqMera application (see ML406).  Primers are designed as needed af ter consulting the 
database of amplification primers already in -house.  The primer sequences used for variant confirmation are stored in an Excel sheet 
on the Genetics Lab shared drive.  
 
POLICY  
• Confirmation testing is performed to confirm a potentially reportable sequence change that has been found using the WES 
workflow.  
• Sanger confirmation of variants found using the NGS workflow are sequenced in the forward and reverse direction unless 
one of those reactions does not give clear results due to the nature of the sequence (i.e. homopolymer region).  
 
REAGENTS  
Amplification:  
• Primers (containing M -13 sequence) for confirmation are designed as needed.  The primer sequences are stored in 
an Excel file that is updated as more primers are ordered.  
Diluted to 10 
 M (Stock=100
 M, dilute each primer 1:10)  
Stored in -80
C freezer.  
 
QUALITY CONTROL  
Confirmation primers are considered to be validated if the NGS change is confirmed.  This method ensures that subsequent test ing 
using those primers (including family members of the patients with confirmed changes) are performed with validated primers.  A 
record of the validated primers is located in the CRE Sanger Primers Record, located in the Genetics Lab share drive.  
 
PROCEDURE  
1. Check the NM number that was exported from Cartagenia with the NM number for the gene as listed in HGMD.  Primers 
should be designed using the NM number listed in HGMD.  
a. If the NM number from Cartagenia does not match the one in HGMD, check to see if Cartagenia also lists the other 
available NM numbers by pulling up the variant of interest and expanding the NM number tract (click the arrow 
next to the top NM number; boxed in red in snapshot below).  The export only pulls the top line from Cartagenia; 
therefore, the HGMD NM numb er may also be listed in Cartagenia but it may not be located on the top line.  
b. If the HGMD NM number is listed, check the exon number for which primers need to be designed, as it may not be 
the same as the exon listed on the top line (see below)  
c. If the HGMD NM number is not listed, check the exon sequence of the HGMD NM transcript number against the 
surrounding sequence provided in Cartagenia associated with the variant of interest to ensure that the exon listed on 
the export matches that exon seq uence in HGMD.  Otherwise, the primers for an incorrect exon might be designed.  
The HGMD NM number sequence and exon number can be accessed via UCSC (http://genome.ucsc.edu/cgi -
bin/hgGateway).  
-In Cartagenia, click on the chromosome and genomic position link under the heading “position” (see 
snapshot below).  
-A window will pop up that indicates the variant with a red line and the surrounding sequence (see snapshot 
below).  
 
2. Use the HGMD listing to create a cDNA file for the gene. Alternatively, follow the steps below to create a cDNA file that can  
be viewed in Sequencher.  
a. Copy the NM number determined above, open NCBI.  
 
 b. In the drop -down, select ‘Nucleotide’.  
c. Search using the NM number.  
d. When the gene file opens, select ‘Send to’ in the drop -down menu on the top right (boxed in red in snapshot).  Click 
the radio button beside ‘File’. Then click “Create File.”  
e. When the file downloads, drag it into the NCBI file folder ( \\Mh\ss\Genetics Office \genetics 
lab\Data_Architecture \Molecular \Sequencing \Sanger \CRE Sanger Confirmations \Sequencing Reads \cDNA 
files\NCBI files) and rename it with the gene name and NM number.  
f. The file can now be dragged into or saved in the Sequencher project when needed for analysis of the patient 
sequence.  
g. To use the cDNA file, drag the file into Sequencher and double click to open it.  
h. Find the 1st base of the coding sequence.  It will be the A of the ATG start codon and will have an M (indicating 
methionine) under it.  Highlight the A.  
i. Go to the ‘Sequence’ menu at the top of the page and hover over ‘Set Base Number’ then select ‘As Base 1’. The 
highlighted base (A of the ATG) now becomes c.1 and is designated “residue 1” at the top of the cDNA window 
(see boxed items below).  The c. numb er is on the left margin with the p. number below it in parentheses.  
j. The sequence can be manipulated in this file to see how the change affects the cDNA.  For example, if a C changes 
to a T in the patient, the user can change the base to a T in that position to see the amino acid change, or can be used 
to name frameshifts b y counting the amino acid residues until the novel stop codon (designated as “.”).  
k. Exons can be visualized by going to the ‘Sequence’ menu and choosing ‘Edit Features’.  
 
Designing a Sequencher reference file for Sanger confirmation  
1. Open Sequencher and select “New Project.”  
2. In the File menu, choose Import and then Sequencher Project from the 2nd menu that opens.  
3. Find the project for the 1st gene exon that needs to be analyzed and import it.  Files are stored in Genetics Lab share drive.  If 
the exon(s) of interest is there, press the Ctrl button and click on it to remove the highlight.  Then right click and select  
“Remove from project” to de lete the unneeded sequences.  Repeat as necessary for other gene exons.  
4. If the exon of interest has not been added to the control project for the gene, follow the steps above to remove all the exon s 
from the new project.   
5. Save the new project using the patient accession number.  The project should be saved Genetics Lab share drive.  
6. Create a new sequence for the exon of interest.  
a. Open the control project for the genes beginning with that letter (i.e. A gene files, C gene files, etc.) found in the 
CRE Sanger folder.  
b. Under the Sequence menu select “New Sequence”.  Name the sequence as “GENE exon #”.  
c. Obtain the NM # for the gene from the cDNA file, Sanger confirmation file or primer list.  
d. Navigate to UCSC Genome Browser.  Search for the gene using the NM#.  
e. Select the highlighted gene on the browser.  
f. Click on the link below “mRNA/Genomic Alignments”.  This opens the gene sequence.  
g. On the left side of the screen, select the block number that corresponds with the exon of interest (i.e. if exon 25 is 
desired, select block 25).  
h. Copy the 10 intronic bases before the exon, all of the exon and 10 bases after the exon. Paste the sequence in the 
window that has opened in Sequencher.  
i. Highlight the exon by counting in 10 bases from the beginning and end of the newly pasted sequence.  Confirm the 
exon sequence by comparing to the UCSC file.  
j. Right click on the highlighted exon sequence and select Edit Features.  
k. On the new window, click the Add button.  Type the gene and exon# in the Feature Name box.  Click Display Style 
to choose a color to display the exon.  Blue is typically used for the exons, red for UTR sequence.  Introns are left 
black.  
l. Click the Done button and close the sequence window.  If the sequence is complete, click “Record as Experimental 
Data” in the window that opens.  
m. The exon is now added to the list of exons in the gene project.  Save the project before closing the gene project.  
7. Return to the patient project.  Add the exon you just created to the patient project by following steps 2 -4 above.  
8. Import the sequencing raw data for the patient.  Assemble the contigs.  The contigs should be named by right clicking on 
each one and selecting ‘Rename Contig’.   
9. Analyze as usual and document results on the file created by the director containing the confirmation exons.  
 
REFERENCES  
Sequencher® version 5.4.6  DNA sequence analysis software, Gene Codes Corporation, Ann Arbor, MI USA   
Cartagenia Bench lab NGS (Agilent Technologies, Santa Clara, CA)  
  
 
 POLICY: ML901 SANGER SEQUENCING  
POLICY VERSION: R  
POLICY EFFECTIVE DATE: 1/22/2018  
 
SCOPE  
 
This procedure is intended for use by the Molecular section of the Fullerton Genetics Laboratory  
 
PRINCIPLE  
 
See appendices for principle of each test  
 
POLICY  
 
For procedures utilizing Polymerase Chain Reaction (PCR), the PCR only pipettes and plugged tips are used.  PCR products are not 
opened in the PCR set -up areas of the lab.  
 
Specimen :  
 
• Isolated DNA in buffered solution  
 
Equipment:  
 
• Thermal cycler (ABI 9700, ABI 2720 or other)  
• Microcentrifuge (Biofuge 13 or other)  
• Tabletop Centrifuge (Sorvall Legend T, Heraeus Megafuge 16 or other)  
• SpeedVac (with rotors for microcentrifuge tubes and 96 -well plates)  
 
Reagents:  (See Appendices for Test Specific Reagents)  
 
• AmpliTaq Gold 360 Master Mix  
Stored in lab refrigerator (4
 C) 
 
• AmpliTaq Gold 360  
Stored in lab freezer ( -20ºC)  
 
• GC Enhancer  
Stored in lab freezer ( -20ºC)  
 
• 6M Betaine.  
Stored in lab freezer ( -20
C) 
 
• Primers M -13-Forward and M -13-Reverse (if applicable)  
Diluted to 10 
 M (Stock=100 
 M, dilute 1:10 for sequencing).  
Stored in -80
C freezer.  
M13 For -short:  GTAAAACGACGGCCAG  
M13 Rev -short: CAGGAAACAGCTATGAC  
 
• Exo-SAP IT  
Stored at –20
C 
 
• ABI prism BigDye Terminator v1.1 Cycle Sequencing Kit with AmpliTaq DNA Polymerase, FS (Ready Reaction Kit)  
Stored in lab freezer ( -20
C) 
 
• BigDye Terminator 5X Sequencing Buffer  
Stored in lab refrigerator (4ºC)  
 
• DyeEx 2.0 Spin Kit  
Stored at room temperature on top shelf of molecular workbench.  
 
 
 • Performa DTR V3 96 -Well Short Plates  
Stored in lab refrigerator (4ºC)  
 
• Hi-Di Formamide  
Stored in lab freezer ( -20
C).  Aliquot into 1.5 ml tubes for long term storage.  
 
Reagent Preparation:  
 
• Mix the 6M Betaine.  Weigh 0.7g of Betaine and mix with 1000µl of sterile deionized water.  The Betaine solution can be 
aliquoted into 1.5 ml tubes and frozen at -80°C.  
Note:  Do not use Betaine with AmpliTaq Gold 360 Master Mix as it inhibits amplification.  
 
Materials:   
 
• 0.2 ml thin walled PCR tubes  
Stored in cabinet of molecular workbench  
 
• 1-20 
 l filter pipette tips  
Stored in the molecular lab  
 
• 1-200 
 l filter pipette tips  
 Stored in the molecular lab  
 
• 1.5 ml microcentrifuge tubes  
Stored in cabinet of molecular work bench  
 
• Pipette tips (1 -200 
 l) 
Stored in the molecular lab  
 
• Blue pipette tips (200 -1000
 l) 
Stored in the molecular lab   
 
• Half-Skirted 96 -well plates  
Stored in the molecular lab   
 
Controls:  
 
One tube containing no DNA  
 
POLYMERASE CHAIN REACTION AMPLIFICATION  
PROCEDURE  
 
NOTE:  See Appendices and Worksheets for Test Specific Details  
 
 
1. See the attached amplification worksheets as listed under “Other Related Documents”  
 
2. Mix the components as listed, multiplying by the number of samples to be tested plus at least 1.  
 
3. Program a thermal cycler to the conditions as listed and place the samples in the sample block to run.  
 
4. Remove the PCR products from the thermal cycler when cycling is complete.  One or 2 
 l of the PCR product can be run on 
a 1-3% gel to confirm amplification, if desired.  
 
5. PCR products must be cleaned prior to sequencing using Exo -SAP It.  For each amplification, label one 200 
 l PCR tube or 
96-well plate.  The “No DNA” tube(s) does not need to be cleaned.  
 
6. Aliquot 5 
 l of the PCR products into the corresponding tube.  Add 2 
 l of Exo -SAP It and pipet up and down to mix.  
Volumes may be increased in this proportion if more volume is needed for sequencing reactions (i.e. 10 
 l of PCR products 
and 4 
 l of Exo -SAP It).  
 
 
 7. Place tubes in a thermal cycler programmed at 37
 C for 15 minutes, 80
 C for 15 minutes, hold at 4
 C. 
 
8. The purified DNA should be stored at 4
 C until sequencing is performed.  Run 2 
 l of the purified products on a 1 -3% gel 
to confirm that all primers have been removed, if necessary.  
 
CYCLE SEQUENCING REACTION  
 
NOTE:  See Appendices and Worksheets for Test Specific Details  
 
PROCEDURE   
 
1. See the attached sequencing worksheets as listed under “Other Related Documents”  
 
2. Mix the components as listed, multiplying by the number of samples to be tested plus at least 1.  
 
3. Place into the thermal cycler programmed for the proper conditions and start.   
 
4. When the thermal cycler is finished running the sequencing cycles, remove the sequenced products and proceed to Clean -up 
of Sequencing Reactions.   
 
CLEAN -UP OF SEQUENCING REACTIONS  
DyeEx Spin Kit (tubes)  
PRODEDURE  
 
1. Prepare one DyeEx spin column and label one 1.5 ml centrifuge tube for each sequenced patient and control.  
 
2. Gently vortex the spin column to resuspend the resin.  Loosen the cap of the column (to prevent a vacuum inside the column), 
and snap off the bottom tip of the column.  Place the column in the 2ml collection tube provided with the kit.  
 
3. Set the speed of the Biofuge 13 microcentrifuge to 3000 rpm for 3 minutes and spin the column inside the collection tube.  
 
4. Transfer the spin column to the labeled 1.5 ml centrifuge tube.  Slowly transfer the sequenced products to the gel bed.  Pipe t 
the products in the center of the slanted gel bed, and allow them to absorb into the gel bed.  It is not necessary to replace  the 
lid on the column.  
 
5. Again, spin the column inside the centrifuge tube at 3000 rpm for 3 minutes.  
 
6. Discard the column.  The cleaned sequencing products are in the 1.5 ml centrifuge tube.  Dry the products in the SpeedVac 
on medium for 20 minutes or until dry.  
 
7. When the samples are completely dry, remove from SpeedVac and add 15 
 l of Hi -Di Formamide.  Set tubes aside while 
preparing the Genetic Analyzer.  See procedure ML311 --ABI Genetic Analyzer Use.  
 
Performa DTR V3 96 -Well Short Plates  
(For use when cleaning ≥24 samples)  
 
PROCEDURE  
 
1. Remove the Performa plate from the refrigerator and unwrap the foil packaging.  
 
2. Peel the bottom adhesive tape from the Performa plate and stack it on top of an empty half -skirted 96 -well plate.  This 96 -
well plate will receive the waste eluate from the Performa plate.  Use small pieces of scotch tape to attach the 2 layers on the 
sides.  
 
3. Peel the top adhesive tape from the Performa plate.   
 
4. Balance the Performa plate assembly using an empty assembly.  Add water to the wells of the empty assembly as necessary 
to balance the two.  
 
5. Remove all the carriers from the tabletop centrifuge buckets.  Place the cushion from the plate carrier directly into the buc ket 
designed to spin plates.  Place the assemblies directly into the bucket (not using the carrier).  
 
 
 Note:  To prevent damage to the centrifuge carriers, it is very important to remove all carriers from the centrifuge before 
spinning at the speeds required for the Performa plates.  
 
6. Spin at 850 x g for 3 minutes (program 2).  
 
7. Remove the Performa plate assembly.  Carefully cut or peel the scotch tape to remove the waste plate and discard the waste.  
 
8. Place the Performa plate into a clean half -skirted 96 -well plate.  Attach the assembly using scotch tape.  
 
9. Using a multichannel pipette, transfer the sequencing reaction products into the center of the wells of the Performa plate, 
taking care not to touch the sides of the wells.  
 
10. Balance the assembly using another empty assembly, adding water as necessary.  Place directly into the centrifuge buckets.  
 
11. Spin at 850 x g for 5 minutes (program 3).  
 
12. Remove the assembly and carefully cut or peel the scotch tape.  Retain the 96 -well plate containing the cleaned sequencing 
products.  There will be some liquid in all of the plates, regardless of whether all the wells were loaded with sequencing 
products.  
 
13. Change the SpeedVac rotor to the plate adaptor.  Place the 96 -well plate into the carrier and balance with an empty plate.  
Dry on high for 35 minutes or until all liquid has evaporated.  
 
14. When the samples are completely dry, remove from SpeedVac and add 15 
 l of Hi -Di Formamide.  Set tubes aside while 
preparing the Genetic Analyzer.  See procedure ML311 --ABI Genetic Analyzer Use.  
 
REFERENCES  
 
Applied Biosystems/ Foster City, CA, “Automated DNA Sequencing Chemistry Guide”, Part Number 4305080B, 2000.  
Qiagen/ Valencia, CA, “DyeEx Handbook for DyeEx 2.0 Spin Kit, DyeEx 96 Kit”, May 2002.  
EdgeBio/ Gaithersburg, MD, “Product Summary -Performa DTR V3 96 -Well Short Plates” v.3.  
 
 
OTHER RELATED DOCUMENTS  
Appendix O -Whole Exome Sanger Confirmation Sequencing  
ML901F59  NGS Confirmation -Sanger Sequencing -AMPLIFICATION  
ML901F56  NGS Sanger Sequencing -Recurrent Drop -outs and Confirmation   
ML316  ABI Genetic Analyzer Use - 3500  
  
 
 POLICY: ML901F59 NGS Confirmations – Sanger Sequencing Amplification Worksheet  
POLICY VERSION: B  
POLICY EFFECTIVE DATE: 7/11/2016  
 
Set-up Date:      Tech Initials:   ___   Experiment #:    
 
Used plugged pipette tips?      Used “PCR Only” Pipettes?      
PROCEDURE  
1. Paste the Sample #, Gene, Exon and Mutation to Confirm (HGVS) columns from the CT panel Sanger confirmation log into the chart on page 2 of this form.  
2. Label PCR plate or tubes for each patient or control to be tested and each gene/exon to be tested.  Circle the “No DNA” contr ol well.  
3. Add 1 
 l of the appropriate primer set into each well using multichannel pipette.  Add one primer set to the “No DNA” control for ea ch exon.  
4. Make up the appropriate reaction stock volume based on the components below without primers or DNA.  Mix gently and spin down . 
5. Aliquot 18 
 l of reaction mix into the “No DNA” control well(s).  
6. Add DNA to the remaining reaction stock, mix gently and spin down.  Aliquot 19
 l of reaction mix to each of the remaining wells.  
7. Place in a thermal cycler and program for the conditions listed below.  
8. After PCR, run 4 
 l on a 3% NuSeive agarose gel and clean with Exo -SAP-It (2.5 
 l of PCR product + 1 
 l of Exo -SAP-It).  Continue with sequencing reaction 
using cleaned PCR products.  
 
Master Mix 1  
1X PCR Reaction 
Volumes ( µl) Component  X Reaction Volumes (
l) 
10 AmpliTaq Gold 360 Master Mix  Lot #:   
8.5 Sterile deionized H 2O   
0.5 Patient DNA @ working solution stock (115 
 g/ml)  (X-1) 
1 Forward and Reverse Primer Mix for each exon  
(stock=100
 M) dil 1:10 each  
(10 
 l of each primer stock + 80 
 l diH 2O=100
 l of primer mix @ 10
 M) In wells  
20 
 l Total Volume   
Optional (for 
primer sets that are 
difficult to amplify 
initially)  Add 1 µl GC Enhancer (as needed)  Lot #:   
   
 
Control & Patient Samples Tested:  
See chart on page 2.  
 
 
 
 
 
 
 
 
 
 
                                                                                                 Thermal Cycler Model (circle one):  9700     or     2720   Thermal Cycler #: __________  Temp. Profile A  
Temp x Time  Cycles  
95°C x 10 min  1 
95°C x 30 sec  
35 60°C x 45 sec  
72°C x 1 min  
72°C x 7 min  1 
4ºC x ∞  1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Primers used --Copied from CT panel Sanger confirmation log  
Amp Plate 
Well #  Sample #  Gene  Exon  Mutation to confirm 
(HGVS)  
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 POLICY: ML901F56 NGS Sanger Sequencing Worksheet  
POLICY VERSION: A  
POLICY EFFECTIVE DATE: 2/16/2015  
 
 
Reference:   
 
Set-up Date:      Tech Initials:   ___   Experiment #:    
 
Used plugged pipette tips?      Used “PCR Only” Pipettes?      
 
PROCEDURE  
1. Label half -skirted 96 -well plate and aliquot 1
 l of cleaned PCR product into each well of a 96 -well plate.  One set of PCR 
products will be sequenced in the forward direction, a second set will be sequenced in the reverse direction.   
2. Label two 1.5 ml tubes:  one for the forward primer, one for the reverse primer.  
3. Mix the components (listed below) and add 9 
 l to each well, ensuring the forward and reverse cocktails are added to the correct 
wells.  
4. Seal the plate using film and spin down.  Place in a thermal cycler and program for the conditions listed below.  Place a 
compression pad on top of the plate to ensure proper sealing of plate.  
5. Clean sequencing products using the Performa 96 -well plates or Dye -Ex Spin kit.  Run on one of the ABI capillary sequencers.   
 
Lot #’s:  ExoSap -it: ____________________________________  
DyeEx kit or Performa plate: ______________________  
HiDi formamide: ________________________________  
 
Sequencer Used:        
 
Reaction 
Volumes ( µl) Component  X Reaction Volumes (
 l) 
Forward  Reverse  
1 Cleaned PCR product (dil 1:3)  In wells  In wells  
6 Sterile deionized water    
1 Big Dye Terminator 5X Sequencing Buffer  
Lot #:    
1 Big Dye Terminator Ready Reaction Mix  
Lot # :    
1 M13 Primer Forward and Reverse  
(stock= 100
 M--dil 1:10 for 10
 M working stock)    
10 
 l Total Volume    
 
Control & Patient Samples Tested:      
Temp x Time  Cycles  
94°C x 5 min  1 
94°C x 10 sec  
25 50°C x 5 sec  
60°C x 2 min  
4ºC x ∞  1 
 
Thermal Cycler Model (circle one):  9700     or     2720   Thermal Cycler #: __________  
 
 
 
POLICY: ML316 GENETIC ANALYZER USE (3500)  
POLICY VERSION: C  
POLICY EFFECTIVE DATE: 2/12/2018  
 
  
 
SCOPE  
 
This procedure is intended for use by the Molecular section of the Fullerton Genetics Laboratory  
 
PRINCIPLE  
 
The 3500 Genetic Analyzer automates fragment analysis by separating DNA fragments according to length using capillary 
electrophoresis.  The fragments are fluorescently tagged to produce different wavelengths of light when excited by the laser.   The 
CCD camera converts the light (fluorescence) into electronic data for the computer to analyze and provide a profile of the separation.  
 
REAGENTS AND SUPPLIES  
 
Reagents:    
• Anode Buffer Container, 3500 Series ( Applied Biosystems® ) 
• Cathode Buffer Container, 3500 Series ( Applied Biosystems® ) 
• Conditioning Reagent, 3500 Series ( Applied Biosystems® ) 
• POP-7 Polymer pouch (384 samples), 3500 Series ( Applied Biosystems® ) 
• DS-30 Matrix Standard (Dye Set D) ( Applied Biosystems® ) 
• BigDye® Terminator v1.1 Sequencing Standard Kit 3500 Series Genetic Analyzers (Dye Set E)  (Applied Biosystems® 
P/N 4404314 ) 
• PowerPlex® 4C Matrix Standard (Dye Set F) (Promega)  
• Hi-Di™ formamide (Applied Biosystems®)  
 
Storage Requirements :  Store at 4°C with the exception of the Hi-Di™ formamide and BigDye® Terminator v1.1 Sequencing 
Standard which should be stored at -20°C. Store PowerPlex® Matrix Standard at -20°C upon arrival and then 4°C after first use. 
Expiration dates on containers.  
 
Special Supplies:   
• 8-capillary array, 50 cm ( Applied Biosystems®  P/N 4404685)  
• Cathode Buffer Container Septa (3500)  
• Half skirted 96 -Well Reaction Plate  
• Clear Adhesive Film for 96 well plate  
• Genetic Analyzer Plate Septa, 96 -Well  
• 20 ml, all plastic Luer -lock syringe  
• P20, P200, and P1000 pipettes and aerosol -resistant tips  
 
PROCEDURE  
 
1. Start -up the computer.  Enter “Administrator” for both user and password.  Wait for computer to start -up. 
2. After entering the username immediately turn on the 3500 instrument. The Daemon will automatically start and the computer 
will connect to the instrument. This may take a few minutes.  
3. Click (on the desktop) on the “3500” icon to start the software. Enter the password “Administrator1” for the Data Collection 
software.  
4. The Dashboard will open.  The gauges show the status of the polymer, buffers and capillary.  From the Dashboard, the other 
functions of the instrument can be accessed by clicking on either the buttons across the top of the screen, or the menu 
headings in t he top right of the screen.   
 
 
 
 
Preparing a run  
 
1. From the Dashboard, determine if any maintenance of the instrument needs to be done prior to the run.  Click on the 
“Refresh” button to ensure the information is up to date.   
 
 2. Check the number of runs remaining for the polymer and capillary, as the instrument will not link a plate that exceeds those 
numbers of runs.  
3. Click on the Create New Plate button at the top of the Dashboard screen.  
4. In the next window, assign a name to the plate and choose the plate type (Sequencing, Fragment, or Mixed).  You may also 
fill in the Owner Name and Description, but these are optional.  
5. Click the Assign Plate Contents button to move to the next window.  
6. You may use the Plate View or Table View to name the samples. List the sample names in the correct wells.  
7. The lower window on the screen shows 3 columns:  Assays, File Name Conventions and Results Group.  Click on “Add 
From Library” for each of these to choose the file(s) that will be used for the plate.  
Assays  File Name Conventions  Results Group  
FastSeq50_E (Sequencing)  Sequencing  Sequencing  
PowerPlex (MCC)  
Fullerton Sample Naming  Fragment Analysis  
MSI (MSI)  Fragment Analysis  
Fragment_Analysis_Assay (FMR1)  Fragment Analysis  
MLPA_POP7 -50cm -FRAG -
ANALYSIS (MLPA)  MLPA RESULTS  
 
8. The corresponding columns on the Table View must be filled in.  A drop -down menu will appear when clicking on the cells.  
Choose the Assay, File Name Conventions and Results Group for each sample. When the top box is filled in for all 3, 
highlight the boxe s of interest underneath and hold Ctrl D to fill them all in simultaneously.  
9. Press the Tray button on the front of the instrument.  Place the plate in either position A or B (left or right).  Wait for t he 
green light before proceeding to the next step.  
10. Once all columns are filled in, click on the “Link Plate for Run” button at the bottom of the screen.  If a plate has been 
previously run but is still linked, a message window will appear asking if you want to link the plate in position A (the left  
side) o r leave the previous plate in A and link the new plate to B.  Make the appropriate choice, and click “Okay”.  
11. On the next screen, if all plates to be run have been linked, click the “Start Run” button at the bottom of the screen to beg in 
the run.  The RFID tags will be read for all reagents before the run actually begins.  It is best to wait to insure that no m essage 
appears.   
NOTE:  If the polymer has been on the instrument more than 7 days, the instrument will prompt you to choose if you want to 
continue the run.  The run will not begin until after the message window is addressed.  
12. The run can be monitored on the next screen. The column of the plate that is currently being run is highlighted in green.  Th e 
instrument light will flash green when running until complete. When finished the light will remain solid green.    
 
 
Cleaning and Maintenance  
 
Buffer/Flush Water Trap (approximately Biweekly)  
1. The Anode Buffer Container and the Cathode Buffer Container must be changed after it has been installed on the instrument 
for 14 days (hard stop).  The 3500 monitors the time the containers have been on the instrument using RFID tags on all 
reagents.  
2. Remove a new set of buffer containers from the refrigerator and allow to warm to room temperature.  
3. Press the “Tray” button on the front of the instrument.  Wait for the autosampler to move to the front.  
4. Open the door, the light will become orange and flash, remove any plate that may be on the autosampler.  Remove the 
Cathode Buffer Container from the autosampler by pushing it slightly back until it unclips from the 2 notches on the front of  
the autosample r.  Remove both septa and install on the new Cathode Buffer Container.  Set the new Cathode Buffer 
Container in place on the autosampler until it clicks into position.  
5. The Anode Buffer Container must be pulled slightly forward before it can be lowered away from the electrode block and 
removed.  Before the seal is removed on the new Anode Buffer Container, tilt the container to drain the small reservoir and 
pour any buffer th at has overflowed back into the main container.  Peel off the seal and lower the Anode Buffer Container 
under the electrode block.  Lift the container until it can be slid into place toward the back of the instrument and held by the 
frame above the electro de block.  
6. After the buffers have been changed, the water trap should be flushed using the plastic syringe.  
7. Close the door, allow the autosampler to move back into position, the instrument light will turn solid green.  
8. Document maintenance on ML316F1 -ABI Genetic Analyzer Use -3500 Cleaning Record.  
 
  
Polymer/Wash pump and channels -As Needed (approximately monthly)  
1. The polymer has a soft stop that will flag the user after 7 days on the instrument.  However, our experience shows that the 
polymer is stable for up to/exceeding 1 month on the instrument.  The hard stop for the polymer is 384 samples , which 
equals 48 injections .  Once the hard stop is reached, the instrument will not run until the polymer is changed.  
2. Remove the used polymer pouch by lowering the arm that is to the right of the pouch.  The pouch will click as it is lowered 
or raised.  Once the pouch lowers, it can be pulled forward to slide the pouch fitment out of the bracket.  Discard a 
completely use d pouch in the biohazard waste.  
Note: If replacing a Polymer Pouch of the same Lot as the used Pouch, Proceed directly to “Replenish Polymer” 
Wizard under the Maintenance tab and do not run Conditioning Reagent.  
3. Install a new pouch of Conditioning Reagent on to the instrument by sliding the pouch fitment into the bracket and raising th e 
arm to click the pouch into place.  Click on the Maintenance heading at the top left of the screen.  
4. The actions available under the Maintenance menu are listed on the left of the screen.  Click on Maintenance Wizards, and 
choose the “Wash Pump and Channels” button. The wizard will list the steps to follow to perform the wash and install a new 
pouch of po lymer.  This wizard will only work if you are using the same type of polymer.  There is a separate wizard for 
changing polymer type.  
5. Document maintenance on ML316F1 -ABI Genetic Analyzer Use -3500 Cleaning Record.  
 
Capillary Array -As needed (160 -200 injections)  
 
1. The capillary array has a soft stop of 160 injections but may be successfully used for many injections after this point.  If 
quality begins to diminish after 200 injections, the capillary array may need to be changed.  
2. To change the capillary array, click on the Maintenance menu at the top right of the Dashboard.  
3. The actions available under the Maintenance menu are listed on the left of the screen.  Click on Maintenance Wizards, and 
choose the “Change Capillary Array” button.  
4. This wizard will list the steps to follow to change the capillary array and fill it with polymer.  
5. When a new capillary array has been installed, both the Spatial and Spectral calibrations must be performed.  
6. First, perform the Spatial Calibration:  
a. In the Maintenance menu, under the Calibration section (on Left), choose Spatial.  
b. Choose either the Fill or No -Fill option to either fill the capillary array with polymer or not.  
c. Click the Start Calibration button.  
d. When the calibration is complete, look at the peaks to ensure that they are approximately the same height and the 
blue plus -mark is at the top, center of each peak.  If not, click the Reject Results button and repeat the calibration.  
e. If the calibration is good, click the Accept Results button to complete the Spatial Calibration.  
7. Second, perform the Spectral Calibration:  
a. In the Maintenance menu, under the Calibration section (on Left), choose Spectral.  
b. Click on the Calibration Run tab to set up a run.  The Chemistry Standard (Sequencing Standard or Matrix 
Standard), the Dye Set, and starting position must be selected.   
c. The chemistries/dye sets that are used by FGL are:   
i. Matrix Standard DS30=dye set D (for MLPA)  
ii. BigDye® Terminator v1.1 Sequencing Standard Kit = dye set E (for sequencing)  
iii. Matrix Standard for PowerPlex® 4C=dye set F (for Maternal Cell Contamination, and MSI testing)  
d. Refer to ML316 Appendix A for dye specific Spectral Calibration protocols.  
e. Remove the sealing film and replace with a 96 -well septa.  Place the plate in the plate holder for the 3500.   
f. Press the “Tray” button; wait for the autosampler to move forward.  Remove any plate that is installed, and place the 
plate containing the spectral calibration standard in position A.  Close the doors and wait for the green light.  
g. Click the “Start Run” button and wait for the run to be completed.  
h. If the data passes, click the Accept button at the bottom of the screen.  
i. Repeat for each dye set that may be run on the instrument.  Only 1 plate containing 1 spectral calibration standard 
may be run at a time.  
8. Document maintenance on ML316F1 -ABI Genetic Analyzer Use -3500 Cleaning Record.  
 
• Note: Spectral Calibration should be run when a new Dye Set or Polymer type is used on the instrument, or if the CCD 
camera has been realigned/replaced.   
 
  
REFERENCES  
 
Life Technologies/ Foster City, CA, “Applied Biosystems 3500/3500xL Genetic Analyzer User Guide”, Part Number 44011661, Rev. 
B, 08/2009.  
 
Technical Manual: PowePlex® 4C Matrix Standard TMD048. October 2015. Promega Corporation. Madison, WI.  
 
Product Information Sheet: DS -30 Matrix Standard Set (Dye Set D). Rev B. April 2017. Life Technologies Corporation. Carlsbad, 
CA.  
 
Product Insert: BigDye® Terminator v1.1 Sequencing Standard Kit 3500 Series Genetic Analyzers. Rev A 6 March 2009. Applied 
Biosystems. Foster City, CA.  
 
 
  
 
 Appendix XXV. CLIA Lab Tracking in NCGENES 2 Genomic Molecular Workbench 
(GMW)  
NCGENES2 Protocol for Tracking of Clinical 
Laboratory Samples, Sequencing Confirmation, and 
Reports  
Version 1.0  
Overview  
Participants who are randomized to and consent to having genomic sequencing performed as part of the NCGENES2 
project will provide paired samples: one to undergo genomic sequencing through the research lab, and a second which 
will be received in a clinical  laboratory (monitored under CLIA). The clinical laboratory will receive and extract DNA 
from the sample, perform genotyping of a set of polymorphic single -nucleotide variants (the "identity -check" SNVs) and 
hold extracted DNA until confirmation of researc h results (pathogenic, likely pathogenic, or reportable variant of 
uncertain significance) is requested by the molecular sign -out committee. After attempt at confirmation, the clinical 
laboratorian will indicate whether this confirmation was successful. If  confirmation was successful, then the clinical lab 
director will prepare a clinical report to be included in the participant's medical record, and will also record the report t ext 
as part of the study data set.  
System of record  
The system of record for these activities within the NCGENES2 project is the NCGENES2 Genomic Molecular 
Workbench (GMW),  located at https://ncg2.unc.edu  with authentication using a UNC onyen ( https://onyen.unc.edu ). 
Access to this system is restricted to computers on the UNC School of Medicine network or through the UNC Campus 
VPN. Authorization to access this system is controlled by study coordinators.  
Upon login to this system, the user is presented with a role -based list of pending tasks that can be performed (Figure 1)  
 
FIGURE 3:  WHEN  LOGGING  INTO  THE  MOLECULAR  WORKBENCH,  THE  USER  IS PRESENTED  
WITH  A ROLE -BASED  LIST  OF AVAILABLE  TASKS.  IN THIS  EXAMPLE,  THE  SAMPLE  FOR  
PARTICIPANT  TEST_00002  IS AWAITING  SPECIMEN  CHECK -IN, AND  THE  SAMPLE  FOR  
PARTICIPANT  TEST_00001  HAS  B 
Recording receipt of sample  
There are two options for indicating receipt of sample. Option 1 below is preferred since it reduces the possibility of 
improperly indicating sample receipt by allowing for entry of the sample identifier using a barcode scanned  

 
  
FIGURE 4: CLIA  SPECIMEN  CHECK -IN PAGE.  NOTE  THAT  THE  MENU  OPTIONS  ON  THE  LEFT  
WILL  VARY  BASED  ON  THE  USER  ROLE,  BUT  FOR  CLIA  LABORATORIANS  THE  "CLINICAL  LAB"  
GROUP  WILL  ALWAYS  BE AVAILABLE.  
Option 1: Entry of sample ID using barcode reader  
Selection of "Clinical Lab" and then "CLIA specimen check -in" from the menu on the left of the page displays a "CLIA 
specimen check -in" page (Figure 2). The technician will verify that the sample identifier on the tube and on the requisition 
form match, an d use a barcode scanner to enter the specimen ID. This page then remains active and will allow for the 
entry of additional specimen IDs.  
Option 2: Identification of the sample in the list of pending tasks.  
The laboratory technician may identify samples awaiting check -in in this list as having the pending workflow step of 
"UNC CLIA Check in Specimen" or "Mission CLIA Check in Specimen" for the relevant lab where the sample is 
expected. The laboratory technici an can indicate sample receipt by matching the participant number from the sample label 
and requisition form to a pending task in the GMW. Clicking on that task will present a form in which the technician 
provides a response to whether the sample received was adequate or not.  
Recording genotypes of polymorphic single nucleotide variants  
Following DNA extraction, Sanger sequencing is performed on a select set of polymorphic single nucleotide variants. 
These genotypes will be compared to genotypes of the same sites performed in the research labs by genomic sequencing 
as a control against sa mple swap.  
After a specimen has been accessioned into the system, the next pending task related to this specimen for the CLIA 
Laboratorian is "UNC CLIA Save Genotypes" or "Mission CLIA Save Genotypes" for the respective laboratories (for 
example, as seen for particip ant TEST_00001 in Figure 1).. Clicking on the text of this pending workflow step will 
display the interface (Figure 3) for entry of genotypes of these "identity check" polymorphisms. Genotypes for each 
polymorphism (indicated by dbSNP RS identifier) are en tered using a drop -down box of options.  

 
  
FIGURE 3: INTERFACE FOR RECORDING SANGER GENOTYPING OF "IDENTITY CHECK " GENOTYPES  
Requests for confirmation of genomic sequencing results  
Variants which are identified as reportable by the molecular sign -out committee (Pathogenic, Likely pathogenic, or 
reportable Variants of Uncertain Significance) will be marked by the committee within the GMW. This creates a 
notification to individuals wit h the "CLIA Laboratorian" role, and also adds the relevant task ("CLIA Variant Analysis 
Results") to their dashboard.  
Primer design  
Selecting "Clinical Lab" and then "Unresolved variant confirmation" from the menu to the left provides a list of all 
variants for which CLIA confirmation is pending. This list includes a column for amplicon design. The laboratorian will 
click in this column to obtain the sequence surrounding the variant to be confirmed as well as suggested PCR primers.  
Recording of variant confirmation  
The results of variant confirmation are recorded in the workflow step for "CLIA Variant Analysis Results". These are 
recorded in the column labeled "Confirmed" using one of the following codes:  
• P: Pending (used for variants for which confirmation has not been attempted, so will not be a final code)  
• U: Unknown - unable to demonstrate presence or absence of the variant (e.g., unable to design primers to amplify 
the relevant region, or unable to define primers that differentiate between this region and paralogous sequence)  
• N: No, not confirmed - Sanger sequencing indicates that the variant is not present  
• Y: Yes, confirmed - Sanger sequencing indicates that the variant is present.  
When all of the variants have been assigned to one of the final categories (U, N or Y), the laboratorian presses the 
submission button to send the results on to the molecular pathologist for final interpretation.  
Molecular pathologist determination of final result and reporting  
After Sanger sequencing of the requested variants is performed, the molecular lab director determines the final case -level 
result. This includes marking whether the variants requested by the sign -out committee were confirmed, and if so, the 
generation of t he text of the report. When no reportable findings are identified in the research lab (or none of the requested 
findings are confirmed in the clinical lab) then a negative report is generated directly by the GMW. When there are 

 
 findings to report that do confirm, then the laboratory director prepares a report according to their usual clinical practice . 
In addition, the laboratory director provides, within the GMW, the text of the clinical report (without any identifiable 
informat ion) and the classification of the case -level result which can include one or more of the following categories:  
• Definitive positive:  
o One or more Pathogenic variants in a gene, phenotype consistent with condition, with known phase or de 
novo  inheritance consistent with expected inheritance pattern  
• Probable positive:  
o One or more Likely Pathogenic variants in a gene, phenotype consistent with condition, with known 
phase or de novo  inheritance consistent with expected inheritance pattern  
• Inconclusive - due to unknown phase:  
o At least two Pathogenic/Likely Pathogenic variants in AR condition or X -linked recessive condition in 
female with phase not determined  
• Inconclusive - due to variant uncertainty:  
o Case that would otherwise meet Definitive Positive or Probable Positive but at least one of the involved 
variants is a VUS  
• Inconclusive - due to insufficient zygosity:  
o Single Pathogenic or Likely Pathogenic variant identified in AR condition or in female with X -linked 
condition  
• Inconclusive - phenotype mismatch:  
o Case that would otherwise meet Definitive Positive or Probable Positive but where the condition would 
not explain all of the patient’s phenotype, where the patient does not exhibit all characteristics expected of 
the condition, or where there is discordant  co-segregation of phenotype with the variant within a pedigree 
(e.g., implicating incomplete penetrance or phenocopy)  
• Inconclusive - novel gene:  
o Case where the association of the implicated gene with the patient’s phenotype has not been definitively 
established  
• Negative  
 
 
  
 
 Appendix XXVI . Registering for UNC LMS and UNC EPIC Training   
Below is the process for getting write access in EPIC in order to pend research phlebotomy orders (for non -clinicians):  
1. Must complete UNC HIPAA training.   Need HIPAA certificate to send to Joe Baker  
2. Must complete UNC Citi trainings (1) GCP for US FDA trials, and 2) Human Subjects Biomedical Group 
1).   Need both certificates to attach and send to Joe Baker  
3. Must be on an approved IRB protocol.    Need IRB approval letter to send to Joe Baker   (You need HIPAA and 
both Citi trainings recorded in order to be approved on a UNC IRB protocol)  
4. Must complete and sign a UNC Health Care Confidentiality Statement (ask Study Coordinator)  
5. Must complete and have signed an University Employee EPIC Access Request Form (ask Study Coordinator)  
 
All completed/signed copies of above documents should be sent to Joe Baker (Baker, Joseph J. 
Joseph.Baker@unchealth.unc.edu ).    There should be a total of 6 documents you send to Joe.   You should request a 
UNC LMS account for EPIC training/access.     Within 48 hours you will get an email from Joe with your “u” number and 
instructions on how to log in to LMS the first time.    Once in LMS, you will need to take the following trainings:  
1.  Go to Library (book icon)  
2.  Click on ISD Training -EPIC@UNC and get drop -down menu  
3.  Go to Research  
4.  Go to Research Assistant (Read -Only Access) and take this online course for read -only access to EPIC  
5.  Go to Research Coordinator Oncology (Non -CPO) and register for this curriculum.  
• There are 4 -5 courses that need to be taken.   Some are onsite in Morrisville and some are here at TraCs  
 
6. Once you have completed the Research Coordinator (Non -CPO) curriculum you are technically able to pend 
orders, but you will need to contact EPIC admin first who has to set you up in EPIC.   They should tell you who to 
contact at one of these courses.  
7. Once you pend an order, you will need to show the provider how to find it in EPIC (see attached quick reference).  
 
Stephanie Mascaro is a good contact if you happen to have any trouble once in EPIC.    
 
 Appendix  XXVII. Creating a  UNC EPIC Order  
1. In Epic, create an orders only encounter for the participant. (See item 12 below as well as UNC Epic 
TRAINING REQUIREMENTS – in the Appendix section)  
 
2. Choose “Other” as the reason for visit in the visit info section.  
 
 
 

 
 3. Go to the Meds & Orders section and begin searching for your lab by typing “research.” Hit enter to search.  
 
 
4. Select “Phlebotomy - Research Draw” and then click “Accept.”  
 
 
 
 
5. The order should now appear as an “unsigned order.” Click on the order name to open it. You need to open the 
order to check on the collection methodology and associate it with a diagnosis code.  
 
 
6. Make sure that the “Class” is Lab Collect.  
 
 

 
 7. Click the “Associate” button.  
 
 
8. In the search bar, type “research” and hit Enter.  
 
 
9. Highlight “Research Exam” and click Accept.  
 
 

 
 10. Check the box to associate the research draw with the research exam, and click Accept.  
 
 
11. Click the Sign button in the Unsigned Orders section.  
 
 
12. In the Order Mode box, type “per” and hit enter. Then choose “Per protocol: cosign required” by clicking on that 
option.  NOTE: there are 3 courses (2 in person) for EPIC research training that will allow a staff member to pend 
research blood order.  The r esearch blood draw order (8243) must be set up in EPIC ahead of the appointment so 
that the physician can sign it.  It has to be put in as a “LAB” not as a “CLINIC” order if phlebotomy is drawing 
the blood which will always be the case.  If the patient is randomized to no sequencing or doesn’t show/cancels, 
the Epic blood order can be cancelled.)  

 
  
 
13. In the Authorizing provider box, begin typing the name of the attending physician that the participant is seeing in 
a UNC Pediatric Specialty Clinic, and hit Enter. Select the correct physician by clicking on their name. Then click 
Accept.  
 
 

 
 14.  Click on the red text “No cosigner entered.”  
 
 
15. Search for the same attending physician to co -sign the visit. Select their name, then click the green sign visit box. 
 
 
 

 
 Appendix XXVIII. Creating a Mission Health Cerner Order  
1. Enter GENE Order.   
2. Under order comments section type “NCGENES 2 Research Phlebotomy blood draw - see kit for instructions and 
tubes”.  
3. Sign order.   
 
 
  

 
 Appendi x XXIX. Mission Health Cerner EHR Training Requirements  
See training video on MissionOnDemand.  
\\mh\ss\Learning and Development \Completed Captivates \PCA \PCA Orders \PCA Orders.htm  
 
   

 
 Appendix XXX. Laboratory Directory  
UNC Biospecimen Processing Facility (BSP)  
1. Shipping Address and Lab Directory  
 
Shipping Address:  
Attn: Dr. Patricia Basta, Lab Director  
BioSpecimen Processing Facility  
Michael Hooker Research Center, Rm 3213  
135 Dauer, Drive  
Campus Box 7406  
The University of North Carolina at Chapel Hill  
Chapel Hill, NC  27599 -7435  
Phone : 919 -966-7738  
Website : http://bsp.web.unc.edu  
 
Paige Schmadeke  
Research Specialist  
UNC Biospecimen Processing Facility  
Chapel Hill, NC  
Lab Phone: (919) 966 -7738  
 
 
UNC Hospital CLIA Molecular Genetics Lab  
 
1. Lab UNC Hospital Location and Directory  
 
Location:  
McLendon Clinical Laboratories  
Room 1046 Anderson Pavilion  
CB 7600 (if you need this)  
Fax:  984-974-2496  
 
Karen Weck  
Karen.Weck@unchealth.unc.edu  
Professor and Director of Molecular 
Genetics  
984-974-1825  
 
Roy, Sayanty  
sayanty@email.unc.edu  
Research Specialist, Dept of Pathology  
984-974-1825  
  
Howard Parker  
Howard.Parker@unchealth.unc.edu  
Supervisor, UNC Molecular Genetics 
Laboratory  
984-974-1825  
 
 
Mai Xiong, PhD  
Mai.Xiong@unchealth.unc.edu  
Developmental Specialist  
 
 
 
 
  
 Appendix XX XI. Study Coordinator Contact Information  
University of North Carolina at Chapel Hill (UNC)  
Jeannette Bensen, MS, PhD, NCGENES 2 Clinical Implementation Director  
Bioinformatics Building, Room 3130  
Campus Box 7295  
Chapel Hill, NC 27599 -7295  
Work Phone: 919 -843-1017  
Cell Phone: 919 -801-9267  
Email: jbensen@med.unc.edu  
 
Tracey Grant, MS, NCGENES 2 Study Coordinator  
Bioinformatics Building  
Campus Box 7295  
Chapel Hill, NC 27599 -7295  
Work Phone: 919 -445-2841  
Cell Phone: 919 -306-1410  
Email: traceyg@unc.edu  
 
 
Mission Health – Asheville  
Ellen Rowe, Study Coordinator  
Fullerton Genetics Laboratory  
Mission Health  
9 Vanderbilt Park Drive  
Asheville, NC  28803  
Direct:  828 -213-6817  
Fax:  828 -213-6987  
Email: Ellen.Rowe@HCAHealthcare.com  
 
 
East Carolina University (ECU)  
 
   
 Appendix XXX II. Supplies and Ordering Information  
Blood Collection Kit Supply Ordering: (NEED ORDER INFO FROM PAIGE)  
 
3ml LavTop Vacutainers  
Fisher 23 -021-016 (BD cat. no. 368054)  
$30.53, pack of 100  
  
Biohazard bags – 2 per patient blood  
Fisher 01 -800-05 
9 x 6 in. w/ document compartment + absorbent pad  
$52.87, pack of 500  
  
Blood tube mailers: VWR 76203 -882 at $123.16/case of 20  
  
Cold packs – included in mailer above  
 
Gloves – purple nitrile (to handle filled blood tubes)  
 
DNA Genotek Saliva Kits  
1) OGR -575 - same as above but the tube is round -bottom and there is no barcode. Price right now is the same as OGR -
675. 
2) OC-175 - contains I sponge for assisted collection of saliva for infants <6 months old. Company stated yield is 2ug.  
3) The option to purchase FDA approved saliva kits is not necessary and not preferred for NCGENES 2. The saliva kits 
designed for research are preferred.  
 
Barcode label printer and labels (ordered by clinical team not lab):  
 
DYMO LabelWriter 450 – available at Staples  
DYMO 45010 1/2 -Inch High -Performance Permanent Self -Adhesive Polyester Label Tape for Label Makers, Black on 
Clear Sold at Staples by the roll  
Avery 5364 Shipping Labels 3 1/3” x 4” (for the pre -addressed small bubble mailer for return of saliva to BSP).  
 
 
 
Mailers and cold packs for blood transport (each NCGENES site has funding to support postage so each site will link to 
their institution -specific billing account):  
VWR 76203 -882 – See picture below  
 
BLOOD MAILER KIT with Cold Packs (put in refrigerator ) 

  
 
Once blood is placed in the packaging above (sleeve, pouch and box), the box is placed in the FedEx Clinical Pak 
(described below) for ease of mailing  
 
 
 
  

 Mailers for saliva kits (mail out to patient and return to BSP lab)  
Fold the pre -paid mailer – the smaller bubble mailer – and place it inside the larger bubble mailer.  Instruct parent to 
return swabs to plastic bag and then insert in pre -paid mailer.   
 
 
 
 
 
 
  

 Appendix XXXII I. NCGENES 2 BSP Lab Requisition Form  
  
 
 
NCGENES II  
LAB REQUISITION FORM  
Please do not include any PHI on sample tube or form.  
 
Donor ID              (PLACE ID LABEL HERE)                                                    
Location (please circle  one):        UNC            ECU        Mission  
 
Container Type :    3ml LAV TOP EDTA  
Blood volume  (in milliliters):  ______                        
 
Collection Date:   ________   (day/month/year)                                           
Collection Time:  _______        am      pm (circle one)                                 
Collected By  (NCGENES 2 staff ): ______________________________  
____________________________________                                                                                                                  

 Appendix XXXI V. NCGENES 2 UNC MGL Patient Blood CLIA lab form  
  

 Appendix XXXV. Example of Completed UNC MGL Patient Blood CLIA Lab Form  
(Blue items are patient or physician specific. A set of MGL CLIA forms can be created for each study Physician and 
should include printed name, signature and fax if relevant (ECU), the date of the blood collection and the patient’s label is 
placed on the form after randomization and consent to genomic sequencing.) UNC MGL MD Order Forms for patient 
blood, patient saliva, and parent/relative saliva can all be found in Microsoft Teams.   
IIIIIIIIIIIIIIIIIIIIII  
NCG20001 -00 
ECU place Fax number here  
Physician’s printed name  
 Physician’s signature  
 Today’s date  
 Appendix XXXV I. Example of Completed UNC MGL Patient Saliva CLIA Lab Form   
IIIIIIIIIIIIIIIIIIIIII  
NCG20001 -00 
Today’s date  
 Physician’s signature  
 Physician ’s printed name  
ECU place Fax number here  
 Appendix XXXVI I. Example of Completed UNC MGL Parent/Relative Saliva CLIA Lab 
Form 
 
  
Physician’s signature  
 Today’s date  
 Physician ’s printed name  
ECU place Fax number here  
IIIIIIIIIIIIIIIIIIIIII  
NCG20001 -00 
 Appendix XXXV III. NCGENES 2 Parent/Relative Saliva UNC MGL Additional Form  

 Appendix XXXIX . Mission FGC Laboratory Requisition Form (3 Pages)  
 
 
 
  

 Appendix  XL. Using the LIMS system at the BSP  
1. At the BSP, use the LIMS system (pictured below) to log the samples.  
a. The LIMS system provides instructions for specimen delivery shown here.  
b. First, the study person delivering the sample should enter their name and cell phone number.  
c. Next, select NCGENES 2 from the project name dropdown shown below.  
  

 d. Whenever possible, sample barcodes should be scanned to auto -populate the “Participant” field in the 
LIMS system. If manual entry the participants barcode ID is required, the research assistant should type 
that ID into the LIMS system.1 
e. Manually enter the time of collection, and approximate volume (by comparing to pre -measured vacutainer 
available in BSP), as well as tube type (LAVTOP3.0), and sample type (e.g., blood).  
f. If the tube is not completely filled, mark the “Partial” box. (shown below).  
g. When the form is complete, click the “Finish Dropoff” button to finalize the LIMS entry.  
  
 
1 The participant ID for the BSP is the longer “NCG -2#### -00” and not shorter number used in the Tracking System.  

  
2. Once entered into LIMS, place the blood tubes in the refrigerator (tube rack in the refrigerator directly across 
from the LIMs computer) designated for sample deliveries.  
3. If it is after 4:30 pm , FOR UNC BSP  - place the NCGENES 2 sample in the cold room (rm 3209) in the hallway 
(outside of the BSP and about half way down the hallway – metal door) and log the sample in on the form on the 
clipboard in the cold room.  The samples will be processed the next day.  
 
 
  

 Appendix XLI. Tips for Interviewing  
Being an interviewer  
(Adapted from https://www.institute.org/wp -content/uploads/2011/06/Interviewer_Training_Manual.pdf.pdf)  
 
You are the key to the success of this study, including  
1) Getting people to participate  
2) Helping people do a good job answering the interview questions  
3) Recording their responses clearly and accurately  
Getting people to participate:  
Some people will agree to participate and be interviewed right away. But there will also be people who are suspicious or 
who, at first, do not want to participate. Getting them to participate can be difficult, but is one of the most important job s 
of the i nterviewer. Here are some techniques that have worked with other surveys:  
• Be positive and upbeat, and act confident. Act like you are certain that they will want to participate. Be friendly.  
• Know why this project is important.  
• The more you know, the more convincing you can be.  
Getting people to do a good job answering the interview questions:  
• You set the tone of the interview, and you can affect the quality of the answers you receive.  
• For example, if you rush through the questions, the people you are interviewing may rush through their answers.  
• If you seem bored, the person answering the questions may not want to spend the time thinking through how they 
respond.  
• If you are confused, the person answering will be confused.  
• Make sure you understand the study and the questions, and always feel free to ask the team questions.  
Recording the answers clearly and accurately:  
• You may do a great job interviewing, but if you don’t record the answers accurately, we will never know that. For 
us to use the interviews, you need to keep track of everything clearly and accurately.  
• Be sure that you mark down an answer for every question, unless it is missed through a skip pattern. Some 
questions have a list of possible answers that you are supposed to read to the person you are interviewing. Follow 
the directions for each of these qu estions.  
How to Interview  
You will be asking people questions that have a lot of detail and are somewhat personal. Here is some advice about how 
you can keep control of the interview and collect good information.  
Practice:  
• Be very familiar with the questionnaire, skip patterns, and the entire interview process before doing the first 
interview.  
• If you don’t understand a question, the person you are interviewing will also be confused. Practice asking the 
difficult questions until you can ask them in a simple, matter -of-fact way.  
Asking the Questions:  
• Don’t Show Your Own Feelings or Give Away the “Correct” Answer  
o It is important not to influence how people reply to the questions. Be careful not to show any personal 
feelings and judgments.  
o Do not show surprise, approval, or disapproval.  
 
• Ask the Questions in the Exact Order that they appear  
o In writing the questionnaire, we purposely put the questions in a certain order. Some questions are placed 
after others on purpose. So please don’t change the order of the questions when you are interviewing 
people.  
 
• Ask All of the Questions (Unless You Are Told Not To)  
 o Sometimes in answering one question, the person you are interviewing may also give an answer to a later 
question that you haven’t asked yet.  
o Do not fill in that answer. Wait until you get to that question and then ask it exactly as it is written on the 
form.  
o If the person becomes annoyed at being asked a question again (and may say something like “I just told 
you that”), respond pleasantly by saying: “I need to ask all of these questions in the exact order to make 
sure we have complete information.”  
o Always feel free to blame the researchers for requiring you to ask repetitive questions or to be very clear 
about the answers. You can say: “I know it may sound like I’m being repetitive, but I have to follow the 
instructions I have from the researchers.”  
 
• Ask Each Question Exactly as it is Worded  
o Each interviewer needs to ask the questions in exactly the same way.  
o Any change, even of one or two words, can change the meaning of the question.  
o After all of the interviews are complete, all of the answers will be combined and studied as a group. 
Therefore, all of the questions need to be asked in exactly the same way by all of the interviewers.  
 
• Keep the Focus on the Interview Questions  
o The person you are interviewing may describe things from the past or tell a long story. If they ramble or 
discuss irrelevant topics, you should politely interrupt and get them back on track. This is a very 
important part of your job. It can be hard to keep  the person focused on the questions without being rude.  
o Here are some suggestions. Try saying:  
▪ “That sounds very interesting. So [repeat the question…”]  
▪ “I see what you mean. Let me repeat the last question…”  
 
• What if the Person Says Things That Don’t Makes Sense or Are Inconsistent?  
o People often have opinions that may not be accurate or may not make sense. We are interested in learning 
about those views – even if they are incorrect. So do not try to correct people or point out their mistakes.  
o If you know something about the person you are interviewing and you think they have answered a 
question incorrectly, do not correct them or change the answer  
 
• Make the Person You are Interviewing Feel Comfortable  
o Your goal should be to make the person you are interviewing feel as comfortable as possible. Be friendly 
and calm.  
o If the person seems nervous or says that they feel uncomfortable answering a question, remind them that 
all of their answers will be kept confidential.  
o Also remind them that there are no right or wrong answers to these questions. We are interested in their 
opinions.  
o But remember that the person you are interviewing does have the right to refuse to answer a question.   
 
• Getting a Clear Answer (“Probing”)  
o One of the hardest and most important parts of your job will be getting the person you are interviewing to 
answer the question the way it was asked. People may give only part of an answer or they may 
misunderstand the question or go off on another topic. S ometimes they will be difficult to understand. It is 
your job to get them back on track and to “probe” for a clear answer to the question.  
o When should you probe?  
o Probe when the person misunderstands the question:  
▪ This usually happens when the person you are interviewing didn’t hear or missed a key word or 
phrase in a question.  
▪ Here is an example:  
• Question: Do you smoke cigarettes on a daily basis?  
• Response: “I usually smoke about a pack a week.”  
 ▪ In this example, the person did not hear that the interviewer asked him about his daily smoking 
habits. The interviewer should probe by saying something like, “I see. Well, do you smoke 
cigarettes on a daily  basis?”  
▪ If you stress the key words the second time, the person will understand and give you the answer 
you need.  
 
o Probe when the person finds it hard to remember something:  
▪ Some questions require the person you are interviewing to remember events that took place some 
time ago. If they have a hard time remembering, ask them for their best guess.  
▪ Sometimes it helps to ask if it occurred before or after a holiday or other date.  
 
o Probe when the person says they don’t know:  
▪ Sometimes when a person says that they don’t know, they may really mean that they don’t 
understand the question or that they need some time to think about it.  
▪ Some people may say that they don’t know because they are afraid of giving the wrong answer or 
because the question seems too personal.  
▪ So if the person answers “I don’t know,” do not be in too big of a rush to settle for the “Don’t 
Know” response . If you just wait quietly as if you are expecting an answer, they will usually 
think of something to say. This is usually the best approach for a “Don’t Know” response.  
 
o How do you probe?  
▪ Here is what not to do : 
• Don’t change anything about the question. If you think that the question is confusing, 
make a note in the margin and go to the next question. Discuss this with the study team, if 
possible, before conducting the next interview.  
• Don’t show that you expect a certain answer or that one answer is better than another.  
• Don’t assume anything  
o Here is an example of what can go wrong if you assume something:  
▪ Question: “In general, would you say that your health is excellent, very 
good, good, fair, or poor?”  
▪ Response: “I already told you I have diabetes.”  
▪ Improper Probe: “Then would you say your health is fair or poor?”  
• That probe forces the person who is being interviewed to decide between two choices 
(fair or poor). But she may feel that despite her diabetes, her health is excellent.  
• The interviewer should have just said, “Yes, I remember that,” and then simply repeated 
the question.  
▪ Here is what you should do : 
• Wait as if you are expecting an answer and want the person you are interviewing to 
continue.  
• Show your interest and understanding by saying thing like “Uh -huh” or “I see” or “Yes.”  
• Repeat the question or the possible answers. Many people hearing the question for a 
second time realize what kind of answer is needed. They may not have heard the question 
fully the first time or they might have missed the point of the question.  
• Some questions are open -ended. This means that there is no set of answers to choose 
from or to circle. Instead, you are asked to write down the person’s words exactly. For 
these kinds of questions, you can probe for more information simply by repeating wha t 
the person has already said. You can also say, “Is there anything else you would like to 
add?”  
• If the person’s answer to an open -ended question is confusing you can use questions like 
these:  
o “What do you mean exactly?”  
o “What do you mean by…?”  
 o “Could you please explain that a little? I don’t think I quite understand.”  
• For open ended questions, sometimes you will need to ask them to be more specific. You 
can use questions like these: “Could you be more specific about that?” “Tell me more 
about that: What/who/how/why…?”  
• Sometimes people will be vague about numbers. If they give a range of numbers (for 
example, five to ten), you can probe by saying “I can only put down one number. Can 
you tell me what the best answer is?” If they refuse to choose a number, you should selec t 
the number in the middle.  
• Sometimes you will need to need to pull them back on track. You can use phrases like 
these:  
o “Generally… (and then repeat the exact question)”  
o “Usually…(and then repeat the exact question)”  
o “What is your best guess?”  
o “Which choice comes closest to how you feel?”  
o “I see. Well, let me ask you again…(and then repeat the exact question)”  
  
 Interviewer training  
(Adapted from: http://www.hcsrn.org/en/Tools%20&%20Materials/Plan_Field/HCSRN_InterviewerTraining.pdf ) 
 
Individual Responsibility  
Interviewers must make every effort to protect the anonymity and confidentiality of respondents. Interviewers perform a profe ssional 
function when they obtain information from individuals in personal interviews, and they are expected to maintain professional ethical 
standards of confidentiality regarding what they hear about a respondent.  
1. All information about respondents obtained during the course of the research is privileged information whether it relates to the 
interview itself or includes extraneous observations concerning the respondent's home, family, and activities.  
2. Such information is not to be discussed with anyone but project staff.  
3. A breach of confidentiality is a serious violation.  
4. It is very important that you never conduct an interview with someone you know as a: relative, friend, neighbor, or someon e you 
remotely know. The respondent may feel you are judging him and therefore not respond honestly to the questions. Everyone is e ntitled 
to a confidential interview. Knowing the respondent could compromise confidentiality and the integrity of the interview.  
Basically, if you know the respondent either personally or through a friend or relative, you can not interview that person.  
For your own safety:  
• NEVER give out personal information about yourself.  
• NEVER agree to meet a respondent in person.  
• NEVER reveal the actual location from which you are interviewing  
 
Inadvertent disclosure  
Often you talk to interesting people on the phone. Sometimes you have a conversation that upsets or disturbs you. You may be 
tempted to talk to someone about it – a close friend or partner, or another interviewer. It is important that you do not do this. You may 
think that you can describe the conversation without revealing someone’s identity, but consider how very little you must say before 
someone can be identified. For example, if you were interviewing parents of kids with asthma, and you were amazed by one pare nt’s 
accou nt of raising 7 children, 2 of whom have asthma. The parent is doing this alone, because the other parent was killed tragical ly in 
an auto accident. Suddenly, your friend says, “I heard about a tragedy like that on the news about 6 months ago…” Suddenly, t here is 
enough information revealed to do very little research to find this person.  
Confirmation that the Respondent Understands Informed Consent  
What if you are not convinced that the adult or other respondent understands their rights and responsibilities? We need to be  aware of 
factors that may contribute to miscommunication and misunderstanding; the respondent may be agreeing to participate witho ut fully 
understanding the risks and benefits.  
Suggested Language  
INTERVIEWER: “Before we go on, I need to be sure I’ve told you everything about the study. Would you mind telling me in your 
own words what I’ve told you?” (BE SURE TO THANK THE RESPONDENT.)  
If the respondent is able to summarize in a meaningful way, you may proceed. If you get into the interview, though, and find that the 
questions are not understood, use the language below to terminate the contact.  
Also, if it is clear that the respondent does not understand, say:  
INTERVIEWER: “Thank you so much for your time. Those are all of the questions I have for you.”  
 
Reaffirming informed consent when calling back  
Sometimes the respondent will need to be called back after they’ve heard the Risks and Benefits Section of the interview. The  next 
time the respondent is contacted before beginning or resuming an interview, you must remind the respondent that:  
1. All information is confidential, and will not be identified with the respondent.  
2. Her/his relationship with her health plan will not be affected, and  
3. S/he may skip any question.  
 
Introduction to interviewing  
Interviewing is a conversation with a purpose. As a professional interviewer, your goal is to collect accurate information in  accordance 
with sound interviewing practices. Interviews are designed to obtain accurate and complete information, but to be effec tive the 
information must be collected in a uniform manner from all respondents. The people interviewed must be asked the same questio ns in 
the same way. It is only when each interviewer conducts the interview in the same fashion as all other interviewers that the 
information will be uniformly accurate and ensure that the study produces meaningful and useful results.  
It is important for you to develop your own style of interviewing. Confidence and sincerity can be heard. All respondents sho uld be 
treated with respect and appreciation for their time. Respondents will be more likely to participate if they perceive you as  
knowledgeable, respectful, and sincerely interested in what s/he has to say. You will find that the majority of participants are willing 
to be interviewed. A confident, enthusiastic approach which assumes people are willing to be interviewed is a most eff ective 
technique.  
 In general, consult your supervisor if you have any questions about the interview or about how a situation you're unfamiliar with 
should be handled.  
 
Active Listening  
Good interviewers are skilled professionals and their skills enable participants to give frank, complete, relevant answers to  questions. 
The interviewer must convey that s/he is an understanding person capable of accepting information in a nonjudgmental ma nner and 
that she has an interest in what the participant is saying. A good interviewer is an active listener, one who always listens very 
carefully, respectfully and politely. The participant should enjoy the interview.  
Studies have shown that a participant will often remember more about the interviewer and how the interview was conducted than  
about the topics covered during the interview. The interviewer is a representative of the study team, and the impression the interviewer 
leaves on the participant may be the impression the participant will then have of the study in general. .  
For telephone interviewing you do not have the advantage of talking to the person face -to-face. Your ears will have to be your eyes. 
Listen very carefully when the respondent speaks. Listen for distractions such as running water, a baby crying, a child ask ing 
questions, or another conversation. Before the interview can begin you must first determine if you have the respondent’s atte ntion. If 
you have a respondent on the phone, it is often best to try to complete the interview, because you may not reach him again. On the 
other hand you do not want to compromise the quality of the data because the respondent is not paying attention. Listen very carefully 
and always offer to either hold (or call back).  
Although it is important that all interviewers be trained to administer the questions of a survey over the telephone in the s ame way to 
every respondent, it is also important that we recognize that by interviewing over the telephone, we have the benefit of  interacting 
with a respondent. You are not merely a talking survey. Sometimes what a respondent says is not what we expected to hear, or else the 
answers they give do not fit exactly into our pre -coded response categories. It is at these times that it is important for the interviewer to 
listen carefully  to what the respondent is saying and to respond in a way that reflects that you HEARD what the respondent said . For 
example, you may be asking a series of questions with the response categories of “Strongly agree, agree, disagree, or strongl y 
disagree.” During the course of the interview, perhaps the respondent says, “Sure,” instead of giving one of the pre -coded responses. 
Instead of reading the entire list again, you might just ask, “Would that be strongly  agree or agree?” There is no need to say, “Disagree 
or strongly disagree,” because the respondent has already indicated she is in agreement with the synonym, “Sure.” But it is s till 
important that you do not interpret “Sure” to be “Strongly agree” or “Agr ee,” but rather give the respondent the choice of the most 
reasonable response categories closest to the answer she gave in the first place. Even if the respondent has already talked a bout a 
situation, when it comes time to ask the question, which addresse s the same issue, ask the question and take their response.  
Suggestions for Active Listening  
• Listen attentively without interrupting.  
• Exude warmth, curiosity, interest, and caring - qualities that will make respondents want to talk to you, to share their thoughts and 
feelings.  
• Be present – avoid daydreaming; focus on the respondent and what s/he is saying. Control distractions.  
• Become a "whole body" listener – sit with good posture, use verbals – “uh-huh, hmmm” – to let the speaker know you are hearing 
them.  
• Maintain Neutrality" – it is your job to make your own experiences and opinions of no interest to the respondent, so it is important 
that your reactions to the answers given remain neutral but show that you are listening and paying attention. Avoid words that imply 
value or reaction , like “Good; Oh really?; No!; You’re kidding!; etc.  
• Be aware of your emotions – if someone is saying something that triggers your emotions, it is important that your interactions with 
her remain neutral and do not reflect those emotions.  
• For open -ended questions: Summarizing, paraphrasing and asking for clarification – if the respondent has shared a great deal of 
information with you, you might pull it all together and summarize it or paraphrase it by restating the message in a summary form. 
This is an effective way to demonstrate that you have been listening actively to the respondent and you are now asking for af firmation 
that you heard what you think you heard or that you need clarification of the respondent’s intended message.  
Always keep in the back of your mind: Has this question been answered adequately, do I understand what the respondent has sai d, 
does the answer make sense, is it an answer to this question, and did I get all the information necessary to be able to code this question 
for data entry?  
General Interviewing Practice  
The First 10 Seconds  
The first ten seconds after someone answers the phone is the precious time when people decide what to do with your call. Each  time 
you reach a household, you must be in a “ready” position – speak your name confidently, ask for the designated respondent by name, 
and be prepared to answer any questions that may arise.  
When we are nervous, our voices tend to end every sentence in a higher pitch – like a question. Avoid this – it conveys that you are 
reluctant or uncertain about what you are telling the respondent. Actively listen for distractions in the background, reluc tance in the 
voice of the person you are talking to, and let the person on the phone dictate the volume and pace of your speech.  
Asking the Questions  
Read Exactly as Written  
 • Before fielding a survey, time should be allowed to test the questions for flow, verbal presentation, and understanding. 
Because this time and energy is spent pre -testing the questionnaire, it is mandatory that each interviewer read each question 
EXACTLY a s it is written. The slightest change in wording can bias, or change the meaning of the question for different 
respondents. Each respondent must hear the entire question read exactly as it is written.  
Read in the Order Indicated  
• Questions are ordered in a certain way to prevent some answers from influencing other answers. Information is asked in 
logical progression. Any alteration of the order of questions could bias a respondent's answers. All questions must be read i n 
the order they appear on the questionnaire.  
Use a Conversational Tone  
• Interviewers must be careful to avoid behavior, conscious or unconscious, spoken or unspoken, which could affect the way a 
respondent answers a question. It is important that the facts and opinions a respondent gives are his/her own. Questions 
should be re ad in a conversational tone without intonation that may change the meaning or bias the response. Only those 
words underlined in the questionnaire should be emphasized.  
Read the Entire Question  
• Each respondent must hear the entire question before they answer. If a respondent answers before the entire question has 
been read, there is a chance his/her response would be different if he/she heard the entire question. If the respondent 
interrupts, you  can say, "I want to make sure you hear the entire question before you answer".  
Don’t Skip Questions  
• Sometimes respondents mention information that answers a question that you will ask later in the survey. Don't skip a 
question because the answer was given earlier or because you "know" the response. Although it is tempting to skip a question 
because you feel the respondent has already answered it, always ask each question it its entirety.  The respondent must hear 
each question. However, in those situations in which the respondent has already provided information that probably answers 
the next question, you  may preface the question with some combination of the following phrases:  
o "I know we've talked about this” or "I know you just mentioned this, but I need to ask each question as it appears in 
the questionnaire".  
o "You have already mentioned this, but let me ask you..."  
Do Not Assume You Know the Answer  
• Even if the respondent has already talked about a situation, when it comes time to ask the question, which addresses the same  
issue, ask the question anyway and take their response.  
Probing  
When a respondent answers the question in a way that does not fit one of the categories, you need to probe for a correct answer. 
Probing is a prompt which encourages further conversation without biasing the response. There are three types of probing:  
1. Probing for correctness  
2. Probing for clarity  
3. Probing for completeness  
Probing for Correctness  
Probing for correctness is used on pre -coded questions where you have categories that the respondent is to choose from. Sometimes 
reading the entire question again is an excellent probe to let the respondent know that the answer they gave was incorrect.  
Pausing and asking, "Your answer is," is a very good probe. If the respondent's answer does not fit into the categories you h ave, the 
best probe is to repeat the categories. When you repeat the categories always read ALL of the categories. Tell the respond ent, "I only 
have these categories" and read them all again.  
• Question 4a  
• Respondent: Oh it is a problem.  
• Interviewer: Should I mark “A big problem, a small problem, or not a problem at all”?  
Always read the entire question and all of the categories when repeating. Never help the respondent by telling them which cat egory is 
closest to their response. Be careful never to criticize the survey or express negativity to the respondent. Always let th e respondent 
choose even if they are asking for your help.  
Examples of Probes for Correctness:  
• Which one response is closest to your answer?  
• I don't have a category in between. I only have “yes" or "no".  
• What would your answer be?  
• If you had to choose, which one would you choose?  
 • Why don’t I read the question and possible answers again and you can tell me what is closest to your situation or opinion.  
• I only have these categories. Let me read them again and tell me which one is closest to your answer.  
• There is no right or wrong answers only your opinions.  
• The questionnaire does not offer an explanation or definition, so whatever “[term]” would mean to you. Let me read the 
categories again.  
• I really can’t choose for you, this is your opportunity to be heard and tell us what is important to you or how satisfied you  are. 
• Sometimes fitting into a category is difficult. Let me read them again  
• These categories are a range of opinions, which make it easier for analysis. I realize we speak to many respondents in 
different situations.  
• Let me read the categories again and if you would like I would be happy to record a comment with your response.  
When probing with a scale the same standards would apply. Think of each number as a category. Here is an example.  
• Question Please rate your current health plan. On a scale of 0 to 10 where 0 means the worst health plan possible and 10 
means the best health plan possible, how would you rate your current health plan? You can use any number: 
0,1,2,3,4,5,6,7,8,9 or 10.  
• Respondent: Pretty good…probably one of the best.  
• Interviewer: What number would that be? 0 means the worst health plan possible and 10 means the best health plan 
possible. You can select any number in between.  
• Respondent: What would a five mean?  
• Interviewer: I only have labels for 0 and 10 - 0 means the worst health plan and 10 means the best health plan; you can 
select any number zero through ten.  
• Respondent: I would like to give them an above average rating but I am not sure which number.  
• Interviewer: Scales can be difficult. I’m going to read you the scale again while you think about it. The lowest point of 
the scale is 0 meaning the worst, we move up the scale to 1,2,3,4,5,6,7,8,9,and 10 which means the best.  
• Respondent: Let’s go with an 8.  
Probing for Clarity  
A probe for clarity is often asking the respondent for a more detail about their response, or an explanation of their answer.  Open -ended 
questions tend to be very general (what do you think, why do you feel that way, etc.). Respondents tend to answer these  questions in a 
general way and use general adjectives to describe situations and options. Thus, probing for clarity is often a matter of ask ing for a 
more specific response, or an explanation of an answer.  
Examples of Probes for Clarity:  
• What do you mean?  
• Could you be more specific?  
• Could you say more?  
• Could you explain?  
• I don't understand.  
• What about that?  
The best probes for clarity are ones which tell the respondent exactly what you want to know. When probing for clarity, alway s help 
the respondent know what you don't understand and what you want clarified. Do not assume you understand - ask for an example  or 
an explanation.  
• Question: Is there anything in particular that you didn’t like about the experience?  
• Respondent: The wait is awful.  
• Interviewer: Please tell me what you mean by the wait?  
• Respondent: When I call for an appointment I usually have to wait 90 days before I am seen in the clinic.  
• Interviewer: Is that for any particular type of an appointment or for all appointments?  
• Respondent: No, they are good when I need to get in for my allergies, but for a physical I have to wait 90 days.  
• Interviewer: Is there anything else you would like to comment on?  
• Respondent; No, everything else is fine.  
Here is another example with the same question.  
• Question: Is there anything in particular that you didn’t like about the experience?  
• Respondent: Cost is very good.  
• Interviewer: Could you give me an example of what you mean by costs?  
• Respondent: The co -pays are much lower with this plan than the plan I had last year. I am very pleased with that.  
• Interviewer: Anything else?  
 • Respondent: Yes, the costs for prescriptions are wonderful. I take a lot of allergy medication and I am very happy with the 
low co -pay for these medications.  
• Interviewer: Anything else?  
• Respondent: The people are great!  
• Interviewer: Anyone in particular?  
• Respondent: I’d have to say the office staff that check you in and the nurses. They are always so kind and thoughtful they go  
out of their way to make you feel welcome.  
Probing for Completeness  
Some questionnaires will have questions where the interviewer is instructed to "check all that are mentioned," or probe for " others." 
This is where you would use your probes for completeness.  
Once a clear answer has been obtained, the interviewer should probe for additional responses to the question. The best way to  do this 
is to repeat the substance of the question as part of a request for further information.  
Examples of Probes for Completeness:  
• What else do you like?  
• What other reason did you have?  
• Anything else?  
• Any other comments?  
Each additional response should be probed for clarity as necessary. The interviewer should continue probing for additional re sponses 
until the respondent indicates that he/she has nothing else to say on the subject.  
 
Recording Data  
Types of Questions  
• Close -ended questions with pre -coded responses  
• Open -ended questions – record verbatim responses  
• Open -ended questions with pre -coded responses that are not read to the respondent  
Recording Pre -coded Responses to Close -ended Questions  
Pre-coded questions have response categories that are part of the question; there is a set of pre -planned response options and the 
respondent’s answer must be coded into one of them:  
Example:  
Q. A9. In general, would you say your health is excellent, good, fair or poor?  
• <1> Excellent  
• <2> Good  
• <3> Fair  
• <4> Poor  
• <8> DK (Don’t know)  
• <9> REF (Refused)  
If the respondent answers “excellent,” record 1 as the answer.  
If the respondent answers “good,” record 2, etc.  
Be sure to enter the correct number for the respondent’s response ! If you need to look down at the keyboard while typing it in, go 
ahead. You can fill any brief “dead air” by simply repeating their answer, which is a good thing to do anyway. It helps the r espondent 
know you’re paying attention.  
Below are examples of different pre coded questions.  
Q. B10. In general, how would you say you are these days? Would you say you are very happy, pretty happy, or not too happy?  
• <1> Very happy  
• <2> Pretty happy  
• <3> Not too happy  
• <8> DK (Don’t know)  
• <9> REF (Refused)  
If respondent says "Pretty happy," enter 2.  
If respondent says, "Yes, I am happy” you must try to get respondent to fit the answer into one of the listed categories by r epeating the 
responses closest to what the respondent said (probing).  
You should probe by saying: “Would that be closer to very happy or pretty happy?”  
Show your probe in your F -1 note pad as x and record what the respondent says in the box provided using the pre code.  
Recording Verbatim Responses to Open -ended Questions  
 Sometimes researchers want to know exactly what respondents say when asked a question. When this occurs, the interviewer reco rds 
WORD FOR WORD, or verbatim, what the respondent says. The interviewer should not paraphrase or summarize the respondent's 
answe rs unless instructed specifically to do so. You will record the respondent's verbatim comments, and your probes should be 
recorded in parentheses.  
Most respondents will talk faster than you can record. It will be up to you to slow them down or ask them to wait while you catch up. 
Techniques for recording quickly and for slowing the respondent without inhibiting him/her will be different for each intervi ewer. 
Some examples of the techniques are:  
• Begin writing or typing as soon as the respondent starts answering.  
• Use standard abbreviations.  
• Repeat what you are writing/typing while you are writing/typing.  
• Slow the respondent down as soon as you get lost. Go back to the beginning and let him/her take it from there.  
When you are recording the respondent's comments, be careful not to have too much dead time in the conversation. If the respo ndent 
is just sitting there while you write, they will be bored.  
Use small talk to maintain their attention. Such as:  
• O.K., I need to record all of your responses.  
• This is helpful.  
• I'm sorry I'm typing so slowly, but I want to make sure I write down your comments correctly.  
Other examples of open -ended questions:  
Q.B11. How many years have you been married?  
• 98 DK  
• 99 REF  
___ ___Enter number of years <1 - 80>  
This question shows you a range of appropriate answers and the pre -codes to be used for DK (don’t know) and REF (refused) options. 
Acceptable ranges should be large enough to accommodate any reasonable, realistic response. In the example above an acceptabl e 
range on ages is 1 to 80. If a legitimate response falls outside the acceptable range, probe to make sure the respondent unde rstand the 
question. If the response is still outside the acceptable range then record it in a note with the verbatim response an d proceed to the next 
question.  
Recording Verbatim Responses to Open -ended Questions  
Sometimes researchers want to ask a question in an open -ended fashion, but they have a pretty good idea what the top 5 or 6 responses 
are likely to be. In this case, the interviewer listens to the answer, and if appropriate, records the number correspondin g to the pre -
coded response (usually presented in CAPITAL LETTERS, indicating they are NOT to be read to the respondent). If the answer do es 
not fit into one of the pre -coded responses, the interviewer should record the number corresponding with “other,” t hen record verbatim 
the respondent’s answer.  
Example:  
What is the main reason why you do not eat as many fresh vegetables as you would like or think you should?  
• <1> COST TOO MUCH  
• <2> NOT AVAILABLE WHERE I SHOP  
• <3> TOO DIFFICULT TO PREPARE  
• <4> DON’T KNOW HOW TO PREPARE  
• <5> SPOIL QUICKLY  
• <7> OTHER - SPECIFY  
• <88> DON’T KNOW  
• <99> REFUSED  
Handling Difficult Situations  
People Who Talk Too Much  
There are some respondents who may want to give more information than the interviewer needs or asks for, or who are not able or 
willing to stick to the point of the question. Some may be so concerned with being thorough that they provide answers to ques tions not 
yet asked. Others may be lonely and view the i nterview as an opportunity for companionship and want to engage the interviewer in 
social conversation. Still, other respondents may be naturally chatty and want to talk on and on about themselves. Although m uch of 
the information these respondents give ma y be interesting, an interview that normally takes five minutes should not be allowed to go 
on for fifteen. It is the interviewer’s responsibility to rein the respondent back in by refocusing his attention while remai ning respectful 
of his needs. If the re spondent tends to give long explanations for every answer, politely cut him off, and direct his attention to the 
next question after you've gotten an acceptable response.  
Examples of Ways to Redirect  
• Say, "oh, I see, OK. . ." then immediately proceed to the next question.  
 • Say, "isn't that interesting -- now let me ask you . . ." and repeat the question.  
• If the respondent is very talkative and doesn't answer the question, interrupt at an appropriate point and say "given what 
you've just told me, would you say . . ." or "given all that, if you had to choose, would you say . . ." and repeat the choic es. 
• Offer, “So that I don’t take any more of your time than is needed, let’s go to the next question…”  
• Say "let me stop you so I can write this all down . . . now, given what you've said . . ." and repeat the choices or the ques tion. 
• If the respondent jumps ahead of the question, tell him you will be "asking about this later" and suggest he wait until you g et 
to that part of the interview so you can record the information accurately at that time. Say "we're going to cover that a lit tle 
later" or "we'll get back to that in a bit," then read the next question, or repeat the question you already asked, or repeat  the 
choices you already gave.  
People in a Hurry to Get Off the Phone  
Sometimes the respondent is in a hurry to get off the phone or wants to cut the interview short. This can be a problem with l ong 
interviews. If you are almost done with the interview, let the respondent know, and usually you'll be allowed to finish. It h elps to say 
"just ____ more questions" or "we'll be through in about ____ minutes." If you are not almost done, or if the respondent beco mes truly 
weary of the interview, indicate how much more time you think you'll need to finish and let the respondent deci de whether to continue 
or to reschedule another time to complete the interview. Many research centers allow interviews to be completed in multiple s ittings. It 
is preferable to complete an interview in one sitting, because you never know if you will actual ly be able to contact the respondent 
again. But situations arise – someone comes to the door, something burns on the stove, a child needs attention, or the respondent 
simply has another appointment to get to, and you should have instructions on how to deal  with the interview should such a situation 
arise. If you can resume the interview, try to schedule a specific day and time to call back; if the respondent cannot commit  to an 
appointment readily, find out the best days and times to call back and call the respondent until you reach him/her and are able to 
complete the interview.  
People with Difficulty Hearing or Understanding a Question  
If the respondent has difficulty hearing or understanding a question, repeat the question slowly and clearly without raising your voice. 
For some people the louder the voice, the more distorted it sounds and the harder it is to hear, especially over the ph one. A louder 
voice may convey the impression that the interviewer is getting impatient. Do not reword, explain or interpret the question; simply 
repeat it and encourage the respondent to do the best she can. If she cannot come to an understanding of the q uestion, move on to the 
next and note in the margin or comments section of the CATI program what happened.  
People Who Are Defensive  
Health research telephone interviews often involve personal or sensitive questions. Sometimes they are conducted with patient s who 
participated in a behavior change program in the past to follow up and see how they are doing now. People who try to quit smo king, 
lower cholesterol, or lose weight but do not succeed may feel that they have failed. They may be unwilling to participate in an 
interview, or they may answer questions defensively. It is imperative that the interviewer provide a safe, nonjudgmental e nvironment 
where the respondent feels safe sharing the results of his/her experience, even if it didn’t result in the desired outcome. T o minimize 
the respondent’s defensiveness, remain neutral; ask all questions in a direct, matter -of-fact tone of voice, especially when asking 
questions about income, education, weight, etc. Be careful to avoid criticism or even praise.  
Suggestions for Reducing Defensiveness  
• "There are no right or wrong answers"  
• "Your medical care will not be affected if you participate.”  
• Explain, "it is important to talk to you and get information from you because your experience may differ from the experience 
of others we talk to.”  
• “I understand that you may not want to participate, but we need the information only you can give us" and that "others may 
benefit from your experience."  
People Who Are Upset with the Health Plan or Angry in General  
If the respondent is mad at the study or angry about something else, listen to what s/he is saying and acknowledge -- rather than deny 
or minimize -- the anger. A statement like "I can understand why you're upset" will validate the respondent’s feelings and help 
establish a trust between interviewer and respondent. Accept all opinions without showing surprise, approval or  disapproval, 
agreement or disagreement. Telling the respondent "your opinions are very important to us -- we want your feedback - we can benefit 
from your experience" may diffuse the respondent’s anger and enlist his/her participation. Often the responden t just needs to vent 
frustration with the health plan in general and nothing more, but if you feel the respondent would benefit by discussing the complaint 
with someone else, consider referring the respondent to the health plan’s customer service/consumer helpline. If the respondent has a 
complaint about the research process – the advance letter or the phone call – note the details and inform your supervisor immediately. 
The research center’s supervisory staff and/or the project staff may decide to follow u p with the respondent.  
Suggestions for Interviewing Angry Respondents  
• Say "I can understand why you're upset"  
• Explain, “your opinions are very important to us -- we want your feedback - we can benefit from your experience."  
• “I can pass on your comments about your experience to the study leaders or I can provide you with the number if you wish to 
talk with them.”  
 People who are Difficult to Reach  
A household member may try to keep the interviewer from connecting with the respondent.  
Some examples include:  
• The household member wants more information about the purpose of your call than you can comfortably give.  
• The household member is reluctant to put you through to the respondent.  
• The household member tells you the respondent is not interested in participating.  
In these situations, you need to be extremely diplomatic to avoid losing the respondent completely.  
If the respondent is not home, ask when a good time to call back would be, thank the household member, and hang up. If asked,  say 
you will call back, that there is no need for your call to be returned, and there's no message. If pressed, it's OK to explai n that you're 
calling from [name your institution] and that you'll call back, and that it's not urgent and there is no problem (a call from  health care 
institution makes many people wonder what's wrong). Due to HIPAA privacy issues, we must reveal minimal i nformation to anyone 
other than the respondent, but we also do not wish to alarm the household.  
If the household member says he can answer the questions for you --"I'm her husband" -- say you appreciate his interest and offer, but 
explain that you really need to speak to the respondent directly. If you sense after repeated attempts to reach the respo ndent that a 
household member is intentionally blocking your access to the respondent, say that you need to speak to the respondent "for j ust a 
minute, for one quick question" that it's "very important;" or try calling at different times when you suspect t he household member 
might not be there.  
If you're told by a household member that the respondent is not interested in participating, thank him for the information an d let him 
know that participation is voluntary so it's OK if the respondent is not interested, but that you would like to speak wit h the respondent 
briefly anyway. The interviewer’s best strategy for reaching the respondent is to remain polite but persistent and try to gai n the trust of 
the resistant household member.  
Voice mail Protocols -- Example  
Most people have voice mail and some people use it to screen calls. Here is a sample protocol written for one study that prov ides 
guidelines for working with voice mail and leaving messages.  
Sample Protocol for Leaving Messages:  
We use messages to let respondents know we are trying to reach them.  
For instance, a study could decide to leave up to 3 messages. The case is eligible to be re -called on the next “shift.”  
You can count the shifts as:  
• Day, 9am -5pm = 1 shift.  
• Evenings = 1 shift,  
• Saturday = 1 shift,  
• Sunday = 1 shift.  
The first message is left on the first call attempt after all numbers are dialed and voice mail or no contact is encountered. This is so the 
respondent connects the advance materials to the call. Try to leave the first message at the home number. If you don’t know w hich 
phone number is th e home number, leave the message on the voice mail where the respondent’s name is listed if it does not appear to 
be a work number.  
If no name is listed on any of the messages, you choose one of the numbers to leave the message. This is <INTV NAME>from “The  
Health Institution”< MR/S FNAME LNAME > we sent you a letter about a study and will call you back soon. Our voice mail number  
is … ….. 
The 2nd message should be left in 5 days or the next call after 5 days, or on the 4th day if, in the interviewer’s judgment, the situation 
calls for it. This message gives more information along with the phone number asking the respondent to return the cal l. It is your 
choice to include or not include day, date & time.  
Leave this message as the 2nd message: This is <INTV NAME>from <SITE/HEALTH PLAN> Mr/s. FName LName we sent you a 
letter about a study. (Today is DAY/DATE/TIME) We return calls days, evenings and week -ends Please call our voicemail at 
……….leave your first & last name and several good times to reach you.  
(If the situation calls for it go ahead and add thanks for returning our last call, we are sorry we missed you or Sorry we ar e playing 
phone tag, we will keep trying Again our Voicemail number is ……….. .  
3rd Message:  
The third message is left after the supervisor/sample manager directs it or, if in the interviewer’s judgment, the situation calls for it. 
The third message always occurs by the 10th call if there is constantly no -answer. If you are unsure of what to do, t hen wait for the 
supervisor to direct you when/if to leave the third and final message.  
The parameters are to leave a message that encompasses the situation. There is no script.  
Talking points for the final message are:  
• Leave your name  
• The study voice mail number  
• Where you are calling from/or on behalf  
• Address the person whom we are calling  
 • Tell them we have been trying to reach them about a study.  
• Leave neutral information regarding ‘study letter’ and ask them to call back with times & numbers where they can be reached  
• It is okay to say to a live contact I can call right back and leave this on the voice mail for the respondent if you’d like.  
• It is okay to say that this is the only number we have and ask them to call us back with additional numbers and best times to  
be reached.  
People with a Language Barrier  
The respondent must understand both the consent and content of the survey. Where English is not the first language, children 
sometimes serve as translators for the adults in official interactions. We cannot accept a translated consent process. Some r esearc h 
organizations have large enough populations of non -English speaking respondents to go through a translation and re -translation of 
survey instruments; others choose to complete the interview or intervention with only English -speaking respondents. The stud y 
protocol will tell you more specifically how to address language barriers.  
People Who are Deceased  
Occasionally you may contact a household to find the person you are trying to reach has died. Sometimes the death is recent, but 
sometimes it occurred in the not -so-recent past. It is wise to express sympathy, indicate you will note this and we will not ca ll again. If 
you have indicated that you are calling from the health plan, be prepared to answer questions about why you didn’t KNOW the 
respondent was deceased, especially if s/he died at a health plan facility. You might offer, “I do not actually have ac cess to the medical 
record. Sometimes it takes awhile for this to be recorded in the record. I will note this, and we will not contact you again. ” 
If the respondent was already enrolled in a study, it may be important to the IRB to record when the death occurred so the re searcher 
can take steps to explore if it was related to study participation. In this case, you might offer sympathy, indicate that you don’t have 
access to the medical record, could the person you are talking with please tell you when this happened so you can note it in your 
records?  
Preventing Refusals  
A refusal is a person who states that they do not want to do the interview or do not want to participate further. Then, after you have 
taken the opportunity to explain the importance of the study, probed for concerns and responded to their individual situation , the 
person still states that they do not want to participat e. 
First, try to prevent a firm refusal. Figure out why the respondent does not want to do the interview, or why the respondent wants to 
leave the study, and be prepared with a response that addresses the issue. If the respondent says s/he does not have time,  offer that you 
can call back any time that is convenient, and the interview can be completed in more than one sitting, if needed (and if pos sible at the 
respective site or within the study protocol). If the respondent says s/he is too old, offer that it i s important that you speak with 
respondents of all ages.  
Before you begin interviewing on any study, try to think of all of the reasons that a reluctant or refusing respondent might give you, 
and craft a response that is appropriate for each reason. These are often called “recommended responses,” and study staff  may provide 
them to you. However, it is important that your responses to the respondent concerns flow naturally from you, so practice the m, and be 
prepared.  
Preparation will allow you to speak with confidence about the study. Be yourself! Relax before you make the call, and then as sert 
yourself confidently. Refusals seldom reflect the respondent’s feelings about YOU in particular – they usually result because you have 
called at a bad time, the respondent does not have enough information to make an informed decision, or the respondent just do es not 
participate in surveys. Do not take refusals personally.  
If the respondent does not agree to participate immediately, try to end the conversation with, "I'm sorry I caught you at an 
inconvenient time. Take some time to think about the study."  
Seldom must you force a reluctant respondent to make a decision immediately, but rather, allow some time to review the advanc e 
letter and think about your conversation, and perhaps a follow up phone call will be in order.  
When a potential respondent says s/he is not interested, try to determine if s/he really has enough information about the stu dy. It is 
legitimate for the respondent to be reluctant to share personal information by phone, so s/he may want to verify the stud y, verify your 
identity as an interviewer for [health plan], etc. Be polite, confident, and clear and answer all questions.  
No Contacts  
If someone says “Do not call back,” “Please don’t call this number again,” or “Take me off your list,” be sure to note the ve rbatim in 
the notes and inform the study team. If you contact a respondent who tells you:” I am not supposed to be called I was put  on your list 
and they promised me I would not be bothered again,” say “I am sorry to have bothered you. I will refer this to the superviso r and we 
will not call you again.”  
In-Person Interviewing  
There are many similarities between in -person and telephone interviewing. Chiefly, data collection for the study is dependent on your 
interaction with the respondent. However, in -person interviewing differs from telephone interviewing a few key ways, which  are 
described below.  
Attend to the Respondent  
Allow enough time to attend to the person in front of you, the interviewee. You should plan so you are not rushed either in r eality or 
having the appearance of being rushed. Organize your study materials before the interviewee is in the room. Become famili ar with 
 your surroundings, where the lights are, how to adjust the blinds, etc…. Know how to direct the respondent to restrooms or dr inking 
fountains if necessary.  
Introduce the Study  
You can use the basic techniques for introducing the study discussed previously. In addition, you can show the respondent stu dy 
materials to help convince her to participate. For example, the interviewer can show a copy of the advance letter or a descri ption of the 
study.  
Identification  
As an interviewer and representative of the project, you should wear your ID badge with your name, picture, and the instituti on. The 
ID shows the respondent, or any other family member, that you are legitimate.  
Be Aware of Non -Verbal Cues  
Interaction goes beyond voice. Be aware of your own non -verbal communication such as smiling, raising your eyebrows, grimacing, 
yawning. You will also have the opportunity to monitor the respondent’s non -verbal cues. Do they look tired? Are they distracted ? 
Setting  
Once you have introduced yourself, you are ready to begin the interview by first arranging for a proper setting. The followin g two 
conditions are important:  
1. Avoid an Audience: It may require ingenuity and tact to obtain privacy. The following are some suggested approaches you 
could use:  
Example:  
• “Could we go into another room so we can have privacy?”  
• “If your husband will excuse us, maybe we could go into another room. The interview will go much faster.”  
• “It’s best if you answer these questions privately. Could we go into another room?”  
 
2. Arrange for Suitable Seating:  
The interviewer should suggest sitting at a table, if one is available. Sit across from the respondent —not side -by-side. The 
respondent’s attention will be too divided with trying to read ahead on the questionnaire if they can see it.  
 
 
  
 Appendix XLII. SC and RA Checklists  
The following checklists were  created by Ellen Roe at Mission health and may be useful to all NCGENES 2 sites.  
  
Appt Date: ___________________  
   Patient Name______________ ___________  
SC Tasks Prior to Visit 1  
 
_____ Determine patient eligibility  
_____ Enter in Tracking System  
_____ Sent Introductory Letter  
_____ Call parent ~ a week after mailing Intro Letter  
_____ If agreeable, proceed with Randomization 1 for Pre -Visit Prep  
_____ Add note on appointment in Cerner “NCGENES 2 patient”  
_____ Email Paula to note appointment in Allscripts  
_____ Send Outlook invite  from NCG calendar to Steph a nd Ellen t o block appt time  
_____ Note phone call reminder on Outlook calendar 1 week prior to appt  
_____ Mail Pre -Visit packet  
_____ Phone cal l reminder ~ 1 week before appt  (note: let parent know other reminders will be 
sent from Genetic Center; we need them there 30 min prior to appt time for study 
related tasks)  
_____ Note NCG patient on 2 white boards in clinic (routinely done every Monday)  
 
SC Task Checklist for Visit 1  
____  Prepare RA bag  for visit  
(RA will text  SC while parent completing post -visit survey)  
_____ Discuss Randomization 2 and consent process ; mention gift ca rd as a thank you at 
completion of this visit.  
_____ If not interested , thank them for parti cipation in the pre -visit portion; present gift 
card and get signature of receipt; give child their gift.  
_____ If interested , proceed with Consent process.  
_____ SC co mpletes C onsent to Randomization (assent also if applicable)  
_____ Randomization completed in Tracking System; parent informed.  
_____ No GS – thank parent and give g ift card; get receipt signature; give child gift.  
_____ GS – continue with process for next consent.   
_____  SC notifies GC that parent is ready for Consent to  GS. 
_____ GC co mpletes Consent to GS on laptop (and assent if applicable)  
____ _ Give parent gift card, get receipt signature, and give child their gift.  
_____ Pr oceed to MCS Lab for blood draw with specimen collection baggie.  
 _____ Let phlebotomist know:  a) 2 add’l tubes needed for research study OR  
         b) blood draw for research study only  
 
_____ Remind MD to complete Post -Visit survey and PhenoTips!  
 
_____ Prepare and mail one tube (with most volume) to UNC  
_____ Enter order in Helix and give other tube to accessioning for processing.  
_____ Uplo ad audio recording per protocol (to GENERAL Documents/not PT SPEC Documents)  
_____ Note upload on file from Maggie (Google doc).   
   
Date: ___________________  
   Patient Initials /ID # :_____ ____________  
NCGENES 2  
RA Task Checklist           RA via laptop  
Parent via laptop  
_____ Set  up in consult room; pull patient up in Tracking System.  
_____ Greet parent/patient  after they are registered and seated ; escort to consult room.   
_____ Explain what their visit will involve today (pre -visit survey….clinic visit….post -visit survey, 
informa tion/randomization to next part of study if interested).  
_____ Confirm appointment details  in Tracking System . 
_____ Retrieve Intake Survey  (or give them envelope and/or survey to take home)  
_____ Record receipt of survey in Tracking System  (or whether it was sent home with them).  
_____ Copy/paste Survey Code on right side of Tracking screen on the Survey tab screen.  
_____ Have parent complete the Pre -Visit Survey on laptop.  
 _____ Offer iPad to chil d for entertainment if needed (passcode 1 21110).  
_____  Ask permission for audiotaping ; if agreed , get signature in Tracking System.   
_____ Remove recorder from bag.  
_____ Notify Med Asst that patient is ready ; ask what room they will be in.  
_____ Place audio recorder in room w hile Med Asst retrie ves patient ; turn on  recorder ; state 
recorder # and patient ID #; leave in room.  
_____ Text /call  SC to let her know pre -visit activities have been completed.  
_____ When  doc in with patient, place post -it note on his computer as a reminder to complete survey 
and PhenoTips  
_____ When clinic visit complete, get info from doc : 
_____  Blood draw  ordered ?  
_____ D evelopmental  age of child  (only ask if patient is ≥ 7) 
_____ Remo ve audio record er from room (stop recording)  and place back in bag.  
_____ Escort parent/patient back to consultation room.  
_____ Parent completes Post -Survey visit on laptop while child is occupied with iPad and offered a 
snack.    
_____ Notify SC when  the parent is completing survey ; should be ready in a few min.  
_____ Give SC patient folder and iPad  (child may be using iPad)  
_____  Share info with SC that doc provided – along with any fee dback or clinic ops information.  
_____ Enter Intake Survey answers in Tracking System  (if parent brought survey in).  
 (This can be done anytime during or after the visit when time allows. ) 
 Appendix XLIII. CLIA Template for Reporting Positive Results  
Diagnostic Testing Report  
Confirmatory Testing of Whole Exome Sequencing Analysis  
 
INDICATION FOR TESTING:  
The UNC Hospitals Clinical Molecular Genetics Laboratory performed Sanger DNA sequencing analysis to confirm the 
presence of genetic variants identified through the NCGENES2 research project at the University of North Carolina by 
massively parallel exome sequencin g analysis .   
 
 
RESULT:  
Homozygous/Heterozygous/Hemizygous for a INSERT GENE VARIANT variant/variant of uncertain significance.  
 
OR if KP:  
Positive for a homozygous/heterozygous/hemizygous INSERT GENE VARIANT mutation.  
 
INTERPRETATION:  
 
 
REFERENCES:  
 
 
COMMENTS:  
The nucleotide and protein numbering for the human XXXXX gene are according to the current entries for this gene in the 
NCBI RefSeq database (NM_XXXXX and NP_XXXXXX). The genomic coordinates for the reported variants in the 
hg38 reference genome are NC_YYYYYYYY  
 
METHOD:  
Bi-directional Sanger sequencing of approximately 200 base pairs surrounding the relevant variants was performed using 
genomic DNA extracted from a peripheral blood or saliva sample.  
 
 
 
 
This test was developed and its performance characteristics determined by the UNC Hospitals Molecular Genetics Laboratory.  It has not been  
approved by the US Food and Drug Administration. However, such approval is not required for clinical implementation. This lab orato ry is CAP 
accredited and CLIA certified to perform high complexity testing.  
 
 